I. **BIOGRAPHICAL DATA**

A. James M. Cook Date of Birth: August 6, 1945

B. **Education**

BS in Chemistry with Honors, West Virginia University, 1963‑1967.

PhD, Organic Chemistry, University of Michigan, 1968‑1971 with Professor Philip LeQuesne; Thesis Title: I. Alkaloidal N‑Oxides in Hallucinogenic Drugs. II. Studies on the Alkaloids of *Alstonia muelleriana* Domin."

Postdoctoral Appointment: "Synthesis of the Antitumor, *Vinca* Alkaloids," University of British Columbia," 1972‑1973 with Professor James P. Kutney.

C. **Positions Held**

Laboratory Technician, Fikes Chemicals, Nitro, W. Va., l964‑1965.

Supervisor of Research Laboratory and Pilot Plant, Fikes Chemicals, Summer 1965‑1966.

Plant Foreman, Thiourea Production, Fikes Chemicals, Nitro, WV, Summer, l967, Mr. Elmer Fike, President.

Graduate Student, University of Michigan, Ann Arbor, l968‑1971.

NIH Postdoctoral Fellow, University of British Columbia, 1972‑1973.

Assistant Professor of Chemistry, UW‑Milwaukee, September 1973‑1979.

Associate Professor of Chemistry, UW-Milwaukee, September 1979‑1986.

Professor of Chemistry, University of Wisconsin‑Milwaukee, 1986‑present.

Chair, Department of Chemistry, 1996-1999.

University Distinguished Professor, 2002-present

D. **Special Honors and Award**

Member of Phi Lambda Upsilon Chemistry Honorary.

General Mills Summer Fellowship (1969); NASA Traineeship (1969).

Univ.of Michigan "Travel Award" for Excellence in Teaching and Research (1971).

National Institutes of Health Predoctoral Fellowship (1970‑1972).

National Institutes of Health Postdoctoral Fellowship (1972‑1973).

UW‑Milwaukee Foundation Award for Research (1981).

National Institute for Alcohol and Drug Abuse Study Section for Contracts (1985).

Member of 3‑Man Review Committee to Evaluate CNS Program for G.D. Searle and Co., Skokie, IL (1986).

NSF Study Panel ‑ Review of SBIR Grants (1987‑1989), NIH (BNP-adhoc, 1994).

Milwaukee Section ACS Award in Chemistry (1989). NIMH Study Panel-Program on Psychotherapeutic Drug Development (1997); Medications Development (Contracts) 2003.

WiSys (Wisconsin System) 2006 Innovation Scholar Award.

UW – Milwaukee 2007 Innovator Award.

Hector DeLuca Scientific Achievement Award from BIOFORWARD (October 12, 2022).

Japanese Society for the Promotion of Science Fellowship (2001).

Faculty of the Year 2016-17, Chemistry and Biochemistry, UW-Milwaukee and 2018-2019.

Member, Editorial Advisory Board, *Journal of Medicinal Chemistry* (1996-2001).

Editorial Advisory Board, *Medicinal Chemistry Research* (1996-2015).

Member, Editorial Board,Expert Opinion on Therapeutic Patents (1999-2016).

Member, Editorial Advisory Board, Current Topics in Medicinal Chemistry (2001- 2016).

Member, Editorial Advisory Board, Current Organic Synthesis (2002-2016).

Member, Editorial Board, Clinical Pharmacology: Advances and Applications (2016-2018).

Member, Editorial Board, Drug Design, Development and Therapy (2007-2016).

Member, Editorial Board, Journal of Clinical Pharmacology (2009-2016).

Member, Editorial Advisory Board, International Journal of Drug Design and Discovery (2009 - 2016).

II. **GRANTS, CONTRACTS AND RESEARCH AWARDS**

A. **External Funds**

Research Corporation, "Synthesis of Antihypertensive Agents," $6,625, 1974‑1976.

National Institutes of Health, "The Synthesis of Alpha and Beta Adrenergic Antagonists," $117,000, 1976‑1980.

Department of the Army, "Synthesis of Antimalarial Agents from 1,6‑Diazaphenalene Derivatives," $135,000, 1977‑1980.

National Science Foundation, U. Weiss and J.M. Cook (P.I.), "General Method for the Synthesis of Cyclopentanoid Compounds," $97,500, 1979‑1982.

Petroleum Research Foundation, "Synthetic Approach Toward Planar Tetracoordinate Carbon," $30,000, 1980‑1982.

Aldrich Chemical‑Alfred Bader, "Medicinal Chemistry and Polyquinanes." (unrestricted funds) $10,000, 1979‑1982.

Money donated to program from other contributors, $10,000.

National Science Foundation, U. Weiss and J.M. Cook (P.I.), "General Approach for the Synthesis of Polyquinanes," $175,990, 1982‑1985.

Shell Development Company, "Biological Screening of Compounds," $7,612, 1984‑1985.

National Institutes of Health, "ß‑Carbolines: Search for Valium Agonists and Antagonists," $220,000, 1985‑1987.

Shaw Foundation, "Synthesis of Anxiolytic Agents With No Sedative‑Hypnotic Effects and Search for Selective Hypnotic Agents," $3,500, 1986‑1987.

University of Wisconsin‑Sea Grant, "The Persistence of Organic Pollutants in a Great Lakes Estuary," $77,877,1986‑1988. Cook (Associate, l5% of Award).

Petroleum Research Fund, "Synthetic Approach Toward Planar Four Coordinate Carbon," $52,500, 1986‑89. Project SEED, $1,000, 1987.

Petroleum Research Fund, Summer Research Supplement, $4,500, 1988.

National Institute of Drug Abuse, "Characterization of Bz Receptors and Punished Responding," $66,000, 1988‑1989.

National Institutes of Health, "General Approach for the Synthesis of Macroline Alkaloids," $165,000, 1986‑1989.

National Institutes of Environmental Health Sciences, "Purchase of Analytical HPLC," $9,704, 1988‑1989.

National Science Foundation, "General Approach Toward the Synthesis of Polyquinenes," $180,500, 1986‑1990.

Searle Research Laboratories, "The Synthesis of ß‑Carbolines as Cognitive Enhancers," $10,000, l987‑1992.

Monsanto Agricultural Division, $6,600, 1989‑1992.

Private Donation, $25,000, 1989‑1994.

National Institutes of Mental Health, "ß‑Carbolines: Search for Valium Agonists and Antagonists," $470,000, 1988‑1993.

National Science Foundation, "Fenestrane Approach to Planar Tetracoordinate Carbon," $215,800, 1991‑1994.

NIH Small Instrumentation Grant. "Purchase of an IR," $13,000, 1995.

National Institute of Mental Health, "Rigid Probes: Modeling Selective Anxiolytics for BzR," $580,000, 1991-1996.

Merck‑Sharp and Dohme, England, "Synthesis of Ligands Selective for α5 or α6 Benzodiazepine Receptor Sites. II. Characterization of the GABA/Cl- Channel," $38,000, 1993‑1996.

NSF, "Upgrade of NMR Spectroscopy Laboratory", One of 5 Principle Contributors (D. Petering, P.I.) $245,000, (University match $245,000, 1995).

ASTRA and Dupont Companies, “Broad Screening of Organic Compounds,” $27,600, 1997-2000.

ASTRA/ARCUS, “Broad Screening of Organic Compounds, $67,000, 1997-99.

CALBIOCHEM**,** Tryprostatin B, $4000, 1998-1999.

National Institute of Mental Health "Selective Anxiolytics *via* BzR Subtype Specific Ligands," $655,043, 1996-2000.

Eli Lilly, “Broad Screening of Organic Compounds,” $13,800, 2000-2002.

Wyeth-Ayerst, Fellowship for Student Salaries, Screening,” $20,000, 2000-2002.

Aldrich Chemical Company, $20,000, 2000-2002.

National Institutes of Health, “Ligands that Modulate Memory,” $146,000, 2000-2002(with Dr. Helmstetter, Psychology); 40% to Chemistry.

National Institute of Health (NIMH), “Selective Anxiolytics *via* BzR Subtype Specific Ligands,” (minority postdoctoral supplement), $118,000, 12/1/03-11/30/05.

NIH SBIR (subcontract) “Attenuation of Memory Impairment Using BDZR Ligands,” $48,756 (DC+IC) 2003-2005.

National Institute of Mental Health, “Selective Anxiolytics *via* BzR Subtype Specific Ligands,” $1,687,717, 2000-2006.

National Institute of Health, NIMH, “Selective Anxiolytics *via* BzR Subtype Specific Ligands,” $221,000, 12/1/03-11/30/06.

Searle Laboratories, “Process Development Chemistry,” Donation of Equipment, $80,000, 2000-2005. $130,000 more, 2004-2008.

National Institutes of Health (NIAAA), (IUPUI/U of Maryland, subcontract with Harry June) "GABAA Receptor Subunits in Alcohol Reinforcement," $330,000, 2002-2008.

Bristol Myers Squibb, Unrestricted Funds for Medicinal Chemistry, $95,000, 2004 – 2008.

Bristol Myers Squibb (WISIS License Agreement) $280,000, 2006 – 2008.

Aldrich Chemical, Purchase of Chemical Compounds, $35,000, 2005-2009.

Biotechnology Alliance Collaborative Grant Program with Marquette University and Medical College of Wisconsin. “Cysteine Prodrugs in the Treatment of Schizophrenia,” $56,000. 2006-2008.

Wisconsin Applied Research Program (WITAG) with UW-LaCrosse, “Synthesis of Substituted Phenoxystyrenes as Novel Antimicrobial Agents,” $23,500. 2006 – 2008.

UW-Milwaukee, Research Growth Initiative, “Novel GABA(A) Ligands for Treating Alzheimers-related Cognitive Deficits,” $215,257. 2006 – 2008.

National Institutes of Health (Johns Hopkins University subcontract, Dr. Elise Weerts), “Preclinical Assessment of Medications for Alcohol Abuse,” $66,000. 2007 – 2009.

Catalyst Grant, Lynde and Harry Bradley Foundation, “Synthesis of Beta Carbolines to Treat Alcohol Abuse,” $60,908 (7/1/08 – 6/30/09 –extended to December 31, 2009.

NIH, SBIR with David Baker at Marquette University and Promentis, “Cysteine Prodrugs to Treat Schizophrenia,” Total UW-Milwaukee amount, $285,895, 2008-2011.

National Institutes of Health (University of Maryland subcontract, Dr. Harry June), NIAAA “Alcoholism and Anxiety: Novel Benzodiazepine Treatments,” $60,000 (2009-2010).

Research Growth Initiative, “ New GABAergic Drugs to Treat Epilepsy Devoid of Sedative Ataxic and Amnesic Side Effects which Do Not Develop Tolerance,” $130, 944.

Catalyst Grant, Lynde and Harry Bradley Foundation, “Synthesis of Nonsedating Anticonvulsants,” $60,000 (7/1/2010-6/30/2011).

National Institutes of Health (Johns Hopkins University subcontract, Dr. Nancy Ator), “GABA(A)-Alpha 5 Cognitive Enhancers: Pharmacology and Neuropsychology in Macaques,” $300,000. 2007 – 2012.

National Institutes of Drug Abuse (P.I. David Baker, Marquette), “Targeting System Xc- for the Treatment of Drug Addiction,” $201,000 (2009-2012).

National Institutes of Health (Harvard Medical School subcontract, Dr. James Rowlett, P. I.), “Novel GABA – A Modulators as Cognitive Enhancers,” $600,000 (UWM-share), July, 2010 – June 30, 2016.

NIAAA (Harvard Medical School subcontract, Dr. Donna Platt) “GABA(A) Receptor Subtype Mechanisms in Non Human Primate Models of Alcohol Abuse,” $183,750. 2006 – 2017. (36,000/year)

Dupont Pharmaceuticals, Ag Division. Purchase of Chemical Compounds, $34,800, 2005 – 2017.

MiTAG (UW-Milwaukee), Synthesis of Subtype Selective GABAergic Agents to Treat Schizophrenia, $95,000, 2007-2017.

NIH “Synthesis of Alpha2/Alpha3 GABA Agonists to Treat Neuropathic Pain” J. M. Cook (P.I.), $1,323,000, (2012-2017).

NIH “New Therapeutic Agents to treat Schizophrenia,” J. M. Cook (P.I.) $1,880,000 (2013-2018).

UWM-Grant “Purchase of a Mass Spectrometer,” J. M. Cook (P.I.) $76,058 (2013).

UWM Foundation Catalyst Grant “Pharmacological Proof of Concept for a First-in-Class Asthma Therapy,” J. M. Cook (P.I.) $50,000 (2014-2015).

NIH “Development of a GABA (A) Agonist to Control Airway Hyperresponsiveness and Inflammation in Asthma”, J. M. Cook (P.I.), $1,400,000 (2014-2019).

NIH “Development of New Drugs for Asthma by Targerting GABA (A) Receptors in the Lung (C. Emala, PI), UWM-subcontract, J.M. Cook (P.I.) $200,808 (2015-2019).

**PRESENT**

NIDA “Tolerance and Physical Dependence after Chronic Benzodiazepine Treatment”, J. M. Cook (UWM P.I.) $582,517 (2016 – 2021), James Rowlett (P.I. Miss State Med School).

NIH-NIDA “Development of Non-sedative Parasitic Selective Benzodiazepines to Treat the Neglected Tropical Disease Schistosomiasis”, J. M. Cook (UWM P.I.) $117,000 (10/1/2020 – 9/30/2022).

NIH “GABA(A) Receptor Subtype Mechanisms in Nonhuman Primate Models of Alcohol Abuse”, J. M. Cook (UWM P.I.) $220,000 (11/01/2020 – 10/31/2025).

NIDA “Benzodiazepines and Polydrug Use”, S. Huskinson (UMMC P.I.), J. M. Cook (UWM P.I.) $383,642 (07/01/2021 – 06/30/2026).

**PENDING**

DOD “A Novel Subunit-selective Potentiator of GABA(A) Receptors for Treatment of Post Traumatic Epilepsy”, J. M. Cook (UWM P.I.) $53,895 (04/01/2021 – 03/31/2024).

NIH “KRM-II-81 as a Novel Treatment for Post-Traumatic Epilepsy”, J. M. Cook (UWM P.I.) $21,280 (04/01/2021 – 03/31/23).

DOD “KRM-II-81 as a Novel Treatment for Pain” J. M. Cook (UWM P.I.) under construction (07/01/2021 – 06/30/2024).

B. **Internal Funds**: *James M. Cook, P.I.*

Graduate School Research Award, "The Synthesis of Antihypertensive Agents," $7,894, 1974‑1975.

Graduate School Research Award, "The Synthesis of Antihypertensive Agents," $3,400, 1975‑1976.

Graduate School Research Award, "The Synthesis of Cardioselective and Chronoselective Antihypertensive Agents," $4,200, 1976‑1977.

Graduate School Research Award, "The Synthesis of Antileishmanial Agents," $4,200, 1982‑1983.

Graduate School Seed Money, c. $2,500, 1981‑1982.

Graduate School Matching Funds *vis a vis* Grant Proposals, c. $30,000, 1974‑1984.

Graduate School Matching Funds *vis a vis* Grant Proposals, $40,000, 1985‑1987.

Shaw Foundation, $1,000 (133‑H654).

Graduate School Matching Funds *vis a vis* Grant Proposals, $30,000, 1988.

Graduate School Matching Funds *vis a vis* Grant Proposals, $45,000, 1989‑1990.

Graduate School Matching Funds *vis a vis* Grant Proposals, $33,000, 1991‑1992.

Graduate School Matching Funds *vis a vis* Grant Proposals, $56,000, 1993-1995.

Graduate School Matching Funds *vis a vis* Grant Proposals, $50,000, 1996-1997.

Graduate School Matching Funds *vis a vis* Grant Proposals, $40,000, 1997-1998.

Graduate School Matching Funds *vis a vis* Grant Proposals, $30,000, 1998-1999.

Graduate School Matching Funds *vis a vis* Grant Proposals, $40,000, 1999-2000.

Graduate School Bridging Funds for Anxiolytics, $50,000, 2005

MiTag grant ($85,000), 2007-2008.

Research Growth Initiative ($215, 000), 2006-2008

Catalyst Grant ($60,000), 2008-2009

Catalyst Grant ($50,000), 2013-2014

Catalyst Grant ($56,000), 2014-2015

III. **RESEARCH**

A. **Scholarly Publications**

1. "Alstonerine, a New Indole Alkaloid from *Alstonia muelleriana*," J.M. Cook and P.W. LeQuesne, *Chem. Commun.*, 1306‑1307 (1969).
2. "The Structure of Alstonisidine: A Novel Dimeric Indole Alkaloid," J.M. Cook and P.W. LeQuesne, *J. Org. Chem.*, **36**, 582‑586 (1970).
3. "Some Aspects of Drug Usage, Trade and Plant Domestication Among the Yanomamo Indians of Venezuela and Brazil," N. Chagnon, P.W. LeQuesne, and J.M. Cook, *Acta Cient. Venezolana*, **21**, 186‑193 (1970).
4. "Yanomamo Hallucinogens: Anthropological, Botanical and Chemical Findings," N. Chagnon, P.W. LeQuesne, and J.M. Cook, *Current Anthropology*, **12**, 72‑74 (1971).
5. "Macralstonine from *Alstonia muelleriana*," J.M. Cook and P.W. LeQuesne, *Phytochem*., **10**, 737‑738 (1971).
6. "A Model Iron‑Catalyzed Biomimetic Cyclization of a Cyclic Tryptamine N‑Oxide," G. Scherer, C. Dorschel, J.M. Cook, and P.W. LeQuesne, *J. Org. Chem*., **37**, 1083‑1085 (1971).
7. "Biomimetic Synthesis and Structure of the Bisindole Alkaloid Alstonisidine," D.E. Burke, J.M.Cook, and P.W. LeQuesne, *Chem. Commun*., 697 (1972).
8. "Biomimetic Synthesis of the Bisindole Alkaloid Macralstonine," D.E. Burke, J.M. Cook, C. DeMarkey, and P.W. LeQuesne, *Chem. Commun.*, 1346‑1347 (1972).
9. "Further Alkaloids of *Alstonia muelleriana*," D.E. Burke, G.A. Cook, J.M. Cook, H. Lazar, K. Heller, and P.W. LeQuesne, *Phytochem.*, **12**, 1467‑1474 (1973).
10. "Biomimetic Synthesis of Villalstonine and Alstonisidine," D.E. Burke, J.M. Cook, and P.W. LeQuesne, *J. Amer. Chem. Soc.*, **95**, 546‑553 (1973).
11. "Studies on *Vinca* Alkaloids. The Structure of Vincarodine," J.P. Kutney, G. Cook. J. Cook, I. Itoh, J. Clardy, J. Fayos, P. Brown, and G. Svoboda, *Heterocycles*, **2**, 73‑78 (1974).
12. "11‑Methoxyakuammicine from *Alstonia muelleriana*," J.M. Cook and P.W. LeQuesne, *J. Org. Chem*., 1367 (1975).
13. "Studies on the Synthesis of Bisindole Alkaloids. Structure and Absolute Configuration of 18'‑Epi‑4'‑Epi‑Vinblastine, 18'‑Decarbometh‑oxy‑18'‑Epi‑4'‑Epi‑ Vinblastine and 18'‑Epi‑3',4'‑Dehydrovinblastine," J.P. Kutney, J. Cook, K. Fuji, A. Treasurywala, J. Clardy, J. Fayos, and H. Wright, *Heterocycles*, **3**, 205‑212 (1975).
14. "Total Synthesis of Indole and Dihydroindole Alkaloids. VIII. Studies on the Synthesis of Bisindole Alkaloids in the Vinblastine‑Vincristine Series. The Chloro-indolenine Approach," J.P. Kutney, J. Beck, F. Bylsma, J.M. Cook, W. Cretney, K. Fuji, R. Imhof, and A. Treasurywala, *Helv. Chim. Acta*, **58**, 1690‑1719 (1975).
15. "Reaction of 1,2 and 1,3 Dicarbonyl Compounds with Dimethyl ß‑Ketoglutarate. I. Synthesis of Methyl 5,6,7,8‑Tetrahydro‑5‑oxocoumarin‑ß(41H)‑Acetate," D. Yang, J. Oehldrich, D. Foerst, and J.M. Cook, *J. Org. Chem*., **41**(4), 743 (1976).
16. "Reactions of Dicarbonyl Compounds with Dimethyl ß‑Ketoglutarate. II. Simple Synthesis of Compounds of the [10.3.3] and [6.3.3] Propellane Series," J.M. Cook and D. Yang, *J. Org. Chem.*, **41**, 1903‑1907 (1976).
17. "Pictet‑Spengler Condensations in Refluxing Benzene," J. Sandrin, D. Soerens, L. Hutchins, E. Richfield, F. Ungemach, and J.M. Cook, *Heterocycles*, **4**, 1101‑1105 (1976).
18. "13C‑NMR of 1,3‑Disubstituted 1,2,3,4‑Tetrahydro‑ß‑Carbolines," J. Sandrin, D. Soerens, and J.M. Cook, *Heterocycles*, **4**, 1249‑1255 (1976).
19. "Reactions of Dicarbonyl Compounds with Dimethyl ß‑Ketoglutarate. IV. Isolation of 1:1 Adducts," J. Oehldrich, M. Mueller, D. Wichman, D. Yang, J.M. Cook, and U. Weiss, *J. Org. Chem.*, **41**, 4053‑4058 (1976).
20. "Reactions of Dicarbonyl Compounds with Dimethyl ß‑Ketoglutarate. V. Simple Synthesis of Tricyclo [6.3.0.01,5]undecane‑3,7,9‑Trione: A Novel Cyclopentanoid Compound," J. Oehldrich, J.M. Cook, and U. Weiss, *Tetrahedron Lett.*, 4549‑ 4552 (1976).
21. "Reactions of Dicarbonyl Compounds with ß‑Ketoglutaric Acid III: Synthesis of 4‑Hydroxy‑3,4‑diphenylcyclopent‑2‑enone‑2‑carboxylic Acid," J. Oehldrich and J.M. Cook, *Can. J. Chem.*, **55**, 82‑84 (1977).
22. "Reactions of Dicarbonyl Compounds with Dimethyl ß‑Ketoglutarate. VI. Revision of the Structure of the Reaction Product of Cyclohexane‑1,3‑dione and Dimethyl ß‑Ketoglutarate and Conversion into 4‑Substituted‑5,6,7,9 ‑Tetrahydro‑5‑oxo‑2‑ quinolones," J. Oehldrich and J.M. Cook, *J. Org. Chem*., **42**, 889‑894 (1977).
23. "Synthesis of 1,2,3,4‑Tetrahydro‑ß‑Carbolines," J. Sandrin, D. Soerens, P. Mokry, and J.M. Cook, *Heterocycles*, **6**, 1133‑1139 (1977).
24. "Reaction of Carbonyl Compounds with Dimethyl ß‑Ketoglutarate. Synthesis of Bicyclic Furan Derivatives," O. Campos and J.M. Cook, *J. Hetero. Chem.*, **14**(5), 711‑715 (1977).
25. "General Method for the Synthesis of [n.3.3]Propellanes, n > 3," R. Weber and J.M. Cook, *Can. J. Chem.*, **56**, 198‑192 (1978).
26. "Synthesis of the Antibiotic (±)‑Pyridindolol," G.S. Wu, E. Yamanaka, and J.M. Cook, *Heterocycles*, **9**, 175‑183 (1978).
27. "Synthesis of a Tetraketone of the Tetracyclo[5.5.1.0.4,13O10,13]tridecane ("Staurane") Series," R. Mitschka, U. Weiss, and J.M. Cook, *J. Am. Chem. Soc.*, **100**, 2973‑2974 (1978).
28. "The Spiroindolenine Intermediate: A Review," F. Ungemach and J.M. Cook, *Heterocycles*, **9**, 1089‑1119 (1978).
29. "Simple Entry into the 1,6‑Diazaphenalene Ring System," M.I. El‑Sheikh, J.‑C. Chang, and J.M. Cook, *Heterocycles*, **9**, 1561‑1570 (1978).
30. "Study of the Pictet‑Spengler Reaction in Aprotic Media: Synthesis of the ß‑Galactosidase Inhibitor, Pyridindolol," D. Soerens, J. Sandrin, F. Ungemach, P. Mokry, G.S. Wu, E. Yamanaka, L. Hutchins, M. DiPierro, and J.M. Cook, *J. Org. Chem.*, **44**, 535‑545 (1979).
31. "Selenium Dioxide Entry into 3‑Acylindoles," O. Campos and J.M. Cook, *Tetrahedron Lett*., 1025‑1028 (1979).
32. "Synthesis of 1,6‑Diazaphenalene, a Vinylogous Imidazole," J.‑C. Chang, M.I. El‑ Sheikh, and J.M. Cook, *Heterocycles*, **12**, 903‑907 (1979).
33. "Stereospecific Synthesis of *Trans*‑1,3‑Disubstituted‑1,2,3,4‑Tetrahydro ß-Carbo-lines," F. Ungemach, M. DiPierro, R. Weber, and J.M. Cook, *Tetrahedron Lett.*, 3225‑3228 (1979).
34. "A Convenient Preparation of Cyclopentane‑1,2‑dione," J. Wrobel and J.M. Cook, *Synthetic Commun*., **10**, 333‑337 (1980).
35. "General Method for the Assignment of Stereochemistry of 1,3‑Disubstituted‑1,2,3,4‑ Tetrahydro‑ß‑Carbolines by Carbon‑13 Spectroscopy," F. Ungemach, D. Soerens, R. Weber, M. DiPierro, O. Campos, P. Mokry, J.V. Silverton, and J.M. Cook, *J. Am. Chem. Soc.*, **102**, 6976‑6984 (1980).
36. "Selenium Dioxide Oxidations in the ß‑Carboline Area," O. Campos, M. DiPierro, M. Cain, R. Mantei, A. Gawish, and J.M. Cook, *Heterocycles*, **14**, 975‑984 (1980).
37. "New Perspectives on the Semmler‑Wolff Aromatization Reaction," M.I. El‑Sheikh and J.M. Cook, *J. Org. Chem*., **45**, 2585‑2587 (1980).
38. "Stereospecific Synthesis of 1,3‑Disubstituted‑1,2,3,4‑Tetrahydro ß‑Carbolines," F. Ungemach, M. DiPierro, R. Weber, and J.M. Cook, *J. Org. Chem*., **46**, 164‑168 (1981).
39. "General Approach for the Synthesis of Polyquinanes: Stereospecific, Regiospecific Entry into the Tetracyclo[6.6.0.01,5.O8,12]tetradecane System," A. Gawish and J.M. Cook, *Tetrahedron Lett*., **22**, 211‑214 (1981).
40. "3‑Hydroxymethyl ß‑Carboline Antagonizes Some Pharmacologic Actions of Diazepam," P. Skolnick, S.M. Paul, K.C. Rice, S. Barker, J.M. Cook, R. Weber, and M. Cain, *Eur. J. Pharmacol*., **69**, 525‑527 (1981).
41. "Reaction of Dicarbonyl Compounds with Dimethyl 3‑ketoglutarate. Influence of Steric Effects on Success of the Condensation," K. Avasthi, M.N. Deshpande, W.‑C. Han, U. Weiss, and J.M. Cook, *Tetrahedron Lett.*, **22**, 3475‑3478 (1981).
42. "The Chemistry of 1,6‑Diazaphenalene. Electrophilic Substitution and Reaction with Singlet Oxygen," K. Avasthi, S.‑J. Lee, J.M. Cook, J.E. Pickett, and H.H. Wasserman, *Heterocycles*, **16**, 1453‑1461 (1981).
43. "General Approach for the Synthesis of Polyquinanes, Facile Generation of Molecular Complexity *via* Reaction of 1,2‑Dicarbonyl Compounds with Dimethyl 3‑keto-glutarate," R. Mitschka, J. Oehldrich, K. Takahashi, J.M. Cook, U. Weiss, and J.V. Silverton, *Tetrahedron* (Symposium in Print, ed. by L.A. Paquette), 37, 4521‑4542 (1981).
44. "Synthesis of 1,6‑Diazaphenalene," M.I. El‑Sheikh, J.C. Chang, A. Harmon, K. Avasthi, and J.M. Cook, *J. Org. Chem.*, **46**, 4188‑4193 (1981).
45. "Chemistry of 1,6‑Diazaphenalene, Halogenation," S.‑J. Lee and J.M. Cook, *Heterocycles*, **16**, 2125‑2131 (1981).
46. "Regiospecific Cleavage of Strained Tri‑ and Tetraquinane ß‑Diketones *via* a Retro‑ Claisen Reaction," W.C. Han, K. Takahashi, J.M. Cook, U. Weiss, and J.V. Silverton, *J. Am. Chem. Soc*., **104**, 318‑321 (1982).
47. "Do Benzodiazepine Receptors Play a Role in Sleep Regulation? Studies with the Benzodiazepine Antagonist, 3‑Hydroxymethyl‑ß‑Carboline," W. Mendelson, M. Cain, J.M. Cook, S.M. Paul, and P. Skolnick, in "Beta‑Carbolines and Isoquinolines," ed. by Earl Usdin, A.R. Liss, Inc., New York, 233‑252 (1982).
48. "ß‑Carbolines and Benzodiazepine Receptors: Structure‑Activity Relationships and Pharmacologic Activity," P. Skolnick, E.F. Williams, J.M. Cook, M. Cain, K.C. Rice, J.M. Crawley, and S.M. Paul, in "Beta‑Carbolines and Isoquinolines," ed. by Earl Usdin, A.R. Liss, Inc., New York, 253‑262 (1982).
49. "ß‑Carbolines: Synthesis, Neurochemical and Pharmacological Actions on Brain Benzodiazepine Receptors," M. Cain, R. Weber, F. Guzman, J.M. Cook, S.A. Barker, K.C. Rice, and P. Skolnick, *J. Med. Chem*., **25**, 1081‑1091 (1982).
50. "Synthesis of 9‑Methoxy‑1,6‑Diazaphenalene," R.W. Weber and J.M. Cook, *Heterocycles*, **19**, 2089‑2095 (1982).
51. "Benzodiazepine Receptor‑Mediated Experimental 'Anxiety' in Primates," P.T. Ninan, T.M. Insel, R.M. Cohen, J.M. Cook, P. Skolnick, and S.M. Paul, *Science*, **218**, 1332‑1334 (1982).
52. "Chemistry of 1,6‑Diazaphenalene. Reaction with Alkylating and Acylating Agents," K. Avasthi and J.M. Cook, *J. Heterocyclic Chem*., **19**, 1415‑1419 (1982).
53. "Biomimetic Approach to Potential Benzodiazepine Agonists and Antagonists," M. Cain, F. Guzman, J.M. Cook, K.C. Rice, and P. Skolnick, *Heterocycles*, **19**, 1003‑ 1007 (1982).
54. "Blockade of 3‑Carbomethoxy ß‑Carboline Induced Seizures by Diazepam and the Benzodiazepine Antagonists, Ro 15‑1788 and CGS‑8216," M. Schweri, M. Cain, J. Cook, S. Paul, and P. Skolnick, *Pharmac. Biochem. Behav*., **17**, 457‑460 (1982).
55. "Halogenation of 1,6‑Diazaphenalene. Theoretical and Experimental Results," R.W. Weber, S.J. Lee, S. Milosevich, J.M. Cook, and W.B. England, *Can. J. Chem.*, **60**, 3049‑3054 (1982).
56. "DDQ Oxidations in the Indole Area: Synthesis of Crenatine," M. Cain, R. Mantei, and J.M. Cook, *J. Org. Chem.*, **47**, 4933‑4936 (1982).
57. "Selenium Dioxide Oxidations in the Indole Area. Synthesis of ß‑Carboline Alkaloids," M. Cain, O. Campos, F. Guzman, and J.M. Cook, *J. Am. Chem. Soc.*, **105**, 907‑913 (1983).
58. "Stereocontrolled Synthesis of (±) Modhephene *via* the Weiss Reaction," J. Wrobel, K. Takahashi, V. Honkan, S. Bertz, G. Lannoye, and J.M. Cook, *J. Org. Chem.*, **48**, 139‑141 (1983).
59. "Synthesis of Azaphenalenes," S.J. Lee and J.M. Cook, *Heterocycles*, **20**, 87‑111 (1983).
60. "A Benzodiazepine Receptor Antagonist Decreases Sleep and Reverses the Hypnotic Actions of Flurazepam," W.B. Mendelson, M. Cain, J.M. Cook, S.M. Paul, and P. Skolnick, *Science*, **219**, 414‑416 (1983).
61. "Increased Wakefulness in Rats is Induced by 3‑Hydroxymethyl ß‑Carboline, a Benzodiazepine Antagonist," W. Mendelson and J.M. Cook, Sleep 1982, 6th Eur. Congr. Sleep Res., Zurich 1982, Karger, Basel, 279‑281 (1983).
62. "Pictet‑Spengler Reactions in Aprotic Media," M. Jawdosiuk and J.M. Cook, *J. Org. Chem.*, **49**, 2699‑2701 (1984).
63. "Biomimetic Approach to Potential Benzodiazepine Receptor Agonists and Antagonists," F. Guzman, M. Cain, P. Larscheid, T. Hagen, J. Cook, M. Schweri, P. Skolnick, and S. Paul, *J. Med. Chem.*, **27**, 564‑570 (1984).
64. "Organocuprate Reactions with Cyclopropanes. Evidence for Three Types of Mechanisms and Against Direct Nucleophilic Displacement of ß‑Cyclopropyl-α,ß‑Unsaturated Ketones," S.H. Bertz, G. Dabbagh, J.M. Cook, and V. Honkan, *J. Org. Chem.*, **49**, 1739‑1843 (1984).
65. "Isolation of the Key Intermediate in the Formation of *cis*‑Bicyclo[3.3.0]octane‑3,7‑ diones from Dimethyl 3‑ketoglutarate and 1,2‑Dicarbonyl Compounds," G. Kubiak, U. Weiss, and J.M. Cook, *J. Org. Chem.*, **49**, 561‑564 (1984).
66. "Structural Features of the Quinidine and Quinine Molecule Necessary for Binding of Drug‑Induced Antibodies to Human Platelets," D.J. Christie, R. Weber, P. Mullen, J.M. Cook, and R. Aster, J. Laboratory and Clinical Medicine, 104, 730‑740 (1984).
67. "ß‑Carboline‑3‑Carboxylate‑t‑Butyl Ester: A Selective Bz‑1 Receptor Antagonist," H.E. Shannon, N.J. Katzman, F. Guzman, and J.M. Cook, *Life Sci.*, **35**, 2227‑ 2236 (1984).
68. "Interactions Between the Benzodiazepine Receptor Antagonist Ro 15‑1788 (Flumazenil) and the Inverse Agonist BCCE: Behavioral Studies with Squirrel Monkeys," J.E. Barrett, L.S. Brady, J.M. Witkin, J.M. Cook, and P. Larscheid, *Life Sci.*, **36**, 1407‑1414 (1985).
69. "Midazolam‑Ethanol Interactions and Reversal with a Benzodiazepine Antagonist," P. Van Gorder, W. Hoffman, V. Baughman, R. Albrecht, D. Miletich, F. Guzman, and J.M. Cook, *Anesth. Analg.*, **64**, 129‑135 (1985).
70. "Cerebrovascular and Cardiovascular Metabolic Effects of Flurazapam and a Benzodiazepine Antagonist 3‑Hydroxymethyl ß‑Carboline," W. Hoffman, J.M. Feld, P. Larscheid, J.M. Cook, R.F. Albrecht, and D.J. Miletich, *Eur. J. Pharmacol*. **106**, 585‑591 (1985).
71. "A Benzodiazepine Antagonist Inhibits the Cerebral Metabolic and Respiratory Depressant Effects of Fentanyl," N. Naughton, W.E. Hoffman, P. Larscheid, J.M. Cook, R.F. Albrecht, and D.J. Miletich, *Life Sci.*, **36**, (23) 2239‑2245 (1985).
72. "Synthetic Studies in the ß‑Carboline Area. New Entry into 4‑Substituted and 3,4‑ Disubstituted ß‑Carbolines," N. Fukada, M.L. Trudell, B. Johnson, and J.M. Cook, *Tetrahedron Lett*., **26**, 2139‑2142 (1985).
73. "Evidence that a Benzodiazepine Receptor Mechanism Regulates the Secretion of Pituitary ß‑Endorphin Levels in Rats," S. Maiewski, P. Larscheid, J.M. Cook, and G. Mueller, *Endocrinology*, **117**, 474‑480 (1985).
74. "General Approach for the Synthesis of Polyquinenes *via* the Weiss Reaction. Preparation of the Chiral Tetracyclo[6.6.0.01,5O.8,12]tetradecane‑3,6,10,13‑ tetraene," M. Venkatachalam, M. Jawdosiuk, M. Deshpande, and J.M. Cook, *Tetrahedron Lett*., **26**, 2275‑2278 (1985).
75. "Studies on the Reaction of 1,2‑Dicarbonyl Compounds with Dimethyl 3‑Ketoglu-tarate. Steric and Electronic Effects," G. Kubiak and J.M. Cook, *Tetrahedron Lett*., **26**, 2163‑2166 (1985).
76. "The Interaction Between Benzodiazepine Antagonists and Barbiturate‑Induced Cerebrovascular and Cerebral Metabolic Depression," R.F. Albrecht, J. Cook, W.E. Hoffman, P. Larscheid, D.J. Miletich, and N. Naughton, *Neuropharmacology*, **24**, 957‑963 (1985).
77. "General Approach for the Synthesis of Polyquinenes. II. Synthesis of Tetracyclo-[5.5.1.04,13.O10,13]tridecane‑2,5,8,11 ‑tetraene," M.N. Deshpande, M. Jawdosiuk, G. Kubiak, M. Venkatachalam, W. Weiss, and J.M. Cook, *J. Am. Chem. Soc.*, **107**, 4786‑4788 (1985).
78. "General Approach for the Synthesis of Polyquinenes. III. Synthesis of Triquinacene *via* the Weiss Reaction," S.H. Bertz, G. Lannoye, and J.M. Cook, *Tetrahedron Lett*., **26**, 4695‑4698 (1985).
79. "The Isolation and Characterization of a New Tetrahydroprotoberberine Alkaloid from *Cordalis clarkei* *Prain*," M.A. Rothera, S. Wehrli, and J.M. Cook, *J. Nat. Products.*, **48**, 802‑808 (1985).
80. "General Approach to the Synthesis of Polyquinanes," M. Venkatachalam, G. Kubiak, J.M. Cook, and U. Weiss, *Tetrahedron Lett*., **26**, 4863‑4866 (1985).
81. “Condensation of Dimethyl-1,3-Acetone dicarboxylate with 1,2–Dicarbonyl Compounds; *cis*‑Bicyclo[3.3.0]octane ‑3,7‑diones," S. Bertz, J.M. Cook, A. Gawish, and U. Weiss, *Org. Syn*., **64**, 27‑38 (1985).
82. "Formation of the Tetracyclo[5.4.2.O2,6.O2,9]tridecane Ring‑system by a Novel Transannular Aldolization Reaction," M.N. Deshpande, S. Wehrli, M. Jawdosiuk, J.T. Guy, Jr., D.W. Bennett, J.M. Cook, M.R. Depp, and U. Weiss, *J. Org. Chem*., **5l**, 2436‑2444 (l986).
83. "Cerebrovascular and Cerebral Metabolic Effects of Physostigmine, Midazolam and a Benzodiazepine Antagonist," W.E. Hoffman, R.F. Albrecht, D.J. Miletich, T.J. Hagen, and J.M. Cook, *Anesth. Analg.*, **65**, 639‑644 (1986).
84. "Differential Antagonism of Diazepam‑Induced Loss of the Righting Response," J. Witkin, J.E. Barrett, J.M. Cook, and P. Larscheid, *Pharm. Biochem. and Behavior*, **24**, 963‑965 (1986).
85. "General Approach to the Synthesis of Polyquinanes. Preparation of *Trans‑Trans*‑ 4,8‑Diacetoxy–tetracyclo [9.3.0.01,5.p7,11]tetradeca‑6‑one *via* the Aldol Approach," M. Venkatachalam, S. Wehrli, G. Kubiak, U. Weiss, and J.M. Cook, *Tetrahedron. Lett*., **27**, 4111‑4114 (1986).
86. "Discriminative and Aversive Stimulus Effects of ß‑Carboline Ethyl Ester in Rhesus Monkeys," K. Takada, G. Winger, J. Cook, P. Larscheid, and J.H. Woods, *NIDA. Res. Mon. Ser.*, **67**, 119‑124 (1986).
87. "Discriminative and Aversive Properties of ß‑Carboline‑3‑Carboxylic Acid Ethyl Ester, a Benzodiazepine Receptor Inverse Agonist, in Rhesus Monkeys," K. Takada, G. Winger, J. Cook, P. Larscheid, and J.A. Woods, *Life Sciences*, **38**, 1049‑1056 (1986).
88. "General Approach for the Synthesis of Polyquinenes," M. Venkatachalam, M.N. Deshpande, M. Jawdosiuk, G. Kubiak, S. Wehrli, U. Weiss, and J.M. Cook, *Tetrahedron*, "Symposium in Print," **42**, 1597‑1605 (1986).
89. "Synthesis of 3,6‑Disubstituted ß‑Carbolines Which Possess Either Benzodiazepine Antagonist of Agonist Activity," T.J. Hagen, F. Guzman, C. Schultz, J.M. Cook, P. Skolnick, and H. Shannon, *Heterocycles*, **24**, 2845‑2855 (l986).
90. "Synthesis of 7,12‑Dihydropyrido[3,4‑*b*:5,4‑*b*']diindoles. A Novel Class of Rigid, Planar Benzodiazepine Receptor Ligands," M.L. Trudell, P. Skolnick, A.S. Basile, H.E. Shannon, and J.M. Cook, *J. Med. Chem*., **30**, 456‑458 (l987).
91. "The Synthesis of Novel 6‑Substituted ß‑Carbolines Which Behave as Benzodiazepine Receptor Antagonists or Inverse Agonists," T.J. Hagen, P. Skolnick, and J.M. Cook, *J. Med. Chem.*, **30**, 750‑753 (l987).
92. "Hydrazine Mediated One‑Pot Amination‑Oxidation Reaction: Facile Synthesis of 4‑Amino ß‑Carbolines and 4‑Aminoisoquinolines," M.L. Trudell, N. Fukada, and J.M. Cook, *J. Org. Chem.*, **52**, 4293‑4296 (l987).
93. "General Approach to the Synthesis of Polyquinenes. IV. Studies Directed Toward the Preparation of Dicyclopenta[cd,gh]pentalene," G. Lannoye and J.M. Cook, *Tetrahedron Lett.*, **23**, 4821‑4824 (l987).
94. "General Approach to the Synthesis of Polyquinanes, Preparation of *Trans-Trans*‑ 4,8‑Diacetoxy‑tetracyclo [9.3.0.0l,5.07,11]tetradeca‑6‑one," M. Venkatachalam, S. Wehrli, G. Kubiak, U. Weiss, and J.M. Cook, *J. Org. Chem*., **52**, 4110‑4115 (l987).
95. "Discriminative Stimulus Effects of Intraveous Nicotine in Squirrel Monkeys," K. Takada, T.J. Hagen, J.M. Cook, S.A. Goldberg, and J.L. Katz, *Pharmacol. Biochem. Behav.*, **30**, 243‑247 (1988).
96. "General Approach to the Synthesis of Polyquinenes *via* the Weiss Reaction. V. Progress Toward the Synthesis of Dicyclopentapentalenes," G. Lannoye and J.M. Cook, *Tetrahedron Lett*., **29**, 171‑174 (1988).
97. "Synthesis of 1‑Methoxycanthine‑6‑one," T.J. Hagen and J.M. Cook, *Tetrahedron Lett.*, **24**, 2421‑2424 (1988).
98. "General Approach To The Synthesis of Polyquinenes *via* the Weiss Reaction. VI. Progress Toward the Synthesis of Dicyclopentapentalenes," G. Lannoye, K. Sambasivarao, S. Wehrli, U. Weiss, and J.M. Cook, *J. Org. Chem.*, **53**, 2327‑2340 (1988).
99. "ß‑Carbolines as Antagonists of the Discriminative Stimulus Effects of Diazepam in Rats," H.E. Shannon, T.J. Hagen, F. Guzman, and J.M. Cook, *J. Pharm. Exp. Ther*., **246**, 275‑281 (1988).
100. "General Approach to the Synthesis of Polyquinenes. VII. Synthesis of a Centro‑ substituted Triquinacene," A.K. Gupta and J.M. Cook, *Tetrahedron Lett*., **24**, 2535‑2538 (1988).
101. "Regioselective Methylation of 7,12‑Dihydropyrido[3,2‑*b*:5,4‑*b*']diindole. Experi-mental and Computational Results," M.L. Trudell, Y.‑C. Tan, and J.M. Cook, *J. Org. Chem.*, **53**, 4873‑4875 (1988).
102. "Antibody‑Mediated Platelet Destruction by Quinine, Quinidine and Their Metabolites," D.J. Christie, H. Diaz‑Arauzo, and J.M. Cook, *J. Laboratory and Clinical Medicine*, **112**, 92‑98 (1988).
103. "Synthesis of Novel 3‑Substituted ß‑Carbolines as Benzodiazepine Receptor Ligands: Probing the Benzodiazepine Receptor Inverse Agonist Site," M.S. Allen, T.J. Hagen, M.L. Trudell, P. Skolnick, and J.M. Cook, *J. Med. Chem*., **31**, 1854‑1861 (1988).
104. "General Approach to the Synthesis of Polyquinenes. IX. The Monofunctional-ization and Alteration of the Symmetry of the *cis*‑Bicyclo[3.3.0]octane‑3,7‑dione Unit," G. Lannoye, G. Kubiak, K. Sambasivarao, and J.M. Cook, *J. Org. Chem*., **53**, 5173‑5175 (1988).
105. "Pictet‑Spengler Reactions in Aprotic Media. Nb‑Benzyl Promoted Retention of Optical Activity in the Synthesis of an Indolo‑substituted Aza‑bicyclo[3.3.1]nonane. A Key Template for the Synthesis of Macroline Alkaloids," L.H. Zhang and J.M. Cook, *Heterocycles*, **27**, 2795‑2803 (1988).
106. "Reactivity of 7,12‑Dihyropyrido[3,2‑b:5,4‑6]diindoles with Electrophilic Reagents. Experimental and Computational Results," M.L. Trudell, S.L. Lifer, Y.‑C. Tan, W.B. England, and J.M. Cook, *J. Org. Chem*., **53**, 4185‑4190 (1988).
107. "Structure‑activity Studies of ß‑Carbolines, Crystal and Molecular Structures of t‑Butyl‑ß‑Carboline‑3‑Carboxylate and 2‑(Methoxycarbonyl) Canthine‑6‑one," P.W. Codding, M.B. Szkaradzinska, A. Roszak, L.J. Aha, T.J. Hagen, and J.M. Cook, *Can. J. Chem*., **66**, 2981‑2986 (1988).
108. "Similarity of the Discriminative Stimulus Effects of N‑Methyl‑D‑Aspartate and ß‑Carboline Ethyl Ester in Pigeons," J.H. Woods, C.P. France, J. Hartman, S. Baron, and J.M. Cook in "Frontiers in Excitatory Amino Acid Research," E.A. Cavalheiro, J. Lehmann, and L. Turski (Ed.), A.R. Liss, New York, N.Y., 317‑324 (1988).
109. "3‑Ethoxy ß‑Carboline: A High Affinity Benzodiazepine Receptor Ligand with Partial Inverse Agonist Properties," R. Trullas, H. Ginter, B. Jackson, P. Skolnick, M. Allen, T. Hagen and J.M. Cook, *Life Sci.*, **43**, 1189‑1197 (1988).
110. "Pictet‑Spengler Reactions in Aprotic Media. Stereospecific Conversion of Optically Active *cis*‑1,3‑Disubstituted ß‑Carbolines into Their Corresponding *Trans* Diastere-omers," L.H. Zhang and J.M. Cook, *Heterocycles*, **27**(6), 1357‑1363 (1988).
111. "Synthesis of 7,12‑Dihydropyridopyrroloindoles(Azapyridodiindoles) *via* the Fischer Indole Cyclization. A Search for Water Soluble Benzodiazepine Receptor Ligands," Y.‑C. Tan, M.L. Trudell and J.M. Cook, *Heterocycles*, **27**(7), 1607‑1614 (1988).
112. "Punishment of Behavior with Response‑produced Injections of Drugs in Squirrel Monkeys," J.L. Katz, K. Takada, J.E. Barrett and J.M. Cook, *Psychopharmacol*., **96**, S30 (1988).
113. "General Approach to the Synthesis of Polyquinenes. VIII. Synthesis of Triquinacene, 1,10‑Dimethyltriquinacene and 1,10‑Cyclohexanotriquinacene," A.K. Gupta, G. Lannoye, G. Kubiak, J. Schkeryantz, S. Wehrli and J.M. Cook, *J. Am. Chem. Soc.*, **11**, 2169‑2179 (1989).
114. "Modeling the Benzodiazepine Receptor Using Structural and Theoretical Characterization of Novel ß‑Carbolines," P.W. Codding, A.W. Roszak, M.B. Szkaradzinska, J.M. Cook, and L.J. Aha, Trends in Medicinal Chemistry "88, H. Van der Goot, G. Domany, L. Pallos, and H. Timmerman (eds.), Budapest Hungary, August 1988, Pharmochemistry Library, Elsevier Science Publishers, Amsterdam, The Netherlands, 109‑120 (1989).
115. "Drug Discrimination in Pentylenetetrazol‑Trained Baboons: Generalization to Buspirone and ß‑CCE But Not Lorazepam or Pentobarbital," N.A. Ator, J.M. Cook, and R.R. Griffiths, *Drug Dev. Res.*, **16**, 257‑267 (1989).
116. "Behavioral Effects of Benzodiazepine Antagonists in Chlordiazepoxide Tolerant and Non‑Tolerant Rats," K. Takada, T. Suzuki, T.J. Hagen, J.M. Cook, and J.L. Katz, *Life Sci.*, **44**, 289‑299 (1989).
117. "DDQ Oxidations in the Indole Area. Synthesis of 4‑Alkoxy ß‑Carbolines Including the Natural Products Crenatine and 1‑Methoxy Canthine‑6‑one," T.J. Hagen, K. Narayanan, J. Names and J.M. Cook, *J. Org. Chem.*, **54**, 2170‑2178 (1989).
118. "Studies on the Formation of Oxindoles From Their Azabicyclo[3.3.1]nonane Counterparts and the Implications for the Biogenesis of Alstonisine," S.P. Hollinshead, D.S. Grubisha, D.W. Bennett and J.M. Cook, *Heterocycles*, **29**, 529‑537 (1989).
119. "Reinvestigation of the Mechanism of the Acid Catalyzed Epimerization of Reserpine to Isoreserpine," L.‑H. Zhang, A.K. Gupta and J.M. Cook, *J. Org. Chem.*, **54**, 4708‑4712 (1989).
120. "Inhibition of Sleep and Benzodiazepine Receptor Binding by a ß‑Carboline Derivative," Joseph V. Martin, P. Skolnick, J.M. Cook and T.J. Hagen, and W.B. Mendelson, *Pharm. Biochem. Behav*., **34**, 37‑42 (1989).
121. "Behavioral Differentiation of Benzodiazepine Ligands After Repeated Administration in Baboons," C.A. Sannerud, J.M. Cook and R.R. Griffiths, *Eur. J. Pharmacol*., **167**, 333‑343 (1989).
122. "Total Synthesis of (±) Suaveoline," M.L. Trudell and J.M. Cook, *J. Am. Chem. Soc.*, **111**, 7504‑7507 (1989).
123. "Pictet‑Spengler Reactions in Aprotic Media. Stereospecificity in the Pictet‑Spengler Reaction," J. Sandrin, S.P. Hollinshead and J.M. Cook, *J. Org. Chem.*, **54**, 5636‑ 5640 (1989).
124. "[3,3,]Sigmatropic Rearrangements in Indoloazabicyclo[3,3,1]nonene Systems, Reversal of the Stereofacial Selectivity in the Claisen *vs*. Orthoester Claisen Rearrangement," S.P. Hollinshead, L.‑H. Zhang, M. Trudell and J.M. Cook, *J. Am. Chem. Soc*., **111**, 8263‑8265 (1989).
125. "Structural Requirements for Agonist Actions at the BzR: Studies with Analogs of ZK‑93423," S.P. Hollinshead, M.L. Trudell, P. Skolnick and J.M. Cook, *J. Med. Chem.*, **33**, 1062‑1069 (1990).
126. "Synthesis of 10,11‑Dihydroxydihydroquinidine N‑oxide, A New Metabolite of Quinidine. Preparation and Proton NMR Spectroscopy of the Metabolites of Quinine and Quinidine and Conformational Analysis *via* 2‑D COSY NMR Spectroscopy," H. Diaz‑Arauzo, D.J. Christie and J.M. Cook, *J. Nat. Prod*., **53**, 112‑124, (1990).
127. "Synthetic and Computer‑Assisted Analyses of the Pharmacophore of the Benzodiazepine Receptor Inverse Agonist Site," M.S. Allen, Y.‑C. Tan, M.L. Trudell, K. Narayanan, L.R. Schindler, M. Martin, C. Schultz, T.J. Hagen, K.F. Koehler, P.W. Codding, P. Skolnick and J.M. Cook, *J. Med. Chem.*, **33**, 2343‑2357 (1990).
128. "Synthesis of 7,12‑Dihydropyrido[3,2‑*b*:5,4‑*b*']diindoles: Rigid Planar Templates of the Inverse Agonist/Antagonist Benzodiazepine Receptor Binding Site," M.L. Trudell, Sherry Lifer, Y.‑C. Tan, M.J. Martin, Li Deng, P. Skolnick and J.M. Cook, *J. Med. Chem.*, **33**, 2412‑2420 (1990).
129. "Molecular Yardsticks: Synthesis of Higher Homologs of 7,12‑Dihydropyrido-[3,4‑b:5,4‑b']diindole. Probing the Dimensions of the Benzodiazepine Receptor Inverse Agonist Site," K. Narayanan and J.M. Cook, *Heterocycles*, **31**, (2), 203‑209 (1990).
130. "General Approach to the Synthesis of Polyquinenes *via* the Weiss Reaction. XI. Transient Formation of *cis*‑Tetracyclo[7.2.1.04,11.06,10]dodeca‑3,5,7,9‑tetraene and Approach Toward 10,11‑Dimethyl‑*cis*‑Tetracyclo [7.2.1.04,11.06,10] dodeca‑3,5,7,9-tetraene," A.K. Gupta, K. Sambasivarao, B. Opansky and J.M. Cook, *J. Org. Chem*., **55**, 4480‑4483 (1990).
131. "General Approach to the Synthesis of Polyquinenes *via* the Weiss Reaction. II. Synthetic Approach to Pentaleno[2,1‑b:5,4‑b']diindoles," K. Sambasivarao, S.P. Hollinshead, D. Grubisha, F. Laib, D.W. Bennett, and J.M. Cook, *J. Org. Chem.*, **55**, 3858‑3866 (1990).
132. "Carboxyl‑Mediated Pictet‑Spengler Reaction. Direct Synthesis of 1,2,3,4‑Tetrahydro ß‑Carbolines from Tryptamine 2‑Carboxylic Acids," K. Narayanan and J.M. Cook, *Tetrahedron Lett*., **31**, 3397‑3400 (1990).
133. "General Approach to the Synthesis of Macroline‑Related Alkaloids. Stereospecific Total Synthesis of (-)-Alstonerine," L.‑H. Zhang and J.M. Cook, *J. Am. Chem. Soc*., **112**, 4088‑4090 (1990).
134. "Improved Method for Bisallylation of *cis*‑Bicyclo[3.3.0]octane‑3,7‑dione *via* the Claisen Rearrangement," K. Sambasivarao and J.M. Cook, *Org. Prep. and Procedures. International*, **22**(5), 630‑632 (1990).
135. "General Approach for the Synthesis of Polyquinenes *via* the Weiss Reaction. XII. The Chugaev Approach to Ellacene (1,10‑Cyclododecanotriquinacene). X. Fu and J.M. Cook, *Tetrahedron Lett*., **31**, 3409‑3412 (1990).
136. "General Approach for the Synthesis of Polyquinenes *via* the Weiss Reaction XIII. Aldol Approach to Fenestranes," G. Kubiak, X. Fu, A. Gupta and J.M. Cook, *Tetrahedron Lett*., **31**, 4285‑4288 (1990).
137. "Stereospecificity in the Pictet‑Spengler Reaction. Kinetic *vs*. Thermodynamic Control," L. Deng, K. Czerwinski and J.M. Cook, *Tetrahedron Lett.*, **32**, 175‑178 (1991).
138. "Carboxyl‑Mediated Pictet‑Spengler Reaction. Direct Synthesis of 1,2,3,4‑ Tetrahydro ß‑carbolines From Tryptamine‑2‑carboxylic Acids," K. Narayanan, L. Schindler and J.M. Cook, *J. Org. Chem.*, **56**, 359‑365 (1991).
139. "Inverse Agonists. Probes to Study the Structure, Topology and Function of the Benzodiazepine Receptor," J.M. Cook, H. Diaz‑Arauzo, and M.S. Allen, presented at the 52nd Annual Scientific Meeting of the Committee on Problems of Drug Dependence, Inc., June 10‑14, 1990, Richmond, Virginia. NIDA Research Monograph Series, 133‑139 (1991).
140. "General Approach for the Synthesis of Polyquinenes *via* the Weiss Reaction," A.K. Gupta, X. Fu, J.P. Snyder and J.M. Cook, Tetrahedron Report Number 291, *Tetrahedron*, **47**, 3665‑3720 (1991).
141. "Synthetic and Computer Assisted Analysis of the Pharmacophore for Agonists at Benzodiazepine Receptors," H. Diaz‑Arauzo, K. Koehler, T. Hagen and J.M. Cook, *Life Sci*., **49**, 207‑216 (1991).
142. "The Agonist Pharmacophore of the Benzodiazepine Receptor. Synthesis of a Selective Anticonvulsant/Anxiolytic," H. Diaz‑Arauzo, G. Evoniuk, P. Skolnick and J.M. Cook, *J. Med. Chem.*, **34**, 1754‑1756 (1991).
143. "Structure of 2‑Chloro‑7,12‑dihydropyrido[3,2‑*b*:5,4‑*b*']diindole," M.B. Szkaradzinska, A. Roszak, M.L. Trudell, J.M. Cook and P.W. Codding, *Acta Crystallographica*, **C48**, 382‑384 (1991).
144. "Carboxy‑Mediated Pictet‑Spengler Reaction. Improved Synthesis of 2,3,5,6,11,11b‑ Hexahydro‑3‑OXO‑1H‑indolizino [8,7‑b]indoles from Tryptamine‑2‑Carboxylic Acids," K. Narayanan and J.M. Cook, *J. Org. Chem*., **56**, 5733‑5736 (1991).
145. "DDQ Oxidation of Ring‑A Methoxylated 11b‑Methoxycarbonyl‑2,3,5,6,11,11b‑Hexahydro‑3‑OXO‑1H‑indolizino [8,7‑b]indoles," K. Narayanan and J.M. Cook, *Heterocycles*, **32**, 2005‑2015 (1991).
146. "Behavioral Effects of Benzodiazepine Ligands in Non‑Dependent, Diazepam Dependent and Diazepam Withdrawn Baboons," C.A. Sannerud, M. Allen, J. M. Cook and R.R. Griffiths, *Eur. J. Pharmacol*., **202**, 159‑169 (1991).
147. "Pictet‑Spengler Reactions in Aprotic Media. The Total Synthesis of (±) Suaveoline," M.L. Trudell, D. Soerens, R. Weber, L. Hutchins, D. Grubisha, D. Bennett and J.M. Cook, *Tetrahedron*, **48**, 1805‑1822 (1992).
148. "Synthesis of Novel 2‑Phenyl‑2*H*‑pyrazolo[4,3‑*c*]isoquinolin‑3‑ols: Topological Comparisons with Analogues of 2‑Phenyl‑2,5‑dihydropyrazolo[4,3‑*c*]quinolin‑3(3H)‑ ones at Benzodiazepine Receptors," M.S. Allen, P. Skolnick and J.M. Cook, *J. Med. Chem.*, **35**, 368‑374 (1992).
149. "Stereospecificity in the Pictet‑Spengler Reaction. Enantiospecific Synthesis of (6S,10S) (‑)‑5‑Methyl‑9‑oxo**‑**12‑Benzyl ‑6,7,8,9,10,11‑Hexahydro‑6,10‑Imino‑5H‑cyclooct[b]indole, A Template for the Preparation of Macroline/Sarpagine Alkaloids," L.‑H. Zhang, Y. Bi, F. Yu, G. Menzia and J.M. Cook, *Heterocycles*, **34** (3), 517‑547 (1992).
150. "Punishment of Schedule‑Controlled Behavior with ß‑Carboline Injections: Antagonism and Comparisons with Other Compounds," K. Takada, J. Barrett, M.S. Allen, J.M. Cook and J.L. Katz, *J. Pharmacol. and Exp. Thera.*, **261**, 138‑145 (1992).
151. "The Synthesis of Polyquinanes and Polyquinenes *via* the Weiss Reaction," X. Fu and J.M. Cook, *Aldrich Chimica Acta*, **25**, 43‑54 (1992).
152. "Enantiospecific Total Synthesis of the Ajmaline Related Alkaloids (‑)Suaveoline, (‑)Raumacline and (‑)Nb‑Methylraumacline," X. Fu and J.M. Cook, *J. Am. Chem. Soc.*, **114**, 6910‑6912 (1992).
153. "Mechanism Driven *Trans* Stereospecificity in the Pictet Spengler Reaction. Stereospecific Formation of *Trans*‑1,2,3‑Trisubstituted‑tetrahydro ß‑Carbolines by Condensation of Nb‑Diphenylmethyl‑tryptophan Isopropyl Esters with Aldehydes," K. Czerwinski, L. Deng and J.M. Cook, *Tetrahedron Lett*., **33**, 4721‑4724 (1992).
154. "Predictive Binding of ß‑Carboline Inverse Agonists and Antagonists *via* the CoMFA/ GLOPE Approach," M.S. Allen, A. LaLoggia, L. Dorn, M.J. Martin, G. Costantino, T.J. Hagen, K. Koehler, P. Skolnick and J.M. Cook, *J. Med. Chem.*, **35**, 4001‑4010 (1992).
155. "Entry into 6‑Methoxy‑D(+)‑Tryptophans. Stereospecific Synthesis of 1‑Benzene-sulfonyl‑6‑methoxy‑D(+)‑tryptophan Ethyl Ester," M. Allen, L. Hamaker, A. LaLoggia and J.M. Cook, *Synthetic Comm.*, **22**, (14) 2077‑2102 (1992).
156. "The Agonist Pharmacophore of the Benzodiazepine Receptor. Synthesis of a Selective Anticonvulsant/Anxiolytic," H. Diaz‑Arauzo, P. Skolnick and J.M. Cook, National Institute on Drug Abuse Research Monograph Series 119, Problems of Drug Dependence 1991: Proceedings of the 53rd Annual Scientific Meeting, p. 354 (1992).
157. "General Approach for the Synthesis of Polyquinenes *via* the Weiss Reaction. XIV. Synthesis of Ellacene (1,10‑Decanotriquinacene) and Studies of the Proposed Dimerization to a Substituted Dodecahedrane," X. Fu and J.M. Cook, *J. Org. Chem*., **57**, 5121‑5128 (1992).
158. "Molecular Yardsticks. Rigid Planar Ligands to Define the Spatial Dimensions of the Benzodiazepine Receptor Binding Site," M. Martin, M.L. Trudell, H. Diaz‑Arauzo, M.S. Allen, A. LaLoggia, Li Deng, C.A. Schultz, Y.‑C. Tan, Y. Bi, K. Narayanan, L. Dorn, K. Koehler, P. Skolnick and J.M. Cook, *J. Med. Chem.*, **35**, 4105‑4117 (1992).
159. "High Pressure Raman Studies of Triquinacene and Dodecahedrane," S.H. Bertz, G.A. Kourouklis, A. Jayaraman, G. Lannoye and J.M. Cook, *Can. J. Chem*., **71**, 352‑357 (1993).
160. "The Synthesis of Macroline Related Alkaloids," Y. Bi, L. Hamaker and J.M. Cook, chapter of a book titled *Studies in Natural Products Chemistry, Bioactive Natural Products*, Part A, A.T. Rahman and F. Basha, eds., Elsevier, Amsterdam, Volume 13, pp. 383‑432 (1993).
161. "General Approach for the Synthesis of Polyquinenes *via* the Weiss Reaction XV. Synthesis of the [5.5.5.5]Fenestrane System *via* the Aldol Approach and Studies Directed Toward the [5.5.6.6]Fenestranes," X. Fu, G. Kubiak, W. Zhang, W. Han, A.K. Gupta and J.M. Cook, *Tetrahedron*, **49**, 1511‑1524 (1993).
162. "Novel Pyridodiindoles, Azadiindoles and Indolopyridoimidazoles *via* the Fischer‑ Indole Cyclization," M. Martin, L.J. Dorn and J.M. Cook, *Heterocycles*, **36**, 157‑189 (1993).
163. "Synthetic and Computer‑Assisted Analysis of the Structural Requirements for Selective, High‑Affinity Ligand Binding to Diazepam‑Insensitive Benzodiazepine Receptors," G. Wong, K.F. Koehler, P. Skolnick, Z‑Q. Gu, S. Ananthan, P. Schönholzer, W. Hunkeler, W. Zhang and J.M. Cook, *J. Med. Chem.*, **36**, 1820‑1830 (1993).
164. "General Approach to the Synthesis of the Ajmaline‑Related Alkaloids. Enantio-specific Total Synthesis of (‑)Suaveoline, (‑)Raumacline and (‑)Nb‑ Raumacline," X. Fu and J.M. Cook, *J. Org. Chem.*, **58**, 661‑672 (1993).
165. "Novel Organic Reactions in the Search for Anxioselective Anxiolytics at the Benzodiazepine Receptor," W. Zhang and J.M. Cook, in *Drug Design for Neuroscience*, Ed. by A. Kozikowski, Raven Press, New York, 87‑117 (1993).
166. "Evaluation of Substituted ß‑Carbolines as Noncompetitive Indoleamine 2,3‑Dioxy-genase Inhibitors," A.C. Peterson, A.J. La Loggia, L.K. Hamaker, R.A. Arend, P.L. Fisette, Y. Ozaki, J.A. Will, R.A. Brown and J.M. Cook, *Med. Chem. Res*, **3**, 473‑482, (1993).
167. "The Regiospecific Synthesis of Ortho Aminonaphthophenones *via* the Addition of Carbanions to Naphthoxazine‑4‑ones," W. Zhang, R.Y. Liu and J.M. Cook, *Heterocycles*, **36**, 2229‑2236 (1993).
168. "General Approach for the Synthesis of Macroline/Sarpagine Alkaloids. The Total Synthesis of (+)‑Macroline," Y. Bi and J.M. Cook, *Tetrahedron Lett*., **34**, 4501‑4504 (1993).
169. "Discriminative‑stimulus Effects of Azaspirodecanedione Anxiolytics in Baboons Trained to Discriminate ß‑Carboline‑3‑carboxylic Acid Ethyl Ester or Pentylene-tetrazole," N.A. Ator, J.M. Cook, M.S. Allen and R.R. Griffiths, *Behav. Pharmacol*., **5**, 176‑188 (1994).
170. "Epoxide Metabolite of Quinine and Inhibition of the Multidrug Resistance Pump in Human Leukemic Lymphoblasts," P. Wigler, K. Lyon, F. Patterson, A. LaLoggia, H. Diaz‑Arauzo, M. Sreenivasa Reddy and J.M. Cook, *Mol. Pharmacol*., **46**, 563‑567 (1994).
171. "Synthesis of Benzo‑Fused Benzodiazepines Employed as Probes to Study the Agonist Pharmacophore of the Benzodiazepine Receptor," W. Zhang, P. Skolnick, K. Koehler, B. Harris and J.M. Cook, *J. Med. Chem.*, **37**, 745‑757 (1994).
172. "Evaluation of Functionalized Tryptophan Derivatives and Related Compounds as Competitive Inhibitors of Indoleamine 2,3‑Dioxygenase," A.C. Peterson, M.T. Migawa, M.M. Martin, L.K. Hamaker, K.C. Czerwinski, Wei Zhang, R.A. Arend, P.L. Fisette, Y. Ozaki, J.A. Will, R.R. Brown and J.M. Cook, *Med. Chem. Res*., **4**, 531‑544 (1994).
173. "Studies on the Enantiospecific Synthesis of Oxindole Alkaloids," A. Peterson and J.M. Cook, *Tetrahedron Lett*., **35**, 2651‑2654 (1994).
174. "The Enantiospecific Synthesis of (‑)‑Alstonerine, and (+)Macroline, as Well as a Partial Synthesis of (+)Villastonine," Y. Bi, L.‑H. Zhang, L. Hamaker and J.M. Cook, *J. Am. Chem. Soc.*,**116**, 9027-9041 (1994).
175. "Facile Formation of Dihydroacepentalene Dianions from *Centro*‑Substituted Tribenzotriquinacenes with C‑C Bond Cleavage," R. Haag, D. Kuck, X. Fu, J.M. Cook and A. de Meijere, *Synlett.*, 340‑342 (1994).
176. "A Partial Synthesis of the *Alstonia* Bisindole Alkaloid Villalstonine," Y. Bi, P. LeQuesne and J.M. Cook, *Tetrahedron Lett.*, **35**, 3877‑3878 (1994).
177. "The Synthesis of Roeharmine and (‑)‑1,2,3,4‑Tetrahydroroeharmine", M.S. Reddy and J.M. Cook, *Tetrahedron Lett*., **35**, 5413‑5416 (1994).
178. "Weiss's *Endo*‑ and *Exo*‑Tetracyclo[5.5.1.02,6.010,13]tridecane‑4,8,12‑trione: Analysis of 1H‑NMR Couplings in a System of Fused 5‑Membered Rings," S.H. Bertz, W. Zhang, J.M Cook, M.D. Bruch and L. Jelinski, *Can. J. Chem.*, **72**, 1926-1932 (1994).
179. "Development of a Comprehensive Pharmacophore Model for the Benzodiazepine Receptor," W. Zhang, K. Koehler, P. Zhang and J.M. Cook, *Drug Design and Discovery*., **12**, 193-248 (1995).
180. "The Synthesis of Macroline Related Sarpagine Alkaloids," L.K. Hamaker and J.M. Cook, "Alkaloids: Chemical and Biological Perspectives," Ed. by W. Pelletier, Elsevier Science, Oxford, Vol. 9, 23-84 (1995).
181. "Structure‑Activity Relationships in Antagonist and Inverse Agonist Ligands for the Benzodiazepine Receptor," P.W. Codding, A.W. Roszak, M.B. Szaradzinska, J.M. Cook, T.J. Hagen and M.S. Allen, *Can. J. Chem*., **73**, 449-512 (1995).
182. "Dimethyl 1,3‑acetonedicarboxylate," M.R. Reddy and J.M. Cook, *Encyclopedia of Reagents for Organic Synthesis*, Ed. by L.A. Paquette, John Wiley & Sons, New York, **3**, 1989-1992 (1995).
183. "Butane‑2,3‑dione," M.R. Reddy and J.M. Cook, *Encyclopedia of Reagents for Organic Synthesis*, Ed. by L.A. Paquette, John Wiley & Sons, New York, **2**, 817-819 (1995).
184. "Glyoxylic acid," M.R. Reddy and J.M. Cook, *Encyclopedia of Reagents for Organic Synthesis*, Ed. by L.A. Paquette, John Wiley & Sons, New York, **4**, 2620-2622 (1995).
185. "Glyoxal," M.R. Reddy and J.M. Cook, *Encyclopedia of Reagents for Organic Synthesis*, Ed. by L.A. Paquette, John Wiley & Sons, New York, **4**, 2616-2618 (1995).
186. "The Synthesis of 5‑Thienyl and ‑Furyl Substituted Benzodiazepines Employed as Probes of the Agonist Pharmacophore of Benzodiazepine Receptors," W. Zhang, R. Liu, Qi Huang, B. Harris, P. Skolnick and J.M. Cook, *Eur. J. Med Chem.*, **30**, 483-496 (1995).
187. "Synthesis and SAR Study of Novel Imidazobenzodiazepines at 'Diazepam‑insensitive' Benzodiazepine Receptors," P. Zhang, W. Zhang, R. Liu, B. Harris, P. Skolnick and J.M. Cook, *J. Med. Chem.*, **38**, 1679-1688 (1995).
188. "Studies Directed Toward the Enantiospecific Synthesis of *Gardeneria, Voacanga*, and *Alstonia* Oxindole Alkaloids," A.C. Peterson and J.M. Cook, *J. Org. Chem*., **60**, 120 (1995).
189. "Regiospecific Bromination of 3-Methylindoles with N-Bromosuccinimide," P. Zhang, R. Liu and J.M. Cook, *Tetrahedron Lett.*, **36**, 3103-3106 (1995).
190. "Enantiospecific Synthesis of 5-Methoxy-D(+)- or L(‑) Tryptophan," P. Zhang and J.M. Cook, *Syn. Commun.*, **25**, 3883-3900 (1995).
191. "The Pictet Spengler Condensation: New Directions for an Old Reaction," E. Cox and J.M. Cook, *Chem. Rev.*, **95**, 1797-1842 (1995).
192. "Synthesis of Novel Imidazobenzodiazepines Selective for the α5β2γ2 (Bz5) GABAA/ Benzodiazepine Receptor Subtype," R. Liu, P. Zhang, R. McKernan, K. Wafford, and J.M. Cook, *Med. Chem. Res.*, **5**, 700-709 (1995).
193. "Studies of Novel Imidazobenzodiazepine Ligands at GABAA/BzR Subtypes: Effect of C(3) Substituents on Receptor Site Selectivity," P.W. Zhang, R. Liu, R. McKernan, K. Wafford and J.M. Cook, *Med. Chem. Res.*, **5**, 487-495 (1995).
194. "A Successful Acid Promoted Asymmetric Pictet-Spengler Reaction of Na-BOC Protected Tryptophans. Effect of the BOC Group on Reactivity and Stereoselectivity," P.W. Zhang and J.M. Cook, *Tetrahedron Lett*., **36**, 6999-7002 (1995).
195. "Bz1 Receptor Subtype Specific Ligands. Synthesis and Biological Properties of ßCCt, A Bz1 Receptor Subtype Specific Antagonist," E. Cox, T. Hagen, R. McKernan and J.M. Cook, *Med. Chem. Res.,* 5, 710-718 (1995).
196. "An Enantiospecific Synthesis of L ‑ and D -6-chloro-5-hydroxytryptophan: An Unusual Amino Acid Residue from the Cyclic Hexapeptide Keramamide A," P. Zhang, R. Liu and J.M. Cook, *Tetrahedron Lett.*, **36**, 7411-7414 (1995).
197. "A Concise Synthesis of Optically Active 2-Bromotryptophan Amino Acids Present in Konbamide and Jaspamide *via* a Regiospecific Bromination Procedure," P. Zhang, R. Liu and J.M. Cook, *Tetrahedron Lett.*, **36**, 9133-9136 (1995).
198. "Chemical and Computer‑Assisted Development of An Inclusive Pharmacophore for the Benzodiazepine Receptor. The Inclusive Pharmacophore," W. Zhang, K. Koehler, H. Diaz‑Arauzo, M. Allen and J.M. Cook, in *Studies in Medicinal Chemistry*, Vol 2, Biological Inhibitors, M. Iqbal Choudhary, (Ed.), Harwood Academic Publishers, 303-373 (1996).
199. "Stereochemical Control of the Pictet-Spengler Reaction in the Synthesis of Natural Products,"K. Czerwinski and J.M. Cook, in *Advances in Heterocyclic Natural Product Synthesis*, W. Pearson (Ed.), JAI Press, Greenwich, Vol. 3, 217-277 (1996).
200. "Synthesis and Pharmacological Properties of Novel 8-Substituted Imidazobenzo-diazepines: High Affinity, Selective Probes for α5 Containing GABAA Receptors," R. Liu, R. Hu, P. Zhang, Phil Skolnick and J.M. Cook, *J. Med. Chem.*, **39**, 1928-1934 (1996).
201. "General Approach for the Synthesis of Macroline/Sarpagine Related Indole Alkaloids *via* The Asymmetric Pictet-Spengler Reaction: The Enantiospecific Synthesis of (-)- Anhydromacrosalhine-methine," T. Gan and J.M. Cook, *Tetrahedron Lett*., **37**, 5033-5036 (1996).
202. "Partial Synthesis of The Antiamoebic Bisindole Alkaloid (-)-Macrocarpamine," T. Gan and J.M. Cook, *Tetrahedron Lett*., **37**, 5037-5038 (1996).
203. "Benzo-fused Benzodiazepines Employed as Topological Probes for the Study of Benzodiazepine Receptor Subtypes" Qi Huang, W. Zhang, R. Liu, R. McKernan and J.M. Cook, *Med. Chem. Res.*, **6**, 384-391 (1996).
204. “Generation of Four Five-membered Rings in a One Pot Process. Studies Directed Toward The Synthesis of Dicyclopenta[a,d]pentalene via The Tadem Pauson-Khand Reaction,” S. Van Ornum and J.M. Cook, T*etrahedron Lett*., **37**, 7185-7188 (1996).
205. “Evidence for C(1)-N(2) Bond Scission in the Isomerization of cis-Nb-Benzyl-1, 3-Disubstituted -1,2,3,4-Tetrahydro β-carbolines into Their Trans-Nb-Benzyl-1,3- Disubstituted Diastereomers Under Acidic Conditions,” E.Cox, J. Li, L. Hamaker, P. Yu, and J.M. Cook, *Chem. Commun*., 2477-2478 (1996).
206. "Enantiospecific Formation of *trans*-1,3-Disubstituted Tetrahydro ß-Carbolines by the Pictet-Spengler Reaction and Conversion of *cis* Diastereomers into their *Trans* Counterparts by Scission of the C1/N2 Bond," E. Cox, L. Hamaker, J. Li, P. Yu, K. Czerwinski, L. Deng, D.W. Bennett, W. Watson, M. Krawiec and J.M. Cook, *J. Org. Chem.*, **62**, 44-61 (1997).
207. "Evidence for the Conservation of Conformational Topography at Five Major GABAA/Benzodiazepine Receptor Subsites. Potent Affinities of The (S)-Enantiomers of Framework Constrained 4,5-Substituted Pyrroloimidazobenzodiazepines," R. Liu, P. Zhang, T. Gan, R. McKernan and J.M. Cook, *Med. Chem. Res.*, **7**, 25-35 (1997).
208. “Effect of β-Carboline-3-Carboxylate-t-Butyl Ester on Ventilatory Control,” H. Greenberg, M. Scharf, W. Mendelson, J.M. Cook, E. Cox and S. Scharf, *Life Sci*., **60**, 485-492 (1997).
209. “Enantiospecific Total Synthesis of Tryprostatin A,” T. Gan and J.M. Cook, *Tetrahedron Lett.*, **38**, 1301-1304 (1997).
210. “Unexpected Stereoselectivity in The Weiss-Cook Condensation of Dimethyl 1,3-Acetonedcarboxylate with 2,3-Pentanedione”, R. V. Williams, V. Gadgil, A. Vig, J. Cook, G. Kubiak and Q. Huang, *Perkin Trans I*., 1425-1428 (1997).
211. “Mode of Action of β-Carboline Convulants on the Insect Nervous System and Their Poetential as Insecticides.” J. Bloomquist, H. Ferguson, E. Cox, M. Reddy, J.M. Cook. *Pesticide Science*, **51,** 1-6 (1997).
212. “Steric and Electronic Effects on The Weiss Reaction. Isolation of 1:1 Adducts,” S. Van Ornum, G. Kubiak and J.M. Cook, *Perkin Trans I.*, 3471-3478 (1997).
213. “Formation of Six Carbon-Carbon Bonds in a One Pot Process. Generation of the Dicyclopenta[a,e]pentalene Ring system *via* The Tandem Pauson-Khand Reaction,” S. G. Van Ornum and J. M. Cook, *Tetrahedron Lett*., **38**, 3657-3658 (1997).
214. “[3H]RY-080: A High Affinity, Selective Ligand for GABAA Receptors Containing α5 Subunits,” P. Skolnick, R. Hu, C. Cook, S. Hunt, J. Trometer, R. Liu, Qi Huang and J.M. Cook, *J. Pharm. Exper*. *Thera*., **283**, 488-493 (1997).
215. “Synthesis of GABAA Active Ligands by the Stille Process,” T. Gan, S.G. Van Ornum and J.M. Cook, *Tetrahedron Lett*., **38,** 8453-8456 (1997).
216. “General Approach for the Synthesis of Macroline/Sarpagine Related Indole Alkaloids via the Asymmetric Pictet-Spengler Reaction: The Enantiospecific Synthesis of the Na-H, Azabicyclo[3.3.1]Nonane Template,” P. Yu, T. Wang, F. Yu and J.M. Cook, *Tetrahedron Lett*., **38**, 6819-6822 (1997).
217. “Regiospecific Bromination 3-Methylindoles with NBS and Its Application to the Concise Synthesis of Optically Active Unusual Tryptophans Present in Marine Cyclic Peptides,” R.Liu, P. Zhang, T. Gan and J.M. Cook, *J. Org. Chem*., **62**, 7447-7456 (1997).
218. “Diastereospecific Synthesis of Ketooxindoles. Potential Intermediates for the Synthesis of Alstonisine as well as for Voachalotine Related Oxindole Alkaloids,” P. Yu and J. M. Cook, *Tetrahedron Lett*., 8799-8802 (1997).
219. “Conservation of Conformational Topography at Five GABAA/Benzodiazepine Receptor Subtypes,” X. He, T. Gan and J.M. Cook, NIDA Research Monograph Series, Number 178, Problems of Drug Dependence 1997: Proceedings of the 59th Annual Scientific Meeting, p. 72 (1998).
220. “Enantiospecific Total Synthesis of (-)-Anhydromacrosalhine-methine and Partial Synthesis of the Antiamoebic Bisindole Alkaloid, (-)-Macrocarpamine,” T. Gan and J.M. Cook, *J. Org. Chem*., **63**, 1478-1483 (1998).
221. “Synthesis and Evaluation of Analogues of the Partial Agonist 6-(Propyloxy)-4-(methoxymethyl)-βcarboline-3-carboxylic Acid Ethyl Ester (6-PBC) & the Full Agonist 6-(Benzyloxy)-4-(methoxymethyl)-βcarboline-3- carboxylic Acid Ethyl Ester (ZK-93423) at BzR sites” Eric D. Cox, Hernando Diaz-Arauzo, Q. Huang, M. Reddy, B. Harris, R. McKernan, P. Skolnick, and J.M. Cook. *J. Med. Chem*., **41**, 2537-2552 (1998).
222. “GABAA - Benzodiazepine Receptors in the Striatum Are involved in the Sedation Produced by a Moderate, but Not an Intoxicating Ethanol Dose in Outbred Wistar Rats,” H. June, S. H. Chen, G. Cheatem, R. Liu, T. Gan and J.M. Cook. *Brain Research*, **794**, 103-118 (1998).
223. “Enantiospecific Total Synthesis of (+)-Ajmaline and Alkaloid G *via* the Asymmetric Pictet-Spengler Reaction,” J. Li and J.M. Cook, *J. Org. Chem.*, **63**, 4166-4167 (1998).
224. “Enantiospecific Synthesis of Optically Active 6-Methoxytryptophan Derivatives and Total Synthesis of Tryprostatin A,” T. Gan, R. Liu, P. Yu., S. Zhao and J.M. Cook, *J. Org. Chem*., **62**, 9298-9304 (1998).
225. “Predictive Models for GABAA/Benzodiazepine Receptor Subtypes: Studies of Quantitative Structure-Activity Relationships (QSAR) for Imidazobenzodiazepines at Five Recombinant GABAA/BzR Subtypes [αxβ3γ2(x=1-3,5,6] *via* CoMFA,” Q. Huang, R. Liu, P. Zhang, R. McKernan, D. Bennett, T. Gan, X. He and J.M. Cook,” *J. Med. Chem*., **41**, 4130-4142 (1998).
226. “The Enantiospecific Total Synthesis of Norsuaveoline,” T. Wang, P. Yu, J. Li and J.M. Cook, *Tetrahedron Lett.*, **39,** 8009-8012 (1998).
227. “Total Synthesis of Trypostatin A and B as Well as Their Enantiomers,” S. Zhao, T. Gan, Peng Yu and J.M. Cook, *Tetrahedron Lett*., **39**, 7009-7012 (1998).
228. “The Livinghouse Catalytic Approach to the Tandem Pauson-Khand Reaction. Entry into the Parent Ring Systems of Dicyclopenta[a,f]pentalene and Dicyclopenta[a,e]pentalene, S. Van Ornum, M. Bruendl and J.M. Cook, *Tetrahedron Lett*., **39**, 6649-6650 (1998).
229. “Identification of Quinine Metabolites in Urine After Oral Dosing in Humans,” P. Bannon, P. Yu, J. M. Cook, L. Roy and J-P. Villeneuveo, *J. Chromatography B, Biomedical Science and Applications*, **715**, 387-393 (1998).
230. “Enantiospecific Total Synthesis of the Sarpagine Related Indole Alkaloids Talpinine and Talcarpine. The Oxyanion Cope Approach.” P. Yu and J.M. Cook, *J. Org*. *Chem.*, **63**, 9160-9161 (1999).
231. “General Approach for the Synthesis of Ajmaline/ Sarpagine Indole Alkaloids. Enantiospecific Total Synthesis of (+) Ajmaline, Alkaloid G, and Novsuaveoline *via* the Asymmetric Pictet-Spengler Reaction,” J. Li, T. Wang, P. Yu, A. Peterson, D. Soerens, R. Weber, D. Grubisha, D. Bennett, and J. M. Cook, *J Am. Chem. Soc*., **121**, 6998-7010 (1999).
232. “Studies of Molecular Pharmacophore/Receptor Models for GABAA/Benzodiazepine Receptor Subtypes: Binding Affinities of Substituted β-Carbolines at Recombinant αxβ3γ2 Subtypes and Quantitative Structure-Activity Relationship Studies *via* a Comparative Molecular Field Analysis,” Q. Huang, E. Cox, T. Gan, C. Ma, D. Bennett, Ruth McKernan and James M. Cook, *Drug Des. Disc.*, **16**, 55-76, (1999).
233. “Concise Synthesis of Optically Active Ring-A Substituted Tryptophans,” C. Ma., X. Liu, S. Yu, S. Zhao and J.M. Cook, *Tetrahedron Lett*., **40**, 657-660 (1999).
234. “Exploration of Regions L2 and LD1 of Pharmacophore/Receptor Models for GABAA/ BzR Subtypes, Problems of Drug Dependence, 1998: Proceedings of the 60th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc., ed. Louis Harris, *NIDA Research Monograph*, **179**, 303 (1999).
235. “Extension of the Tandem Pauson-Khand Reaction to [5.6.6.5]Tetracycles: A Unique Entry into *cis*-Fused Decalins,” M. Bruendl, S. Van Ornum, Tze-Ming Chan and J.M. Cook, *Tetrahedron Lett*., **40**, 1113-1116 (1999).
236. "Studies in the Search for α5 Subtype Selective Agonists for GABAA/BzR Sites," S. Yu, C. Ma, X. He, R. McKernan, and J.M. Cook, *Med. Chem. Res.*, **9**, 71-88 (1999).
237. "Studies in Search of α2 Selective Ligands for GABAA/BzR Receptor Subtypes. Part 1. Evidence for the Conservation of Pharmacophoric Descriptors for DS Subtypes," S. Yu, X. He, C. Ma, R. McKernan , and J.M. Cook, *Med. Chem. Res.*, **9**, 186-202, (1999).
238. "Studies of Molecular Pharmacophore/Receptor Models for GABAA/BzR Subtypes: Binding Affinities of Symmetrically Substituted Pyrazolo[4,3-c]quinolin-3-ones at Recombinant αxβ3γ2 Subtypes and Quantitative Structure-Activity Relationship Studies via Comparative Molecular Field Analysis," X. He, Q. Huang, S.Yu, C. Ma, R. McKernan, and J.M. Cook, *Drug Des. Disc.*, **16**, 77-91, (1999).
239. "Effect of the Leaving Group on Alkylation Diastereoselectivity of the Schöllkopf Chiral Auxillary," C. Ma, X. He, X. Liu, S. Yu, S. Zhao, and J.M. Cook, *Tetrahedron Lett.*, **40**, 2917-2918 (1999).
240. “Pharmacophore/Receptor Models for GABAA/BzR Subtypes (α1β3γ2, α5β3γ2, and α6β3γ2) via a Comprehensive Ligand-Mapping Approach,” Qi Huang, X. He, C. Ma, R. Liu, S. Yu, R. McKernan, G. Wenger, C. Dayer, and J. M.Cook, *J. Med. Chem.*, **43**, 71-95 (2000).
241. “Efficient Asymmetric Synthesis of Important Tryptophan Analogues for Biological Research via the Schöllkopf Chiral Auxillary,” C. Ma, S. Yu, X. He, X. Liu, and J.M. Cook, *Tetrahedron Lett*., **41**,2781-2785 (2000).
242. “Enantiospecific Total Synthesis of the Sarpagine Related Indole Alkaloids Talpinine and Talcarpine, as well as the Improved Total Synthesis of Alstonerine and Anhydromacrosalhine-methine *via* the Asymmetric Pictet-Spengler Reaction,” P. Yu, T. Wang, J. Li, and J.M. Cook, *J. Org. Chem.*, **65**, 3173-3191 (2000).
243. “Pharmacophore/Receptor Models for GABA(A)/BzR α2β3γ2, α3β3γ2, α4β3γ2 Recombinant Subtypes. Included Volume Analysis and Comparison to α1β3γ2, α5β3γ2 and α6β3γ2 Subtypes,” X. He, Q. Huang, C. Ma, S. Yu, R. McKernan, and J.M. Cook, *Drug Des. Disc.*, **17**, 131-171 (2000).
244. “General Approach for the Synthesis of Sarpagine/Ajmaline Indole Alkaloids. Stereospecific Total Synthesis of the Sarpagine Alkaloid (+)-Vellosimine,” T. Wang and J.M. Cook, *Org. Letters*, **2**, 2057-2059 (2000).
245. “The Molybdenum-Mediated Tandem Pauson-Khand Reaction. High Yield Entry into [5.5.5.5] Tetracyclic Systems,” H. Cao, S.G. Van Ornum, and J.M. Cook, *Tetrahedron Lett.*, **41**, 5313-5316 (2000).
246. "Utility of the Tandem Pauson-Khand Reaction in the Construction of Tetracycles,” S. Van Ornum, M. Bruendel, H. Cao, M. Reddy, D. Grubisha, D. Bennett, and J.M. Cook, *J. Org. Chem.*, **65**, 1957-1971 (2000).
247. “General Approach for the Synthesis of Indole Alkaloids *via* the Asymmetric Pictet- Spengler Reaction. First Enantiospectific Total Synthesis of (-)-Corynantheidine as well as the Enantiospecific Total Synthesis of (-)-Corynantheidol (-)-Geissoschizol, and (+)-Geissoschizine,” S. Yu, M. Berner, and J.M. Cook, *J. Am. Chem. Soc.*, **122**, 7827-7828 (2000).
248. “Enantiospecific Total Synthesis of the Enantiomer of the Indole Alkaloid Affinisine,” X. Liu, T. Wang, Q. Xu, C. Ma, and J.M. Cook, *Tetrahedron Lett*., **41**, 6299-6303 (2000).
249. “Determinants of Recognition of Ligands Binding to Benzodiazepine Receptor/GABAA Receptors Initiating Sedation,” D.L. Harris, T.M. DeLorey, X. He, J.M. Cook, and G.H. Loew, *Eur. J. Pharmacol.*, **401**, 271-287 (2000).
250. “A Single Amino Acid Residue on the α5 Subunit (Ile215) Is Essential for Ligand Selectivity at α5β3γ2 GABA(A) Receptors,” M. Strakhova, S. Harvey, C. Cook, J.M. Cook, and P. Skolnick, *Mol. Pharmacol*, **58**, 1434-1440 (2000).
251. “Simultaneous Determination of Quinine and Four Metabolites in Plasma and Urine Using High Performance Liquid Chromatography,” Rajaa Mirghani, Orjan Ericsson, J. Cook, P. Yu, and Lars Gustafsson, *J. of Chromatography, B*., **754(1)**, 57-64 (2001).
252. “Stereocontrolled Total Synthesis of Alkaloid G *via* the Oxy-anion Cope Rearrangement and Improved Total Synthesis of (+)-Ajmaline,” T. Wang, Q. Xu, P. Yu, X. Liu, and J.M. Cook, *Org. Lett.*, **3**(3), 345-348 (2001).
253. “Stereocontrolled Conversion of Quinine into 10(R), 11 Dihydroxydihyroquinine *via* the Sharpless Osmylation Process,” T. Zheng, Judy Flippen-Anderson, T. Wang, P. Yu, R. Mirghani, and J.M. Cook, *J. Org. Chem.*, **66**, 1509-1511 (2001).
254. “Efficient Asymmetric Synthesis of Biologically Important Tryptophan Analogues *via* a Palladium Heteroannulation Reaction,” C. Ma, X. Liu, X. Li, J. Flippen-Anderson, S.Yu, and J.M. Cook, *J. Org. Chem*., **66**, 4525-4542 (2001).
255. “Model of the BzR Binding Site: Correlation of Data From Site-Directed Mutagenesis and the Pharmacophore/Receptor Model,” X. He, C. Zhang, and J.M. Cook, *Med. Chem. Res.*, **10**, 269-308 (2001).
256. “GABA(A)-Receptors Containing α5 Subunits In the CA1 and CA3 Hippocampal Fields Regulate Ethanol-Motivated Behaviors: An Extended Ethanol Reward Circuitry,” H. June, P. Mc Kay, S. Harvey, K. Foster, M. Garcia, D. Mason, R.Cummings, C. Grey, S. Mc Cane, L. Williams, T. Johnson, X. He, S. Rock, and J.M. Cook, *J. Neurosci.*, **21**, 2166-2177 (2001).
257. “Zolpidem, Triazolam and Diazepam Decrease Distress Vocalizations in Mouse Pups: Differential Antagonism by Flumazenil and β-Carboline-3-carboxylate-*t*-butyl Ester (βCCt),” J. Rowlett, W. Tornatzky, J.M. Cook, C. Ma, and K. Miczek, *J. Pharmacol. Exp. Ther*., **297**,247-253 (2001).
258. “Different Types of GABAA  Receptors May Mediate the Anticonflict and Response Rate-decreasing Effects of Zaleplon, Zolpidem and Midazolam in Squirrel Monkeys,” C. Parnois, E. Cox, J.M. Cook, and J. Bergman, *Psychopharmacology*, **156**, 461-468, (2001).
259. “Influence of Benzodiazepine Binding Site Ligands on Fear-Conditioned Contextual Memory,” T. M. DeLorey, R. Lin, B. McBrady, X. He, J. M. Cook, J.Lameh, G. Loew, *Eur. J. Pharmacol.*, **426**, 45-54 (2001).
260. “Differential Sensitivity to Inverse Agonists of GABAA/benzodiazepine Receptors in Rats with Genetic Absence-Epilepsy,” M. Vergnes, A. Boehler, X. He, H. Greney, M. Dontenwill, J.M. Cook, and C. Marescauk, *Epilepsy Res.*, **47**, 43-53, (2001).
261. “Differential Role of GABAA/Benzodiazepine Receptors Containing α1 and α5 Subunits in the Discriminative Stimulus Effects of Triazolam in Squirrel Monkeys,” S. Lelas, J. Rowlett, R. Spealman, J. Cook, C. Ma, X. Li, and W. Yin, *Psychopharmacology*, **161**, 180-188 (2002).
262. “Enantiospecific, Stereospecific Total Synthesis of (+)-Majvinine, (+)-10-Methoxyaffinisine and (+)-*N*a-Methylsarpagine as well as the Total Synthesis of the *Alstonia* Bisindole Macralstonidine,” S. Zhao, X. Liao, and J.M. Cook, *Org. Lett.*, **4**, 687-690 (2002).
263. “Selective Antagonism of the Ataxic Effects of Zolpidem and Triazolam by the GABA(A)/1-Preferring Antagonist β-CCt in Squirrel Monkeys,” D. Platt, J. Rowlett, R. Spealman, J.M. Cook and Chunrong Ma, *Psychopharmacology*, **164**, 151-159 (2002).
264. “General Approach for the Synthesis of Sarpagine/Macroline Indole Alkaloids. Enantiospecific Total Synthesis of the Indole Alkaloid Trinervine,” Xiaoxiang Liu and James M. Cook, *Org. Lett.*, **3**, 4023-4026 (2002).
265. “Enantiospecific Total Synthesis of the Enantiomer of the Indole Alkaloid Intermediate Macroline,” Xiaoxiang Liu, Chunchun Zhang, Xuebin Liao, and James M. Cook, *Tetrahedron Letters*, **43**, 7373-7377 (2002).
266. “Discriminative Stimulus Effects of Benzodiazepine (BZ)1 Receptor-selective Ligands in Rhesus Monkeys,” L.R. McMahon,L.R. Gerak, L. Carter, C. Ma, J.M. Cook, and C.P. France, *J. Pharmacol. Exp. Ther*., **300**, 505-512, (2002).
267. “Biological Activity of the Tryprostatins,” S. Zhao, K. Smith, A. Deveau, C. Dieckhaus, M. Johnson, T.L. McDonald, and J.M. Cook, *J. Med. Chem.*, **45**, 1559-1562 (2002).
268. "The GABAA Receptor α1 Subtype in the Ventral Pallidum Regulates Alcohol-Seeking Behaviors," S. Harvey,, K. Foster,P. McKay, M. Carroll, R. Seyoum, J.E. Woods II, C. Grey, C. Jones S. McCane, R. Cummings, D. Mason, C. Ma, J.M. Cook, and H. June *J. Neuroscience*, **22**, 3765-3775 (2002).
269. “Effects of Hippocampal Injections of a Novel Ligand Selective for the α5β2γ2 Subunits of the GABA/Benzodiazepine Receptor on Pavlovian Conditioning,” D.Bailey, J. Tetzlaff, J.M. Cook, X. He, and F. Helmstetter, *Neurobiology of Learning and Memory*, **58**, 1-10 (2002).
270. “Enzyme Kinetics for the Formation of 3-Hydroxyquinine and Three New Metabolites of Quinine in Vitro; 3-Hydroxylation by CYP3A4 is Indeed the Major Metabolic Pathway,” R.A. Mirghani, U. Yasar, T. Zheng, J.M. Cook, L.L. Gustafsson, G. Tybring, and O. Ericsson, *Drug Metab. Dispos*., **30**, 1368-1371 (2002).
271. “The Enantiospecific, Stereospecific Total Synthesis of the Oxindole Alkaloid Alstonisine,” X.Z. Wearing and J.M. Cook, *Org. Lett*., **4**, 4237-4240 (2002).
272. “Regiospecific, Enantiospecific Total Synthesis of the Alkoxy-Substituted Indole Bases, 16-*epi*-Na-Methygardneral, 11-Methoxyaffinisine, and 11-Methoxymacroline as Well as the Indole Alkaloids Alstophylline and Macralstonine,” Xiaoxiang Liu and James M. Cook, *Org. Lett.*, **4**, 3339-3342 (2002).
273. “Stereospecific Enantiospecific Total Synthesis of the Sarpagine Indole Alkaloids (E)16-Epiaffinisine, E(16)-Epinormacusine B and Dehydro-16-epiaffinisine,” J.Yu, X. Liao, and J.M. Cook, *Org. Letters*, **4**, 4681-4684 (2002).
274. “General Approach for the Total Synthesis of the Sarpagine-related Indole Alkaloids(+)-Na-Methyl-16-Epipericyclivine, (-)-Alkaloid Q3 and (-)-Panarine *via* the Asymmetric Pictet-Spengler Reaction,” Jianming Yu, Xiangyu Wearing, and James M. Cook, *Tetrahedron Lett.*, **44**, 543-547 (2003).
275. “Discriminative Stimulus Effects of a High Dose of Zolpidem in Squirrel Monkeys: Evidence for a Primary Role of GABA(A)/α1 Receptors,” J.K Rowlett, R. Spealman, S. Lelas, J.M. Cook, and W. Yin, *Psychopharmacology*, **165**, 209-215 (2003).
276. “The Enantiospecific, Stereospecific Total Synthesis of the Ring-A Oxygenated Sarpagine Indole Alkaloids (+)-Majvinine, (+)-10-Methoxyaffinisine and (+)-*N*a–Methylsarpagine as well as the First Total Synthesis of the *Alstonia* Bisindole Alkaloid Macralstonidine,” S. Zhao, X. Liao, T. Wang, J. Flippen-Anderson , and J.M. Cook, *J. Org. Chem.,* **68**, 6279-6295 (2003).
277. “The Reinforcing Properties of Alcohol are Mediated By GABA(A1) Receptors in the Ventral Pallidum,” H. June. K. Foster, P. McKay, M. Carroll, J. E. Woods II, Scott C. Harvey, Regat Seyoum, William J. H. Eiler II, Collette Grey, Shannon McCane, Cecily Jones, W. Yin, D. Mason, R. Cummings, M. Garcia, C. Ma, P.V.V.S. Sarma, James M. Cook, and P. Skolnick, *Neuropsychopharmacology*, **28**, 2124-2137 (2003).
278. “The Synthesis of a Dicyclopenta[a,e]pentalene *via* a Molybdenum Hexacarbonyl-Mediated Tandem Allenic Pauson-Khand Reaction,” H. Cao, J. Flippen-Anderson, and J.M. Cook, *J. Am. Chem. Soc.*, **125**, 3230-3231 (2003).
279. “Studies on the Rh and Ir-Mediated Tandem Pauson-Khand Reaction. A New Entry into the Dicyclopenta [*a,d*] cyclooctene Ring System,” H. Cao, S. R. Mundla, and J.M. Cook, *Tetrahedron Lett.*, **44**, 6165-6168 (2003).
280. “General Approach for the Synthesis of Sarpagine Indole Alkaloids. Enantiospecific Total Synthesis of (+)-Vellosimine, (+)-Normacusine B, (-)-Alkaloid Q3, (-)-Panarine, (+)-*N*a-Methylvellosimine, and (+)*N*a-Methyl-16-epipericyclivine, J. Yu, T. Wang, X. Liu, J. Deschamps, J. Flippen-Anderson, X. Liao, and J.M. Cook, *J. Org. Chem*., **68**, 7565-7581 (2003).
281. “Studies in Search of Diazepam-Insensitive Subtype Selective Agents for GABAA/Bz Receptors,” X. Li, C. Ma, X. He, J. Yu, D. Han, C. Zhang, J. Atack, and J.M. Cook, *Med. Chem. Res.*, **9**, 504-537 (2003).
282. “The First Enantiospecific Synthesis of (-)-Koumidine *via* the Intramolecular Palladium-catalyed Enolate Driven Cross Coupling Reaction. The Stereospecific Introduction of the 19-(*Z*) Ethylidene Side Chain,” Hui Cao, Jianming Yu, Xiangyu Z. Wearing, Chunchun Zhang, Xiaoxiang Lui, Jeffery Deschamps, and James M. Cook, *Tetrahedron Lett*., **44**, 8013-8017, (2003).
283. “Synthesis, in Vitro Affinity, and Efficacy of a Bis 8-Ethynyl-4*H*-imidazo[1,5*a*]-[1,4]benzodiazepine Analogue, the First Bivalent α5 Subtype Selective BzR/GABAA Antagonist”, Li, X.; Cao, H.; Zhang, C.; Furtmueller, R.; Fuchs, K.; Huck, S.; Sieghart, W.; Deschamps, J.; Cook, J.M., *J. Med. Chem*., **46**, 5567-5570 (2003).
284. “Enantiospecific Total Synthesis of (-)-(E)-Epiaffinisine, (+)-E(16)-Epinormacusine B, and (+)-Dehydro-16-epiaffinisine as well as the Stereocontrolled Total Synthesis of Alkaloid G,” J. Yu, T. Wang, X. Wearing, J. Ma, and James M. Cook, *J. Org. Chem.*, **68**, 5852-5859 (2003).
285. “Regiospecific, Enantiospecific Total Synthesis of the 12-Alkoxy-Substituted Indole Alkaloids, (+)-12-Methoxy-*N*a-methylvellosimine, (+)-12-Methoxyaffinisine, and (-)-Fuchsiaefoline”, Hao Zhou, Xuebin Liao, and James M. Cook, *Org. Lett*., **6**, 249-252, (2004).
286. “GABAA and Opioid Receptors of the Central Nucleus of the Amygdala Selectively Regulate Ethanol-Maintained Behaviors,” K. Foster, P. McKay, R. Seyoum, D. Milbourne, W. Yin, P.V.V.S. Sarma, J.M. Cook, and H. June, *Neuropsychopharmacology*, **29**, 269-284 (2004).
287. “Stereocontrolled Total Synthesis of (-)-Vincamajinine and (-)-11-Methoxy-17-epivin-camajine,” Jianming Yu, Xiangyu Wearing, and J.M. Cook, *J. Am. Chem. Soc*., **126**, 1358-1359 (2004).
288. “RY 023: A Selective High Affinity Ligand for GABA(A)-Receptor Containing α5 Subunit Attenuates Ethanol-Maintained Responding Following Systemic and Microinjection Into the CA1 and CA3 Hippocampal Fields,” S. Harvey, K. Foster, P. Mc Kay, M. Garcia, D. Mason, R. Cummings, C. Grey, S. McCane, X. He, J.M. Cook, and H.L. June, submitted.
289. “GABAA/α1 Receptor Agonists and Antagonists: Effects on Species-typical and Heightened Aggressive Behavior After Alcohol Self-Administration in Mice,” R. Almeida, J.K. Rowlett, J.M. Cook, W. Yin, and K. Miczek, *Psychopharmacology*, **172**, 255-263 (2004).
290. “A High Affinity Ligand for GABA(A)-Receptor Containing α5 Subunit Antagonizes Ethanols Neurobehavioral Effects in Long-Evans Rats,”, P. McKay, K. Foster, D. Mason, R. Cummings, M. Garcia, L. Williams, C. Grey, *S. McCane, X. He, J.M. Cook and H.L. June, Psychopharmacology, 172, 455-462 (2004).*
291. “Determination of the Stable Conformation of GABA(A)-Benzodiazepine Receptor Bivalent Ligands by Low Temperature NMR and X-ray Analysis,” D. Han, F.H. Försterling, X. Li, J. Deschamps, H. Cao and J.M. Cook, *Bioorg. Med. Chem. Lett*., **14**, 1465-1469 (2004).
292. “The First Enantiospecific Total Synthesis of a C-quaternary Voachalotine Alkaloid, (+)-Dehydrovoachatoline,” J. Yu, A. Wearing, and J.M. Cook, *Tetrahedron Lett.*, **45**, 3937-3940 (2004).
293. “Bartoli Indole Synthesis, in Name Reactions in Heterocyclic Chemistry” J. Li, J. M. Cook; J. J. Li, Ed.; John Wiley & Sons: Hoboken, NJ, pp. 100-103 (2004).
294. “Batcho-Leimgruber Indole Synthesis, in Name Reactions in Heterocyclic Chemistry” J. Li; J. M. Cook; J. J. Li, Ed.; John Wiley & Sons: Hoboken, NJ, pp. 104-109 (2004).
295. “Fischer Indole Synthesis, in Name Reactions in Heterocyclic Chemistry” J. Li, J. M. Cook; J. J. Li, Ed.; John Wiley & Sons: Hoboken, NJ, pp. 116-127 (2004).
296. “Gassman Indole Synthesis, in Name Reactions in Heterocyclic Chemistry” J. Li, J. M. Cook; J. J. Li, Ed.; John Wiley & Sons: Hoboken, NJ, pp. 128-131 (2004).
297. “Graebe-Ullmann Carbazole Synthesis, in Name Reactions in Heterocyclic Chemistry” J. Li, J. M. Cook; J. J. Li, Ed.; John Wiley & Sons: Hoboken, NJ, pp. 132-134 (2004).
298. “Madelung Indole Synthesis, in Name Reactions in Heterocyclic Chemistry” J. Li, J. M. Cook; J. J. Li, Ed.; John Wiley & Sons: Hoboken, NJ, pp. 140-144 (2004).
299. “Nenitzescu Indole Synthesis, in Name Reactions in Heterocyclic Chemistry” J. Li, J. M. Cook; J. J. Li, Ed.; John Wiley & Sons: Hoboken, NJ, pp. 144-153 (2004).
300. “Reissert Indole Synthesis, in Name Reactions in Heterocyclic Chemistry” J. Li, J. M. Cook; J. J. Li, Ed.; John Wiley & Sons: Hoboken, NJ, pp. 154-158 (2004).
301. “Pinner Pyrimidine Synthesis, in Name Reactions in Heterocyclic Chemistry” J. Li, J. M. Cook; J. J. Li, Ed.; John Wiley & Sons: Hoboken, NJ, pp. 534-537 (2004).
302. “Von Richter Cinnoline Synthesis, in Name Reactions in Heterocyclic Chemistry” J. Li, J. M. Cook; J. J. Li, Ed.; John Wiley & Sons: Hoboken, NJ, pp. 538-540 (2004).
303. "Bidirectional Effects of Benzodiazepine Binding Site Ligands in the Elevated Plus Maze: Differential Antagonism by Flumazenil and BCCt," M. Savić, D. Obradović, N. Ugrešić, J.M. Cook, W. Yin and D. Bokonjić, *Pharmacol. Biochem. Behav.*, **79**, 279-290 (2004).
304. "Development of Selective Ligands for Benzodiazepine Receptor Subtypes by Manipulating the Substituents at Positions -3 and -7 of Optically Active BzR Ligands," X. Li, J. Yu, J. Atack, and J.M. Cook, *Med. Chem. Res*, **13**, 259-281 (2004)
305. "Synthesis of Optically Active Ring-A Substituted Tryptophans as IDO Inhibitors," X. Li, W. Yin, P.V.V. S. Sarma, H. Zhao, J. Ma and J. M. Cook, *Tetrahedron Lett.*, **45**, 8569-8573 (2004).
306. “Benzodiazepines and Heightened Aggressive Behavior in Rats: Reduction by GABAA/α1 Receptor Antagonists,” S. Gourley, J.Debold, W. Yin, J. Cook, and K. Miczek, *Psychopharmacology*, **178**, 232-240 (2005).
307. "The Synthesis of Dicyclopenta[a,e]pentalenes via a Molybdenum Carbonyl-Mediated Tandem Allenic Pauson-Khand Reaction and the X-ray Crystal Structure of a Planar Dicyclopenta[a,e]pentalene," H. Cao, S. Van Ornum, J. Deschamps, J. Flippen-Anderson, F. Laib, J.M. Cook, *J. Am. Chem. Soc.*, **127**, 933-943 (2005).
308. "Bidirectional Effects of Benzodiazepine Binding Site Ligands in the Passive Avoidance Task: Differential Antagonism by Flumazenil and BCCt," M. Savic, D. Obradovic, N. Ugresic, J.M. Cook, W. Yin and D. Bokonjic, *Behavioral Brain Res.*, **158**, 293-300 (2005).
309. "A General Strategy for the Synthesis of Vincamajine-related Indole Alkaloids: Stereocontrolled Total Synthesis of (+)-Dehydrovoachalotine, (-)-Vincamajinine and (-)-11-Methoxy-17-epivincamajine, as well as the Related Alcohols, Quebrachidinediol, Vincamajinediol and Vincarinol," J. Yu, A. Wearing and J. M. Cook, *J. Org. Chem.*, **70**, 3963-3979 (2005).
310. "Bidirectional Effects of Benzodiazepine Binding Site Ligands in the Active Avoidance Acquisition and Retention: Differential Antagonism by Flumazenil and BCCt," M. Savić, D. Obradović, N. Ugrešić, J.M. Cook, P.V.V.S. Sarma and D. Bokonjić, *Psychopharm*., **180**, 455-465 (2005).
311. “Benzodiazepines and Heightened Aggressive Behavior in Rats: Reduction by GABA(A)/alpha(1) Receptor Antagonists,” S. L. Gourley, J. F. DeBold, W. Y. Yin, J. M. Cook, K. A. Miczek, *Psychopharm.*, **178**, 232-240 (2005).
312. "Contribution of α1 GABAA and α5 GABAA Receptor Subtypes to the Discriminative Stimulus Effects of Ethanol in Squirrel Monkeys" D. Platt, A. Duggan, R. Spealman, J.M. Cook, X. Li, W. Yin and J. K. Rowlett, *J. Pharm. Exp. Therapeut.*, **313**, 658-667 (2005).
313. “Contribution of GABAA Receptor Subtypes to the Anxiolytic-Like, Motor, and Discriminative Stimulus Effects of Benzodiazepines: Studies with the Functionally Selective Ligand SL651498 [6-Fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1*H*-pyridol[3,4-*b*]indol-1-one]” S. Licata, D. Platt, J.M. Cook, P.V.V.S. Sarma, G. Griebel and J. Rowlett, *J. Pharm. Exp. Therapeut.*, **313**, 1118-1125 (2005).
314. “First Regiospecific, Enantiospecific Total Synthesis of Gardnerine and Gardnutine” H. Zhou, P.V.V.S. Sarma, D. Han, J. Deschamps and J. M. Cook, *Tetrahedron Lett.*, **46**, 4219-4224 (2005).
315. “Confirmation of the Structure of (3S)-3-Hydroxyquinine: Synthesis and X-ray Crystal Structure of Its 9-Aceto Analogue” P.V.V.S. Sarma, D. Han, J. Deschamps and J. M. Cook, *J. Nat. Prod.*, **68**, 942-944 (2005).
316. “Selective Antagonism of GABAA Receptor Subtypes: An *In Vivo* Approach to Exploring the Thereapeutic and Side Effects of Benzodiazepine-Type Drugs,” J.K. Rowlett, J. M. Cook, A.N. Duke, D. M. Platt. *CNS Spectr*., **10**, 40-48 (2005).
317. “Synthesis of Bivalent Ligands of β-Carboline-3-Carboxylates Via a Palladium-Catalyzed Homocoupling Process” W. Yin, P.V.V.S. Sarma, J. Ma, D. Han, J. L. Chen and J. M. Cook, *Tetrahedron Lett.*, **46**, 6363-6368 (2005).
318. “The First Regiospecific, Enantiospecific Total Synthesis of 6-Oxoalstophylline and and Improved Total Synthesis of Alstonerine and Alstophylline as Well as the Bisindole Alkaloid Macralstonine” X. Liao, H. Zhou, X. Z. Wearing, J. Ma and J. M. Cook, *Org. Lett.*, **7**, 3501-3504 (2005).
319. “Selective GABAA α5 Benzodiazepine Inverse Agonist Antagonizes the Neurobehavioral Actions of Alcohol” J. B. Cook, K. L. Foster, W. J. A. Eiler II, P. F. McKay, J. Woods II, S. C. Harvey, M. Garcia, C. Grey, S. McCane, D. Mason, R. Cummings, X. Li, J. M. Cook and H. June, *Alcohol Clin. Exp. Res.*, **29**, 1390-1401 (2005).
320. “ABCG2 Expression, Function and Promoter Methylation in Human Multiple Myeloma,” J. G. Turner, J. L. Gump, C. C. Zhang, J. M. Cook, D. Marachion, L. Hazelhurst, P. Munster, M. J. Schell, W. S. Dalton and D. M. Sullivan, *Blood*, **108**, 3881-3889 (2006).
321. “ABCG2 Expression, Function, and Promoter Methylation in Human Multiple Myeloma,” J. Turner, J. Gump, C. Shang, J.M. Cook, D. Marchion, L.Hazlehurst, P. Munster, M. Schell, W. Dalton, and D. Sullivan, *Blood*, **108**, 3881-3889 (2006).
322. “General Approach for the Synthesis of 12-Methoxy-substituted Sarpagine Indole Alkaloids Including (-)-12-Methoxy-Nb-methylvoachalotine, (+)-12-Methoxy-Na-methylvellosimine, (+)-12-Methoxyaffinisine and (-)-Fuchsiaefoline,” H. Zhao, X. Liao, W. Yin, J. Ma and J. M. Cook, *J. Org. Chem.*, **71**, 251-259 (2006).
323. “An Improved Total Synthesis of (+)- Macroline and Alstonerine as Well as the Formal Total Synthesis of (-)- Talcarpine and (-)-Anhydromacrosalhine-methine,” X. Liao, H. Zhou, J. Yu, and J. M. Cook, *J. Org. Chem.*, **71**, 8884-8890 (2006).
324. “Enhanced Sucrose Pellet Consumption Induced by Benzodiazepine-Type Drugs in Squirrel Monkeys: Role of GABA(A) Receptor Subtypes,” A. Duke, D. Platt, J. M. Cook, S. Huang, W. Yin, B. Mattingly, and J. K. Rowlett, *Psychopharmacol. (Berlin)*, **187**, 321-330 (2006).
325. “Enantiospecific Synthesis of (+)-Na-Methyl-pericyclivine and (-)-Na-Methylakuammidine as well as the Ring-A Oxygenated Natural Products, (+)-10-Methoxy-Na-Methylpericyclivine and 10-Hydroxy-Na-Methylpericyclivine,” *Org. Lett.,* **8**, 1017-1020 (2006).
326. “Benzodiazepine Site Inverse Agonists and Locomotor Activity in Rats: Bimodal and Biphasic Influence,” M. Savic, D. Obradovio, N. Ugresic, J. M. Cook, W. Yin, M. Van Linn and D. R. Bonkonjic, *Pharmacol. Biochem. Behav.*, **84**, 35-42 (2006).
327. “Conformational Analysis of the *Cis* and *Trans* Adducts of the Pictet-Spengler Reaction. Evidence for the Structural Basis for the C(1)-N(2) Scission Process in the *Cis* to *Trans* Isomerization,” D. Han, F. Forsterling, J. Deschamps, D. Parrish, X. Liu, W. Yin, S. Huang and J. M. Cook, *J. Nat. Prod. (Lloydia)*, **70**, 75-82 (2007).
328. “An Updated Unified Pharmacophore Model of the Benzodiazepine Binding Site on γ – Aminobutyric AcidA Receptors: Correlation with Comparative Models,” T. Clayton, J. Chen, M. Ernst, L.Richter, B.A. Cromer, C.J. Morton, H.Ng, C. Cook – Kaczorowski, F.J. Helmstetter, R. Furtmüeller, G. Ecker, M.W. Parker, W. Sieghart and J.M. Cook, *Curr. Med. Chem.*, **14**, 2755-2775 (2007).
329. "Conformational Analysis in the Asymmetric Pictet-Spengler Reaction, Evidence for the C(1)-N(2) Scission Process in the Cis to Trans Isomerization" D. Han, F. H. Försterling, J. Deschamps, D. Parrish, X. Liu, S.Huang, W. Yin, and J.M. Cook, *J. Nat. Prod.*, **70**, 75-82 (2007).
330. “The First Enantiospecific Total Synthesis of the Important Biogenetic Intermediates, (+)- Polyneuridine and (+)-Polyneuridine Aldehyde, as well as 16-Epi-vellosimine and Macusine-A,” W. Yin, J. Ma, F. Rivas and J. M. Cook, *Org. Lett.*, **9**, 295-298 (2007).
331. “Dopamine and Benzodiazepine-Dependent Mechanisms Regulate the EtOH-Enhanced Locomotor Stimulation in the GABAA 1 Subunit Null Mutant Mice,” H. L. June Sr., K. L. Foster, W. J.A. Eiler, J. Goergen, J. B. Cook, N. Johnson, B. Mensah-Zoe, J. O. Simmons, H. L. June Jr., W. Yin, J. M. Cook, and G. E. Homanics, *Neuropsychopharmacology*, **32**, 137-152 (2007).
332. “An Efficient Palladium Catalyzed Negishi Cross-Coupling Reaction with Aryvinyl Iodides: Facile Regioselective Synthesis of E-Stilbenes and their Analogues,” M. Shahjahan Kabir, A. Monte and J. M. Cook, *Tetrahdron Lett.*, **48**, 7269-7273 (2007).
333. “Total Synthesis of the Opioid Agonistic Indole Alkaloid, Mitragynine, as well as the First Total Synthesis of 9- Methoxygeissoschizol and 9-Methoxy-Nb-methyl-geissoschizol,” Jun Ma, W. Yin, H. Zhou and J.M. Cook, *Org. Lett.*, **9**, 3491-3494 (2007).
334. “Cascade Approach toward the Core Structure of Neosarpagine,” X. Liao, S. Huang, D. Parrish and J.M. Cook, *Org. Lett.*, **9**, 1469-1471 (2007).
335. “Are GABAA Receptors Containing α5 Subunits Contributing to the Sedative Properties of α5 Agonists?” M. Savic, S. Huang, R. Furtmueller, T. Clayton, S. Huck, D. Obradovic, N. Ugresic, W. Sieghart, D. Bokonjic and J. M. Cook, *Neuropsychopharmacology*, **33,** 332-339 (2008).
336. “Synthesis and Structure Activity Relationships of Tryprostatin A: An Inhibitor of Breast Cancer Resistant Protein,” H. Jain, C. Zhang, S. Zhao, H. Zhou, Amy Deveau, C. Dieckhaus, M. Johnson, K. Smith, T. MacDonald, H. Kakeya, H. Osada and J.M. Cook, *Bioorg. and Med. Chem.*, **16**, 4626-4651 (2008).
337. “PWZ-029, a Compound with Moderate Inverse Agonist Functional Selectivity at GABAA Receptors Containing Alpha 5 Subunits, Improves Passive, but not Active, Avoidance Learning in Rats”, Savic, M.; Clayton. T.; Furtmueller, R.; Gaurilovic, I.; Samardzic, J.; Savic, S.; Sieghart W,; Cook, J.M., Brain Res., 1208, 150-159 (2008).
338. “Selective Influence on Contextual Memory: Physiochemical Properties Associated with Selectivity of Benzodiazepine Ligands at GABA(A) Receptors Containing the α5 Subunit,” D. Harris, T. Clayton, J. Cook, R.Halliwell, P. Sahbaie, W. Sieghart, R. Furtmueller, and T. DeLorey, *J. Med. Chem.*, **51**, 3788-3803 (2008).
339. “The Syntheisis of the Macroline Alkaloids: A Recent Review,” C.S. Edwanker, R. Edwanker, S. Rallapalli, and J.M. Cook, *Nat. Prod. Commun*, **3**, 1839-1870 (2008).
340. "Stereo- and Regiospecific Cu-Catalyzed Cross-Coupling Reaction of Vinyl Iodides and Thiols: A Very Mild and General Route for the Synthesis of Vinyl Sulfides," M. Kabir, M.L. Van Linn, A. Monte, and J.M. Cook, *Org. Lett.*, **10**, 3363-336 (2008).
341. “Enantiospecific Synthesis of (+)-Alstonisine via a Streospecific Osmylation Process,” Y. Yang, A. Wearing, J. DeChamps, P. LeQuesne and J.M. Cook, *J. Nat. Prod.*, **71**, 1431-1440 (2008).
342. “New Classes of Gram-positive Selective Antibacterials: Inhibitors of MRSA and Surrogates of the Causative Agents of Anthrax and Tuberculosis,” M. Shahjahan Kabir, Kathleen Engelbrecht, Rebecca Polanowski, Sara M. Krueger, Rachel Ignasiak, Marc Rott, William R. Schwan, Mary E. Stemper, Kurt D. Reed, David Sherman, James M. Cook, Aaron Monte, *Bioorg. and Med. Chem.*, **18**, 5745-5749 (2008).
343. “A Study of the Structure-activity Relationship of GABAA-benzodiazepine Receptor Bivalent Ligands by Conformational Analysis with Low Temperature NMR and X-ray Analysis,” Dongmei Han, F. Holger Forsterling, Xiaoyan Li, Jeffrey R. Deschamps, Damon Parrish, Hui Cao, Sundari Rallapalli, Terry Clayton, Yun Teng, Samarpan Majumder, Subramaniam Sankar, Bryan L. Roth, Werner Sieghart, Roman Furtmuller, James K. Rowlett, Michael R. Weed, James M. Cook, *Bioorg. and Med. Chem.*, **16**, 8853-8862 (2008).
344. “Contribution of α1 Subunit – containing γ-Amino-butyric Acid (A) Receptors to Benzodiazepine – Induced Ataxia and Myorelaxation in Squirrel Monkeys,” S.Licata, D. Platt, J. Cook, M. Van Linn, and J. Rowlett, *Psychopharmacology*, 203, 539-546 (2009).
345. “Glutamatergic and GABAergic Modulations of Ultrasonic Vocalizations During Maternal Separation Distress in Mouse Pups,” Takahashi, A.; Yap, J.J.; Bohager, D.Z.; Faccidomo, S.; Clayton, T.; Cook, J.M.; Miczek, K.A., *Psychopharmacol.* (Berlin, Ger.) , 204, 61-71 (2009).
346. “General Approach to the Total Synthesis of 9-Methoxy-Substituted Indole Alkaloids: Synthesis of Mitragynine, as well as 9-Methoxygeissoschizol and 9-Methoxy-Nb-Methylgeissoschizol,” Jun Ma, Wenyuan Yin, Hao Zhou, Xuebin Liao, James M Cook, *J. Org. Chem.*, **74**, 264-273 (2009).
347. “Antiseizure Activity of Novel γ-Aminobutyric Acid (A) Receptor Subtype-Selective Benzodiazepine Analogs in Mice and Rat Models,” Rivas, F.; Stables, J.; Murphree, L.; Edwankar, R.; Edwankar, C.; Huang, S.; Jain, H.; Zhou, H.; Majumder, H.; Roth, B.; Sanker, S.; Ramerstorfer, J.; Furtmuller, R.; Sieghart, W.; Cook, J. M., J. Med. Chem., 52, 1795-1798 (2009).
348. “Study of the *Cis* to *Trans* Isomerization of 1-Phenyl-2,3-Disubstituted Tetrahydro-Beta-Carbolines. Evidence for the Carbocation-Mediated Mechanism,” H. Kumpaty, M. Van Linn, M. S. Kabir, F. Forsterling, J. Dechamps and J.M. Cook, *J. Org. Chem*, **74**, 2771-2779 (2009).
349. “The Differential Role of α1 and α5 – Containing GABA(A) Receptors in Mediating Diazepam Effects on Spontaneous Locomotor Activity and Water-Maze Learning and Memory in Rats”, M. Savic, M. Milinkovic, S. Rallapalli, T. Clayton Sr., S. Joksimovic, M. Van Linn, J. M. Cook, *Neuropsychopharmacology*, **12**, 1179-1193 (2009).
350. “An Improved Process for the Synthesis of 4H-Imidazo-[1,5 – a][1,4] benzodiazepines,” J. Yang, Y. Teng, S. Ara, S. Rallapalli, James M. Cook, *Synthesis*, **6**, 1036-1040 (2009).
351. “Dissociating Anxiolytic and Sedative Effects of GABA(A)ergic Drugs Using Temperature and Locomotor Responses to Acute Stress,” C. Vinkers, M. Van Linn, Seth Hopkins and J.M. Cook, *Psychopharmacology*, 204, 299-311 (2009).
352. “Discriminative Stimulus Effects of L-838, 417: Role of GABA(A) Receptor Subtypes”, S. Licata, J. Rowlett, D. Platt, M. Van Linn, J. M. Cook, *Neuropharmacology*, **58**, 357-364 (2009).
353. “Effects of Concurrent Administration of Nevirapine on the Disposition of Quinine in Healthy Volunteers,” Soyinka JO, Onyeji CO, Omoruyi SI, Owolabi AR, Sarma PV, Cook JM,  *J Pharm Pharmacol.* **61(4)**, 439-443 (2009).
354. “Recent Progress in the Total Synthesis of Indole Alkaloids”, C. Edwankar, R. Edwankar, O. Namjoshi, S. Rallapalli, J. Yang, J. M. Cook, *Current Opinion in Drug Discovery and Development*, **12**, 752-771 (2009).
355. “Contribution of 1 Subunit-Containing -Aminobutyric Acid A (GABA A) Receptors to The Motor-Impairing Effects of Benzodiazepines in Squirrel Monkeys,” S. Licata, D. Platt, J. Cook, M. Van Linn, J. Rowlett, *Psychopharmacology*, **203**, 539-546 (2009).
356. “The 1 Subunit of the GABA (A) Receptor Modulates Fear Learning and Plasticity in the Lateral Amygdala,” B. Wiltgen, Godsil, Z. Peng, F. Saab, H. June, M. Van Linn, J. M. Cook, C. Houser, T. O'.Dell, G. Homanics, M. Fanselow, *Frontiers in Behav. Neurosc*., **3**, (article 37), pp 1-12 (2009).
357. “Novel Positive Allosteric Modulators of GABA(A) Receptors: Do Subtle Differences in Activity at Alpha 1 Plus Alpha 5 Versus Alpha 2 Plus Alpha 3 Subunits Account for Dissimilarities in Behavioral Effects in Rats”, M Savic, S. Majumder, S.Huang, R. Edwankar, R. Furtmuller, S. Joksimovic, T. Clayton, J. Ramerstovfer, M. Milinkovk, B. Roth, W. Sieghart, J. M. Cook, *Progress in Neuro-Psychopharmacology and Behavioral Psychiatry,* **34,** 376-386 (2010).
358. “Pharmokinetic Interactions Between Ritonavir and Quinine in Healthy Volunteers Following Concurrent Administration”, Cyp Onyesi, S. Pullela, J. M. Cook, Bri. *J. Clin. Pharmacol*, **69**, 354-364 (2010).
359. “First Application of an Efficient and Versatile Ligand for Copper-Catalyzed Reactions of Vinyl Halides with N-Heterocycles and Phenols,” M. Kabir, M. Lorenz, O. Namjoshi, J.M. Cook, *Org. Lett*., **12**, 464-467 (2010).
360. “The First Enantiospecific Total Synthesis of the 3-Oxygenated Sarpagine Indole Alkaloids Affinine and 16-Epiaffinine, as well as Vobasinediol and 16-Epivobasinediol”, Jie Yang, Sundari K Rallapalli, James M Cook, *Tetrahdron Lett.*, **51**, 815-817 (2010).
361. “A Two Step Synthesis of BzR/GABAergic Active Flavones via a Wacker-related Oxidation,” M. Lorenz, M. Kabir, J. M. Cook, *Tetrahdron Lett.*, **51**, 1095-1098 (2010).
362. “Synthesis, Pharmacological Studies and Molecular Modeling of Some Tetracyclic 1,3 – Diazepinium Chlorides,” J, -A. Grant, T. Bonnick, M. Gossell- Williams, T. Clayton, J. M. Cook, Yvette Jackson, *Biorg. Med. Chem*., **18**, 909-921 (2010).
363. "Design, Synthesis and Subtype Selectivity Effects of 3,6-Disubstituted Beta Carbolines at Bz/GABA(A)ergic Receptors. SAR and Studies Directed Toward Agents for Treatment of Alcohol Abuse," Yin, W., Majumder, S., Clayton, T., Petrou, S., VanLinn, M., Ma, C., June, H.L., Cromer, B.A., Roth, B.L., Luddens, H., Cook, J.M. *Bioorg and Med. Chem*., **21**, 7548-7564 (2010).
364. "Enantiospecific Total Synthesis of the Important Biogenetic Intermediates Along the Ajmaline Pathway, (+) Polyneuridine and (+) Polyneuridine Aldehyde, as well as 16-Epivellosimine and Macusine A," Yin, W., Kabir, S.M, Wang, Z., Rallapalli, S.K., Ma, J.,Cook, J.M., *J. Org. Chem.,* **75**, 3339-3349 (2010).
365. "The Asymmetric Pictet-Spengler Reaction," Lorenz, M., VanLinn, M. L., Cook, J. M. *Curr. Org. Syn*., **7**, 189-223 (2010).
366. "Mechanistic Studies on the Cis to Trans Epimerization of Trisubstituted 1, 2, 3, 4-Tetrahydro--carbolines,” VanLinn, M. L., Cook, J.M., *J. Org. Chem.,* **75**, 3587-3599 (2010).
367. “Anxiolytic-like Effects of 8-Acetylene Imidazobenzodiazepines in a Rhesus Monkey Conflict Procedure,”Fischer, B.; Licata, S.; Edwankar, R.; Wang, Z-J.; Huang, S.; He, X.; Yu, J. Zhou, H.; Johnson, Jr., E. M.; Cook, J.; Furtmuller, R.; Ramerstorfer, J.; Sieghart, W.; Roth, B.; Majumder, S.; Rowlett, J., , *Neuropharmacology*, **59**, 612-618, (2010), doi: 10.1016/j.neuropharm.2010.08.011.
368. “A Very Active Cu-Catalytic System for the Synthesis of Aryl, Heteroaryl, and Vinyl Sulfides,” Kabir, S.M., Lorenz, M., Van Linn, M. L., Namjoshi, O. A., Ara, S., Cook, J.M. *J. Org. Chem.,* **75**, 3626-3643 (2010).
369. "A New Class of Potential Anti-Tuberculosis Agents: Synthesis and Preliminary Evaluation of Novel Acrylic Acid Ethyl Ester Derivatives," Kabir, S. M., Namjoshi, O. A., Verma, R., Polanowski, R., Krueger, S. M., Sherman, D., Rott, M. A., Schwan, W. R., Monte, A., Cook, J. M. *Bioorg and Med. Chem..,* **18**, 4178-4186 (2010).
370. “Discriminative Stimulus Effects of L-838,417 (7-tert-Butyl-3-(2,5-difluoro-phenyl)-6-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)-[1,2,4]triazolo[4,3-b]pyridazine): Role of GABA A Receptor Subtypes,” Licata, S. C.; Platt, D. M.; Rüedi-Bettschen, D.; Atack, J. R.; Dawson, G. R.; Van Linn, M. L.; Cook, J. M.; Rowlett, J. K., *Neuropharmacology*, **58**, 357-364 (2010).
371. “Behavioral Characterization of Four Endemic Staachys taxa,” Savic, M.; Kukic’, J.; Grayer, R.; Milinkovic’, M.; Marin, P.; Divljakovic’, J.; Van Linn, M.; Cook, J.M.; Petrovic’, S.D.; *Phytother.Res*., **24**, 1309-1316 (2010).
372. “Development of a Two-step Route to 3-PBC and βCCt, Two Agents Active Against Alcohol Self-Administration in Rodent and Primate Models,” Namjoshi, O. A. ; Grzybkowska, A.; Fonseca, G. O.; Van Linn, M.; Wang, Z.; Deschamps. J. R.; Cook, J. M., *J. Org. Chem*., **76** (11), 4721–4727 (2011).
373. “HZ-166, A Novel GABAA Receptor Subtype-Selective Benzodiazepine Site Ligand, Is Antihyperalgesic in Mouse Models of Inflammatory and Neuropathic Pain,” Di Lio, A.; Benke, D.;Besson,M.; Desmeules, J.; Daali, Y.; Wang, Z.J.; Edwankar, R.; Cook, J. M.; Zeilhofer., *Neuropharmacology,***60**, 626-632, 2011, doi: 10.1016/j.neuropharm.2010.11.026.
374. “4-Containing GABA (A) Receptors are Required for Antagonism of Ethanol-Induced Motor in Coordination and Hypnosis by the Imidazobenzodiazepine Ro15-4513,” Iyer, S. V.; Benavides, R. A.; Chandra, D.; Rallapalli, S.; Cook, J.; June, H. L.; Homanics, G. E., *Frontiers in Pharmacology*, **2**, 18, 1-7 (2011).
375. “Regiospecific, Enantiospecific Total Synthesis of C-19 Methyl Substituted Sarpagine Alkaloids Dihydroperaksine-17-al and Dihydroperaksine,” Edwankar, R. V.; Edwankar, C, R.; Deschamps, J.; Cook, J.M., *Org Lett*., 13,5216-5219 (2011).
376. “A Novel 5 GABAAR-Positive Allosteric Modulator Revereses Hyperactivation of the Dopamine System in the MAM Modle of Schizophrenia,” Gill, K.; Lodge, D.; Cook, J. M.; Ara, S.; Grace, A*., Neuropsychopharmacology*, **36**, 1903-1911 (2011).
377. “Lifelong CRF Overproduction is Associated with Altered Gene Expression and Sensitivity of Discrete GABA (A) and mGlu Receptor Subtypes,” Vinkers, C.; Hendriksen, H.; Oorshot, R.; Cook, J.; Rallapalli, S.; Huang, S.; Millian, M.; Oliver, B.; Groenink, L., *Psychopharmacology*, **219**, 897-908 (2012).
378. “The Role of 1 and 5 Subunit-Containing GABAA Receptors in Motor Impairment Induced by Benzodiazepines in Rats”, Milic, M.; Divljakovic, J.; Rallapalli, S.; Van Linn, M.L.; Timic, T.; Cook, J. M.; Savic, M. M., *Behav. Pharmacol*.,**23**, 191-197 (2012).
379. “GABAA Receptor  Subunits Differentially Contribute to Diazepam Tolerance After Chronic Treatment,” Vinkers, C.; Hansen, H.; Nielsen, E.; van Oorschot, R.; Cook, J. M.; Groenink, L.; Olivier, B.; Mirza, N., PLOS ONE, **7 (8)** e43054, 1-11 (2012), doi.org/10.1371/journal.pone.0043054.
380. “Targeting the Restricted  Subunit Repertoire of Airway Smooth GABA (A) Receptors Augments Airway Smooth Muscle Relaxtion,” Gallos, G.; Yim, P.; Chang, S.; Zhang, Y.; Xu, D.; Cook, J. M.; Gerthoffer, W.; Emala, Sr. C., *Am. J. Physiol. Lung Cell Mol. Physiol.*, **302**, 248-256 (2012).
381. “Base-Mediated Stereospecific Synthesis of Aryloxy and Amino Substituted Ethyl Acrylates”, Kabir\*, M.S.; Namjoshi, O. A.;Verma, R.;Lorenz, M.; Tiruveedhula,V.V.N.P.; Monte, A.; Bertz, S. H.;Schwabacher\*, A.; Cook\*, J. M., *J. Org. Chem*., **77**, 300-310 (2012).
382. “Brønsted Acid Mediated Cyclization of Enaminones. Rapid and Efficient Access to the Tetracyclic (ABCE) Framework of the Strychnos Alkaloids”, Edwankar, R. V.; Edwankar, C. R.; Namjoshi, O. A.; Deschamps, J. R.; Cook\*, J. M., *J. Nat. Prod*., **75**, 181-188 (2012).
383. “Synthesis and Minimum Inhibitory Concentrations of SK-03-92 against *Staphylococcus aureus* and other gram-positive bacteria”, Schwan, W. R.; Kabir, M. S.; Kallaus, M.; Krueger, S.; Monte, A.; Cook, J. M., *J. Infect. Chemother*., **18**, 124-126 (2012).
384. “Comparison of Cell Expression Formats for the Characterization of the GABA Channels using Microfluidic Patch Clamp System,” Chen, Q.; Yim, P.; Yuan, N.; Johnson, J.; Cook, J.; Smith, S.; Ionescu-Zanetti, C.; Wang, Z.; Arnold, A.;Emala, C., *Assay and Drug Development Technologies*, **10**, 325-335 (2012).
385. “Nature-Inspired Stereospecific Total Synthesis of the (P)-Atropodiastereomer of (+)-Dispegatrine via a Non-Phenolic Intermolecular Biaryl Oxidative Coupling,” Edwanker, C.; Edwankar, R.; Deschamps, J.; Cook, J., *Angew. Chemie. Ind. Ed.,* **51,** 11762-5 (2012).
386. “Recent Adventures with the Pauson-Khand Reaction in Total Syntheis,” Van Ornum, S.; Hoerner, S.; Cook, J.M., in *The Pauson-Khand Reaction: Scope, Variations and Applications*, First Edition. Edited by Ramon Rios Torres. John Wiley and Sons, Ltd., Chapter 8, 211-238 (2012).
387. “Modulation of the Reinforcing Effects of Ethanol in Rhesus Monkeys by 5 GABA (A) Receptor-Selective Ligands,” Rüedi-Bettschen, D.; Rowlett, J. K.; Rallapalli, S.; Clayton, T.; Cook, J. M.; Platt, D. M., *Alcoholism Clinical and Experimental Research*, 37, 624-634 (2013).
388. “Exposure to Cocaine Alters Fast Synaptic Transmission from the Ventral Tegmental Area to the Nucleus Accumbens,” Ishikawa, M.; Otaka, M.; Neumann, P.; Wang, Z.; Cook, J. M.; Schluter, O.; Dong, Y.; Huang, Y., *J. Physiol.,* **591** (Pt 19),427-41 (2013).
389. “Benzodiazepine – Induced Spatial Learning Deficits in Rats are Regulated by the Degree of Modulation of 1 GABA (A) Receptors,” Joksimovic, S.; Divljakovic, J.; vanLinn, M.; Varagic, Z.; Brajkovic, G.; Milinkovic, M.; Yin, W.; Timic, T.; Sieghart, W.; Cook, J.; Savic, M. M., *European J. Neuropsychopharmacology*, **23**, 390-399 (2013).
390. “The Ability of Flumazenil to Reverse Diazepam Withdrawal-Induced Anxiety in Rats is Mediated by 1 GABAA Receptors”, J. Divljakovic, M. Milic, O. Namjoshi, Phani Babu, J. Cook, M. Savic, *Brain Res. Bulletin*, **91**, 1-7 (2013).
391. “Search for 3β2/3γ2 Subtype Selective Ligands that are Stable on Human Liver Microsomes and In Vitro and In Vivo Evaluation of Metabolically Stable Bioisosteric Analogs,” Namjoshi, O.; Wang, Z.; Rallapalli, S.; Johnson, E. M.; Johnson, Yun-Teng; Ng, H.; Ramerstorger, J.; Sieghart, W.; Roth, B.; Rowlett, J.K.; Cook, J. M., *Bioorg. and Med. Chem*., **21**, 93–101 (2013), doi:10.1016/j.bmc.2012.10.057.
392. “Role of Gamma-aminobutyric Acid Type A Receptor Subtypes in Acute Benzodiazepine Physical Dependence: Evidence from Squirrel Monkeys Responding Under a Variable Schedule of Food Presentation,” Fischer, B.l Teixeri, L.; Van Linn, M.; Namjoshi, O.; Cook, J.; Rowlett, J.K., *Psychopharmacology*, **227** (2), 347-54 (2013).
393. “Enhancing the Function of Alpha 5-Containing GABA(A) Receptors Promotes Action Potential Firing of Neocortical Neurons During Upstates,” Drexler, B.; Zinser, S.; Huang, S.; Poe, M. M.; Rudolph, U.; Cook, J. M.; Antkowiak, B. *Eur. J. Neuropsychopharmacology,*  18-24 (2013).
394. “Effects of the Benzodiazepine GABA α1 Selective Ligand 3-Propoxy-β-Carboline (3PBC) on Alcohol Seeking and Self-Administration in Baboons,” Kaminski, B.; Van Linn, M.; Cook, J.; Yin, Wenyuan; Weerts, E., *Psychoparmacology,* **227**, 127-136 (2013).
395. “βCCT, an Antagonist Selective for α(1)GABA(A) Receptors, Reverses Diazepam Withdrawal-induced Anxiety in Rats.” Divljaković ,J.; Milić, M.; Namjoshi, O. A.; Tiruveedhula, V. V.; Timić, T.; Cook, J. M.; Savić ,M. M. *Brain Res. Bull.,* **91**:1-7 (2013).
396. “Cognition Impairing Effects of Benzodiazepine Type Drugs: Evaluation of the Role of GABAA Receptor Subtypes in Spatial Recognition Memory and Executive Function Tasks in Rhesus Monkeys”, L. Makaron, C. Moran, O. Namjoshi, S. Rallapalli, J. Cook, J. Rowlett, *Pharmacol.Biochem.Behav.,***104**, 62-68 (2013).
397. “Subtype Selectivity of +γ Site Ligands of GABAA Receptors-Identification of the First Highly Specific Positive Modulators at 6(2/3)2 Receptors”, Z. Varagic, J. Ramerstorfer, S. Huang, S. Rallapalli, I.Sarto-Jackson, J. Cook, W.Sieghart, E. Margot*., Bri. J. Pharmacol*., **169**, 384-399 (2013).
398. “PWZ-029, An Inverse Agonist Selective for 5 GABAA Receptors, Improves Object Recognition, But Not Water-Maze Memory in Normal And Scopolamine-Treated Rats,” Milica,M.; Timica, T.; Joksimovica, S.; Biawat, P.; Rallapalli, S.; Divljakovica, J.; Radulovica, T.; Cook, J. M; Savic, M. M. *Behav. Brain Res.*, **241,** 206–213 (2013).
399. “Insights into Functional Pharmacology of 1 GABA (A) Receptors: How Much Does Partial Activation at the Benzodiazepine Site Matter,” Joksimovic, S.; Divljakovic, J.; Varagic, Z.; Van Linn, M.; Milic, M.; Rallapalli, S.; Timic, T.; Sieghart, W.; Cook, J. M.; Savic, M., *Psychopharmacology*, **230**, 113-23 (2013).
400. “Stereospecific Approach to the Synthesis of Ring-A Oxygenated Sarpagine Indole Alkaloids. Total Synthesis of the Dimeric Indole Alkaloid Dispegatrine and Six Other Monomeric Indole Alkaloids", Edwankar, C.R.; Edwankar, R.V.; Namjoshi, O. A.; Deschamps, J.; Liao, X.; Cook, J. M. *J. Org. Chem.*, **78**, 6471—6487 (2013).
401. “Identification of Novel Positive Allolsteric Modulators and Null Modulators at the GABAA Receptor + Interface”, Varagic, Z.; Wimmer, L.; Schnürch, M.; Mihovilovic, M .D.; Huang, S.; Rallapalli, S.; Cook, J. M.; Mirheydari, P.; Ecker, G.F.;Sieghart,W.;Ernst,M. *Brit. J. of Pharmaco.***169**, 371-383 (2013).
402. “Design and Synthesis of Novel Antimicrobials with Activity Against Gram-Positive Bacteria and Mycro-bacterial Species, Including M. Tuberculosis”, Tiruveedhula, V. V. N.; Witzigmann, C.; Verma, R.; Shahjahan, M.; Rott, M.; Schwan, W.; Monte, A.; Sherman, D.; Cook, J. M. *Bioorg. and Med. Chem.*, **21**, 7830-40 (2013).
403. “Ethanol Not Metabolized in Brain, Significantly Reduces Brain Metabolism, Probably via Action Specific GABA(A) Receptors and has Measurable Metabolic Effects at Very Low Concentrations,” Rae, C; Davidson, J.; Maher, A.; Rowlands, B.; Kashem, M.; Nasrallah, F.; Rallapalli, S.; Cook, J.M.; Balcar, V., *J. Neurosci.,* **21**, 7830-7840 (2013) doi: 10.1111/jnc.12634.
404. “Allsoteric Modulation of GABA(A) Receptor Subtypes Effect on Visual Recognition and Visualspatial Working Memory in Rhesus Monkeys,” Soto, P.; Ator, N.; Rallapalli, S.; Biawat, P.; Clayton, T.; Cook, M.; Weed, M., *Neuropsychopharmacology*, **38**, 2315-2325, (2013).
405. “Exposure to Cocaine Regulates Inhibitory Synaptic Transmission from the Ventral Tegmental Area of the Nucleus Accumbens,” Ishikawa, M.; Otaka, M.; Neumann, P.A.; Wang, Z.; Cook, J.M.; Schluter, O.M.; Dong, Y.; Huang, Y.H., *J.* *Physiol*, **591** (Pt 19), 4827-41 (2013).
406. “Zebrafish Heart Failure Models for the Evaluation of Chemical Probes and Drugs,” Cheng, J.; Cook, J.M.; et. al., *Assay Drug Dev. Technol.* (9-10) 561-72 (2013).
407. “Development of Vitamin D Receptor-Coactivator Inhibitors, “ Sidhu, P.; Nassif, N.; McCallum, M.; Teske, k.; Felke, BI; Yuan, N.; Nandhikondu, P.; Cook, J.; Singh R.; Bickle, D.; Arnold, A.; *Med. Chem. Lett.* **5**, 199-204 (2014).
408. “SH-I-048A, An *In Vitro* Nonselective Super Agonist at Benzodiazepine Site at GABA (A) Receptors; The Approximate Activation of Receptor Subtypes May Explain Behavioral Results,” Savic, M.; Obradovic, A.; Joksimovic, S.; Huang, S.; Rammastorter, J.; Vargic, Z.; Namjoshi, O.; Batinic, B.; Radulovic, T.; Markovic, B.; Sieghart, J.; Cook, J., *Brain Res*., **1554**, 36-48 (2014).
409. “Antihyperalgesia by Alpha 2 GABA (A) Receptors Occurs via a Genuine Spinal Action and Does not Involve Supraspinal Sites,” Paul, J.; Yevenes, G.; Benke, D.; DiLio, A.; Ralvenius, W.; Witschi, R.; Scheuer, L.; Cook, J. M.; Rudolph, U.; Fritschy, J. M.; Zeilhofer, H. U., *Neuropsychopharmacology*, **39**,(2), 477-487 (2014), doi:0.1038/npp.2013.221.
410. **“**Prior Antipsychotic Drug Treatment Prevents Response to Novel Antipsychotic Agent in MAM Model of Schizophrenia,” Gill, K.; Cook, J.; Poe, M.; Grace, A., *Schizophrenia Bulletin*, March, **40** (2), 341-50 (2014).
411. “Little Evidence of a Role for the  GABAA Subunit – Containing Receptor in a Rhesus Monkey Model of Alcohol Drinking,” Sawyer, E.; Moran, C.; Madelynn S.; Szafir, M.; Van Linn, M.; Namjoshi, O.; Tiruveedhula, P.B.; Cook, J.M.; Platt, D., *Alcoholism Clinical and Experimental Research*, **38** (4), 1108-1117 (2014).
412. “The First Enantiospecific Total Synthesis of the Indole Alkaloid Ervincidine, Establishment of the C-6 Hydroxyl Stereochemistry,” Rallapalli, S.; Deschamps, J.; Cook, J.M., *J. Org. Chem.,* **79**, 3776-3780 (2014).
413. “5-GABA(A) Receptors Negatively Regulate MYC-Amplified Medulloblastoma Growth,” Sengupta, S.; Weeraratne, S.D.; Sun, H.; Phallen, J.; Rallapalli, S.K.; Tieder, N.; Kosaras, B.; Amani, V.; Pierre-Francois, J.; Tang, Y.; Nguyen, B.; Yu, F.; Schubert, S.; Balansay, B.; Mathios, D.; Lechpammer, M.; Archer, T.C.; Tran, P.; Reimer, R.J.; Cook, J.M.; Lim, M.; Jensen, F.E.; Pomeroy, S.L.; Cho, Y.J., *Acta Neuropathol*, **127** (4), 539-603 (2014).
414. “Duration of Treatment and Activation of ∝1-Containing GABA(A) Receptors Variably Affect the Level of Anxiety and Seizure Susceptibility After Spontaneous Diazepam Withdrawal in Rats,” Kovacevic, J.; Timic, T.; Tiruveedhula, V.; Batinic, B.; Milic, M.; Joksimovic, S.; Cook, J.M.; Savic, M., *Brain Res. Bull.* **104**,1-6 (2014).
415. “Glo 1 Inhibitors for Neuropsychiatric and Anti-epileptic Drug Dev.,” McMurray, K.; Distler, M.; Sidhu, P.; Arnold, L.A.; Cook, J.M.; Palmer, A.; Plant, L., *Biochem. Soc. Trans*., DOI: 10.1042/BST20140027, **42**, 461-467 (2014).
416. “Identification of VDR Antagonists Among Nuclear Receptor Ligands Using Virtual Screening,” Teske, K,; Nandhidonda, P.; Bogart, J.; Feleke,; Sidhu, P.; Yuan, N.; Preston, J.; Goy, R.; Singh, R.; Bikle, D.; Cook, J.M.; Arnold, A., *Nuclear Receptors Res.,* **1**, 1-8 (2014).
417. “General Strategy for Synthesis of C-19 Methyl-Substituted Sarpagine/Macroline/Ajmaline Indole Alkaloids including Total Synthesis of 19 (S), 20 (R) -Dihydroperaksine, 19 (S), 20 (R)- Dihydroperaksine-17-al and Peraksine, “Edwankar, R.; Edwankar, C.; Deschamps, J.; Cook, J., *J.Org.Chem*, **79**, 10030-10048 (2014).
418. “Expression Quantitative Trait Loci and Receptor Pharmacology Implicate Arg1 and The GABA-A Receptor as Therapeutic Targets in Neuroblastoma,” Hackett, C.; Quigley, D.; Wong, R.; Chen, J.; Cheng, C.; Song, C.; Wei, J.; Pawilkowska, L.; Bao, Y.; Goldenberg, D.; Nguyen, K.; Gustafson, W.; Rallapalli, S., Cho, Yoon-Jae; Cook, J.M.; Kozlov, S.; Mao, J.-H.; Dyke, T.; Kwok, P.-Y.; Khan, J.; Balmain, A.; Fan, Q.; Weiss; William; *Cell Reports*, **9**, 1-13 (2014).
419. “Delayed Behavioral Effects of SH-I-048A, A Novel Nonselective Positive Modulator of GABA (A) Receptors, After Peripheral Nerve Injury in Rats,” OBradovic’, L.; Joksimovic’, S.; Poe, M.; Timic, T.; Cook, J.; Savic, M. Afta. Veterinaria-Beograd, **64**, 189-199 (2014); DOI: 10.2478/ACVE-2014-0018.
420. “Role of α3 GABAA Receptor Modulation in the Anticonflict Effects of Benzodiazepine-Type Drugs in Monkeys, “ Sawyer, E.; Fischer, B.; Meng, Z.; Poe, M.; Namjoshi, O.; Cook, J.; Rowlett, J.; *Abstracts Drug and Alcohol Dependence,* 140, e196-e197 (2014).
421. “Anticancer Activity of VDR-Co-regulator Inhibitor PS121912,” Sidhu, P.; A.; Sidhu, P.; Romano, N.; Hill, E.; Horan, T.; Nandhikonda, P.; Teske, K.; Feleki, B.; Yuan, N.; Guthrie, M.; Fernstrum, G.; Vyas, N.; Cook, J.; Han, L.; Silvaggi, N.; Bikle, D.; Moore, R.; Singh, R.; Arnold, L.A., *Cancer Chemothera. Pharmacol,* **74** (4) 787-798 (2014).doi 10.1007/500280-014-2549-y (2014).
422. “Selective Targeting of the α5 Subunit of GABAA Receptors Relaxes Airway Smooth Muscle and Inhibits Cellular Calcium Handling,” Gallos, G.; Yocum, G.; Siviski, M.; Yim, P.; Fu, X-W; Poe, M.; Cook, J.; Harrison, N.; Emala, C.; *Am. J Physiol. Lung Cellular and Mol. Phosiol.,* **308 (9)**: L931-42 (2015); doi:10.1152/ajplung.00107.2014.
423. “Early Life Stress is a Risk Factor for Excessive Alcohol Drinking and Impulsivity in Adults and is Mediated via a CRF/GABAA Mechanism,” Gondre-Lewis, M.; Warnock, K.; Wang, H.; June, Jr., H.; Bell, K.; Rabe, H.;, Luddens, H.; Cook, J.; Babu, P.; Aurelians, L.; June Sr., H.L.,; Gondre-Lewis, M., *Stress,* 2016, 235-247*,* DOI:10.3109/10253890.2016.1160280.
424. “Negative Modulation of α5 GABAA Receptors in Rats May Partially Prevent Memory Inpairment Induced By MK-801, But Not Amphetamine or MK-801-Elicited Hyperlocomotion.” Timic-Stamenic, T.; Joksimovic, S.; Biawat, P.; Radulovie, T.; Markovic, B.; Cook, J.; Savic, M., *J. of Psychopharmacolgy, 00, 0000-0000* (2015); DOI: 10.1117/02698811155901601jop.sagepub.com.
425. “Behavorial Effects of the Benzodiazepine-Positive Modulator SH-053-2′F-S-CH3 in an Immune-Mediated Neurodevelopmental Disruption Model,” Richetto, J.; Labouesse, M.; Poe, M.M.; Cook, J.M.; Grace, A.; Riva, M.; Meyer, U., *Int. J. of Neuropsychopharmacology*, 1-11 (2015).
426. “Triple Monoamine Uptake Inhibitors Demonstrate a Pharmacologic Association Between Excessive Drinking and Impulsivity In High Alcohol-Preferring (HAP) Mice,” O'Tousa, D. S.; Warnock, K. T.; Matson, L. M.; Namjoshi, O. A.; Van Linn, M. L.; Tiruveedhula, V.V.; Halcomb, M.E.; Cook, J. M.; Nicholas J. Grahame, N. J.; June**,**H. L., ***Addiction Biology****,* **20**, 236-247 (2015). DOI: 10.1111/adb.12100.
427. “A Review: Updated Pharmacophore for the Alpha 5 GABA(A) Benzodiazepine Receptor Model”, Clayton, T.; Poe, M.; Rallapalli, S.; Biawat, P.;Savic, M.; Rowlett, J.; Gallos, G.; Emala, C.; Kaczorowski, C.; Stafford, D.; Arnold, L.; Cook, J. M.*, Int J.Med.Chem*., Volume 2015, Article ID 430248, http//dx.doi.org/10.1155/2015/430248.
428. “Regulating Anxiety with Extrasynaptic Inhibition,” Botta, P.; Demmou, L.; Xu, C.; Lu, T.; Poe, M.M.; Xu, L.; Cook, J.M.; Rudolph, U.; Sah, P.; Luthi, A., doi: 10.1038/nn.4102. *Nature Neuroscience*, 18, 1493-1499 (2015).
429. “First Stereospecific Total Synthesis of (-)-Affinisine Oxindole as well as Facile Entry Into the C (7) – Diastereomeric Chitosenine Stereochemistry, “Fonseca, G.; Wang, Z.; Namjoshi, O.; Deschamps, J.’ Cook, J.; Tetrahedron Lett, **56**,3052-3056 (2015).
430. “Anti-tumor Activity of 3-Indolylmethanamines 31B and PS121912”, Guthrie, M.; Preetpal, S; Hill, E.; Horan, T.; Premchendar, N.; Teske, K.; Yuan, N.; Gutherie, L.; Sidorko, M.; Kodali, R.; Cook, J.; Han, L.; Silvaggi, N.; Bikle, D.; Moore, R.; Singh, R.; Arnold, A.; *Anticancer Res* ***35(11)****,* 6001-6007 (2015.)
431. “Pharmacokinetic/Toxicity Properties of the New Anti-Staphylococcal Lead Compound SK-03-92,” Schwan, W.; Kolesar, J.; Kabir, M.S.; Elder Jr, E.; Williams, J.; Minerath, R.; Cook, J.M.; Witzigmann, C.; Monte, A.; Flaherty, T.; *Antibiotics*, 4, 617-626 (2015).
432. “Targeting the γ-Aminobutyric Acid A Receptor α4 Subunit in Airway Smooth Muscle to Alleviate Bronchoconstriction”, Yocum, G.T., Gallos, G., Zhang, Y., Jahan, R., Stephen, M.R., Varagic, Z., Puthenkalam, R., Ernst, M., Cook, J.M. and Emala, C.W., *American Journal of Respiratory Cell and Molecular Biology*, 54(4), pp.546-553 (2016), doi: 10.1165/rcmb.2015-0176OC.
433. “Effects of Hz-166, A Novel α2 and α3 Subunit-containing GABA(A) Receptor Agonist, On Inflammatory Pain and Operant Behavior in Mice, “Fischer, B.; Kroll, C.; Poe, M.; Cook, J.; *Abstracts Drug and Alcohol Dependence*, 146, e278 (2015).
434. “Genetic and Pharmacological Manipulation of Glyoxalase 1 Regulates Voluntary Ethanol Consumption in Mice,” McMurray, K.; Sidhu, P.; Arnold, A.; Cook, J.; Palmer, A., *Addiction Biology,* doi.org/10.1111/adb.12333, Dec 2015.
435. “Indentification of a Repressor of *Staphylococcal* *Sortase* Sensor(RssS) / Regulator (RssR) Rwo-Component Regulatory System tied to Drug Persistence and Represiion of The Staphylococcal *aureus* Sortase Gene,” Chwan, W.; Medina-Beilski, S.; Baker, A.; Lane, M.; Cook, J.; Kabir.; Shahjahan, M. *Microbiology*, submitted.
436. “Sex-dependent anti-stress effect of an α5 subunit containing GABAA receptor positive allosteric modulator”, Piantadosi, S.; French, B.; Poe, M.; Timic, T.; Markovic, B.; Pabba, M.; Seney, M.; Oh, H.; Orser, B.A.; Savic, M.; Cook, J.; Sibille, E.; *Frontiers in Pharmacology,*2016, doi: 10.3389/fphar.2016.00446.
437. “Synthesis of Aza and Carbocyclic β-Carbolines for The Treatment of Alcohol Abuse. Regiospecific Solution to the Problem of 3, 6-Disubstitued β-and Aza- β-Carboline Specificity,” Tiruveedhula, V.V.N, Methuku, K,; Deschamps, J.; Cook, J.; *Org. and Bimol. Chem*, 13, 10705-10715 (2015).
438. “Influence of Nigerian Honey on CYP3A4 Biotransformation of Quinine in Health Volunteers.” Igbinoba, S.; Akanmu, M.; Onyeji, C.; Soyinka, J.; Owolabi, A.; Nathaniel, Ti.; Pullela, S.; Cook, J.; *J of Clin Pharmacy and Therapeutics*, 40, 545-549 (2015), doi:10.0000/jcpt.12303.
439. “Ester to Amide Substitution Improves Selectivity, Efficacy and Kinetic Behavior of a Benzodiazepine Positive Modulator of GABA(A) Receptors Containing the α5 Subunit,” Stamenić, T.; Poe, M.; Rehman, S.; Santrać, A.; Divović, B.; Scholze, P.; Ernst, M.; Cook, J.; Savic, M.; *Eur. J. Pharmacol.*,791, 433-433 (2016).
440. “Metabolic Studies of Drug Candidates for Neurological Disorders and Asthma Based on GABAA Receptor Subtype Selective Ligands Using Mass Spectrometry”, Kodali, R.; Guthrie, M.; Poe, M.; Stephen, M.; Jahan, R.; Emala, C.; Cook, J.M.; Stafford, D.; Arnold, L., *Shimadzu Journal*, Vol.3, Issue3-Dec 2015.
441. “Effect of Dehusked Garcinia Kola Seed on the Overall Pharmokinetics of Quinine in Healthy Human Volunteers,” Igbinoba, S.; Onyeji, C.; Akanmu, M.; Soyinka, J.; Owolabi, J.; Puellea, S.; Savina, V.V.; Cook, J.M., *J.Clin*.*Pharmacol*.,**55**, 348-354 (2015).
442. “Antagonism of Triazolam Self-Administration in Rhesus Monkeys Responding Under a Progressive-ratio Schedule: *In vivo* Apparent pA2 Analysis,” Fischer, B; Platt, D.; Rallapalli, S.; Namjoshi, O.; Cook, J.; Rowlett, J.; Drug and Alcohol Dependence, 158, 22-29 (2016).
443. “eEF2 Pathway Controls Dentrate Gyrus Dependent Behaviour and Excitation-inhibition Balance,” Heise, C.; Taha, E.; Murru, L.; Ponzoni, L.; Cattaneo, A.; Guarnieri, F.C.; Montani, C.; Mossa, A.; Vezzoli, E.; Ippoliot, G.; Zapata, J.; Berrera, I.; Ryazanov, A.G.; Benfante, R.; Braida, D.; Francolinin, M.; Proud, Poe, M.M.; Stephen, M.; Cook, J.M.; C.; Valtorta, F.; Passafaro, M.; Sala, M.; Bachi, A.; Verpelli, C.; Rosenblum, K.; Sala, C.; *Cerebral Cortex,* doi: 10.1093/cercor/bhw075, 27, 2226-2248 (2017).
444. “First in Vivo Testing of Novel Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development,” Jonas, O.; Calligaris, D.; Methuku, K.; Poe, M.M,; Tranghese, F.; Changelian, A.; Francois, J.; Sieghart, W.; Ernst, M.; Krummel, D.; Cook, J.M.; Pomeroy, S.; Cima, M.; Agar, N.; Langer, R.; Sengupta, S.; J. of Biomedical Nanotechnology, 12, 1297-1302 (2016).
445. “Effects of the Benzodiazepine GABAA α1-Preferring Antagonist 3-Isopropoxy-β-Carboline Hydrochloride (3-ISOPBC) on Alcohol Seeking and Self-Administration in Baboons,” Holtyn, A., Tiruveedhula V.V.N., Stephen MR, Cook J.M., Weerts EM.; *Drug* and *Alcohol Dependence,* 170*,* 25-31 (2017).
446. “Sarpagine and Related Alkaloids,” O. Namjoshi; J.M. Cook, in “*The Alkaloids,”* Volume 76, Hans-Joachim Knölker, Editor, Elsevier, N.Y. pp. 64-171 (2016).
447. “Synthesis and Evaluation of Vitamin D Receptors-mediated Activities of Cholesterol and Vitamin D Metabolites,” Teske, K.; Bogart, J.; Sanchez, L.; Yu, O.; Preston, J.; Cook, J.; Silvaggi, N.; Bikle, D.; Arnold, L.; *Eur. J. Med. Chem,* 109, 238-246 (2016).
448. “Development of GABAA Receptor Subtype-Selective Imidazobenzodiazepines as Novel Asthma Treatments”, Forkuo, G.S.; Guthrie, M.; Yuan, N; Nieman, A.; Kodali, R; Jahan, R; Yocum, G.; Treven, M.; Stephen, M.; Poe, M.; Li, G.; Yu, O.; Hartzler, B.; Zahn, N.; Ernst, M.; Emala,C.; Stafford, D.; Cook, J.M.; Arnold, L.A., *Molecular Pharmaceutics*, (ACS), DOI: 10.1021/acs.molpharmaceut.6600159; 13, 2026-2038 (2016).
449. “Neonatal Bladder Inflammation Induces Long-term Visceral Pain and Altered Responses of Spinal Neurons in Adult Rats”, Kannampalli, P.; Babygirija,R.’ Zhang,J.; Poe,M.; Li,G.; Cook, J.M.; Shaker,R.; Banerjee, B.; Sengupta, J.; *Neuroscience*, doi.org/10.1016/j.neuroscience.2017.01.021 (2017); 346, 349-364, PMID: 28126369 PMCID: PMC5337157 (2017).
450. “Modern Methods for Total Synthesis of Important Oxindole Alkaloids”, Fonseca, G.; Cook, J.M.; *Organic Chemistry Insights* 2016: 6 1-55 DOI: 10.4137/OCI.S17958.
451. “Early Life Stress is a Risk Factor for Excessive Alcohol Drinking and Impulsivity in Adults and is Mediated *via* a CRF/GABAA Mechanism”, Gondré-Lewis, M.C., Warnock, K.T., Wang, H., June Jr, H.L., Bell, K.A., Rabe, H., Tiruveedhula, V.V.N.P.B., Cook, J., Lüddens, H., Aurelian, L. and June Sr, H.L., 2016. *Stress*, 19(2), pp.235-247, DOI: 10.3109/10253890.2016.1160280 (2016).
452. “Synthesis and Characterization of a Novel γ-Aminobutyric Acid Type A (GABAA) Receptor Ligand that Combines Outstanding Metabolic Stability, Pharmacokinetics, and Anxiolytic Efficacy”, Poe, M.; Methuku, K.; Li, Guanguan; Verma, A.; Teske, K.; Stafford, D.; Arnold, L.A.; Cramer, J.; Jones, T.; Cerne, R.; Krambis, M.; Witkin, J.; Jambrina, E.; Rehman, S.; Ernst, M.; Cook, J.M.; and Schkeryantz, J.; *J. Med. Chem,* **59, 10800-10806** (2016).
453. “Total Synthesis of Macrocarpine D and E *via* an Enolate-Driven Copper-Mediated Cross-Coupling Process: Replacement of Catalytic Palladium with Copper Iodide”, Rahman, Md. T.; Deschamps, J.; Schwabacher, A.; Cook, J.M.; *Org Lett*., 18, 4174-4177 (2016).
454. “Brain Vaculation Resulting from Administration of Low Impact (Type II) AmpaKines are an Artifact Related to AMP aKine Molecular Structure”, Purcell, R.; Lynch, G.; Gill, C.; Johnson, S.; Sheng, Z.; Stephen, M.R.; Garman, R.; Jorther, B.; Bolon, B.; Lippa, A., *Toxicol Sci.*, 162(2):383-395. doi: 10.1093/toxsci/kfx277, 04/01/2018, PMID: 29253237.
455. “Pharmacological and Antihyperalgesic Properties of the Novel α2/α3 Prefering GABA(A) Receptor Ligand MP-III-024”,

Fischer B.; Schlitt, R.; Hamade, B. Z.; Rehman, S.; Ernst, M.; Poe, M.; Li, G.; Kodali, R.; Arnold, L.A.; Cook, J.M., *Brain Res*., Bull., doi: 10.1016/j. brainresbull.2017.03.001 (2017).

1. “Antinociceptive Effects of a Novel α2/α3-Subtype Selective GABAA Receptor Positive Allosteric Modulator”, Lewter L.; Fisher J.; Siemian J.; Methuku K.; Poe M.; Cook J.M.; Li J., ACS Chem Neurosci, 2017 Jun 21;8(6):13-05-1312 PMID: 28150939 PMCID: PMC5686453 02/06/2017.
2. “Characterization of GABAA Receptor Ligands with Automated Patch-Clamp Using Human Neurons Derived from Pluripotent Stem Cells”, Yuan, N.Y.; Poe, M.M.; Witzigmann, C.; Cook, J.M.; Stafford, D.C.; Arnold, L.A., *J Pharmacol Toxicol Methods,* doi. Org/ 10.1016/j. vascn.2016.08.006 (2016); 82: 109-114 (2016).
3. “Optimization of Substituted Imidazobenzodiazepines as Novel Asthma Treatments”, Jahan, R.; Stephen, M.R.; Forkuo, G.S.; Kodali, R.; Guthrie, M.L.; Nieman, A.N.; Yuan, N.Y.; Zahn, N.M.; Poe, M.M.; Li, G.; Yu, O.B.; Yocum, G.T.; Emala, C.W.; Stafford, D.C.; Cook, J.M.; Arnold, L.A., *Eur J. Med. Chem.,* doi: 10.1016/j.ejmech.2016.11.045*,* 126, 550-560 (2017).
4. “Synthesis of Bisindole Alkaloids from The *Apocynaceae* Which Contain a Macroline or Sarpagine Unit: A Review”, Rahman, M.T.; Tiruveedhula, V.V.N.; Cook, J.M., *Molecules,* 2016, 21, 1525; doi: 10.3390/molecules21111525 (2016).
5. “Benzodiazepine Ligands with Improved α5 Selectivity and Their Airway Smooth Muscle Relaxant Effect”, Puthenkalam, R.; Treven, M.; Ramerstorfer, J.; Steudle, F.; Scholze, P.; Gallos, G.; Poe, M.M.; Methuku, K.R.; Li, Guanguan; Arnold, L.A.; Seighert, W.; Santrac, Anja.; Savic, M.; Emala, C.; Cook, J.M.; Ernst, M., *Mol. Pharmacology*, 00,0000-0000 (2017).
6. “Alleviation of Multiple Asthmatic Pathologic Features with Orally Available and Subtype Selective GABAA Receptor Modulators”, Forkuo GS, Nieman AN, Yuan NY, Kodali R, Yu OB, Zahn NM, Jahan R, Li G, Stephen MR, Guthrie ML, Poe MM, Hartzler BD, Harris TW, Yocum GT, Emala CW, Steeber DA, Stafford DC, Cook JM, Arnold LA, *Mol Pharm*, doi: 10.1021/acs.molpharmaceut.7b00183, 14(6):2088-2098, PMID: 28440659, PMCID: PMC5497587, 2017.
7. “Trigeminal neuropathic pain development and maintenance in rats are suppressed by a positive modulator of α6 GABAA receptors”, Vasović, D.; Divović, B.; Treven, M.; Knutson, D.; Steudle, F.; Scholze, P.; Obradović, A.; Fabjan, J.; Brković, B.; Seighart, W.; Ernst, M.; Cook, J.M.; Savić, M., *Eur. J. Pain.*, doi.org/10.1002/ejp.1365, 23:973-984, Jan 2019.
8. “Cerebellar α6 subunit‐containing GABAA receptors: A novel therapeutic target for disrupted prepulse inhibition in neuropsychiatric disorders”, Lee, H.-J.; Ernst, M.; Huang, W.-J.; Chiou, J.-F.; Chen, H.-L.; Mouri, A.; Chen, L.-C.; Mamiya, T.; Fan, P.-C.; Knutson, D.; Witzigmann, C.; Cook, J.; Seighart, W.; Nabeshima, T.; Chiou, L.-C.; *Br. J. Pharmacol*, doi.org/10.1111/bph.14198, March 2018.
9. “Abuse-related effects of subtype-selective GABAA receptor positive allosteric modulators in an assay of intracranial self-stimulation in rats”, meyer KL, Li G, Poe MM, Cook JM, Banks ML, Stevens Negus S, *Psychopharmacology* (Berl), 2017 July ; 234(14): 2091–2101. doi:10.1007/s00213-017-4615-8.
10. “Further evaluation of the potential anxiolytic activity of imidazo[1,5-a][1,4]diazepin agents selective for α2/3-containing GABAA receptors”, Witkin JM, Cerne R, Wakulchik M, S J, Gleason SD, Jones TM, Li G, Arnold LA, Li JX, Schkeryantz JM, Methuku KR, Cook JM, Poe MM, *Pharmacol Biochem Behav* 2017 Jun;157:35-40 PMID: 28442369 PMCID: PMC5519285 04/27/2017.
11. “Negative allosteric modulation of alpha 5-containing GABAA receptors engenders antidepressant-like effects and selectively prevents age-associated hyperactivity in tau-depositing mice”, Xu, N.; Ernst, M.; Cerne, R.; Wakalchik, M.; Li, X.; Jones, T.; Gleason, S.; Morrow, D.; Schkeryantz, J.; Rahman, Md.T.; Li, G.; Poe, M.; Cook, J.M.; Witkin, J., *Psychopharmacology,* DOI: doi.org/10.1007/s00213-018-4832-9, 235 (4), 1151–1161, 2018.
12. “Positive modulation of α5 GABAA receptors in preadolescence prevents reduced locomotor response to amphetamine in adult female but not male rats prenatally exposed to lipopolysaccharide”, Batinić B, Santrač A, Jančić I, Li G, Vidojević A, Marković B, Cook JM, Savić MM, *Int J Dev Neurosci* 2017 Oct;61:31-39 PMID: 28610974 PMCID: PMC5563212 06/15/2017.
13. “Concise Total Synthesis of (-)-Affinisine Oxindole, (+)-Isoalstonisine, (+)-Alstofoline, (-)-Macrogentine, (+)-Na -Demethylalstonisine, (-)-Alstonoxine A, and (+)-Alstonisine”, Stephen MR; Rahman MT; Tiruveedhula VVNPB; Fonseca GO; Deschamps JR; Cook JM, *Chem. Eur. J.*, DOI: 10.1002/chem.201703572, 2017 Nov 07, 23(62):15805-15819, PMID: 28875520 09/07/2017.
14. “Identification of Staphylococcus aureus Cellular Pathways Affected by the Stilbenoid Lead Drug SK-03-92 Using a Microarray”, Schwan WR, Polanowski R, Dunman PM, Medina-Bielski S, Lane M, Rott M, Lipker L, Wescott A, Monte A, Cook JM, Baumann DD, Tiruveedhula VVNPB, Witzigmann CM, Mikel C, Rahman MT, *Antibiotics* 2017 Sep 11;6(3) PMID: 28892020 PMCID: PMC5617981 09/12/2017.
15. “Neurobiological correlates of state-dependent context fear”, Meyer MAA, Corcoran KA, Chen HJ, Gallego S, Li G, Tiruveedhula VV, Cook JM, Radulovic J, *Learn Mem*, DOI: 10.1101/lm.045542.117, 2017 Sep; 24(9):385-391, PMID: 2881-4463, PMCID: PMC5580530 08/18/2017.
16. “Identification of a novel, fast-acting GABAergic antidepressant”, McMurray, K.M.; Ramaker, M.J.; Barkley-Levenson, A.M.; Sidhu, P.S.; Elkin, P.K.; Reddy, M.K.; Guthrie, M.L.; Cook, J.M.; Rawal, V.H.; Arnold, L.A.; Dulawa, S.C.; Palmer, A.A., *Mol Psychiatry*., doi:10.1038/mp.2017.14, PMID: 28322281, PMCID: PMC5608625, March 2017.
17. “Total Synthesis of Sarpagine Related Bioactive Indole alkaloids”, Rahman, M. T.; Deschamps, J. R.; Imler, G. H.; Cook, J. M., *Chem. Eur. J*., doi: 10.1002/chem.201705575, 24 (10), 2354-2359, 02/06/2018.
18. “The α6 subunit-containing GABAA receptor: A novel drug target for inhibition of trigeminal activation”, Fan, P.C.; Lai, T.H.; Hor, C.C.; Lee, M.T.; Huang, P.; Sieghart, W.; Ernst, M.; Knutson, D.E.; Cook, J.; Chiou, L.C., *Neuropharmacology*, doi: 10.1016/j.neuropharm.2018.07.017, 2018, September; 140: 1-13.
19. “A novel orally available asthma drug candidate that reduces smooth muscle constriction and inflammation by targeting GABA(A) receptors in the lung", Forkuo G.; Nieman, A.; Zahn, N.; Kodali, R.; Li, G.; Roni, S.; Stephen, M.; Harris, T.; Jahan, R.; Guthrie, M.; Yu, O.; Fisher, J.; Yocum, G.; Emala, C.; Steeber, D.; Stafford, D.; Cook, J.; Arnold, L., *Molecular Pharmaceutics* (2018), 15 (5), 1766-1777; DOI: 10.1021/acs.molpharmaceut.7b01013.
20. “Design and Synthesis of Novel Deuterated Ligands Functionally Selective for the γ-Aminobutyric Acid Type A Receptor (GABAAR) α6 Subtype with Improved Metabolic Stability and Enhanced Bioavailability”, Knutson, D.; Kodali, R.; Divović, B.; Treven, M.; Stephen, M.; Zahn, N.; Dobričić, V.; Huber, A.; Meirelles, M.; Verma, R.; Wimmer, L.; Witzigmann, C.; Arnold, A.; Chiou, L.; Ernst, M.; Mihovilovic, M.; Savić, M.M.; Sieghart, W.; Cook, J., J. Med. Chem., 2018, 61 (6), 2422–2446, DOI: 10.1021/acs.jmedchem.7b01664.
21. “Attaining in vivo selectivity of positive modulation of α3βγ2 GABAA receptors in rats: a hard task!”, Batinić, B.; Stanković, T.; Stephen, M.; Kodali, R.; Tiruveedhula, V.V.N.; Li, G.; Scholze, P.; Marković, B.; Obradović, A.L.; Ernst, M.; Cook, J.; Savić, M., *Eur Neuropsychopharmacol*, doi: 10.1016/j.euroneuro.2018.05.014, PMID: 29891214, Jun 2018.
22. “Novel Benzodiazepine-Like Ligands with Various Anxiolytic, Antidepressant, or Pro-Cognitive Profiles”, Prevot, T.; Li, G.; Vidojevic, A.; Misquitta, K.; Santrac, A.; Knutson, D.; Stephen, M.; Kodali, R.; Zahn, N.; Arnold, L.; Scholze, P.; Fisher, J.; Marković, B.; Banasr, M.; Cook, J.; Savić, M.; Sibille, E., *Mol Neuropsychiatry*, DOI 10.1159/000496086, Jan 23, 2019.
23. “Synthesis of chiral GABAA receptor subtype selective ligands as potential agents to treat schizophrenia as well as depression”, Li, G.; Stephen, M.; Kodali, R.; Zahn, N.; Poe, M.; Tiruveedhula, V.V.N.; Huber, A,; Schussman, M.; Qualmann, K.; Panhans, C.; Raddatz, N.; Baker, D.; Prevot, T.; Banasr, M.; Sibille, E.; Arnold, A.; Cook, J., *Arkivoc*, 2018, part iv, 158-183.
24. “Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABAA receptors: improved bioavailability enhances anticonvulsant efficacy”, J. M. Witkin, J. L. Smith, X. Ping, S. D. Gleason, M. M. Poe, G. Li, X. Jin, J. Hobbs, J. M. Schkeryantz, J. S. McDermott, A. I. Alatorre, J. N. Siemian, J.W. Cramer, D. C. Airey, K. R. Methuku, T. M. Jones, M. J. Krambis, J. L. Fisher, J. M. Cook, R. Cerne, *Neuropharmacology*, DOI: 10.1016/j.neuropharm.2018.05.006.
25. "Evidence that Sedative Effects of Benzodiazepines Involve Unexpected GABAA Receptor Subtypes: Quantitative Observation Studies in Rhesus Monkeys", Duke, A.; Meng, Z.; Platt, D.; Atack, J.; Dawson, G.; Reynolds, D.; Tiruveedhula, V.V.N.; Li, G.; Stephen, M.; Sieghart, W.; Cook J.; Rowlett, J. K., *J. Pharmacol. Exp. Ther.,* DOI: [10.1124/jp-et.118.249250](https://doi.org/10.1124/jp-et.118.249250), May 2018.
26. “Improved Synthesis of Anxiolytic, Anticonvulsant and Antinociceptive α2/α3-GABA(A)ergic Receptor Subtype Selective Ligands as Promising Agents to Treat Anxiety, Epilepsy, as well as Neuropathic Pain”, Li, G.; Golani, L. K.; Jahan, R.; Rashid, F.; Cook, J. M, *Synthesis*, 2018, 50(20): 4124-4132, DOI: 10.1055/s-0037-1610211.
27. “An Antidepressant-Related Pharmacological Signature for Positive Allosteric Modulators of alpha 2/3-Containing GABAA Receptors”, Methuku, K.R.; Li, X.; Cerne, R.; Gleason, S.; Schkeryantz, J.M.; Tiruveedhula, V.V.N.; Golani, L. K.; Li, G.; Poe, M.; Rahman, M.T.; Cook, J.; Fisher, J.; Witkin, J.; *Pharmacol. Biochem. Behav.*, DOI: 10.1016/j.pbb.20-18.04.009, April 2018.
28. “Unprecedented stereocontrol in the synthesis of 1,2,3‐ trisubstituted tetrahydro‐β‐carbolines via a new asymmetric Pictet—Spengler reaction towards sarpagine‐type indole alkaloids”, Rahman, M.T.; Cook, J., *Eur. J. Org. Chem*, DOI: 10.10-02/ejoc.201800600, April 2018.
29. “Different Benzodiazepines Bind with Distinct Binding Modes to GABAA Receptors”, Elgarf, A.; Siebert, D.; Steudle, F.; Draxler, A.; Li, G.; Huang, S.; Cook, J.; Ernst, M.; Scholze, P., *ACS Chem Biol.*, DOI: 10.1021/acschembio.8b00144, May 16 2018.
30. “α5GABAA subunit-containing receptors and sweetened alcohol cue-induced reinstatement and active sweetened alcohol self-administration in male rats”, Chandler C.M.; Reeves-Darby J.; Jones SA.; McDonald JA.; Li G.; Rahman M.T.; Cook J.M.; Platt D.M., *Psychopharmacology (Berl)*, doi: 10.1007/s00213-018-5163-6, Jan 12, 2019.
31. “Zolpidem activation of alpha 1-containing GABAA receptors selectively inhibits high frequency action potential firing of cortical neurons”, Neumann, E.; Rudolph, W.; Knutson, D.; Li, G.; Cook, J.M.; Antkowiak, B.; Drexler, B., *Pharmacol.,* doi.org/10.3389/fphar.2018.01523, Jan 09, 2019.
32. “Effects of the α2/α3-subtype-selective GABAA receptor positive allosteric modulator KRM-II-81 on pain-depressed behavior in rats: comparison with ketorolac and diazepam”, Moerkea, M.J.; Li, G; Golani, L.K.; Cook, J.M.; Negus, S.S., *Behav Pharmacol.*, doi: 10.1097/FBP.0000000000000464, Jan 10, 2019.
33. “A Novel GABAA Receptor Ligand MIDD0301 with Limited Blood-Brain Barrier Penetration Relaxes Airway Smooth Muscle *Ex Vivo* and *In Vivo*”, Yocum, G.T.; Perez-Zoghbi, J.F.; Danielsson, J.; Kuforiji, A.S.; Zhang, Y.; Li, G.; Rashid Roni M.S.; Kodali, R.; Stafford, D.; Arnold, L.A.; Cook, J.M.; Emala, C.W., *Am J Physiol Lung Cell Mol Physiol*. , doi.org/10.1152/ajplung.00356.2018, Nov 29, 2018.
34. “Evaluation of the anti-conflict, reinforcing, and sedative effects of YT-III-31, a ligand functionally selective for α3 subunit-containing GABAA receptors”, Meng, Z.; Berro, L.F.; Sawyer, E.K.; Rüedi-Bettschen, D.; Cook, J.E.; Li, G.; Platt, D.M.; Cook, J.M.; Rowlett, J.K., *J Psychopharmacol.*,2020, 34(3): 348–357, doi: 10.1177/0269881119882803.
35. “Modulating native GABAA receptors in medulloblastoma with positive allosteric benzodiazepine-derivatives induces cell death”, Kallay, L.; Keskin, H.; Ross, A.; Rupji, M.; Moody, O.A.; Wang, X.; Li, G.; Ahmed, T.; Rashid, F.; Stephen, M.R.; Cottrill, K.A.; Nuckols, T.A.; Xu, M.; Martinson, D.E.; Tranghese, F.; Pei, Y.; Cook, J.M.; Kowalski, J.; Taylor, M.D.; Jenkins, A.; Pomeranz Krummel, D.A.; Sengupta, S., *J Neurooncol.* (2019), 142, 411-422, doi: 10.1007/s11060-019-03115-0.
36. “The C-19 Methyl Substituted Sarpagine-Macroline-Ajmaline Alkaloids: Diversity, Occurrence, Bioactivity, and Synthesis”, Rahman, M. T.; Cook, J. M., Studies in Natural Products Chemistry, Vol. 64, Atta-ur-Rahman, Ed.; Elsevier: Amsterdam, 2020, doi: 10.1016/B978-0-12-817903-1.00001-2.
37. “The α2,3-selective potentiator of GABAA receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in rats”, Witkin, J.M.; Cerne, R; Davis P.G.; Freeman, K.b.; Carmo, J.M.; Rowlett, J.; Methuku, K.R.; Okun, A.; Gleason, S.D.; Li, X.; Poe, R.M.; Li, G.; Schkeryantz, J.M.; Jahan, R.; Yang, L.; Guo1, W.; Anderson, W.H.; Catlow, J.T.; Jones, T/M.; Porreca, F.; Smith, J.l.; Knopp, K.L.; Cook, J.M., *Pharmacol. Biochem. Behav.* (2019), 180: 22-31, doi.org/10.1016/j.pbb.2019.02.013.
38. “The value of human epileptic tissue in the characterization and development of novel antiepileptic drugs: The example of CERC-611 and KRM-II-81”, Witkin, J.M.; Ping, X.; Cerne, R.; Mouser, C.; Jin, X.; Hobbs, J.; Tiruveedhula, VVNPB; Li, G.; Jahan, R.; Rashid, F.; Golani, L.; Cook, J.M.;, Smith, J.L., *Brain. Res.*  (2019), doi.org/10.1016/j.brainres.2019.146356.
39. “MIDD0301 – A first‐in‐class anti‐inflammatory asthma drug targets GABAA receptors without causing systemic immune suppression”, Zahn, N.M.; Huber, A.T.; Mikulsky, B.N.; Stepanski, M.E.; Kehoe, A.S,; Li, G.; Schussman, M.; Rashid Roni, M.S.; Kodali, R.; Cook, J.M.; Stafford, D.C.; Steeber, D.A.; Arnold, L.A., *Basic Clin Pharmacol Toxicol.*, doi: 10.1111/bcpt.13206, Jan 2019.
40. “The Ambidextrous Pictet–Spengler Reaction: Access to the (+)- or (–)-Enantiomers of the Bioactive C-19 Methyl-Substituted Sarpagine/Macroline/Ajmaline Alkaloids from Either d- or l-Tryptophan”, Rahman, M.T.; Cook, J.M., *Synthesis*, DOI: 10.1055/s-0037-1610687, Feb, 2019.
41. “GABAA α2/α3 receptor subtypes and the abuse-related effects of ethanol in rhesus monkeys: Experiments with selective positive allosteric modulators”, Berro, L.F.; Rüedi-Bettschen, D.; Cook, J.E.; Golani, L.K.; Li, G.; Jahan, R.; Rashid, F.; Cook, J.M.; Rowlett, J.K.; Platt, D.M., *Alcohol. Clin. Exp. Res*. (2019), 43 (5), doi.org/10.1111/acer.14000.
42. “The positive allosteric modulator of α2/3-containing GABAA receptors, KRM-II-81, is active in pharmaco-resistant models of epilepsy and reduces hyperexcitability after traumatic brain injury”, Witkin J.M.; Li, G.; Golani, L.; Xiong, W.; Smith, J.L.; Ping, X.; Rashid, F.; Jahan, R.; Cerne, R.; Cook, J.M.; Jin X., *J. Pharmacol. Exp. Ther.*, 2019, doi: 10.1124/jpet.119.260968 .
43. “Insight into Novel Treatment for Cognitive Dysfunctions across Disorders”, Prevot, T.D.; Li, G.; Cook, J.M.; Sibille, E., *ACS Chem. Neurosci*., 2019, DOI: 10.1021/acschemneuro.9b00148.
44. “Non-sedating benzodiazepines cause paralysis and tissue damage in the parasitic blood fluke Schistosoma mansoni”, McCusker, P.; Mian, M. Y.; Li, G.; Olp, M. D.; Phani Babu, V. V. N.; Rashid, F.; Golani, L. K.; Verma, R. S.; Smith, B. C.; Cook, J.M.; Chan, J.D., *PLoS NTD*, 2019, doi: 10.1371/journal.pntd.0007826, PMCID: PMC6881066.
45. “Facilitation of Social Support through Negative Allosteric Modulation of α5-Associated GABAA Receptors: A Novel Mechanism for the Treatment of Depression, Agitation, and Aggression in the Elderly”, Witkin, J.M.; Golani, L.K.; Cerne, R,; Rahman, M.T.; Li, G.; Poe, M.M.; Cook, J.M. ; Smith, J.L., *OBM Geriatrics* (2019), doi: 10.21926/obm.geriatr.1903073.
46. “The effects of pH on the structure and bio-availability of Imidazobenzodiazepine-3-Carboxylate MIDD0301”, Roni, M. R.; Li, G.; Mikulsky, B.N.; Knutson, D. E.; Mian, Y.; Zahn, N. M.; Cook, J.M.; Stafford, D. C.; Arnold, L. A., *Mol. Pharmaceutics* (2020), doi: 10.1021/acs.molpharmaceut.9b01210.
47. "Improvements in the pharmacological profile of diazepam by KRM-II-81, an imidazodiazepine positive allosteric modulator of a2/3-containing GABAA receptors: Preclinical data predict enhanced efficacy for epilepsy, chronic pain, anxiety, and depression”, Cerne, R.; Fisher, J.L.; Siemian, J. N.; Smith, J.L.; Knutson, D.E.; Cook, J.M.; Witkin, J.M., *J Pharmaceut Biomed*, 2 (1):117, Dec 2019.
48. “Reversal of age-related neuronal atrophy by α5-GABAA receptor positive allosteric modulation”, Prevot, T.; Sumitomo, A.; Tomoda, T.; Knutson, D.E.; Li, G.; Mondal, P.; Banasr, M.; Cook, J.M.; Sibille, E., *Cerebral Cortex*, 2020, doi: 10.1093/cercor/bhaa310.
49. “Targeting nitric oxide production in microglia with novel imidazodiazepines for nonsedative pain treatment”, Nieman, A.; Li, G.; Zahn, N.M.; Mian, Y.; Mikulsky, B.N.; Hoffman, D.A.; Wilcox, T.M.; Kehoe, A.S.; Luecke, I.W.; Poe, M.M.; Alvarez-Carbonell, D.A.; Cook, J.M.; Stafford, D.C.; Arnold, L.A., *ACS Chemical Neuroscience* (2020)*,* doi:10.1021/acschemneuro.0c00324.
50. “The Imidazodiazepine Anticonvulsant, KRM-II-81, Produces Novel, Non-diazepam-like Antiepileptogentic Effects”, Knutson, D.; Smith, J.; Ping, X.; Jin, X.; Golani, L.; Li, G. ; Tiruveedhula, V. V. N.; Rashid, F.; Mian, Y.; Jahan, R.; Sharmin, D.; Cerne, R.; Cook, J.; Witkin, J., *ACS Chem. Neurosci*., 2020; 11(17):2624-2637. doi: 10.1021/acschemneuro.0c00295.
51. “α6GABAA receptor positive modulators alleviate migraine-like grimaces in mice via compensating GABAergic deficit in trigeminal ganglia”, Tzeng, H.; Lee, M.T.; Fan, P.; Knutson, D.E.; Lai, T.; Seighert, W.; Cook, J.M.; Chiou, L., *Neurotherapeutics,* 2021, 18(1):569-585, doi: 10.1007/s13311-020-00951-1.
52. “Nanocrystal dispersion of DK-I-56-1, a poorly soluble pyrazoloquinolinone positive modulator of α6 GABAA receptors: formulation approach toward improved in vivo performance”, Mitrovic, J.R.; Divović, B.; Knutson, D.E.; Dokovic, J.B.; Vulic, P.J.; Randjelovic, D.V.; Dobricic, V.D.; Calija, B.R.; Cook, J.M.; Savić, M.M.; Savic, S.D., *Eur J Pharm Sci*, 2020, 152:105432, doi: 10.1016/j.ejps.2020.105432.
53. “Design, synthesis and characterization of novel gamma‑aminobutyric acid type A receptor ligands”, Pandey, K.P.; Khan, Z.A.; Golani, L.K.; Mondal, P.; Mian, Y.; Rashid, F.; Tiruveedhula, V. V. N.; Knutson, D.; Zahn, N.M.; Arnold, L.A.; Witkin, J.; Cook, J., Arkivoc (2020), part vii, 242-256, doi: 10.24820/ark.5550190.p011.398.
54. “Improved scale-up synthesis and purification of clinical asthma candidate MIDD0301”, Knutson, D.E.; Rashid Roni, M.S.; Mian, Y.; Cook, J.M.; Stafford, D.C.; Arnold, L.A., *Org. Process Res. Dev.*, 2020, 24, 8, 1467–1476, doi: 10.1021/acs.oprd.0c00200.
55. “The α2,3-selective potentiators of GABAA receptors, KRM-II-81 and MP-III80, produce anxiolytic-like effects and block chemotherapy-induced hyperalgesia in mice without tolerance development”, Biggerstaffa, A.; Kivella, B.; Smith, J.L.; Mian, Y.; Golani, L.K.; Rashid, F.; Sharmin, D.; Knutson, D.E.; Cerne, R.; Cook, J.M.; Witkin, J.M., *Pharmacol Biochem Behav.*, 2020, 196:172996. doi: 10.1016/j.pbb.2020.172996.
56. “A review of the updated pharmacophore for the alpha 5 GABA(A) benzodiazepine receptor model”, In: Ayuk Eugene Lakem, editor. Prime Archives in Chemistry. Hyderabad, India: Vide Leaf. 2020.
57. “Melanoma cell intrinsic GABAA receptor enhancement potentiates radiation and immune checkpoint inhibitor response by promoting direct and T cell-mediated anti-tumor activity”, Krummel, D.A.P.; Nasti, T.H.; Kaluzova, M.; Kallay, L.; Bhattacharya, D.; Melms, J.C.; Izar, B.; Xu, M.; Burnham, A.; Ahmed, T.; Li, G.; Lawson, D.; Kowalski, J.; Cao, Y.; Switchenko, J.M.; Ionascu, D.; Cook, J.M.; Medvedovic, M.; Jenkins, A.; Khan, M.K.; Sengupta, S*., Int J Radiat Oncol Biol Phys.*, 2021, 09(4):1040-1053, doi: 10.1016/j.ijrobp.2020.10.025.
58. “Nebulized MIDD0301 reduces airway hyperresponsiveness in moderate and severe murine asthma models”, Zahn, N.; Mikulsky, B.; Rashid Roni, M.S.; Yocum, G.; Mian, Y.; Knutson, D.; Cook, J.; Emla, C.W.; Stafford, D.; Arnold, L.A., ACS Pharmacol. Transl. Sci. (2020), 3, 6, 1381–1390, doi:10.1021/acsptsci.0c00180.
59. “Synergistic antihyperalgesic and antinociceptive effects of morphine and methyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate (MP-III-024): a positive allosteric modulator at α2GABAA and α3GABAA receptors", Rahman, A.; Keck, T.M.; Poe, M.M.; Sharmin, D.; Cook, J.M.; Fischer, B.D., Psychopharmacology, 2021, doi: 10.1007/s00213-021-05791-1.
60. “The enantiospecific synthesis of indole alkaloids which culminated in the ambidextrous Pictet-Spengler reaction for the C-19 methyl-substituted sarpagine family” Rahman, M.T.; Namjoshi, O.A.; Cook, J.M., Progress in Heterocyclic Chemistry, Vol. 32 (Ch. 1), Gordon Gribble and John Joule Eds.; Elsevier: Amsterdam, December 2020, Print ISBN: 9780323898126.
61. “The α6 GABAA receptor positive allosteric modulator DK-I-56-1 reduces tic-related behaviors in mouse models of tourette syndrome”, Cadeddu, R.; Knutson, D.E.; Mosher, L.J.; Loizou, S.; Odeh, K.; Fisher, J.L.; Cook, J.M.; Bortolato, M., Biomolecules, 2021,11(2):175. doi: 10.3390/biom11020175.
62. “Blockade of α1 subtype GABAA receptors attenuates the development of tolerance to the antinociceptive effects of midazolam in rats”, Lewter, L.A.; Golani, L.K.; Cook, J.M.; Li, J., *Behav Pharmacol.*, 2021, 32(4):345-350. doi: 10.1097/FBP.0000000000000614.
63. “Vasodilatory effects of a variety of positive allosteric modulators of GABAA receptors on rat thoracic aorta”, Boji´c, M.G.; Todorovi´c, L.; Santraˇc, A.; Mian, Y.; Sharmin, D.; Cook, J.M.; Savi´c, M.M., *Eur J Pharmacol*., 2021, 899:174023, doi: 10.1016/j.ejphar.2021.174023.
64. “Modulation of relapse-like drinking in male Sprague-Dawley rats by ligands targeting the α5GABAA receptor”, Chandler, C.M.; Reeves-Darby, J.; Jones, S.A.; Li, G.; Rahman, M.T.; Cook, J.M.; Platt, D.M., *Neuropharmacology*, 2021, doi: org/10.1016/j.neuropharm.2021.108785.
65. “Positive modulation of cerebellar α6GABAA receptors for treating essential tremor: a proof-of-concept study in harmaline-treated mice”, Huang, Y.; Lee, M.T.; Sieghart, W.; Knutson, D.; Wimmer, L.R.; Sharmin, D.; Cook, J.; Mihovilovic, M.D.; Chiou, L-C., *bioRxiv.*, 2021, doi: 10.1101/2021.04.19.440397.
66. “Symptomatic and Disease-Modifying Effects of GABAA Receptor Positive Allosteric Modulation in a Mouse Model of Chronic Stress”, Bernardo, A.; Lee, P.; Marcotte, M.; Mian, Y.; Khan, Z.A.; Sharmin, D.; Cook, J.M.; Sibille, E.; Prevot, T.D., *bioRxiv.*, 2021, doi: 10.1101/2021.03.22.436517.
67. “8-Substituted Triazolobenzodiazepines: *In Vitro* and *In Vivo* Pharmacology in Relation to Structural Docking at the α1 Subunit-Containing GABAA Receptor”, Golani, L.K.; Platt, D.M.; Rüedi-Bettschen, D.; Edwanker, C.; Huang, S.; Poe, M.M.; Furtmüller, R.; Sieghart, W.; Cook, J.M.; Rowlett, J.K., *Front Pharmacol*, 2021, 12:625233, doi: 10.3389/fphar.2021.625233.
68. “Bisindole Alkaloids from the *Alstonia* Species: Recent Isolation, Bioactivity, Biosynthesis, and Synthesis”, Pandey, K.P.; Rahman, M.T.; Cook, J.M., *Molecules*, 2021, 26(11):3459, doi: 10.3390/molecules26113459.
69. “Tolerance and Dependence following Chronic Alprazolam Treatment in Rhesus Monkeys: Role of GABAA Receptor Subtypes”, Duke, A.N.; Tiruveedhula, V.V.N.P.; Sharmin, D.; Knutson, D.E.; Cook, J.M.; Platt, D.M.; Rowlett, J.K., *Drug Alcohol Depend*, 2021, PMID: 34500240, doi: 10.1016/j.drugalcdep.2021.108985.
70. “Overcoming the Low Oral Bioavailability of Deuterated Pyrazoloquinolinone Ligand DK-I-60-3 by Nanonization: A Knowledge-Based Approach”, Mitrović, J.R.; Divović-Matović, B.; Knutson, D.E.; Đoković, J.B.; Kremenović, A.; Dobričić, V.D.; Randjelović, D.V.; Pantelić, I.; Cook, J.M.; Savić, M.M.; Savić, S.D., *Pharmaceutics*, 2021, 13(8):1188, doi: 10.3390/pharmaceutics13081188.
71. “Behavioral Deficits Induced by Somatostatin-Positive GABA Neuron Silencing Are Rescued by Alpha 5 GABA-A Receptor Potentiation”, Fee, C.; Prevot, T.D.; Misquitta, K.; Knutson, D.E.; Li, G.; Mondal, P.; Cook, J.M.; Banasr, M.; Sibille, E., *Int J Neuropsychopharmacol*, 2021, 24(6):505-518, doi: 10.1093/ijnp/pyab002.
72. “GABAkines – Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors”, Carne, R.; Lippa, A; Poe, M.M.; Smith, J.L.; Jin, X.; Ping, X.; Golani, L.K.; Cook, J.M.; Witkin, J.M., *Pharmacol Ther.*, 2021, doi: 10.1016/j.pharmthera.2021.108035.
73. “Identification and Quantification of MIDD0301 Metabolites”, Rashid Roni, M.S.; Zahn, N.M.; Mikulsky, B.N.; Webb, D.A.; Mian, Y.; Knutson, D.E.; Guthrie, M.L.; Cook, J.M.; Stafford, D.C.; Arnold, L.A., *Curr Drug Metab.*, 2021, 22(14):1114-1123, doi: 10.2174/1389200222666211202093841.
74. “Development of inhaled GABAA receptor modulators to improve airway function in bronchoconstrictive disorders”, Zahn, N.; Rashid Roni, M.S.; Yocum, G.; Meyer, M.; Webb, D.; Mian, Y.; Cook, J.; Stafford, D.C.; Emala, C.; Arnold, L.A., *ACS Pharmacol. Transl. Sci.*, 2022, doi:10.1021/acsptsci.1c00238.
75. “Hippocampal α5-GABAA receptors modulate dopamine neuron activity in the rat ventral tegmental area”, Perez, S.M.; McCoy, A.M.; Prevot, T.D.; Mian, Y.; Carreno, F.R.; Frazer, A.; Cook, J.M.; Sibille, E.; Lodge, D.J., *Biological Psychiatry: Global Open Science*, 2022, doi: 10.1016/j.bpsgos.2021.12.010.
76. “Completion of the Total Synthesis of Several Bioactive Sarpagine/Macroline Alkaloids Including the Important NF-κB Inhibitor N4-Methyltalpinine”, Rahman, M.T.; Tiruveedhula, V.V.N.P.B.; Stephen, M.R.; Rallapalli, S.K.; Pandey, K.P.; Cook, J.M., *Molecules*, 2022, 27(5), doi:10.3390/molecules27051738.
77. “Positive Allosteric Modulation of α5-GABAA Receptors Reverses Stress-Induced Alterations in Dopamine System Function and Prepulse Inhibition of Startle”, McCoy, A.M.; Prevot, T.D.; Mian, M.Y.; Cook, J.M.; Frazer, A.; Sibille, E.L.; Carreno, F.R.; Lodge, *Int. J. Neuropsychopharmacol.*, 2022, doi:10.1093/ijnp/pyac035.
78. “Can GABAkines quiet the noise? The GABAA receptor neurobiology and pharmacology of tinnitus”, Witkin, J.M.; Lippa, A.; Smith, J.L.; Cook, J.M.; Cerne, R., *Biochem Pharmacol*., 2022, 201:115067, doi: 10.1016/j.bcp.2022.115067.
79. “Hydrochloride Salt of the GABAkine KRM-II-81”, Mian, M.Y.; Divović, B.; Sharmin, D.; Pandey, K.P.; Golani, L.K.; Tiruveedhula, V.V.N.P.B.; Cerne, R.; Smith, J.L.; Ping, X.; Jin, X.; Imler, G.H.; Deschamps, J.R.; Lippa, A.; Cook, J.M.; Savić, M.M.; Rowlett, J.; Witkin, J.M., *ACS Omega*, 2022, 7(31), 27550–27559, doi: 10.1021/acsomega.2c03029.
80. “Symptomatic and neurotrophic effects of GABAA receptor positive allosteric modulation in a mouse model of chronic stress”, Bernardo, A.; Lee, P.; Marcotte, M.; Mian, M.Y.; Rezvanian, S.; Sharmin, D.; Kovačević, A.; Savić, M.M.; Cook, J.M.; Sibille, E.; Prevot, T.D., *Neuropsychopharmacology*, 2022, 47 (9), 1608–1619, doi: 10.1038/s41386-022-01360-y.
81. “Metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the α2/3-selective GABAkine KRM-II-81”, Golani, L.K.; Divović, B.; Sharmin, D.; Pandey, K.P.; Mian, M.Y.; Cerne, R.; Zahn, N.M.; Meyer, M.J.; Tiruveedhula, V.V.V.N.P.B.; Smith, J.L.; Ping, X.; Jin, X.; Lippa, A.; Schkeryantz, J.M.; Arnold, L.A.; Cook, J.M.; Savić, M.M.; Witkin, J.M., *Biopharm Drug Dispos*., 2022, 43(2), 66-75, doi: 10.1002/bdd.2313.
82. “Effects of α5 GABAA receptor modulation on social interaction, memory, and neuroinflammation in a mouse model of Alzheimer's disease”, Aranđelović, J.; Santrač, A.; Batinić, B.; Todorović,L.; Stevanović, V.; Tiruveedhula, V.V.V.N.P.B.; Sharmin, D.; Rashid, F.; Stanojević, B.; Cook, J.M.; Savić, M.M., *CNS Neurosci Ther*., 2022, doi: 10.1111/cns.13914.
83. “Development and Validation of LC-MS/MS method for the determination of ARN14988, an acid ceramidase inhibitor, and its application to a pharmacokinetic study in mouse model”, Rajaratnam, V.; Islam, M.M.; Kub, E.F.; Rajaratnam, S.; Kim, K.B.; Rahman, M.T.; Rashid, F.; Benko, A.M.; Cook, J.M.; Arnold, L.A.; Mirza, S.P., *Biomed Chromatogr.,* 2023 Sep 26:e5754, doi: 10.1002/bmc.5754.
84. “An efficient debromination technique using PMHS with a number of ligands containing different functional groups”, Mian, M.Y.; Mondal, P.; Sharmin, D.; Pandey, K.P.; Rashid, F.; Rezvanian, S.; Golani, L.K.; Tiruveedhula, V.V.V.N.P.B.; Rajaratnam, V.; Mirza, S.P.; Chan, J.D.; Witkin J.M.; Cook, J.M., *Arkivoc,* 2021, doi: 10.24820/ark.5550190.p011.712.
85. “Positive and Negative Selective Allosteric Modulators of α5 GABAA Receptors: Effects on Emotionality, Motivation, and Motor Function in the 5xFAD Model of Alzheimer's Disease”, Aranđelović, J.; Santrač, A.; Batinić, B.; Todorović, L.; Khan, M.Z.A.; Rashid, F.; Poe, M.M.; Obradović, A.; Cook, J.M.; Savić, M.M., *J Alzheimers Dis*., 2021, 84(3):1291-1302, doi: 10.3233/JAD-215079.
86. “Distinct sex-dependent behavioral responses induced by two positive allosteric modulators of alpha 5 subunit-containing GABAA receptors”, Souza, A.J.; Cortez, I.L.; Silva, N.R.; Pedrazzi, J.F.; Domingos, L.B.; Braga, M.S.; Santos-Silva, T.; Del-Bel, E.A.; Resstel, L.B.; Li, G.; Mian, M.Y.; Sharmin, D.; Guimarães, F.S.; Cook, J.M.; Gomes, F.V., *Behav Brain Res.*, 2022, 428:113832, doi: 10.1016/j.bbr.2022.113832.
87. “Positive modulation of α5GABAA receptors leads to dichotomous effects in rats on memory pattern and GABRA5 expression in prefrontal cortex and hippocampus”, Santrac, A.; Batinic, B.; Stamenic, T.T.; Arandjelovic, J.; Sharmin, D.; Knutson, D.; Cook, J.M.; Savic, M.M., *Behav. Brain Res*., 2022, doi: 10.1016/j.bbr.2021.113578.
88. “Postweaning positive modulation of α5GABAA receptors improves autism-like features in prenatal valproate rat model in a sex-specific manner”, Santrač, A.; Bijelić, D.; Stevanović, V.; Banićević, M.; Aranđelović, J.; Batinić, B.; Sharmin, D.; Cook, J.M.; Savić, M.M., *Autism Res*., 2022, 15(5):806-820, doi: 10.1002/aur.2699.
89. “Comparative pharmacodynamic and pharmacokinetic study of MIDD0301 and its (S) enantiomer”, Rashid Roni, M.S.; Zahn, N.M.; Yocum, G.T.; Webb, D.A.; Mian, M.Y.; Meyer, M.J.; Tylek, A.S.; Cook, J.M.; Emala, C.W.; Stafford, D.C.; Arnold L.A., *Drug Dev. Res*., 2022, 83(4), doi: 10.1002/ddr.21926.
90. “Rationalizing the binding and α subtype selectivity of synthesized imidazodiazepines and benzodiazepines at GABAA receptors by using molecular docking studies”, Golani, L.K.; Mian, M.Y.; Ahmed, T.; Pandey, K.P.; Mondal, P.; Sharmin, D.; Rezvanian, S.; Witkin, J.M.; Cook, J.M., *Bioorg Med Chem Lett*., 2022, 62:128637. doi: 10.1016/j.bmcl.2022.128637.
91. “Structural analogs of the GABAkine KRM-II-81 are orally bioavailable anticonvulsants without sedation", Pandey, K.; Divović, B.; Rashid, F.; Golani, L., Cerne, R.; Zhan, N.; Meyer, M.; Arnold, A.L.; Sharmin, D.; Mian, M.Y.; Smith, J.; Ping, X.; Jin, X.; Lippa, A.; Tiruveedhula, V.; Cook, J.M.; Savic, M.; Witkin, J., *J Pharmacol Exp Ther*, 2023 Apr, 385(1):50-61. doi: 10.1124/jpet.122.001362.
92. “Comparative anticonvulsant activity of the GABAkine KRM-II-81 and a deuterated analog", Ping, X.; Meyer, M.; Zahn, N. M.; Golani, L.; Sharmin, D.; Pandey, K.; Rezvanian, S.; Mondal, P.; Jin, X.; Arnold, L.; Cerne, R.; Cook, J.; Divovic, B.; Savić, M. M.; Lippa, A.; Smith, J.; Witkin, J. M., *Drug Dev. Res*., 2023 May, 84(3):527-531, doi: 10.1002/ddr.22042.
93. “Cerebellar α6GABAA receptors as a therapeutic target for essential tremor: Proof-of-concept study with ethanol and pyrazoloquinolinones”, Huang, Y.; Lee, M.T.; Hsueh, H.; Knutson, D.E.; Cook, J.M.; Mihovilovic, M.D.; Seighart, W.; Chiou, L., *Neurotherapeutics,* 2023 Mar, 20(2):399-418, doi: 10.1007/s13311-023-01342-y.
94. “KRM-II-81, a beta3 preferring GABAA receptor potentiator, blocks handling-induced seizures in Theiler’s murine encephalomyelitis virus-infected mice”, Sharmin, D.; Pandey, K.P.; Golani, L.K.; Revanian, S.; Mian, M.Y.; Fisher, J.L.; Lippa, A.; Cook, J.M.; Smith, J.D.; Witkin, J.M.; Shafique, H.; Cerne, R., in press, *Neuropharmacology*, Dec 2022.
95. “The orally bioavailable imidazodiazepine, KRM-II-81, is a novel potentiator of α2/3-containing GABAA receptors with analgesic efficacy”, Cerne, R.; Smith, J.L.; Fisher, J.L.; Golani, L.K.; Knutson, D.E.; Cook, J.M.; Witkin, J.M., *The Neurobiology, Physiology, and Psychology of Pain,* Chapter 11 (pp. 117–127), 2022, doi: 10.1016/B978-0-12-820589-1.00011-7.
96. “Behavioural interaction of pyrazoloquinolinone positive allosteric modulators at α6GABAA receptors and diazepam in rats: Anti-diazepam-induced ataxia action as a structure-dependent feature”, Matovic, B.D.; Knutson, D.; Mitrovic, J.; Stevanovic, V.; Stanojevic, B.; Savic, S.; Cook, J.M.; Savic, M.M., *Basic Clin. Pharmacol. Toxicol.*, 2022, doi: 10.1111/bcpt.13801.
97. “GABA-A alpha 2/3 but not alpha 1 receptor subunit ligand inhibits harmaline and pimozide-induced tremor in rats”, Kosmowska, B.; Paleczna, M.; Biała, D.; Kadłuczka, J.; Wardas, J.; Witkin, J.M.; Cook, J.M.; Sharmin, D.; Marcinkowska, M.; Kuter, K.Z., *Biomolecules*, 2023 Jan 18, 13(2):197, doi: 10.3390/biom13020197.
98. “Modeling cue-exposure therapy for alcohol use disorder in rhesus monkeys: Effects of putative cognitive enhancers”, Pareek, T.; Overton, J.S.; Nguyen L.T.; Rahman M.T.; Sharmin D.; Cook, J.M.; Platt, D.M., *Drug and Alcohol Dependence*, 2022, doi: 10.1016/j.drugalcdep.2022.109735.
99. “The imidazodiazepine, KRM-II-81, an example of a newly-emerging generation of GABAkines for neurological and psychiatric disorder”, Witkin, J.M.; Lippa, A.; Smith, J.L.; Jin, X.; Ping, X.; Biggerstaff, A.; Kivell, B.M.; Knutson, D.E.; Sharmin, D.; Pandey, K.P.; Mian, M.Y.; Cook, J.M.; Cerne, R., *Pharmacol. Biochem. Behav*., Feb 2022 ;213:173321, doi: 10.1016/j.pbb.2021.173321.
100. “Better than Xanax”, Witkin, J.M.; Shafique, H.; Lippa, A.; Pandey, K.P.; Smith, J.D.; Cook, J.M.; Cerne, R., *Advances in Health and Disease.*, L. T. Duncan, Ed., Nova Science Publishers, Inc., 2022, pp. 163-182, Hauppauge, NY.
101. “High amount of lecithin facilitates oral delivery of a poorly soluble pyrazoloquinolinone ligand formulated in lipid nanoparticles: Physicochemical, structural and pharmacokinetic performances”, Mitrović, J.R.; Divović-Matović, B.; Knutson, D.E.; Petković, M.; Djorović, D.; Randjelović, D.V.; Dobričić, V.D.; Đoković, J.B.; Lunter, D.J.; Cook, J.M.; Savić, M.M.; Savić, S.D., *Int J Pharm.,* 2023 Feb 25, 633:122613, doi: 10.1016/j.ijpharm.2023.122613.
102. “Synthesis and Receptor Binding Studies of α5 GABAAR Selective Novel Imidazodiazepines Targeted for Psychiatric and Cognitive Disorders”, Sharmin, D.; Mian, M.Y.; Marcotte, M.; Prevot, T.D.; Sibille, E.; Witkin, J.M.; Cook, J.M.; *Molecules*, 2023 Jun 14, 28(12):4771, doi: 10.3390/molecules28124771.
103. “Freeze-dried nanocrystal dispersion of novel deuterated pyrazoloquinolinone ligand (DK-I-56-1): Process parameters and lyoprotectant selection through the stability study”, Mitrović, J.R.; Žiberna, M.B.; Vukadinović, A.; Knutson, D.E.; Sharmin, D.; Kremenović, A.; Grabnar, P.A.; Planinšek, O.; Lunter, D.; Cook, J.M.; Savić, M.M.; Savić, S.D., *Eur J Pharm Sci*, 2023 Oct 1:189:106557, doi: 10.1016/j.ejps.2023.106557.
104. “α5-GABAA receptor modulation reverses behavioral and neurophysiological correlates of psychosis in rats with ventral hippocampal Alzheimer’s Disease-like pathology”, Eassa, N.; Perez, S.M.; Boley, A.M.; Elam, H.; Sharmin, D.; Cook, J.M.; Lodge, D.J., *Int. J. Mol. Sci.*, 2023 Jul 22, 24(14):11788, doi: 10.3390/ijms241411788.
105. “GL-II-73, a Positive Allosteric Modulator of α5GABAA Receptors, Reverses Dopamine System Dysfunction Associated with Pilocarpine-Induced Temporal Lobe Epilepsy”, McCoy A.M.; Prevot T.D.; Sharmin, D.; Cook, J.M.; Sibille, E.L.; Lodge, D.J., *Int J Mol Sci.*, 2023 Jul 18, 24(14):11588, doi: 10.3390/ijms241411588.
106. “Vascular effects of midazolam, flumazenil, and a novel imidazobenzodiazepine MP-III-058 on isolated rat aorta”, Bojić, M.G.; Treven, M.; Pandey K.P.; Tiruveedhula, V.V.N.P.B.; Santrač, A.; Đukanović, Đ.; Vojinović, N.; Amidžić, L.; Škrbić, R.; Scholze, P.; Ernst, M.; Cook, J.M.; Savić, M.M., *Can J Physiol Pharmacol.,* 2023 Nov 1, doi: 10.1139/cjpp-2023-0285.
107. “An alpha 5-GABAa receptor positive allosteric modulator attenuates social and cognitive deficits without changing dopamine system hyperactivity in an animal model for autism”, Souza, A.J.; Sharmin, D.; Cook, J.M.; Guimarães, F.S.; Gomes, F.V., *bioRxiv*., 2023 Aug 26, 2023.08.24.554679. doi: 10.1101/2023.08.24.554679.
108. “Extrasynaptic localization is essential for α5GABA A receptor modulation of dopamine system function”, McCoy, A.M.; Prevot, T.D.; Mian, M.Y.; Sharmin, D.; Ahmad, A.N.; Cook, J.M.; Sibille, E.L.; Lodge, D.J., *bioRxiv*, 2023 Jul 14:2023.07.12.548744, doi: 10.1101/2023.07.12.548744.
109. “GABA(A) receptor activation drives GABARAP-Nix mediated autophagy to radiation-sensitize primary and brain-metastatic lung adenocarcinoma tumors”, Bhattacharya, D.; Barille, R,; Toukam, D.K.; Gawali, V.S.; Kallay, L.; Ahmed, T.; Brown, H.; Rezvanian, S.; Karve, A.; Desai, P.B.; Medvedovic, M.; Wang, K.; Ionascu, D.; Harun, N.; Wang, C.; Baschnagel, A.M.; Kritzer, J.A.; Cook, J.M.; Krummel, D.A.P.; Sengupta, S., *bioRxiv.*, Dec 2023, doi: 10.1101/2023.11.29.569295.
110. “KRM–II–81 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsy”, Smith, J.L.; Wertz, J.; Lippa A.; Ping X.; Jin, X.; Cook J.M.; Witkin J.M.; Cerne, R., *Heliyon*, Dec 2023, doi: 10.1016/j.heliyon.2023.e23752.
111. “New Imidazodiazepine Analogue, 5-(8-Bromo-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole, Provides a Simplified Synthetic Scheme, High Oral Plasma and Brain Exposures, and Produces Antiseizure Efficacy in Mice, and Antiepileptogenic Activity in Neural Networks in Brain Slices from a Patient with Mesial Temporal Lobe Epilepsy’, Sharmin, D.; Divović, B.; Ping, X.; Cerne, R.; Smith, J.L.; Rezvanian, S.; Mondal, P.; Meyer, M.J.; Kiley, M.E.; Arnold, L.A.; Mian, M.Y.; Pandey, K.P.; Jin, X.; Mitrović, J.R.; Djorović, D.; Lippa, A.; Cook, J.M.; Golani, L.K.; Scholze, P.; Savić, M.M.; Witkin J.M., *ACS Chem. Neurosci.*, Jan 2024, doi: 10.1021/acschemneuro.3c00555.

B. **Conference Proceedings and Abstracts** ‑ these are listed below under E.

C. **Patents**

1. Cook, James M.; Huang, Qi; He, Xiaohui; Li, Xioayan; Yu, Jianming; Han, Dongmei; “Anxiolytic Agents with Reduced Sedative and Ataxic Effects,” US Patent 7,119,196 B2 (2006), 94 pages.
2. June, Harry L.; Cook, James M.; Ma, Chunrong. Methods for Reducing Alcohol Cravings in Chronic Alcoholics. U.S. Pat. Appl. Publ. (2003), 60 pp. CODEN: USXXCO US 2003176456 A1 20030918 CAN 139:241570 AN 2003:737374 CAPLUS
3. Cook, James M.; Zhou, H.; Huang, S.; Sarma, P.V.V.S.; Zhang, C. Stereospecific Anxiolytic and Anticonvulsant Agents with Reduced Muscle-Relaxant, Sedative-Hypnotic and Ataxic Effects. Provisional patent application 60/584,143 filed June 30, 2004: PCT patent filed June 30, 2005: US patent filed June 30, 2005. Published in 2006. 2006003995 (2006), 89pp. PCT WO2006/004945 A1. Issued 2009 US 7,618,958 (2009).
4. Cook, James M.; Han, D.; and Clayton, T.; GABAergic Agents to Treat Memory Deficits. Provisional patent filed June 30, 2005. Published in 2006. Patent No. PCT/US 2006018721; US Patent No. 7,595,395; issued 7/24/2009.
5. Cook, James M.; Defoe, L.; Kabir, M. Shahjahan; Monte, A.; Rott, M.; Schwan, W., US CIP for Anti-infective Agents and Methods of Use, Filed on April 6, 2007 (US Application No. 11/697,582); published 2007, CIP of US ser No. 163,421.
6. “Selective Anticonvulsant Agents and Their Uses,” J.M. Cook, R. Edwanker, C.Edwanker, S. Huang, H. Jain, F. Rivas, J. Yang, and H. Zhou, Filed provisional patent on 3/20/08.
7. “GABAergic Receptor Subtype Selective Ligands and Their Uses,” J.M. Cook, T. Clayton, H. Jain, Y. Teng, J. Yang, S. Rallapalli, Filed a provisional patent on 5/4/08.
8. “Anxiolytic Agents with Reduced Sedative and Ataxic Effects,” J.M. Cook, Q. Huang, X. He, X. Li, J. Yu, D. Han, Patent Issue No. 2003230754, 2/29/08. Issued 6/26/2007, Pat 7,265,656.
9. “Anxiolytic Agents with Reduced Sedative and Ataxic Effects,” J.M. Cook, Q. Huang, X. He, X. Li, J. Yu, D. Han, Patent Issue No. 255781, 3/31/08.
10. “Anxiolytic Agents with Reduced Sedative and Ataxic Effects,” J.M. Cook, Q. Huang, X. He, X. Li, J. Yu, D. Han, Patent Issue No. 10-0865410, 10/24/08.
11. “Anxiolytic Agents with Reduced Sedative and Ataxic Effects,” J.M. Cook, Q. Huang, X. He, X. Li, J. Yu, D. Han, Divisional Patent Issue No. 547480, 3/13/08.
12. “Cysteine and Cystine Prodrugs to Treat Schizophrenia and Drug Addiction,” J. Cook, D. Baker, E.M. Johnson and W. Yin, PCT/US 09/047099, filed April 16, 2009; WO 2009/137251A2, International Publication date, Nov. 12, 2009.
13. “Cysteine and Cystine Prodrugs to Treat Schizophrenia and Drug Addiction,” J. Cook, D. Baker, E.M. Johnson and W. Yin, Filed on 8/11/08. Application number 12189516. Published 08/13/2009; PCT WO 2009/100431 A1.
14. “Selective Agents for Pain Suppression”, J.M.Cook, S.Huang, R.Edwankar, O. Namjoshi, Z. Wang, US Patent Pub# US 2010/0317619A1, Pub. Date Dec. 16, 2010.
15. “Gabaergic Receptor Subtype Selective Ligands and their Uses,” Cook, J. M., S. Rallapalli, T. Clayton, H. Jain, J. Yang, Teng, Y., provisional patent filed on 4/28/2011, Application # 6147899.
16. “Cysteine and Cystine Prodrugs to Treat Schizophrenia and Drug Addiction,” J. Cook, D. Baker, E.M. Johnson and W. Yin, US Patent Issued No: US 7,829,709 B1, Nov. 9th 2010.
17. “Aza-Beta-Carbolines and Method of Using Same,” Cook, James; Van Linn, Michael; Yin, Wenyuan, filed US 2009/0306121 A1; Application No/Patent No 09751673.6021/7 PCT/US2009045014.
18. “Broad Spectrum-Gram –Positive –Antimicrobials and Anthemintics with Efficacy Against Drug-Resistant Strains and Mycobacterium Species,” CIP Application filed 12/20/2010, Cook, J.; Monte, A.; Schwan, W.; Kabir, S.; Rott, Marc; Miskowski, J., Serial # 12/973, 078 (2010).
19. “Broad Spectrum-Gram-Positive-Antimicrobials with Efficacy Against Drug-Resistant Strains and Mycobacterium Species,” Cook, J.; Monte, A.; Schwan, W.; Rott, M.; Kabir, S., Provisional filed, 1/15/2010, Serial # 61/295,384 (2010).
20. “Stereospecific Synthesis of Acrylate Ethers and Amines for Industrial and Medicinal Applications,” Kabir, M.; Cook, J.M.; Monte, A.; Rott, M.; Schwan, W.; Witzigmann, C.; Namjoshi, O.; Babu, V.V.N.Phani; Verma, R. Provisional filed 14 March (2012), Serial # 61/610,574.
21. “Cysteine and Cystine Prodrugs to Treat Schizophrenia and Drug Cravings,: Cook, J.; Baker, D.; Johnson, Edward (Merle); Yin, Wenyuan, US Utility Patent, Serial# 12/367,867, Filed 2/9/2009, Issued 5/8/2013; Patent Number: 8,173,809.
22. “Cysteine and Cystine Prodrugs to Treat Schizophrenia and Reduce Drug Cravings,: Cook, J.; Baker, D.; Johnson, E.; Yin, W., US Patent, Divisonal, Serial number 13/465,383; Filed 5/7/2012; Patent Number: 8,962,692.
23. “Selective Agents for Pain Suppression”, J. Cook, S. Huang, R. Edwankar, O. Namjoshi, Z. Wang, US Patent, Published October 27, 2012, Patent number US2010/0261711 A1. Issued September 16, 2014, US8,835,424B2.
24. “Aza-Beta Carbolines and Methods of Using Same”, J. Cook, M. VanLinn, W. Yin, US Patent number: US 8,268,854B2, September 18, 2012.
25. “Cysteine and Cystine Prodrugs to Treat Schizophrenia and Reduce Drug Cravings”, J. Cook, D. Baker, W.Yin, E.M.Johnson II, Pub. No. US2012/0220596A1, Pub. Date: August 30, 2012.
26. “Development of GABA (A) Agonists to Control Airway Hyperresponsiveness and Inflamation in Asthma”, D. Stafford, J. Cook, A. Arnold, C. Emala, Provisional Patent Filed September 21, 2012, Application number 61703902, confirmation number 2765, RAM number 9468. Published 2014.
27. “Cysteine and Cystine Bioisosteres to Treat Schizophrenia and Reduce Drug Cravings”, J. Cook, D. Baker, E. M. Johnson Jr., W. Yin, European Patent Council, 09707256.5, filed 6/9/2010.
28. “Cysteine and Cystine Bioisosteres to Treat Schizophrenia and Reduce Drug Cravings”, J. Cook, D. Baker, E. M. Johnson Jr., W. Yin, European Patent Council, US, 9743238.9, filed 9/16/2010; Japanese Patent Number 5796881 (8/28/2015).
29. “Cysteine and Cystine Bioisosteres to Treat Schizophrenia and Reduce Drug Cravings”, J. Cook, D. Baker, E. M. Johnson Jr., W. Yin, 13/465,383, filed 5/7/2012; Patent Number: 8962,692, Issued 2/24/2015.
30. *“*GABAergic Receptor Subtype Selective Ligands and Their Uses, “Cook, J. M., Clayton, T., Jain, H.D., Rallapalli, S. K., Johnson, Y. T.,Yang, J.,Poe, M.M., Namjoshi, O. A., Wang, Z. Patent publication no US 2012/0295892 A1, Published November 22nd, 2012; Notice of Allowance, 13/458, 168 (2015), Issued on 4/14/15; Patent No. 9006,233.
31. “Cysteine Prodrugs to Treat Schizophrenia and Drug Addiction”, J. Cook, D. Baker, W.Yin, E.M.Johnson II, Pub. No. US 8,435,997 B2, Pub. Date: May 7, 2013, Issued 5/7/2013.
32. “Design and Synthesis of Acrylate Esters with Activity Against Bacteria and Mycobacteria, Including M. Tuberculosis and Methicillin Resistant S. Aurerus (MRSA)., M. Kabir, J.M. Cook, A. Monte, M. Rott, W. Schwan, C. Witzigman, O. Namjoshi, V.V.N. Phani Tiruveedhula, R. Verma, Provisional Patent Applied for 4/10/13. Serial # 61/810, 487.
33. “Novel GABA(A) Agonists and Methods of Using to Control Airway Hyperresponsiveness and Inflamation in Asthma,” D. Stafford, J.M. Cook, A. Arnold, C. Emala, G. Gallos, M.R. Stephen, PCT patent filed 9/20/13; PCT/US13/60859. Published March 27, 2014; WO2014/047413A1, filed again US20150232473A1, Published 08/20/2015.
34. “Cysteine And Cystine Bioisosteres to Treat Schizophrenia and Reduce Drug Cravings,” Cook, J.; Baker, D.; Johnson II, E.M.; Yin, W.; Verma, R., US Application No 14/148959, CIP Application, Pub. No.: US2014/01554410A1, June 5, 2014; Notice of Allowance, 13/465,383.
35. Compounds for the Treatment of Gram-Positive Infections Including Resistant Strains of *Staphylococcus aureus*,” Cook, J.; Witzigman, C.; Tiruveedhula, V.; Monte, A.; Schwan, W.; Rott, M.; provisional patent submitted 4/4/2015.
36. “Cysteine and Cystine Prodrugs to Treat Schizophrenia and Reduce Drug Cravings,” Cook, J.M; Baker, D.; Yin, W.; Johnson II, E.M. Divisional filed Feb. 20th, 2015, Patent No. 14/627,379.
37. “Cysteine and Cystine Prodrugs to Treat Schizophrenia and Reduce Drug Cravings,” Cook, J.M; Baker, D.; Yin, W.; Johnson II, E.M. Japenese Patent, P16851, 885-911 (2014.12.5) 2014, Patent No. 5658137 (1/21/15).
38. “Gabaergic Ligands and Their Uses,” Cook, J.; Poe, M.; Methuku, K.; Li, G.; Provisional Patent filed March 20th, 2015.
39. “Cysteine and Cystine Bioisosteres to Treat Schizophrenia and Reduce Drug Cravings,” Cook, J.M.; Johnson Jr, E.M.; Yin, W.; Baker, D.; Canada Publication date 11/12/2009, Pub No. CA2721433A1, pending in 2015.
40. “Cysteine and Cystine Bioisosteres to Treat Schizophrenia and Reduce Drug Cravings,” Cook, J.M.; Johnson Jr., E.M.; Yin, W.; Baker, D.; EPC, Publication date, 11/24/2011. Pub. No. EP2252596A1, pending in 2015.
41. GABAergic Ligands to Treat CNS Disorders Including Anxiety and Depression as well as Neuropathic Pain,” Cook, J.M.; Poe, M.; Li, G.; Methuku, K.; March 2015, 62/13585.
42. GABAergic Ligands and Their Uses,” Cook, J.M.; Poe, M.; Methuku, K.; Li, G.; 3/20/2015, App#62/35854
43. “Agents for The Treatment of Schizophrenia, TIC Disorders, Attention Deficit Hyperactivity Disorder, Obsessive Compulsive Disorder and Other Related Neuropsychiatric Disorders, as well as Migraine and Myofacial Pain Syndrome via GABAA Receptor Subtype Selective Ligands,” Chiou, L.; Cook, J.; Ernst, M.; Fan, P.; Knutson, D.; Meirelles, M.; Mihorilovic, M.; Varagic, Z.; Verma, R.; filed June, 2015.
44. “Cysteine and Cystine Prodrugs to Treat Schizophrenia and Drug Addiction,” CIP Control Number 14/148,959, Cook, J.; Baker, D.; Johnson, E.; Yin, W.; Filed January 7th, 2014, Notice of Allowance 5/06/2015. Pub # US2015/017559A1, Pub date, 6/25/2015
45. “GABAergic Receptor Subtype Selective Ligands and Their Uses,” Cook, J.; Clayton, T.; Jain, H.; Johnson, Y-T.; Yang, J.; Rallapalli, S.; Wang, Z.; Namjoshi, O.; Poe, M.; Pub. No. US 2015/0258128A1, Pub Date Sept 17th, (2015); Patent No. US 9597,342B2, March 21, 2017.
46. “Compounds for the Treatment of Gram-positive Bacterial Infections Including Resitant Strains of *Staphylococcus aureus*,” Cook, J.; Witzigmann, C.; Tiruveedhula, V.V.N.; Monte, A.; Schwan, W.; Rott, M.; Verma, R.; Verma, A. filed October 2015.
47. “GABAergic Ligands and Thei Uses”, Cook, J. M.; Poe, M. M.; Methuku, K.;Li, G.; PCT Patent filed on March 18,2016; application # PCTUS2016/023209,3/18/2016.
48. “Treatments of Cognitive and Mood Symptoms in Neurodegenerative and Neuropsychiatric Disorders with Alpha 5- Containing GABA Selective Agonists”, Cook, J.M.; Sillibe. E.; Poe, M.; Li, G.; Belzung, C.; Savic, M.; filed on 3/18/2016.
49. “Ligands Selective to Alpha 6 Subunit Containing GABA(A) Receptors and Their Methods of Use”, L. C. Chou; J. Cook; M, Ernst; D. Knutson; M. Savic; R. Verma; C. Witzgmann et al., PCT Patent Int. Pub. No.: US 2021/0047322 A1, 2/18/2021.
50. “GABAergic Ligands and Their Uses”, Cook, J.; Poe, M.M.; Methuku, K.R.; Li, G.; PCT published Sep 29,2016 WO2016/154031 A1 (2016).
51. “Cysteine and Cystine Prodrugs to Traet Schizophrenia and Reduce Drug Cravings”, Cook, J.; Baker, D.; Yin, W.; Johnson II, E.M., Pub date Jan 25, 2015, Pub. No. US2015/0175559A1 (2015).
52. “Novel Combination Therapy for Anxiety, Disorders, Epilelsy and Pain”, Cook, J.; Babu, P.; Li, Jun-Xu, Provosional filed Oct 28, 2016, App# 62414363 (2016).
53. “Treatments of Cognitive and Mood Symptoms in Neurodegenerative and Neuropsychiatric Disorders with Alpha 5 Containing GABA(A) Selective Agonists”, Cook, J.; Poe, M.M.; Li, G.; Sibille, E.; Banasar, M.; Savic, M.; Belzung, C.; et al., Application No. PCT/US2017/023206, Filed March 18, 2017.
54. “GABAergic Subtype Selective Ligands and Their Uses”, Cook, J.; Clayton, T.; Jain, H.; Rallapalli, S.; Johnson, Y.T.; Yang, J.; Poe, M.M.; Namjoshi, O.; Wang, Z.; Filed April 27,2012; Issued US9006233B2, Date of Patent, April 14, 2015.
55. "Novel GABA(A) Receptor Modulators and Methods to Control Airway Hyperresposiveness and Inflammation in Asthma”, Arnold, A.; Stafford, D.; Cook, J.M.; Emala, C.; Forkou, G.; Jahan, R.; Kodali, R.; Li, G.; Stephen, M.R.; PCT Patent Application No. PCT/US2017/, Filed August 16, 2017.
56. “Treatment of Cognitive and Mood Symptoms in Neurodegenerative Disorders with Alpha5-Containing GABAA Receptor Agonists”, James M. Cook; Guanguan L;, Michael Ming-Jin Poe; Miroslav Savic; Etienne Sibille, US Patent No. US 10,906,909 B2, ISSUED Feb.2,2021.
57. “MIDD0301 & #8210; A First-in-class Anti-inflammatory Asthma Drug Targets GABA(A) Receptors Without Causing Systemic Immune Suppression”, Leggy A.; Cook, J.M., BCPT-2018-578/R1 RESUBMISSION - (8181).
58. “Uses of radiation and benzodiazepine derivatives in cancer therapies”, Sengupta, S.; Krummel, D.P., Khan, M.; Nasti, T.; Cook, J., 19109 PCT, International PCT Application No. PCT/US2020/034169, Pub.NO: US2022/0079952 A1, March 17, 2022.
59. “Selective Agents for Pain Suppression”, James M. Cook.; Shengming Huang.; Rahul Edwankar.; Ojas A . Namjoshi.; Zhi - Jian Wang.; Qi Huang , Camarillo.; Xiaohui He .; Xiaoyan Li .; Jianming Yu.; Plainsboro .; Dongmei Han.; United States Reissued Patent, July 2, 2019.
60. “Novel Combination Therapy for Anxiety Disorders, Epilepsy, and Pain”, James M. Cook.; V. V. N. Phani Babu Tiruveedhula.; Jun-Xu Li. International PCT patent WO 2019/070910 A1.
61. “Imidazobenzodiazepines for treatment of cognitive and mood symptoms”, Thomas D. Prevot, Michael J. Marcotte, Etienne L. Sibille, James M. Cook, Guanguan Li, Prithu Mondal, Md Yeunus Mian, Farjana Rashid, Appl. No. 63/334,978.
62. “Brain penetrant chemosensitizer to treat lung cancer”, Soma Sengupta, et al., Appl. No. 63/208,246, PCT/US2022/032163, Nationalized fillings in US, EP, CA, JP, AU.
63. “Small brain penetrant molecule to potentiate temozolomide for glioblastoma”, Soma Sengupta, et al., Appl. No. 63/196,459, PCT/US2022/032163, Nationalized fillings in US, EP, CA, JP, AU.
64. “Novel deuterated benzodiazepine analogs for cancer use”, Soma Sengupta, et al., Appl. No. 63/330,051, PCT/US2023/018272.
65. “Development of a new class of small molecule autophagy modulators for treatment of cancers”, Soma Sengupta, et al., Appl. No. 63/330,143.
66. “Benzodiazepine Analogs for the treatment of cancers”, Soma Sengupta, et al., Appl. No. 63/341,571, PCT/US23/22083.
67. “A new class of immune modulators”, Soma Sengupta, et al., Appl. No. 63/446.980.

D. **Non‑refereed Publications** (including major in-house reports): Progress reports were written to NIH as part of grants.

E. **Papers Presented at Professional Meetings**

"Synthesis of Propellanes with Large and Medium‑sized Rings from Cyclic ‑Diketones and Dimethyl ß‑Ketoglutarate," J. Cook and D. Yang, presented at the 7th Central Regional Meeting of the American Chemical Society, West Virginia University, Morgantown, WV, May 28‑30, 1975, Abstract No. 122.

"Chemistry of 1,2‑ and 1,3‑Dicarbonyl Compounds with Dimethyl ß‑Ketoglutarate: Synthesis of Methyl‑2,3,5,6,7,8 ‑ Hexahydro ‑ 2, 5 ‑ dioxo ‑ 4 H‑ 1‑benzopyran‑4' ‑Acetate," J. Cook, D. Yang, J. Oehldrich, and U. Weiss, presented at the 6th Natural Products Symposium of the West Indies, Mona, Jamaica, January 4‑10, 1976.

"Synthesis of Beta Carbolines: Pictet‑Spengler Condensations in Refluxing Benzene," J. Sandrin, D. Soerens, L. Hutchins, E. Richfield, F. Ungemach, and J. Cook, presented at the 10th Middle Atlantic Regional Meeting of the American Chemical Society, Temple University, Philadelphia, PA, February 24, 1976, Abstract No. K‑25.

"Reactions of 1,2 and 1,3‑Dicarbonyl Compounds with Dimethyl ß‑Ketoglutarate: Preparation of 1:1 Adducts," D. Yang, J. Oehldrich, and J.M. Cook, presented at the 10th Middle Atlantic Regional Meeting of the American Chemical Society, Temple University, Philadalphia, PA, February 25, 1976, Abstract No. K‑41.

"Facile Entry into Biologically Important Ring Systems by Reaction of Dimethyl ß‑Ketoglutarate with Alicyclic 1,3‑Dicarbonyl Compounds or with ‑Halo Ketones," J. Oehldrich, O. Campos, D. Foerst, and J.M. Cook, presented at the 10th American Chemical Society Great Lakes Regional Meeting, Northwestern University, Evanston, IL, June 18, 1976, Abstract No. 179.

"13C‑NMR Studies of 1,3‑Disubstituted‑1,2,3,4‑Tetrahydro‑ß‑Carbolines," J. Sandrin, D. Soerens and J.M. Cook, presented at the 10th American Chemical Society Great Lakes Regional Meeting, Northwestern University, Evanston, IL, June 1, 1976, Abstract No. 280.

"Synthesis and Stereochemistry of 1,3‑Disubstituted‑1,2,3,4‑Tetrahydro ß‑Carbolines," J. Sandrin, D. Soerens and J.M. Cook, presented at the 17th Annual Meeting of the American Society of Pharmacognosy, Telemark Lodge, Cable, WI, July 11‑16, 1976, Abstract No. 23.

"Reaction of Dimethyl ß‑Ketoglutarate with Carbonyl Compounds: Synthesis of Coumarin, Carbostyril, and Furan Derivatives," J. Oehldrich, O. Campos, D. Foerst and J.M. Cook, presented at the 17th Annual Meeting of the American Society of Pharmacognosy, Telemark Lodge, Cable, WI, July 11‑16, 1976, Abstract No. 41.

"Synthesis of Oxo‑substituted Heterocycles from Cyclohexane‑1,3‑dione," R. Mitschka, P. Mokry and J.M. Cook, presented at the 28th Southeastern Regional Meeting of the American Chemical Society," Gatlinburg, TN, October 27‑28, 1976, Abstract No. 372.

"Studies in the Indole Alkaloid Area: C‑13 NMR of 1,3‑Disubstituted‑1,2,3,4‑ Tetrahydro ß‑Carbolines," J. Sandrin, G.S. Wu, F. Ungemach, and J.M. Cook, presented at the 11th Great Lakes Regional Meeting of the American Chemical Society, Stevens Point, WI, June 6‑8, 1977, Abstract No. 180.

"Studies in the Indole Alkaloid Area: Pictet‑Spengler Reactions in Refluxing Benzene," D. Soerens, O. Campos, E. Yamanaka and J.M. Cook, presented at the 11th Great Lakes Regional Meeting of the American Chemical Society, Stevens, Point, WI, June 6‑9, 1977, Abstract No. 181.

"Reactions of Dicarbonyl Compounds with Dimethyl ß‑Ketoglutarate: Synthesis of Cyclopentanoid Derivatives," J.M. Cook, J. Oehldrich, and R. Weber, presented at the 11th Great Lakes Regional Meeting of the American Chemical Society, Stevens Point, WI June 6‑8, 1977, Abstract No. 182.

"Studies in the Indole Alkaloid Area: Pictet‑Spengler Reactions in Aprotic Media," D. Soerens, J. Sandrin and J.M. Cook, presented at the 174th National Meeting of the American Chemical Society, Chicago, IL, August 29‑September 2, 1977, Abstract No. 118.

"Synthesis of the Antibiotic, Pyridindolol, a ß‑Galactosidase Inhibitor from *Streptomyces alboverticillatus*," E. Yamanaka, G.S. Wu, and J.M. Cook, presented at the 7th Natural Products Symposium, University of the West Indies, Mona, Jamaica, January 9‑13, 1978.

"Pictet‑Spengler Reactions in Aprotic Media: Synthesis of Pyridindolol, a ß‑Galactosidase Inhibitor from *Streptomyces alboverticillatus*," D. Soerens, G.S. Wu, E. Yamanaka and J.M. Cook, presented at the 175th American Chemical Society National Meeting, Anaheim, CA, March 12‑17, 1978.

"Reactions of Dimethyl ß‑Ketoglutarate with 1,2‑Dicarbonyl Compounds: General Approach to the Synthesis of Cyclopentanoid Compounds," R. Mitschka, U. Weiss and J.M. Cook, presented at the Joint Central‑Great Lakes Regional Meeting of the American Chemical Society, Butler University, Indianapolis, IN, May 24‑26, 1978, Abstract No. 81.

"Studies Directed toward the Synthesis of 3‑Acylindole Bases," O. Campos and J.M. Cook, presented at the Joint Central‑Great Lakes Regional Meeting of the American Chemical Society, Butler University, Indianapolis, IN, May 24‑26, 1978, Abstract No. 30.

"Studies Directed Toward the Synthesis of Indole Alkaloid, *Suaveoline*," D. Soerens and J.M. Cook, presented at the Joint Central‑Great Lakes Regional Meeting of the American Chemical Society, Butler University, Indianapolis, IN, May 24‑26, 1978, Abstract No. 31.

"Reactions of Dimethyl 3‑Ketoglutarate with 1,2‑Dicarbonyl Compounds: General Approach to the Synthesis of Cyclopentanoid Compounds," R. Mitschka, A. Gawish, C. Wieringa and J.M. Cook, 178th American Chemical Society National Meeting, Washington, DC, September 10‑14, 1979, Abstract No. ORGN‑146.

"Synthesis of 1,6‑Diazaphenalene, a Vinylogous Imidazole," M.I. El‑Sheikh, J.‑C. Chang, R. Weber and J.M. Cook, American Chemical Society Great Lakes Regional Meeting, Rockford College, Rockford, IL, June 4‑5, 1979, Abstract No. 206.

"Stereoselective Synthesis of *trans*‑1‑Substituted‑3‑Methoxycarbonyl‑1,2,3,4‑ tetra-hydro ß‑Carbolines," R. Weber, F. Ungemach, M. DiPierro, D. Soerens, J.V. Silverton and J.M. Cook, American Chemical Society Great Lakes Regional Meeting, Rockford College, Rockford, IL, June 4‑6, 1979, Abstract No. 207.

"Stereoselective Synthesis of *trans*‑1‑Substituted‑3‑methoxycarbonyl‑1,2,3,4‑ tetrahydro ß‑Carbolines," R. Weber, F. Ungemach, M. DiPierro, D. Soerens, J.V. Silverton and J.M. Cook, 11th Central Regional Meeting, Ohio State University, Columbus, OH, May 7‑9, 1979, Abstract No. 23.

"General Approach to the Synthesis of Cyclopentanoid Compounds: Studies Directed Toward the Preparation of Staurane and Modhephene," J.M. Cook, 8th Natural Products Symposium, University of the West Indies, Mona, Jamaica, January 7‑11, 1980.

"*In Vitro* Inhibition of [3H] Diazepam Binding to Benzodiazepine Receptors by ß‑Carbolines," K.C. Rice, P. Skolnick, S.M. Paul, S. Barker, J.M. Cook, R. Weber, and M. Cain, presented at the 2nd Chemical Congress of the North American Continent, August 24‑29, 1980, Las Vegas, NV, Abstract No. MEDI‑069.

"General Approach Toward the Synthesis of Polyquinanes," J.M. Cook, A. Gawish, J. Wrobel, K. Takahashi, and U. Weiss, presented at the 2nd Chemical Congress of the North American Continent, August 24‑29, 1980, Las Vegas, NV, Abstract No. ORGN‑247.

"Selenium Dioxide and DDQ Oxidations in the Indole Area," J.M. Cook, R. Mantei, M. Cain, and M. DiPierro, presented at the 2nd Chemical Congress of the North American Continent, August 24‑29, 1980, Las Vegas, NV, Abstract No. ORGN‑341.

"An Anomalous Semmler‑Wolff Aromatization Reaction," M.I. El‑Sheikh and J.M. Cook, 14th Great Lakes Regional Meeting, June 4‑6, 1980, Western Illinois University, Macomb, IL, Abstract No. 110.

"General Method for the Synthesis of Polycyclopentanoid Compounds. Recent Progress Directed toward the Preparation of Staurane and Modhephene," A. Gawish, J. Wrobel, K. Takahashi, U. Weiss and J.M. Cook, 14th Great Lakes Regional Meeting, June 4‑6, 1980, Western Illinois University, Macomb, IL, Abstract No. 127.

"Studies Directed toward the Synthesis of Potential Antimalarial Agents. Synthesis of 9‑Methoxy and 9‑Amino‑1,6‑diazaphenalene Derivatives," R. Weber, J. Chang, M.I. El‑Sheikh and J.M. Cook, 14th Great Lakes Regional Meeting, June 4‑6, 1980, Western Illinois University, Macomb, IL, Abstract No. 140.

"Selenium Dioxide and DDQ Oxidations in the Indole Area. The Synthesis of ß‑Carboline Alkaloids, 1‑Acetyl‑ß‑Carboline, 1‑Acetyl‑3‑Methoxycarbonyl‑ß‑ Carbo-line and Desmethoxy Crenatine," R. Mantei, M. Cain, M. DiPierro and J.M. Cook, 14th Great Lakes Regional Meeting, June 4‑6, 1980, Western Illinois University, Macomb, IL, Abstract No. 151.

"ß‑Carbolines: Synthesis, Neurochemical, and Pharmacological Actions on Brain Benzodiazepine Receptors," M. Cain, R. Weber, F. Guzman, J.M. Cook, K.C. Rice, and P. Skolnick, 9th Natural Products Symposium, University of the West Indies, Mona, Jamaica, January 4‑8, 1982.

"Synthesis of 3‑Hydroxymethyl‑ß‑Carboline, a Diazepam Antagonist," P. Skolnick, S. Paul, J. Crawley, K. Rice, S. Barker, R. Weber, M. Cain, and J.M. Cook, 1981 Joint Meeting of the Central‑Great Lakes American Chemical Society, Dayton, OH, May 20‑22, 1981, Abstract No. MEDI‑220.

"Studies Directed Toward the Synthesis of Potential Antimalarial Agents, Chemistry of 1,6‑Diazaphenalene and its Derivatives," R.W. Weber, K. Avasthi, S.J. Lee and J.M. Cook, Joint Meeting of the Central‑Great Lakes American Chemical Society, Dayton, OH, May 20‑22, 1981, Abstract No. ORGN‑283.

"Synthesis of 3‑Hydroxymethyl ß-Carboline, a Diazepam Antagonist," M. Cain, R. Weber, J.M. Cook, K. Rice, J.W. Crawley, and P. Skolnick, 28th International Union of Pure and Applied Chemistry Meeting, University of British Columbia, Vancouver, BC, August 24‑28, 1981.

"Anomalous Action of Benzodiazepine Antagonists in Preventing 3‑Carbomethoxy‑ß‑ Carboline (BCCM)‑Induced Convulsions," M. Schwei, M. Cain, J. Cook, S. Paul, and P. Skolnick, ASPET Meeting, Louisville, KY, August, 1982.

"Reaction of 1,6‑Diazaphenalene with Electrophiles. Theoretical and Experimental Results," R. Weber, S.J. Lee, J.M. Cook, and W. England, 16th Annual Meeting of Great Lakes American Chemical Society Region, Illinois State University, Normal, IL, June 7‑9, 1982, Abstract No. 184.

"ß‑Carbolines: Synthesis, Neurochemical and Pharmacological Actions on Brain Benzodiazepine Receptors," M. Cain, F. Guzman, R. Weber, J.M. Cook, K.C. Rice, and P. Skolnick, 16th Annual Meeting of Great Lakes American Chemical Society Region, Illinois State University, Normal, IL, June 7‑9, 1982, Abstract No. 185.

"General Approach Toward the Synthesis of Polyquinanes. Entry into the Triquinacene Ring System," G. Lannoye, V. Honkan, U. Weiss, S. Bertz, and J.M. Cook, 16th Annual Meeting Great Lakes American Chemical Society Region, Illinois State University, Normal, IL, June 7‑9, 1982, Abstract No. 201.

"Reaction of Dicarbonyl Compounds with Dimethyl 3‑Ketoglutarate, Influence of Steric Effects on Success of the Condensation," M.N. Deshpande, G. Kubiak, W.C. Han, U. Weiss and J.M. Cook, 16th Annual Meeting Great Lakes American Chemical Society Region, Illinois State University, Normal, IL, June 7‑9, 1982, Abstract No. 206.

"General Approach for the Synthesis of Polyquinanes. Synthesis of Modhephane and Triquinacene *via* the Weiss Reaction," V. Honkan, G. Lannoye, J. Wrobel, S. Bertz, K. Takahashi and J.M. Cook, 184th American Chemical Society National Meeting, Kansas City, MO, September 12‑17, 1982, Abstract No. ORG‑134.

"Selenium Dioxide and DDQ Oxidations in the Indole Area. Synthesis of the ß‑Carboline Alkaloids Canthine‑6‑one and Crenatine," M. Cain and J.M. Cook, 184th American Chemical Society National Meeting, Kansas City, MO, September 12‑17, 1982, Abstract No. ORG‑15.

"ß‑Carbolines: Synthesis, Neurochemical and Pharmacological Actions on Brain Benzodiazepine Receptors," M. Cain, F. Guzman, P. Larscheid, J.M. Cook, M. Schweri, S. Paul, W. Mendelson, and P. Skolnick, 184th American Chemical Society National Meeting, Kansas City, MO, September 12-17, 1982.

"Synthesis of ß‑Carboline Alkaloids. Search for Valium Agonists and Antagonists," F. Guzman, P. Larscheid, M. Cain, P. Skolnick, M. Schweri and J.M. Cook, 17th Great Lakes Regional Meeting, American Chemical Society, College of St. Catherines, June 1‑3, 1983, Abstract No. 211.

"The Influence of Steric and Electronic Effects on Success of the Wiess Reaction," G. Kubiak, M. Deshpande and J.M. Cook, 17th Great Lakes Regional Meeting, American Chemical Society, College of St. Catherines, June 1‑3, 1983, Abstract No. 205.

"General Approach for the Synthesis of Polyquinanes *via* the Weiss Reaction," G. Lannoye, G. Kubiak, V. Honkan and J.M. Cook, 17th Great Lakes Regional Meeting, American Chemical Society, College of St. Catherines, June 1‑3, 1983, Abstract No. 206.

"Synthesis of ß‑Carbolines and Related Heterocycles, Search for Valium Agonists and Antagonists," F. Guzman, P. Larscheid, M. Cain, J.M. Cook, P. Skolnick, and M. Schweri, 186th National American Chemical Society Meeting, Washington. DC, August 27‑September 2, 1983.

"Characterization of Drug Epitomes Recognized by Antibodies in Quinidine and Quinine‑Induced Thrombocytopenia," D. Christies, R. Weber, J.M. Cook and R.H. Aster, Blood, 62, No. 5 (supplement 1, p. 243a) presented at 25th Am. Soc. of Hematology, San Francisco, CA, December 3‑6, 1983, Abstract No. 875.

"Benzodiazepine Receptor Mediation of Genetically‑Determined Stereotype Abnormal Behavior of Tottering Mice," P.J. Syapin, J.H. Schneider, P. Larscheid and J.M. Cook, Neurosciences Meeting, Boston, MA, 1983.

"Reversal of Cerebrovascular and Metabolic Effects of Flurazepam with a Benzo-diazepine Antagonist, 3‑Hydroxymethyl ß‑Carboline," J. Feld, W.E. Hoffman, V. Baughman, J.M. Cook, D.J. Miletich, and R. Albrecht, *Anesthesiology*, **59**, A‑332, 1983.

"Synthesis of ß‑Carbolines. Search for Chemical Anxiogenic and Anxiolytic Agents," P. Larscheid, F. Guzman, J.M. Cook, P. Skolnick, and S. Paul, 10th Natural Products and Medicinal Chemistry Symposium, University of the West Indies, Mona, Jamaica, January 3‑7, 1984.

"Interactions of Central Benzodiazepine and Barbiturate Receptors," N. Naughton, S.T. Anderson, W.E. Hoffman, J.M. Cook, and P. Larscheid, FASEB, St. Louis, MO, April 1984, Abstract No. 3873.

"Differential Antagonism of Diazepam‑Induced Hypnosis," J.M. Witkin, J.E. Barret, J.M. Cook, and P. Larscheid, FASEB, St. Louis, MO, April 1984, Abstract No. 3774.

"ß‑Carbolines as Antagonists of the Anticonvulsant and Discriminative Effects of Diazepam," H.E. Shannon, P. Larscheid and J.M. Cook, FASEB, St. Louis, MO, April 1984, Abstract No. 3776.

"Midazolam‑Alcohol Interactions and Reversal with a New Benzodiazepine Antag-onist," P. Van Gorder, C. Perkezas, F. Guzman, J.M. Cook, D.J. Miletich, R.F. Albrecht, and W.E. Hoffman, Annual Meeting of the Neuroscience Society, Anaheim, CA, November 13, 1984.

"SAR of ß‑Carbolines as Regards Binding Affinity to Benzodiazepine Receptors," B. Johnson, R. Craig, P. Larscheid, F. Guzman, and J.M. Cook, Joint Great Lakes‑ Central Regional Meeting, Western Michigan University, Kalamazoo, MI, May 23‑25, 1984, Abstract No. 228.

"Synthesis of ß‑Carbolines: Preparation of "Active" Antagonists of the Benzo-diazepines," F. Guzman, P. Larscheid, T. Hagen, C. Schultz, and J.M. Cook, Joint Great Lakes‑Central Regional Meeting, Western Michigan University, Kalamazoo, MI, May 23‑25, 1984, Abstract No. 229.

"Preparation of 2,6‑Disubstituted *cis*‑Bicyclo[3.3.0]octane‑3,7‑Diones," G. Lannoye, G. Kubiak and J.M. Cook, Joint Great Lakes‑Central Regional Meeting, Western Michigan University, Kalamazoo, MI, May 23‑25, 1984, Abstract No. 307.

"Reaction of 1,2‑Dicarbonyl Compounds **1** with Dimethyl ß‑Ketoglutarate **2**. Approach Toward Highly Strained [5.5.m.n.] Fenestranes," G. Kubiak, M.N. Deshpande, M. Jawdosiuk, U. Weiss and J.M. Cook, Joint Great Lakes‑Central Regional Meeting, Western Michigan University, Kalamazoo, MI, May 23‑25, 1984, Abstract No. 365.

"Synthesis of ß‑Carbolines: Search for New and More Stable Valium Antagonists," T. Hagen, F. Guzman, P. Skolnick, W. Hoffman, and J.M. Cook, 19th Great Lakes Regional Meeting of the American Chemical Society, Purdue University, West Lafayette, IN, June 10‑12, 1985, Abstract No. 238.

"Simple Synthesis of 3,4‑Indolosubstituted ß‑Carbolines. A New Class of Benzo-diazepine Antagonists," M. Trudell, R. Craig, P. Skolnick, and J.M. Cook, 19th Great Lakes Regional Meeting of the American Chemical Society, Purdue University, West Lafayette, IN, June 10‑12, 1985, Abstract No. 239.

"General Approach for the Synthesis of Polyquinenes. Synthesis of Staurane‑ 5,8,11‑ Tetraene," M. Deshpande, G. Kubiak, M. Jawdosiuk, U. Weiss, and J.M. Cook, 19th Great Lakes Regional Meeting of the American Chemical Society, Purdue University, West Lafayette, IN, June 10‑12, 1985, Abstract No. 315.

"General Approach for the Synthesis of Polyquinenes *via* the Weiss Reaction. Synthesis of Tetracyclo[6.6.0.0.1,5O.8,12] tetradecane‑3,6,10,13‑tetraene," M. Venkatachalam, M. Jawdosiuk, and J.M. Cook, 19th Great Lakes Regional Meeting of the American Chemical Society, Purdue University, West Lafayette, IN, June 10‑12, 1985, Abstract No. 316.

"Selective Entry into Mono or Dialkylated *cis*‑Bicyclo[3.3.0]octane‑3,7‑dione Systems," G. Kubiak, G. Lannoye, and J.M. Cook, 19th Great Lakes Regional Meeting of the American Chemical Society, Purdue University, West Lafayette, IN, June 10‑12, 1985, Abstract No. 317.

"Simple Synthesis of 3,4‑Indolosubstituted ß‑Carbolines. A New Class of Benzo-diazepine Antagonists," M. Trudell, R. Craig, P. Skolnick, and J.M. Cook, 190th National American Chemical Society Meeting, Chicago, IL, September 8‑13, 1985, Abstract No. MEDI‑87.

"Synthesis of ß‑Carbolines: Search for New and More Stable Valium Antagonists," T. Hagen, F. Guzman, P. Larscheid, P. Skolnick, W. Hoffman, and J.M. Cook, 190th National American Chemical Society Meeting, Chicago, IL, September 8‑13, 1985, Abstract No. ORGN‑82.

"General Approach for the Synthesis of Polyquinenes *via* the Weiss Reaction. Synthesis of Tetracyclo[6.6.0.01,5O.8,12] tetradecane‑3,6,10,13‑tetraene," M. Venkatachalam, M. Jawdosiuk, and J.M. Cook, 190th National American Chemical Society Meeting, Chicago, IL, September 8‑13, l985, Abstract No. ORGN‑50.

"Regiospecific Entry into Mono or Dialkylated *cis*‑Biocyclo[3.3.0]‑octane‑3,7‑dione Systems," G. Kubiak, G. Lannoye, and J.M. Cook, 190th National American Chemical Society Meeting, Chicago, IL, September 8‑13, 1985, Abstract No. ORGN‑49.

"General Approach for the Synthesis of Polyquinenes," J.M. Cook, National Science Foundation Workshop in Organic Synthesis, Pingree Park, CO, July 10‑14, 1985.

"Synthesis of the Anticonvulsant 3‑Chloro‑1H,8H‑Pyrido[2,3‑*b*:4,5‑*b*']diindole. A Selective Benzodiazepine Receptor Agonist with No Sedative Properties," M. Trudell, J.M. Cook, P. Skolnick, and H. Shannon, Eleventh Mona Symposium, on Natural Products and Medicinal Chemistry, UWI, January 6‑10, 1986.

"General Approach for the Synthesis of Polyquinenes," G. Kubiak, G. Lannoye, M. Ventakachalam, U. Weiss, and J.M. Cook, 191st ACS National Meeting, New York, N.Y., April 13‑18, 1986. Abstract No. MEDI‑47.

"Synthesis of 3,6‑Disubstituted ß‑Carbolines Which Possess Either Benzodiazepine Antagonist or Agonist Activity," H.E. Shannon, P. Skolnick, T.J. Hagen, F. Guzman, and J.M. Cook, 191st ACS National Meeting, New York, N.Y., April 13‑18, 1986.

"Synthesis of the Anticonvulsant 2‑Chloro‑7,12‑Dihydropyrido[3,2‑**b**:5,4‑**b**']‑ diindole. A Selective Benzodiazepine Receptor Agonist with No Sedative Activity," M. Trudell, H. Shannon, P. Skolnick and J.M. Cook, 20th Great Lakes Regional ACS Meeting, Marquette University, Milwaukee, WI, June 2‑4, 1986, Abstract No. 261.

"A New Class of Norharman Derivatives Which Potently Bind to Benzodiazepine Receptors: 6‑Substituted Derivatives of Norharman That Bind at 100 nM," T. Hagen, P. Skolnick, H.E. Shannon, and J.M. Cook, 20th Great Lakes Regional ACS Meeting, Marquette University, Milwaukee, WI, June 2‑4, 1986, Abstract No. 262.

"Synthetic Studies in the ß‑Carboline Area. A Simple One‑Pot Oxidation‑ Amination Reaction," M.L. Trudell, N. Fukada, and J.M. Cook, 20th Great Lakes Regional ACS Meeting, Marquette University, Milwaukee, WI, June 2‑4, 1986, Abstract No. 303.

"Dialkylation of *cis*‑Bicyclo[3.3.0]octane‑3,7‑dione Derivatives," G. Lannoye, G. Kubiak, and J.M. Cook, 20th Great Lakes Regional ACS Meeting, Marquette University, Milwaukee, WI, June 2‑4, 1986, Abstract 304.

"General Approach for the Synthesis of Polyquinenes," G. Lannoye, M. Venkatachalam, G. Kubiak, U. Weiss, and J.M. Cook, 20th Great Lakes Regional ACS Meeting, Marquette University, Milwaukee, WI, June 2‑4, 1986, Abstract No. 305.

"General Approach for the Synthesis of Polyquinanes. Synthesis of *cis*‑*cis*‑Tetra-cyclo[9.3.0.01,5.07,11]tetradeca‑4, 8‑diacetoxy‑6‑one *via* the Aldol Approach," M. Venkatachalam, U. Weiss, and J.M. Cook, 20th Great Lakes Regional ACS Meeting, Marquette University, Milwaukee, WI, June 2‑4, 1986, Abstract No. 306.

"General Approach for the Synthesis of Polyquinenes," G. Lannoye, M. Venkatachalam, G. Kubiak, U. Weiss, and J.M. Cook, 8th Rocky Mountain Regional ACS Meeting, Denver, CO, June 8‑12, 1986, Abstract No. ORSY‑383.

"Synthesis of the Anticonvulsant 2‑Chloro‑7,12‑Dihydropyrido[3,2‑**b**:5,4‑**b**'] diindole. A Selective Benzodiazepine Receptor Agonist with No Sedative Activity," M. Trudell, H. Shannon, P. Skolnick, and J.M. Cook, 8th Rocky Mountain Regional ACS Meeting, Denver, CO, June 8‑12, 1986, Abstract No. RSY‑384.

"Behavorial Effects of Benzodiazepine (BZ) Agonist, Antagonist and Inverse Agonists in the Baboon," C.A. Sannerud, S. Tantiraksachai, J.M. Cook, and R.R. Griffiths, Federation Proceedings, **46**(4), 1301 (1987) #5746.

"Alterations of the Behavorial Effects of Benzodiazepine Receptor Ligands During Chronic Diazepam Administration," C.A. Sannerud, J.M. Cook, and R.R. Griffiths, Society of Neuroscience Abstracts, 1987, **13**, 966.

"Synthesis of 6‑Substituted ß‑Carbolines Which Behave as Benzodiazepine Receptor Antagonists or Inverse Agonists," T.J. Hagen, P. Skolnick, and J.M. Cook, 193rd National ACS Meeting, Denver, CO, April 5‑10, 1987, Abstract MED‑035.

"Pyridodiindoles. Synthesis of Rigid, Planar Ligands of Benzodiazepine Receptors," M.L. Trudell, S. Lifer, and J.M. Cook, 193rd National ACS Meeting, Denver, CO, April 5‑10, 1987, Abstract No. MED‑036.

"General Approach to the Synthesis of Polyquinenes *via* the Weiss Reaction. Studies Directed Toward the Preparation of Dicyclopenta[a,d]pentalene, Dicyclopenta-[cd,gh]pentalene and Dicyclopenta[a,e]pentalene," G. Lannoye and J.M. Cook, 193rd National ACS Meeting, Denver, CO, April 5‑10, 1987, Abstract ORGN‑100.

"Hydrazine‑Mediated One Pot Amination‑Oxidation Reaction," M.L. Trudell and J.M. Cook, 193rd National ACS Meeting, Denver, CO, April 5‑10, 1987, Abstract ORGN‑253.

"Synthesis of Pyrido[3,2‑*b*:5,4‑*b*']diindoles and ß‑Carbolines. The Pharmacophore for the Benzodiazepine Receptor Inverse Agonist Site," T.J. Hagen, M.L. Trudell, S. Lifer, Y.‑C. Tan, M.S. Allen, P. Skolnick, P.W. Codding, and J.M. Cook, presented at the 43rd Southwest Regional Meeting of the American Chemical Society, Little Rock, AR, December 2‑4, 1987, Abstract No. 214.

"Repeated Administration of Behavioral Receptor Ligands in the Baboon," C.A.Sannerud, J.M. Cook and R.R. Griffiths, Society of Neuroscience Abstracts, **14(1)**, 345, 1988.

"Pictet‑Spengler Reactions in Aprotic Media. Synthesis of the Indole Alkaloids 1‑Methoxy Canthine‑6‑one and Suaveoline," J.M. Cook, T.J. Hagen, and M.L. Trudell, presented at the 12th Mona Symposium, Natural Products and Medicinal Chemistry, University of the West Indies, Mona, Jamaica, January 4‑8, 1988.

"General Approach to the Synthesis of Polyquinenes *via* the Weiss Reaction," G. Lannoye, K. Sambasivarao, and J.M. Cook, 9th Rocky Mountain Regional Meeting of the American Chemical Society, Las Vegas, NV, March 27‑30, 1988, Abstract No. 49.

"Studies on the Pharmacophore for the Benzodiazepine Inverse Agonist Site. Synthesis of a Potent Long‑Lived Inverse Agonist," M.S. Allen, T.J. Hagen, M.L. Trudell, S. Lifer, Y.‑C. Tan, and J.M. Cook, 9th Rocky Mountain Regional Meeting of the American Chemical Society, Las Vegas, NV, March 27‑30, 1988, Abstract No. 64.

"Pictet‑Spengler Reactions in Aprotic Media. Studies Directed Toward the Synthesis of the Indole Alkaloids Suaveoline and 1‑Methoxy Canthine‑6‑one," M.L. Trudell, T.J. Hagen, and J.M. Cook, 9th Rocky Mountain Regional Meeting of the American Chemical Society, Las Vegas, NV, March 27‑30, 1988, Abstract No. 191.

"General Approach for the Synthesis of Polyquinenes *via* the Weiss Reaction. Synthesis of 1,10‑Disubstituted Triquinacenes Including the First Propellane Triquinacene," A.K. Gupta, U. Weiss, and J.M. Cook, 20th Central Regional Meeting of the American Chemical Society, West Virginia University, Morgantown, WV, June 1‑3, 1988, Abstract No. 113.

"Synthesis of Water Soluble Pyridodiindole Ligands with Potent Affinity for Benzodiazepine Receptors," Y.‑C. Tan, M.L. Trudell, and J.M. Cook, 20th Central Regional Meeting of the American Chemical Society, West Virginia University, Morgantown, WV, June 1‑3, 1988, Abstract No. 114.

"Pictet‑Spengler Reactions in Aprotic Media. Synthesis of the Cytotoxic Alkaloid 1‑Methoxy Canthine‑6‑one," T.J. Hagen and J.M. Cook, 20th Central Regional Meeting of the American Chemical Society, West Virginia University, Morgantown, WV, June 1‑3, 1988, Abstract No. 137.

"Studies Directed Toward the Synthesis of the Indole Alkaloid Suaveoline," M.L. Trudell and J.M. Cook, 20th Central Regional Meeting of the American Chemical Society, West Virginia University, Morgantown, WV, June 1‑3, 1988, Abstract No. 139.

"Facile Alteration of the Symmetry of the *cis*‑Bicyclo[3.3.0]octane‑3,7‑dione Union for the Synthesis of Polyquinenes," K. Sambasivarao, G. Kubiak, and J.M. Cook, 20th Central Regional Meeting of the American Chemical Society, West Virginia University, Morgantown, WV, June 1‑3, 1988, Abstract No. 144.

"Sterochemical Control in the Pictet‑Spengler Reaction. Chirally‑controlled Synthesis of Optically Active 1,3‑Disubstituted‑1,2,3,4‑Tetrahydro‑ß‑Carbolines," L.H. Zhang and J.M. Cook, 20th Central Regional Meeting of the American Chemical Society, West Virginia University, Morgantown, WV, June 1‑3, 1988, Abstract No. 145.

"Synthesis of 3‑Substituted‑ß‑Carbolines as Benzodiazepine Receptor Ligands: Probing the Benzodiazepine Receptor Inverse Agonist Site *via* the Template Approach," M.S. Allen, T.J. Hagen, P. Skolnick, and J.M. Cook, 20th Central Regional Meeting of the American Chemical Society, West Virginia University, Morgantown, WV, June 1‑3, 1988, Abstract No. 168.

"Defining the Pharmacophore of the Benzodiazepine Inverse Agonist Site," K. Narayanan, P. Skolnick, and J.M. Cook, 20th Central Regional Meeting of the American Chemical Society, West Virginia University, Morgantown, WV, June 1‑3, 1988, Abstract No. 169.

"Synthesis and 2 D‑Cosy Characterization of Quinine and Quinidine Metabolites. Antibody‑Mediated Platelet Destruction by Quinine, Quinidine, and Their Metabolites," H. Diaz‑Arauzo, D.J. Christie, and J.M. Cook, 20th Central Regional Meeting of the American Chemical Society, West Virginia University, Morgantown, WV, June 1‑3, 1988, Abstract No. 170.

"Studies on the Pharmacophore for the Benzodiazepine Receptor Inverse Agonist Site: Synthesis of a Potent Long‑lived Inverse Agonist and an Irreversible Inhibitor," M.S. Allen, T.J. Hagen, M.L. Trudell, P. Skolnick, J.M. Cook, 40th ACS Southwest Regional Meeting, Radisson Hotel Atlanta, Atlanta, Georgia, Nov. 9‑11, 1988, Abstract No. 446.

"Synthesis of Higher Homologs of 7,12‑Dihydropyrido‑[3,4‑b:5,4,‑b']diindole. Probing the Dimensions of the Benzodiazepine Receptor Inverse Agonist Site," K. Narayanan, P. Skolnick, J.M. Cook, 197th ACS National Meeting, Dallas, Texas, April 9‑14, 1989, MEDI‑0036.

"The Template Approach to the Pharmacophore of the Benzodiazepine Receptor Inverse Agonist Site," M.S. Allen, P. Skolnick, T.J. Hagen, K. Koehler, J.M. Cook, 197th ACS National Meeting, Dallas, Texas, April 8‑14, 1989, MEDI‑0055.

"Antibody‑Mediated Platelet Destruction by Quinine, Quinidine and Their Metabolites. Synthesis and Conformation of the Metabolites of Quinine and Quinidine," H. Diaz‑Arauzo, D.J. Christie, J.M. Cook, 197th ACS National Meeting, Dallas, Texas, April 9‑14, 1989, MEDI-0081.

"Pictet‑Spengler Reactions in Aprotic Media, Studies Directed Toward the Synthesis of the Macroline Alkaloids Suaveloline and Macroline," M.L. Trudell, L.‑H. Zhang, J.M. Cook, 197th ACS National Meeting, Dallas, Texas, April 9‑14, 1989, ORGN‑0035.

"General Approach for the Synthesis of Polyquinenes *via* the Weiss Reaction. Synthesis of 1,10‑Disubstituted Triquinacenes Including 'Propellane' Triquinancene," A.K. Gupta, X. Fu, J.M. Cook, 197th National ACS Meeting, Dallas, Texas, April 9‑14, 1989, ORGN‑0159.

"Functionalization of the *cis*‑Bicyclo[3.3.0]octane‑3,7‑dione Unit and its Application to the Synthesis of Polyquinenes," K. Sambasivarao, J.M. Cook, 197th National ACS Meeting, Dallas, Texas, April 9‑14, 1989, ORGN‑0194.

"Computer‑assisted Approach to the Pharmacophore of the Benzodiazepine Receptor Inverse Agonist Site, M.S. Allen, P. Skolnick, L. Schindler, J.M. Cook, 22nd ACS Great Lakes Regional Meeting, University of Minnesota‑Duluth, Duluth, MN, May 31‑June 2, 1989, Abstract NO. 28.

"Molecular Yardsticks: Probing the Dimensions of the Benzodiazepine Receptor Inverse Agonist Site with Rigid, Planar Ligands," K. Narayanan, P. Skolnick, J.M. Cook, 22nd ACS Great Lakes Regional Meeting, University of Minnesota‑Duluth, Duluth, MN, May 31‑June 2, 1989, Abstract No. 29.

"Antibody‑Mediated Platelet Destruction by Quinine, Quinidine and Their Metabolites. Synthesis and Conformation of the Metabolites of Quinine and Quinidine," H. Diaz‑Arauzo, D.J. Christie, J.M. Cook, 22nd ACS Great Lakes Regional Meeting, University of Minnesota‑Duluth, Duluth, MN, May 31‑June 2, 1989, Abstract No. 30.

"Pictet‑Spengler Reactions in Aprotic Media. Stereocontrolled Approach to the Synthesis of Macroline Alkaloids," L.‑H. Zhang, J.M. Cook, 22nd ACS Great Lakes Regional Meeting, University of Minnesota‑Duluth, Duluth, MN, May 31‑ June 2, 1989, Abstract No. 76.

"General Approach for the Synthesis of Polyquinenes *via* the Weiss Reaction, Progress Toward the Synthesis of Dicyclopenta[cd,gh]pentalene," A.K. Gupta, J.M. Cook, 22nd ACS Great Lakes Regional Meeting, University of Minnesota‑ Duluth, Duluth, MN, May 31‑June 2, 1989, Abstract No. 86.

"Synthesis of Polyquinenes *via* the Weiss Reaction. Studies Directed Toward the Preparation of Dicyclopenta[a,d]pentalene and Dicyclopenta[a,e]pentalene," K. Sambasivarao, J.M. Cook, 22nd ACS Great Lakes Regional Meeting, University of Minnesota‑Duluth, Duluth, MN, May 31‑June 2, 1989, Abstract No. 87.

"General Approach for the Synthesis of Polyquinenes *via* the Weiss Reaction. Synthesis of Centro‑substituted Triquinacenes Including 1,10‑Cyclododecyl-triquinacene," X. Fu, A.K. Gupta, J.M. Cook, 22nd ACS Great Lakes Regional Meeting, University of Minnesota‑Duluth, Duluth, MN, May 31‑June 2, 1989, Abstract No. 88.

"Studies Directed Toward the Synthesis of Diazapentalenes," S.P. Hollinshead, K. Sambasivarao, J.M. Cook, 22nd ACS Great Lakes Regional Meeting, University of Minnesota‑Duluth, Duluth, MN, May 31‑June 2, 1989, Abstract No. 97.

"The Total Synthesis of the Macroline‑Related Alkaloid Suaveoline," L.H. Zhang, M.L. Trudell, S.P. Hollinshead, J.M. Cook, 198th National Meeting of the ACS, Miami Beach, FL, September 10‑15, 1989, Abstract No. ORGN-113.

"Chiral Control in the Pictet‑Spengler Reaction. Synthesis of Macroline‑Related Alkaloids," J.M. Cook, L.H. Zhang, M. Trudell, and S.P. Hollinshead, The Mona Symposium (1990), National Products and Medicinal Chemistry, University of West Indies, Kingston, Jamaica, January 8‑12, 1990.

"Synthetic Studies on the Pharmacophore for the Benzodiazepine Inverse Agonist Site," J.A. Laloggia, M.S. Allen and J.M. Cook, 20th Annual Undergraduate Research Symposium in Chemistry, Carthage College, April 25‑26, 1990.

"Chiral Control in the Pictet‑Spengler Reaction. Synthesis of Macroline‑Related Alkaloids," J.M. Cook, L.H. Zhang, and M. Trudell, 23rd Great Lakes Regional Meeting of the ACS, NIU, DeKalb, Illinois, May 30 ‑ June 1, 1990, Abstract #167.

"Studies Directed Toward the Synthesis of Polyquinenes *via* the Weiss Reaction," X. Fu, A.K. Gupta, K.S. Rao and J.M. Cook, 23rd Great Lakes Regional Meeting of the ACS, NIU, DeKalb, Illinois, May 30 ‑ June 1, 1990, Abstract #163.

"A Synthetic and Computer Assisted Investigation of the Topography of the Benzodiazepine Receptor Inverse Agonist Site, M. S. Allen, P. Skolnick, T.J. Hagen, K. Koehler and J.M. Cook, 23rd Great Lakes Regional Meeting of the ACS, NIU, DeKalb, Illinois, May 30 ‑ June 1, 1990, Abstract #179.

"Molecular Modelling of the Benzodiazepine Receptor (BzR) Agonist Site. Structural Requirements for ß‑Carbolines," H. Diaz‑Arauzo, M.S. Allen, P. Skolnick and J.M. Cook, 23rd Great Lakes Regional Meeting of the ACS, NIU, DeKalb, Illinois, May 30 ‑ June 1, 1990, Abstract #180.

"General Approach to the Synthesis of Macroline/Sarpagine Alkaloids. Studies Directed Toward the Enantiospecific Preparation of Na‑Methylsarpagine, The Nonmacroline Portion of Macralstonidine," 23rd Great Lakes Regional Meeting of the ACS, NIU, DeKalb, Illinois, May 30 ‑ June 1, 1990, Abstract #182.

"Molecular Yardsticks. Probing the Dimensions of the Benzodiazepine Receptor Inverse Agonist Site with Rigid, Planar Ligands," K. Narayanan, M. Martin, P. Skolnick and J.M. Cook, 23rd Great Lakes Regional Meeting of the ACS, NIU, DeKalb, Illinois, May 30 ‑ June 1, 1990, Abstract #183.

"Carboxyl‑Mediated Pictet‑Spengler Reaction. Synthetic Approach to Cytotoxic, Antileukemic Indole Alkaloids," K. Narayanan, L. Schindler and J. M. Cook, 23rd Great Lakes Regional Meeting of the ACS, NIU, DeKalb, Illinois, May 30 ‑ June 1, 1990, Abstract #184.

"Inverse Agonists. Probes to Study the Structure, Topology and Function of the Benzodiazepine Receptor," J. M. Cook, H. Diaz‑Arauzo and M.S. Allen, 52nd Annual Scientific Meeting of the Committee on Problems of Drug Dependence, Richmond, Virginia, June 10 ‑ 14, 1990.

"The Total Synthesis of Suaveoline, Macroline and Alstonerine," J. M. Cook, Y. Bi and M. Trudell, 200th National Meeting of the ACS, Washington, D.C., August 26 ‑ September 1, 1990, Abstract #208.

"Mechanistic Study of the Acid‑Catalyzed Epimerization of Reserpine to Isoreserpine," A.K. Gupta, L.H. Zhang and J.M. Cook, 200th National Meeting of the ACS, Washington, D.C., August 26 ‑ September 1, 1990.

"CoMFA Approach to Long‑lived Inverse Agonists at Benzodiazepine Receptors," M.S. Allen, T.J. Hagen, K. Koehler and J.M. Cook, 200th National Meeting of the ACS, Washington, D.C., August 26 ‑ September 1, 1990.

"Structural Requirements for Agonist Actions of ß‑Carbolines at the Benzodiazepine Receptor (BzR). Alignment Rule and Pharmacophore for Full and Partial Agonists at the BzR," H. Diaz‑Arauzo, P. Skolnick and J.M. Cook, 200th National Meeting of the ACS, Washington, D.C., August 26 ‑ September 1, 1990.

"Carboxyl‑Mediated Pictet‑Spengler Reaction. Synthetic Approach to Cytotoxic Antileukemic Alkaloids," K. Narayanan and J.M. Cook, The 4th Symposium on the Latest Trends in Organic Synthesis, Blacksburg, Virginia, October 14‑17, 1990.

"ß‑Carbolines Alter Pentobarbital Withdrawal," G.J.Yutrzenka, J. Cook, T. Stone, S. Anderson, ASPET 1991 Meeting, San Diego, CA, 1991.

"The Agonist Pharmacophore of the Benzodiazepine Receptor. Synthesis of a Selective Anticonvulsant/Anxiolytic," 53rd Annual Scientific Meeting of the Committee on Problems of Drug Dependence, the Breakers, Palm Beach, FL, Section on Medicinal Chemistry‑Novel Compounds, June 16‑20, 1991.

"CoMFA Approach to the Benzodiazepine Receptor Inverse Agonist Site," M.S. Allen, T.J. Hagen, K. Koehler and J.M. Cook, 1991 Joint Central‑Great Lakes Regional Meeting of The American Chemical Society, Indiana University‑Purdue University at Indianapolis, Indiana, May 29‑31, 1991, Abstract No. 194.

"The Agonist Pharmacophore of the Benzodiazepine Receptor," H. Diaz‑Arauzo, P. Skolnick and J.M. Cook, 1991 Joint Central‑Great Lakes Regional Meeting of The American Chemical Society, Indiana University‑Purdue University at Indianapolis, Indiana, May 29‑31, 1991, Abstract No. 195.

"Synthesis of Rigid Planar Ligands to Probe the Topography of the Benzodiazepine Receptor Site," L. Dorn, M. Martin and J.M. Cook, 1991 Joint Central‑Great Lakes Regional Meeting of The American Chemical Society, Indiana University‑Purdue University at Indianapolis, Indiana, May 29‑31, 1991, Abstract No. 339.

"Benzosubstituted Benzodiazepine Probes With Which to Study the Topography of the Agonist Pharmacophore of the BzR," Weijiang Zhang, H. Diaz‑Arauzo and J.M. Cook, 1991 Joint Central‑Great Lakes Regional Meeting of The American Chemical Society, Indiana University‑Purdue University at Indianapolis, Indiana, May 29‑31, 1991, Abstract No. 340.

"Stereospecificity of the Pictet‑Spengler Reaction. Kinetic versus Thermodynamic Control," K. Czerwinski, L. Deng and J.M. Cook, 1991 Joint Central‑Great Lakes Regional Meeting of The American Chemical Society, Indiana University‑Purdue University at Indianapolis, Indiana, May 29‑31, 1991, Abstract No. 356.

"Studies Directed Toward the Enantiospecific Synthesis of the Suaveoline Alkaloids. Application of the Oxy‑Cope Rearrangement to the Construction of the Pyridine E‑Ring," F.Yu, X. Fu and J.M. Cook, 1991 Joint Central‑Great Lakes Regional Meeting of The American Chemical Society, Indiana University‑Purdue University at Indianapolis, Indiana, May 29‑31, 1991, Abstract No. 403.

"Carboxyl‑Mediated Pictet‑Spengler Reaction. Synthesis of Antileukemic Cytotoxic Canthine‑6‑one Alkaloids," K. Narayanan and J.M. Cook, 1991 Joint Central‑Great Lakes Regional Meeting of The American Chemical Society, Indiana University‑Purdue University at Indianapolis, Indiana, May 29‑31, 1991, Abstract No. 404.

"General Approach to the Synthesis of Macroline/Sarpagine Alkaloids. Recent Progress Directed Toward the Synthesis of Na‑Methylsarpagine, Talpinine, Talcarpine, and Other *Alstonia* Alkaloids," L.K. Hamaker, Y. Bi and J.M. Cook, 1991 Joint Central‑Great Lakes Regional Meeting of The American Chemical Society, Indiana University‑Purdue University at Indianapolis, IN, May 29‑31, 1991, Abs. No. 405.

"Studies on the Pictet‑Spengler Reaction. New Strategies for the Synthesis of Ring‑A Methoxylated Indole Alkaloids," M.S. Allen, K. Narayanan and J.M. Cook, 32nd Meeting of the American Society of Pharmacognosy: International Research Congress on Natural Products, Chicago, IL, July 21‑26, 1991, Abstract No. O‑42.

"Recent Progress Toward the Synthesis of Macroline/Sarpagine Alkaloids," L.K. Hamaker, Y. Bi, F. Yu, X. Fu and J.M. Cook, 32nd Annual Meeting of the American Society of Pharmacognosy: International Research Congress on Natural Products, Chicago, IL, July 21‑26, 1991, Abstract No. O‑43.

"Probes to Study the Structure and Function of the Benzodiazepine (Valium) Receptor. The Synthesis of a New Selective Anxiolytic/Anticonvulsant Agent," M. Allen, H. Diaz and J.M. Cook, MONA Symposium 1992, Natural Products & Medicinal Chemistry, University of the West Indies, Mona, Jamaica, January 6‑10, 1992.

"Molecular Yardsticks. Probing the Dimensions of the Benzodiazepine Receptor Agonist/Inverse Agonist Binding Site With Rigid Planar Ligands," W. Zhang, H. Diaz‑Arauzo, L. Dorn, M. Martin, P. Skolnick and J.M. Cook, 203rd ACS National Meeting, San Francisco, April 5‑10, 1992, MED 184.

"General Approach to the Synthesis of Macroline/Sarpagine Alkaloids. Total Synthesis of Raumacline, Suaveoline, and 19,20‑Dehydrotalcarpine," X. Fu, Y. Bi, L.K. Hamaker, F. Y. and J.M. Cook, 203rd ACS National Meeting, San Francisco, April 5‑10, 1992, ORG‑490.

"Receptor Mapping of the Benzodiazepine Binding Site," K.F. Koehler, T.J. Hagen, H. Diaz‑Arauzo, M.S. Allen, G. Constantino, P. Skolnick and J.M. Cook, 25th Great Lakes Regional ACS Meeting, Milwaukee, WI, June 1‑3, 1992, ORG‑153.

"Study of the Topography of the Agonist Pharmacophore at the Benzodiazepine Receptor Binding Site," W. Zhang and J.M. Cook, 25th Great Lakes Regional ACS Meeting, Milwaukee, WI, June 1‑3, 1992, ORG‑180.

"Predictive Binding of ß‑Carboline Inverse Agonists and Antagonists *via* the CoMFA Approach," A.J. LaLoggia, M.S. Allen, K. Koehler, (G.D. Searle), P. Skolnick and J.M. Cook, 25th Great Lakes Regional ACS Meeting, Milwaukee, WI, June 1‑3, 1992, ORG‑181.

"Stereospecificity in the Pictet‑Spengler Reaction," K.M. Czerwinski, L. Deng and J.M. Cook, 25th Great Lakes Regional ACS Meeting, Milwaukee, WI, June 1‑3, 1992, ORG‑184.

"Studies Directed Toward the Enantiospecific Preparation of Macroline, Affinisine and Na‑Methylsarpagine," Y. Bi and J.M. Cook, 25th Great Lakes Regional ACS Meeting, Milwaukee, WI, June 1‑3, 1992, ORG‑193.

"General Approach to the Synthesis of Macroline/Sarpagine Alkaloids. Recent Progress Directed Toward the Synthesis of Alstophylline, Talpinine, Talcarpine, and Other *Alstonia* Alkaloids," L.K. Hamaker, M.S. Allen and J.M. Cook, 25th Great Lakes Regional ACS Meeting, Milwaukee, WI, June 1‑3, 1992, ORG‑195.

"Studies Directed Toward the Enantiospecific Synthesis of the Suaveoline Alkaloids. Application of the Anionic Oxy‑Cope Rearrangement to the Construction of the Pyridine E‑Ring," F. Yu and J.M. Cook, 25th Great Lakes Regional ACS Meeting, Milwaukee, WI, June 1‑3, 1992, ORG‑197.

"General Approach to the Synthesis of Macroline/Sarpagine Alkaloids. Total Synthesis of Raumacline, Nb‑Methyl Raumacline, and Suaveoline," X. Fu and J.M. Cook, 25th Great Lakes Regional ACS Meeting, June 1‑3, 1992, ORG‑198.

"Molecular Yardsticks. Rigid Benzodiazepine Receptor Ligands to Probe the Spatial Dimensions of the Binding Site," M.J. Martin, L.J. Dorn, K.F. Koehler, P. Skolnick and J.M. Cook, 25th Great Lakes Regional ACS Meeting, Milwaukee, WI, June 1‑3, 1992, ORG‑263.

"Molecular Yardsticks: Studying the Topopgraphy of the Agonist Pharmacophore at the Benzodiazepine Receptor Binding Site," W. Zhang, P. Skolnick and J.M. Cook, 204th ACS National Meeting, August 23‑28th, 1992, MED‑71.

"General Approach to the Enantiospecific Synthesis of the Suaveoline/Ajmaline Alkaloids: Application of the Anionic Oxy‑Cope Rearrangement to the Construction of the Pyridine E‑Ring," F. Yu, X. Fu and J.M. Cook, 204th ACS National Meeting, August 23‑28th, 1992, ORG‑27.

"Mechanism‑Driven *Trans*‑Stereospecificity in the Pictet‑Spengler Reaction," K.M. Czerwinski, L. Deng and J.M. Cook, 204th ACS National Meeting, August 23‑28th, 1992, ORG‑80.

"General Approach to the Synthesis of Macroline/Sarpagine Alkaloids: The Enantiospecific Preparation of Macroline and Related Alkaloids," Y. Bi and J.M. Cook, 204th ACS National Meeting, August 23‑28th, 1992, ORG‑99.

"Enantiospecific Approach Toward the Synthesis of Alstonerine, Alstophylline, and 10,20‑Dehydrotalcarpine," L.K. Hamaker, M.S. Allen and J.M. Cook, 204th ACS National Meeting, August 23‑28th, 1992, ORG‑100.

"Molecular Yardsticks. Rigid Probes to Study the Topography of the Benzodiaz-epine Receptor Site," NIMH Workshop, Keystone, Colorado, September, 1992.

"Beta Carbolines: The Design of Pharmacologic Probes for the Study of Anterior Hypothalamic Function," M.J. Martin, K. Koehler and J.M. Cook, Cellular Consequences of Sleep, Maui, Hawaii, March 13‑17, 1993.

"The Agonist Pharmacophore of the Benzodiazepine Receptor. Synthesis of a Selective Anticonvulsant/Anxiolytic," E.D. Cox, M.S. Reddy and J.M. Cook, 33rd National Organic Symposium, Bozeman, Montana, June 13‑17, 1993, Abs. A‑50.

"Complete *Trans* Stereoselectivity in the Aprotic Pictet‑Spengler Reaction," K.M. Czerwinski and J.M. Cook, 33rd National Organic Symposium, Bozeman, Montana, June 13‑17, 1993, Abs. A‑54.

"Enantiospecific Approach Towards the Synthesis of Macroline/Sarpagine/Ajmaline Alkaloids," L.K. Hamaker, Y. Bi, F. Yu and J.M. Cook, 33rd National Organic Symposium, Bozeman, Montana, June 13‑17, 1993, Abs. A‑93.

"Synthetic and Computer Assisted Analysis of the Structural Requirements for Selective High Affinity Ligand Binding to 'Diazepam‑Insensitive' Benzodiazepine Receptors," K. Koehler, P. Skolnick, R. Liu, Q. Huang, Z‑Q Gu and J.M. Cook, 33rd National Organic Symposium, Bozeman, Montana, June 13‑17, 1993, Abs. B‑3.

"Design, Synthesis and Evaluation of Indoleamine‑2,3‑Dioxygenase Inhibitors to Combat Aberant Tryptophan Metabolism," A.C. Peterson, M.T. Migawa, J.M. Cook, R.R. Brown and J.A. Will, 33rd National Organic Symposium, Bozeman, Montana, June 13‑17, 1993, Abs. B‑48.

"A Study of the Topography of the Agonist Pharmacophore at the Benzodiazepine Receptor Binding Site and Its Effect on Activity," W. Zhang, P. Skolnick and J.M. Cook, 33rd National Organic Symposium, Bozeman, Montana, June 13‑17, 1993, Abs. B‑135.

"Synthesis and Evaluation of Inhibitors to Combat Aberrant Tryptophan Metabolism Catalyzed by Indoleamine 2,3‑Dioxygenase," A.C. Peterson, M.T. Migawa, J.M. Cook, R.R. Brown and J.A. Will, 206th ACS National Meeting, Chicago, Illinois, August 22‑27, 1993, MEDI‑242.

"Study of the Agonist Pharmacophore of the Benzodiazepine Receptor. The Synthesis of Anxioselective Anxiolytics," W. Zhang, P. Skolnick and J.M. Cook, 206th ACS National Meeting, Chicago, Illinois, August 22‑27, 1993, MEDI‑196.

"Studies Directed Toward the Enantiospecific Preparation of the Bisindole Alkaloid Macralstonidine. The Total Synthesis of (+)‑Macroline and (+)‑Affinisine," Y. Bi, and J.M. Cook, 206th ACS National Meeting, Chicago, Illinois, August 22‑27, 1993, ORGN‑67.

"Approach to the Enantiospecific Synthesis of Norsuaveoline, Macrophylline, and the Related Desmethylmacrophylline," F. Yu and J.M. Cook, 206th ACS National Meeting, Chicago, Illinois, August 22‑27, 1993, ORGN‑68.

"Enantiospecific Approach Towards the Synthesis of Macroline/Sarpagine Alkaloids," L.K. Hamaker, M.S. Allen and J.M. Cook, 206th ACS National Meeting, Chicago, Illinois, August 22‑27, 1993, ORGN‑69.

"Stereochemical Control of the Pictet‑Spengler Reaction," K. Czerwinski, K. Koehler and J.M. Cook, 206th ACS National Meeting, Chicago, Illinois, August 22‑27, 1993, ORGN‑70.

"Effect of Novel ß‑Carboline Compounds on Pentobarbital Induced Sleep," C. LeBeaux, K. Campbell‑Prue, J. Cook and G. Yutrzenka, American Indian Research Opportunities Conference, Bozeman, Montana, August 12‑13, 1993.

"Effect of Novel ß‑Carboline Compounds on Pentobarbital Induced Incoordination," K. Campbell‑Prue, C. LeBeaux, J. Cook and G. Yutrzenka, American Indian Research Opportunities Conference, Bozeman, Montana, August 12‑13, 1993.

"Enantiospecific Approach Towards the Synthesis of Macroline/Sarpagine/Ajmaline Alkaloids," J.M. Cook, Y. Bi, L.K. Hamaker and M.S. Allen, Fifteenth Mona Symposium in Natural Products and Medicinal Chemistry, Mona, Jamaica, January 3‑7, 1994.

"Synthesis and SAR Study of Selective High‑Affinity Ligands That Bind to Diazepam‑ Insensitive Benzodiazepine Receptors," presented at the 207th ACS National Meeting, San Diego, CA, March 13‑17, 1994, MEDI‑187.

"Chemical and Computer‑Assisted Study of the Agonist Pharmacophore of the Benzodiazepine Receptor," W. Zhang, P. Skolnick and J.M. Cook, presented at the 207th ACS National Meeting, San Diego, CA, March 13‑17, 1994, MEDI-188.

"Stereoselective Pictet‑Spengler Reactions: Application to the Synthesis of Optically Active Tetrahydro ß‑Carbolines," M.S. Reddy and J.M. Cook, presented at the 207th ACS National Meeting, San Diego, CA, March 13‑17, 1994, ORGN-312.

"General Approach for the Synthesis of Macroline‑Sarpagine Alkaloids: Enantiospecific Synthesis of (+)Macroline and a Partial Synthesis of (+)Villalstonine," Y. Bi, L. Hamaker and J.M. Cook, presented at the 207th ACS National Meeting, San Diego, CA, March 13‑17, 1994, ORGN-444.

"Effect of 3‑Substituted ß‑Carbolines on Pentobarbital (PB) Induced Sleep," G.J. Yutrzenka, C. LeBeaux, K. Campbell‑Prue and J.M. Cook, XII International Congress of Pharmacology, Montreal, Quebec, July 24‑29, 1994.

"Mode of Action of ß‑Carboline Convulsants on the Insect Nervous System and Their Potential as Insectides," J.R. Bloomquist, A.J. LaLoggia, M.S. Reddy and J.M. Cook, presented in the summer of 1994.

"Chemical and Computer‑Assisted Development of the Inclusive Pharmacophore for the Benzodiazepine Receptor," James Cook, presented at the 28th Middle Atlantic Regional Meeting of the ACS, University of Maryland, Baltimore County, Baltimore, MD, May 25‑27, 1994, ABS 112.

"Synthesis and SAR Study of Selective High Affinity Ligands Which Bind to Benzodiazepine Receptor Subtypes," R. Liu, P. Zhang, P. Skolnick and J.M. Cook, presented at the Joint Great Lakes, Central Regional ACS Meeting, University of Michigan, Ann Arbor, MI, June 1‑3, 1994, ABS 314.

"Synthesis and SAR Study of Novel Imidazobenzodiazepines Which Bind to Diazepam‑ Insensitive Benzodiazepine Receptors," P. Zhang, R. Liu, P. Skolnick and J.M. Cook, presented at the Joint Great Lakes, Central Regional ACS Meeting, University of Michigan, Ann Arbor, MI, June 1‑3, 1994, ABS 315.

"Synthesis of 3,4,6‑Trisubstituted ß‑Carbolines. Probing the Dimensions of the Lipophilic Pockets in the BzR Site(s)," E. Cox and J.M. Cook, presented at the Joint Great Lakes, Central Regional ACS Meeting, University of Michigan, Ann Arbor, MI, June 1‑3, 1994, ABS 316.

"Evaluation of Competitive and Non‑competitive Inhibitors of Indoleamine 2,3‑Dioxygenase to Combat Aberrant Tryptophan Metabolism in Immunological Disease States," A.C. Peterson, E. Cox, J.M. Cook, R.A. Arend and R.R. Brown, presented at the Joint Great Lakes, Central Regional ACS Meeting, University of Michigan, Ann Arbor, MI, June 1‑3, 1994, ABS 319.

"A Chemical and Computer Assisted Study of the Inclusive Pharmacophore of the Benzodiazepine Receptor," W. Zhang and J.M. Cook, presented at the Joint Great Lakes, Central Regional ACS Meeting, University of Michigan, Ann Arbor, MI, June 1‑3, 1994, ABS 320.

"Enantiospecific Synthesis of Macrolin/Sarpagine/Ajmaline‑Related Alkaloids *via* the Pictet‑Spengler Reaction," Y. Bi, L. Hamaker and J.M. Cook, presented at the Joint Great Lakes, Central Regional ACS Meeting, University of Michigan, Ann Arbor, MI, June 1‑3, 1994, ABS 358.

"Enantiospecific Approach Towards the Synthesis of the Macroline‑Related Alkaloids Alstophylline and Macralstonine," L. Hamaker, M.S. Allen and J.M. Cook, presented at the Joint Great Lakes, Central Regional ACS Meeting, University of Michigan, Ann Arbor, MI, June 1‑3, 1994, ABS 381.

"The Aza‑Wittig Approach to the Enantiospecific Synthesis of Norsuaveoline, Macrophylline, and the Related Desmethylmacrophylline," F. Yu and J.M. Cook, presented at the Joint Great Lakes, Central Regional ACS Meeting, University of Michigan, Ann Arbor, MI, June 1‑3, 1994, ABS 396.

"Studies Directed Toward the Enantiospecific Synthesis of *Alstonia*, *Gardneria*, and *Voacanga* Oxindole Alkaloids," A.C. Peterson and J.M. Cook, presented at the Joint Great Lakes, Central Regional ACS Meeting, University of Michigan, Ann Arbor, MI, June 1‑3, 1994, ABS 399.

"Synthetic Approach to Angular Tetraquinanes Related to 14π Cyclo pentapentalenes," M.S. Reddy and J.M. Cook, presented at the Joint Great Lakes, Central Regional ACS Meeting, University of Michigan, Ann Arbor, MI, June 1‑3, 1994, ABS 402.

"Stereochemical Control of the Pictet‑Spengler Reaction," K. Czwerinski, K. Koehler and J.M. Cook, presented at the Joint Great Lakes, Central Regional ACS Meeting, University of Michigan, Ann Arbor, MI, June 1‑3, 1994, ABS 403.

"The Total Synthesis of Roeharmine, (+)Norroecarboline, and (‑)‑1,2,3,4‑ Tetra-hydroroeharmine," M. Sreenivasa Reddy and J.M. Cook, presented at the Joint Great Lakes, Central Regional ACS Meeting, University of Michigan, Ann Arbor, MI, June 1‑3, 1994, ABS 428.

"Search for α5 Benzodiazeping Receptor Subtype Specific Ligands Based on the Structure of Sarmazenil (Ro 15‑4513)," R.Y. Liu, N.P. Gillard, Z‑Q. Gu, K. Rice, R. McKernan and J.M. Cook. Presented at the 56th Annual Scientific Meeting of the College on Problems of Drug Dependence, The Breakers, West Palm Beach, June 18‑23, 1994, Oral Communications VI.

"Chemical and Computer‑Assisted Study of the Inclusive Pharmacophore/Receptor Model of the Benzodiazepine Receptor Binding Site," W. Zhang, R. Liu, Q. Huang, P. Zhang, K.F. Koehler and J.M. Cook, presented at the 208th National ACS Meeting, Washington, D.C., August 21‑25, 1994, MED-191.

"Use of ß‑Carbolines to Further Differentiate the Agonist/Inverse Agonist Pharmacophore at the BzR," E.D. Cox and J.M. Cook, presented at the 208th National ACS Meeting, Washington, D.C., August 21‑25, 1994, MED-192.

"Synthesis and SAR Study of Novel Imidazobenzodiazepines at Diazepam‑ Insensitive and Diazepam‑Sensitive Benzodiazepine Receptors," P. Zhang, W. Zhang, R. Liu and J.M. Cook, presented at the 208th National ACS Meeting, Washington, D.C., August 21‑25, 1994, MED-195.

"Total Synthesis of Roemeria Alkaloids. A Study of the Racemization in (‑)‑1,2,3,4‑ Tetrahydroroeharmine," M.S. Reddy and J.M. Cook, presented at the 208th National ACS Meeting, Washington, D.C., August 21‑25, 1994, ORG 259.

"Enantiospecific Approach Toward the Synthesis of the *Alstonia* Alkaloid Alstophylline and the Bisindole Macralstonine," L.K. Hamaker and J.M Cook, presented at the 208th National ACS Meeting, Washington, D.C., August 21‑25, 1994, ORG 269.

"Studies Toward the Enantiospecific Synthesis of Suaveoline Alkaloids. Aza‑Wittig Approach to the Construction of the Pyridine E‑Ring Systems," F. Yu and J.M. Cook, presented at the 208th National ACS Meeting, Washington, D.C., August 21‑25, 1994, ORG 270.

"Studies Directed Toward the Diastereoselective Synthesis of *Alstonia* Oxindole Alkaloids," A.C. Peterson and J.M. Cook, presented at the 208th National ACS Meeting, Washington, D.C., August 21‑25, 1994, ORG 271.

"Recent Advances in GABAA/Benzodiazepine Receptor Subtype Selectivity," J.M. Cook, 27th Annual Mardi Gras Symposium on Chemistry in Drugs of Abuse: Recent Advances in Chemistry and Pharmacology, University of New Orleans, February 24, 1995.

"Synthesis of Ligands Selective for the α5 Benzodiazepine Receptor (BzR) Subtype," R.Y. Liu, P.W. Zhang, N.P. Gillard, R. McKernan and J.M. Cook, presented at the 209th National ACS Meeting, Anaheim, CA, April 2-6, 1995, MED 1.

"Evidence for Cleavage Across the C(1)N(2) Bond in the Epimerization of 1,2,3,4-Tetrahydro-ß-Carbolines," E.D. Cox, L.K. Hamaker, M.S. Reddy, P. Zhang, K. Czerwinski and J.M. Cook, presented at the 209th National ACS Meeting, Anaheim, CA, April 2-6, 1995. ORG 356.

"Stereospecific Approach to 19,20-Dehydro-10-methoxytalcarpine. The Enantio-specific Synthesis of 5-Methoxy-D-(+)-or L(-)-tryptophan," P.W. Zhang and J.M. Cook, presented at the 28th Great Lakes Regional Meeting of the ACS, La Crosse, WI, June 5-8, 1995, #142.

"A Chemical and Computer Assisted Study of the Inclusive Pharmacophore of the Benzodiazepine Receptor," Q. Huang, W. Zhang and J.M. Cook, presented at the 28th Great Lakes Regional Meeting of the ACS, La Crosse, WI, June 5-8, 1995, #169.

"Scission of the C(1)-N(2) Bond in the Epimerization of 1,2,3,4-Tetrahydro ß-Carbolines," E.D. Cox, M. S. Reddy and J.M. Cook, presented at the 28th Great Lakes Regional Meeting of the ACS, La Crosse, WI, June 5-8, 1995, #183.

"Synthesis and SAR Study of Novel Imidazobenzodiazepines Which Bind to 'Diazepam-Insensitive' GABAA Receptors," P. Zhang, R. Liu, B. Harris, P. Skolnick and J.M. Cook, presented at the 28th Great Lakes Regional Meeting of the ACS, La Crosse, WI, June 5-8, 1995, #199.

"Synthesis and Study of Ligands Selective for the α5β2γ2 BzR Subtype," R.Y. Liu, P.W. Zhang, N.P. Gillard, R. McKernan and J.M. Cook, presented at the 28th Great Lakes Regional Meeting of the ACS, La Crosse, WI, June 5-8, 1995, #200.

"Studies Directed Toward the Rapid Construction of Angular Tetraquinanes Related to 14π Cyclopentapentalenes," S. Van Ornum, M.S. Reddy and J.M. Cook, presented at the 28th Great Lakes Regional Meeting of the ACS, La Crosse, WI, June 5-8, 1995, #210.

"Pharmacophore Mapping: Synthesis of Ligands Selective for the α5β2γ2 BzR Site," R.Y. Liu, P.W. Zhang, Q. Huang, N.P. Gillard, R. McKernan and J.M. Cook, presented at the 57th Annual Scientific Meeting of the College on Problems of Drug Dependence, Scottsdale, Arizona, June 10-15, 1995, P.S. II #35.

"Synthesis of Novel Imidazobenzodiazepines: The Selective Ligands for the GABAA Receptor Subtype," P. Zhang, R. Liu, P. Skolnick and J.M. Cook, presented at the 210th ACS National Meeting, Chicago, Illinois, August 20-24, 1995, MEDI-0148.

"Chemical and Computer-Assisted Study of the Inclusive Pharmacophore of the Benzodiazepine Receptor," Q. Huang, W. Zhang and J.M. Cook, presented at the 210th ACS National Meeting, Chicago, Illinois, August 20-24, 1995, MEDI -159.

"Synthesis of Ligands Selective for the α-5 Benzodiazepine Receptor (BzR) Subtype," R.Y. Liu, P.W. Zhang, N.P. Gillard, R. McKernan and J.M. Cook, presented at the 210th ACS National Meeting, Chicago, Illinois, August 20-24, 1995, MEDI-160.

"Enantiospecific Synthesis of Macroline/Sarpagine/Ajmaline-related Indole Alkaloids *via* the Pictet-Spengler Reaction," J. Li, L. Hamaker, K. Czerwinski, P. Zhang and J.M. Cook, presented at the 210th ACS National Meeting, Chicago, Illinois, August 20-24, 1995, ORGN-212.

"Studies Toward the Synthesis of the Antiamoebic Bisindole Alkaloid (‑)‑Macrocarpamine: The Partial Synthesis of (‑)‑Anhydromacrosalhine-methine," T. Gan and J.M. Cook, presented at the 210th ACS National Meeting, Chicago, Illinois, August 20-24, 1995, ORGN-213.

"Stereospecific Approach to 19,20-Dehydro-10-methoxytalcarpamine: The Enantio-specific Synthesis of 5-Methoxy-D(+)- or L(‑)‑Tryptophan," P. Zhang, T. Gan and J.M. Cook, presented at the 210th ACS National Meeting, Chicago, Illinois, August 20-24, 1995, ORGN-214.

"Studies Directed Toward the Diastereoselective Synthesis of *Alstonia* Oxindole Alkaloids," A.C. Peterson, P. Yu and J.M. Cook, presented at the 210th ACS National Meeting, Chicago, Illinois, August 20-24, 1995, ORGN-215.

"Scission of the C(1)-N(2) Bond in the Epimerization of 1,2,3,4-Tetrahydro-ß-Carbolines," E.D. Cox, L.K. Hamaker, M.S. Reddy, P. Zhang, K.M. Czerwinski and J.M. Cook, presented at the 210th ACS National Meeting, Chicago, Illinois, August 20-24, 1995, ORGN-216.

"Studies Directed Toward the Construction of Angular Tetraquinanes Related to 14π Cyclopentapentalenes," S.G. van Ornum, M.S. Reddy and J.M. Cook, presented at the 210th ACS National Meeting, Chicago, Illinois, August 20-24, 1995, ORGN-217.

"Studies Directed Toward Enantiospecific Synthesis of the Antiamoebic Alkaloid Macrocarpanine and 10-Methoxymacrocarpamine," J.M. Cook and T. Gan, presented at the Sixteenth Mona Symposium on Natural Products and Medicinal Chemistry, Mona, Jamaica, January 8-12, 1996.

“Partial Synthesis of the Antiamoebic Alkaloid Macrocarpamine *via* the Asymmetric Pictet-Spengler Reaction," J.M. Cook and T. Gan, presented at the 211th ACS National Meeting, New Orleans, March 23-28, 1996, ORGN-116.

"The Partial Synthesis of the Antiamoebic Alkaloid Macrocarpamine *via* The Asymmetric Pictet-Spengler Reaction,” T. Gan and J.M. Cook presented at the 29th Great Lakes Regional ACS Meeting, Illinois State University, Normal, IL, May 19-22, 1996, Abstract No. 130.

"Studies Directed Toward the Construction of Angular Tetraquinanes Related to 14π Cyclopentapentalenes,” S. van Ornum, M.S. Reddy and J.M. Cook, presented at the 29th Great Lakes Regional ACS Meeting, Illinois State University, IL, May 19-22, 1996, Abstract No. 251.

"Synthesis of Ligands Selective for the α5 Benzodiazepine Receptor (BzR) Subtype," R. Liu, P.W. Zhang, N.P. Gillard, R. McKernan and J.M. Cook, presented at the 29th Great Lakes Regional ACS Meeting, Illinois State University, Normal, IL., May 19-22, 1996, Abstract No. 255.

"Enantiospecific Synthesis of Macroline/Sarpagine/Ajmaline-Related Indole Alkaloids *via* The Pictet-Spengler Reaction,” J. Li, L. Hamaker, K. Czerwinski, P. Zhang and J.M. Cook, presented at the 29th Great Lakes Regional ACS Meeting, Illinois State University, Normal, IL, May 19-22, 1996, Abstract No. 256.

“Scission of The C(1)-N(2) Bond in the Epimerization of 1,2,3,4-Tetrahydro β-Carbolines,” E. Cox, L.K. Hamaker, M.S. Reddy, P. Zhang, K. Czerwinski and J.M. Cook, presented at the 29th Great Lakes Regional ACS Meeting, Illinois State University, Normal, IL, May 19-22, 1996, Abstract No. 257.

“General Approach to The Diasteroselective Synthesis of Alstonia Oxindole Alkaloids,” P. Yu, A. Peterson and J.M. Cook, presented at the 29th Great Lakes Regional ACS Meeting, Illinois State University, Normal, IL, May 19-22, 1996, Abstract No. 258.

“Studies of the Pharmacophore-Receptor Models for Benzodiazepine Receptor Subtypes: Binding Affinities of Substituted β-Carbolines for αxβ3γ2(X=1,2,3,5 or 6) Subtypes and a Comparative Molecular Field Analysis,” Q. Huang, E.D. Cox, T. Gan, D.W. Bennett and J.M. Cook, presented at the 212th ACS National Meeting, Orlando, Florida, August, 25-29, 1996, MEDI-0157.

“Partial Synthesis of The Antiamoebic Alkaloid Macrocarpamine via the Asymmetric Pictet-Spengler Reaction,” T. Gan and J.M. Cook, presented at the 212th ACS National Meeting, Orlando, Florida, August 25-29, 1996, ORGN-0042.

“The *cis* the *trans* Epimerization 1,2,3,4-Tetrahydo β-carbolines Employed in the Total Synthesis of Indole Alkaloids: Further Evidence for Cleavage Across the C(l) - N(2) Bond,” E. Cox, J. Li, P. Yu, and J.M. Cook, presented at the 212th ACS National Meeting, Orlando, Florida, August, 25-29, 1996, ORGN-0044.

“Studies Directed Toward the Construction of Angular Tetraquinanes Related to 14π- Cyclopentapentalenes,” S. Van Ornum, M. Reddy and J.M. Cook, presented at the 212th ACS National Meeting, Orlando, Florida, August 25-29, 1996, ORGN-0068.

“Generation of Four Five-membered Rings in a One-pot process: Studies Toward the Synthesis of Dicyclopenta[a,e]pentalene via the Tandem Pauson-Khand Reaction,” S.G. Van Ornum, M. S. Reddy, and J.M. Cook, presented at the 213th ACS National Meeting, San Francisco, CA, April 13-17, 1997, ORGN-0498.

“Enantiospecific Total Synthesis of Tryprostatin A,” T. Gan and J.M. Cook, presented at the 213th ACS National Meeting, San Francisco, CA, April 13-17, 1997, ORGN-0595.

“Enantiospecific Total Synthesis of (+)-Ajmaline and Alkaloid G via the Asymmetric Pictet-Spengler Reaction,” J. Li, and J.M. Cook, presented at the 213th ACS National Meeting, San Francisco, CA, April 13-17, 1997, ORGN-0455.

“Evidence for the Conservation of Conformational Topography at Five Major GABAA/Benzodiazepine Receptor Subsites: Potent Affinities of the S-Enantiomers of Framework-constrained 4,5-Substituted Pyrroloimidazobenzodiazepines,” Q. Huang, R. Liu, J.M. Cook and R.M. McKernan, presented at the 213th ACS National Meeting, San Francisco, CA, April 13-17, 1997, MEDI-0175.

“A Study of Pharmacophore/Receptor Models for Benzodiazepine Receptor Subtypes and SAR Study via a Ligand-mapping Approach,” Q. Huang, E.D. Cox, T. Gan, X. He, C. Ma, and J.M. Cook, presented at the 213th ACS National Meeting, San Francisco, CA, April 13-17, 1997, MEDI-0040.

“Synthesis of Polyquinanes via the Tandem Pauson-Khand Reaction. Studies Directed Toward the Preparation of Dicyclopenta[a,d]pentalene and Dicyclopenta-[a,e]pentalene,” S.G. Van Ornum, and J.M. Cook, presented at the 30th Great Lakes Regional ACS Meeting, Loyola University, Chicago, IL., May 28-30, 1997, Org 97.

“Enantiospecific Total Synthesis of Tryprostatin A,” Tong Gan and James M. Cook, presented at the 30th Great Lakes Regional ACS Meeting, Loyola University, Chicago, IL., May 28-30, 1997, Org 132.

“Conservation of Conformational Topography at Five GABAA/Benzodiazepine Receptor Subtypes,” Xiaohui He, Qi Huang, Tong Gan, and James M. Cook, presented at the 30th Great Lakes Regional ACS Meeting, Loyola University, Chicago, IL., May 28-30, 1997, Org 203.

“Search for New Antianxiety Agents: Subtype Selectivity at α1β3γ2 and α5β3γ2 Receptor Subtypes,” Chunrong Ma, E.D. Cox, R. McKernan and J.M. Cook, presented at the 30th Great Lakes Regional ACS Meeting, Loyola University, Chicago, IL., May 28-30, 1997, Org 204.

“General Approach to the Enantiospecific Synthesis of *Alstonia* Oxindole Alkaloids,” Peng Yu, F. Yu, T. Wang, A.C. Peterson and J.M. Cook, presented at the 30th Great Lakes Regional ACS Meeting, Loyola University, Chicago, IL., May 28-30, 1997, Org 216.

“Enantiospecific Total Synthesis of (+)-Ajmaline *via* the Asymmetric Pictet-Spengler Reaction,” Jin Li and J.M. Cook, presented at the 30th Great Lakes Regional ACS Meeting, Loyola University, Chicago, IL., May 28-30, 1997, Org 217.

“Approach to the Enantiospecific Total Synthesis of Quebrachidine and Vincamajine,” Tao Wang, P. Yu, J. Li and J.M. Cook, presented at the 30th Great Lakes Regional ACS Meeting, Loyola University, Chicago, IL., May 28-30, 1997, Org 218.

“Approach to Sarpagine Indole Alkaloids. Stereospecific Synthesis of (6S, 10S)-2-Methoxy-9-OXO-12-benzyl-6,7,8,9,10,11-hexahydro-6,10-imino-5H-cyclooct [b]indole via the Asymmetric Pictet-Spengler Reaction,” S. Zhao, Q. Huang, R. Liu, P. Zhang and J.M. Cook, presented at the 30th Great Lakes Regional ACS Meeting, Loyola University, Chicago, IL., May 28-30, 1997, Org 219.

“Generation of Four Five-Membered Rings in a One Pot Process. Studies Directed Toward the Synthesis of Dicyclopenta[a,e]pentalene via the Tandem Pauson-Khand Reaction,” S.G. Van Ornum and J.M. Cook, presented at the 30th Great Lakes Regional ACS Meeting, Loyola University, Chicago, IL., May 28-30, 1997, Org 231.

“Conservation of Conformational Topography at Five GABAA/Benzodiazepine Receptor Subtypes,” Q. Huang, X. He, T. Gan and J.M. Cook, presented at the 59th Annual Scientific Meeting of the College on Problems of Drug Dependence, Nashville, TN, June 14-19, 1997, Oral Communications III.

“Pharmacophore - receptor Models for Five Major Benzodiazepine Receptor Subtypes,” J.M. Cook, Q. Huang, E.D. Cox R. Liu, T. Gan, X. He and C. Ma, presented at the 214th ACS National Meeting, Las Vegas, Nevada, September 6-11, 1997, MEDI-124.

“Enantiospecific Total Synthesis of (+)-Ajmaline,” J. Li and J.M. Cook, presented at the 214th ACS National Meeting, Las Vegas, Nevada, September 6-11, 1997, ORGN-190.

“Diastereospecific Synthesis of Ketooxindoles: Potential Intermediates for the Synthesis of Alstonisine as well as Voacanga-related Oxindole Alkaloids,” P. Yu and J.M. Cook, presented at the 214th ACS National Meeting, Las Vegas, Nevada, September 6-11, 1997, ORGN-340.

“Studies Directed Toward the Synthesis of Dicyclopenta[a,e]pentalene and Dicyclopenta [a,d]pentalene via the Tandem Pauson-Khand Reaction,” S. Van Ornum and J.M. Cook, presented at the 214th ACS National Meeting, Las Vegas, Nevada, September 6-11, 1997, ORGN-356.

“Enantiospecific Synthesis of Ajmaline, Alkaloid G, Talpinine and Talcarpine via the Asymmetric Pictet-Spengler Reaction,” J. Li, P. Yu, and J.M. Cook, presented at the Seventeenth Mona Symposium, 1998 in Mona, Jamaica, January 5-9, 1998.

“GABAERGIC Regulation of the Reinforcing Properties of Alcohol in Wistar rats,” C. R. Cason, H. L. June, M. Fredericks, G. Cheatham, A. Chen, J. Cook, T. Gan and J. M. Murphy, 27th Annual Meeting of Society for Neuroscience, New Orleans, October 25-30, 1997, abstract 381.5.

“Exploration of the L2 Region of Pharmacophore/Receptor Models for Benzodiazepine Receptor Subtypes *via* Preparation of Rigidly Substituted Pyrazoloquinolinones (CGS-Series),” Qi Huang, X. He, C. Ma and J.M. Cook, 215th ACS National Meeting, Dallas Texas, March 29-April 2, 1998, abstract MEDI-136.

“Search for Selective Ligands for Benzodiazepine Receptor Subtypes by Probing the Pharmacophore/Receptor Models of GABAA/BzR Subtypes *via* Optically Active BzR Ligands,” S. Yu, X. He, C. Ma, X. Liu and J.M. Cook, 215th ACS National Meeting, Dallas, Texas, March 29-April 2, 1998, abstract MEDI-137.

“First Enantiospecific Total Synthesis of Talcarpine and Talpinine from D-(+)-Tryptophan via the Asymmetric Pictet-Spengler Reaction,” P. Yu and J.M. Cook 215th ACS National Meeting, Dallas, Texas, March 29-April 2, 1998, abstract ORGN-175.

“Enantiospecific Total Synthesis of (+)-Ajmaline via the Asymmetric Pictet Spengler Reaction,” J. Li and J.M. Cook, 215th ACS National Meeting, Dallas, Texas, March 29-April 2, 1998, abstract ORGN-176.

“Synthetic Approach Toward The Synthesis of Dicyclopenta[a,d]pentalene and Dicyclopenta[a,e]pentalene *via* The Tandem Pauson-Khand Reaction,” S.G. Van Ornum and J.M. Cook, 215th ACS National Meeting, Dallas, Texas, March 29-April 2, 1998, abstract ORGN-275.

“Enantiospecific Total Synthesis of (+)-Ajmaline *via* the Asymmetric Pictet-Spengler Reaction,” Jin Li and J.M. Cook, 31st Great Lakes Regional Meeting of the ACS, University of Wisconsin-Milwaukee, Milwaukee, WI, June 1-3, 1998, abst. 185.

“Exploration of Region L2 of Pharmacophore/Receptor Models for GABAA/BzR Subtypes,” J.M. Cook, Q. Huang, C. Ma, X. He and S. Yu, presented at The College on Problems of Drug Dependence, Sixtieth Annual Scientific Meeting, Scottsdale, AZ, June 13-18, 1998, poster session III, #124.

“Enantiospecific Total Synthesis of Talcarpine 1 and Talpinine 2 *via* the Asymmetric Pictet-Spengler Reaction,” Peng Yu and J.M. Cook, 31st Great Lakes Regional Meeting of the ACS, University of Wisconsin-Milwaukee, Milwaukee, WI, June 1-3, 1998, abst. 186.

“The Enantiospecific Total Synthesis of Norsuaveoline *via* The Pictet-Spengler Reaction,” Tao Wang and J.M. Cook, 31st Great Lakes Regional Meeting of the ACS, University of Wisconsin-Milwaukee, Milwaukee, WI, June 1-3, 1998, abst. 187.

“Utility of The Tandem Pauson-Khand Reaction Directed Toward The Synthesis of Dicyclopenta[a,d]pentalene and Dicyclopenta[a,e]pentalene,” M.M. Bruendl, S.G. Van Ornum and J.M. Cook, 31st Great Lakes Regional Meeting of the ACS, University of Wisconsin-Milwaukee, Milwaukee, WI, June 1-3, 1998, abst. 200.

“Synthesis and Evaluation of Functionalized Tryptophan Derivatives and Substituted β-Carbolines As Inhibitors of Indoleamine 2,3-Dioxygenase,” Xiaoxiang Liu, Chunrong Ma, Andrew C. Peterson and J.M. Cook, 31st Great Lakes Regional Meeting of the ACS, University of Wisconsin-Milwaukee, Milwaukee, WI, June 1-3, 1998, abst. 206.

“Enatiospecific Total Synthesis of Tryprostatin A,” Shuo Zhao, Tong Gan, Peng Yu and J.M. Cook, 31st Great Lakes Regional Meeting of the ACS, University of Wisconsin-Milwaukee, Milwaukee, WI, June 1-3, 1998, abst. 227.

“Synthetic Approach Directed Toward The Synthesis of Dicyclopenta[a,d]pentalene and Dicyclopenta[a,e]pentalene *via* the Tandem Pauson-Khand Reaction,” S.G. Van Ornum and J.M. Cook, 31st Great Lakes Regional Meeting of the ACS, University of Wisconsin-Milwaukee, Milwaukee, WI, June 1-3, 1998, abst 235.

“Search for Selective Ligands for α5-Benzodiazepine Receptor Subtypes By Probing The Pharmacophore/Receptor Models of GABAA/BZR Subtypes *via* Chiral BzR Ligands,” Xiaoxiang Liu and J.M. Cook, 31st Great Lakes Regional Meeting of the ACS, University of Wisconsin-Milwaukee, Milwaukee, WI, June 1-3, 1998, abst 245.

“The Agonist Pharmacophore of The Benzodiazepine Receptor. Synthesis of A Selective Anticonvulsant/anxiolytic,” Chunrong Ma, E.D. Cox, R. McKernan and J.M. Cook, 31st Great Lakes Regional Meeting of the ACS, University of Wisconsin-Milwaukee, Milwaukee, WI, June 1-3, 1998, abst 246.

“Evidence of Conservation of Conformational Topography at Five GABAA/BzR Subtypes,”Xiaohui He, Qi Huang, Tong Gan and J.M. Cook, 31st Great Lakes Regional Meeting of the ACS, University of Wisconsin-Milwaukee, Milwaukee, WI, June 1-3, 1998, abst 248.

“Exploration of the L2 Region of Pharmacophore/Receptor Models For Benzodiazepine Receptor Subtypes *via* Preparation of Rigidly Substituted Pyrazoloquinolinones (CGS Series),” Qi Huang, Xiaohui He, Chunrong Ma and J.M. Cook, 31st Great Lakes Regional Meeting of the ACS, University of Wisconsin-Milwaukee, Milwaukee, WI, June 1-3, 1998, abst 249.

“Study of Pharmacophore/Receptor Models for Benzodiazepine Receptor Subtypes via Preparation of Rigidly Substituted Pyrazoloquinolinones,” Q. Huang, X. He, S. Yu, C. Ma and J. M. Cook, 216th National ACS Meeting, Boston, MA, August 23-27, 1998, abst MEDI-96.

“Development of Selective Ligands for Benzodiazephine Receptor Subtypes By Manipulating the Stereochemistry of Optically Active BzR Ligands,” S. Yu, X. He, C. Ma, X. Liu and J. M. Cook, 216th National ACS Meeting, Boston, MA, August 23-27, 1998, abst MEDI-97.

“Synthesis and Study of Bz1 Receptor Subtype Specific Ligands,” C. Ma, X. He, S. Yu, R. McKernan and J. M. Cook, 216th National ACS Meeting, Boston, MA, August 23-27, 1998, abst MEDI-98.

“In Search of Inhibitors for the Indoleamine 2,3-dioxygenase (IDO) Enzyme System, X. Liu, C. Ma, A. C. Peterson and J. M. Cook, 216th National ACS Meeting, Boston, MA, August 23-27, 1998, abst ORG-105.

“Photochemical Tandem Pauson-Khand Reaction: Studies Directed Toward The Synthesis of Dicyclpenta[a,f]pentalene and Dicyclopenta[a,e]pentalene,” M. M. Bruendl, S. G. Van Ornum, J. M. Cook, 216th National ACS Meeting, Boston, MA, August 23-27, 1998, abst ORG-117.

“General Approach to The Diastereospecific Synthesis of Indole Alkaloids: Total Synthesis of Talcarpine, Talpinine, Alstonerine, and Anhydromacrosalhine-Methine *via* the Asymmetric Pictet-Spengler Reaction,” P. Yu, J. Li, T. Wang and J. M. Cook, 216th National ACS Meeting, Boston, MA, August 23-27, 1998, abst. ORG-554.

“General Approach to the Synthesis of Sarpagine/Ajmaline Alkaloids: Enantiospecific Total Synthesis of (+)-Ajmaline via the Asymmetric Pictet-Spengler Reaction,” J. Li and J. M. Cook, 216th National ACS Meeting, Boston, MA, August 23-27, 1998, abst. ORG-555.

“Total Synthesis of Norsuaveoline From D-(+)-Tryptophan via an Asymmetric Pictet-Spengler Reaction and Regioselective Oxyanion Cope Rearrangement,” T. Wang, P. Yu, J. Li and J. M. Cook, 216th National ACS Meeting, Boston, MA, August 23-27, 1998, abst. ORG-556.

“Enantiospecific Total Synthesis of the Enantiomers of Tryprostatin A and B,” S. Zhao, T. Gan, P. Yu and J. M. Cook, 216th National ACS Meeting, Boston, MA, August 23-27, 1998, abst. ORG-557.

“Study of Pharmacophore/Receptor Models for GABAA/BzR Subtypes via QSAR Analysis of Symmetrically Substituted Pyrazoloquinolinones,” X. He, S. Yu, C. Ma, Q. Huang, R. McKernan, and J.M. Cook, 217th National ACS Meeting, Anaheim, CA, March 21-25, 1999, abst. MEDI-095.

“Studies in Search of Memory-enhancing Agents that Act via GABAA/Bz Receptors: Part 1. Evidence for the Conservation of Pharmacophoric Descriptors at all DS Sub-types,” S. Yu, X. He, C. Ma, J.M. Cook, 217th National ACS Meeting, Anaheim, CA, March 21-25, 1999, abst. MEDI-096.

“Manipulation of Stereochemistry of Optically Active BzR Ligands: Development of Selective Ligands for Benzodiazepine Receptor Subtypes,” M.M. Bruendl, X. He, C. Ma, J.M. Cook, 217th National ACS Meeting, Anaheim, CA, March 21-25, 1999, abst. MEDI-097.

“Synthesis of [5.5.5.5]- and [5.6.6.5]Tetracycles via the Tandem Pauson-Khand Reaction,” M.M. Bruendl, H. Cao, J.M. Cook, 217th National ACS Meeting, Anaheim, CA, March 21-25, 1999, abst. ORG-271.

“Studies Toward the Enantiospecific Total Synthesis of Pleiocarpamine via a Novel Pictet-Spengler Reaction,” S. Yu, E.D. Cox, J.M. Cook, 217th National ACS Meeting, Anaheim, CA, March 21-25, 1999, abst. ORG-405.

“Novel Synthesis of Optically Active Tryptophan Derivatives,” C. Ma, X. Liu, S. Yu, S. Zhao, J.M. Cook, 217th National ACS Meeting, Anaheim, CA, March 21- 25, 1999, abst. ORG-416.

“Synthesis of Chiral Imidazobenzodiazepines Employed in the Development of Selective Ligands for Benzodiazepine Receptor Subtypes,” M.M. Bruendl, X. He, C. Ma, and J.M. Cook, 36th National Organic Chemistry Symposium, University of Wisconsin-Madison, Madison, WI, June 13-17, 1999, abst. 29.

“Study of Pharmacophore/Receptor Models for GABAA/BzR Subtypes By Synthesis of Rigidly Substituted Imidazobenzodiazepines and Pyrazoloquinolinones,” X. He, S. Yu, C. Ma, M. Bruendl, and J.M. Cook, 36th National Organic Symposium, University of Wisconsin-Madison, Madison, WI, June 13-17, 1999, abst. 102.

“Approach to the Total Synthesis of Indole Alkaloid Alstophylline,” X. Liu, C. Ma, L. Hamaker, and J.M. Cook, 36th National Organic Symposium, University of Wisconsin- Madison, Madison, WI, June 13-17, 1999, abst. 160.

“Efficient Synthesis of Optically Active Tryptophan and Isotryptophan Derivatives,” C. Ma, X. Liu, S. Yu, X. He, and J.M. Cook, 36th National Organic Symposium, University of Wisconsin-Madison, Madison, WI, June 13-17, 1999, abst. 169.

“Enantiospecfic Total Synthesis of Norsuaveoline via Asymmetric Pictet-Spengler Reaction and Regioselective Oxyanion Cope Rearrangement,” T. Wang and J.M. Cook, 36th National Organic Symposium, University of Wisconsin-Madison, Madison, WI, June 13-17, 1999, abst. 279.

“Studies Directed Toward the Enantiospecific Total Synthesis of Indole Alkaloid Pleiocarpamine via a Novel Pictet-Spengler Reaction,” S. Yu, E.D. Cox, and J.M. Cook, 36th National Organic Symposium, University of Wisconsin- Madison, Madison, WI, June 13-17, 1999, abst. 302.

“Sarpagine Indole Alkaloids. Stereospecific Synthesis of (6s, 10s)-2-Methoxy-9-oxo-12-benzyl-6,7,8,9,10,11-hexahydro-6,10-imino-5H-cyclooct[b]indole via Asymmetric Pictet-Spengler Reaction,” S. Zhao and J.M. Cook, 36th National Organic Symposium, University of Wisconsin-Madison, Madison, WI, June 13-17, 1999, abst.310.

“Development of Selective Ligands for Benzodiazepine Receptor Subtypes by Manipulating the Stereochemistry of Optically Active BzR Ligands,” M.M. Bruendl, X. He, C. Ma, and J.M. Cook, 218th National ACS Meeting, New Orleans, LA, August 22-26, 1999, abst. MEDI-127.

“Search for Selective Ligands for GABAA/BZR Subtypes and Their Role as Inverse Agonists/Antagonists in Alteration of Alcohol Dependence,” X. He, C. Ma, M. Bruendl, S. Yu, H. June, R. McKernan, and J.M. Cook, 218th National ACS Meeting, New Orleans, LA, August 22-26, 1999, abst. MEDI-128.

“Search for Bz1 Selective Ligands For GABAA/Benzodiazepine Receptor Subtypes,” C. Ma, X. He, M. Bruendl, R. McMcKernan, and J.M. Cook, 218th National ACS Meeting, New Orleans, LA, August 22-26, 1999, abst. MEDI-129.

“Total Synthesis of Tryprostatin A and B, and Enantiomers,” S. Zhao, T. Gan, P. Yu and J.M. Cook, 218th National ACS Meeting, New Orleans, LA, August 22-26, 1999, abst. ORGN-155.

“General Approach for the Synthesis of Ajmaline and Sarpagine Indole Alkaloids: Enantiospecific Total Synthesis of Norsuaveoline via Asymmetric Pictet-Spengler Reaction,” T. Wang and J.M. Cook, 218th National ACS Meeting, New Orleans, LA, August 22-26, 1999, abst. ORGN-156

“Enantiospecfic Synthesis of Tryptophans and Tryprostatins via the Schöllkopf Chiral Auxillary,” S. Zhao, C. Ma, and J.M. Cook, MONA Symposium-2000, Mona, Jamaica, January 2-7, 2000.

“Enantiospecific Synthesis of Tryprostatins *via* the Schöllkopf Chiral Auxiliary,” S. Zhao, C. Ma, X. Liu, and J.M. Cook, 219th National ACS Meeting, San Francisco, CA, March 26-30,2000, abst. ORGN- 749.

“General Approach for the Synthesis of Suaveoline and Sarpagine Indole Alkaloids. Enantiospecific Total Synthesis of Norsuaveoline and Vellosimine,” T. Wang and J.M. Cook, 219th National ACS Meeting, San Francisco, CA, March 26-30, 2000, abst. ORGN- 752.

“Search for Selective Ligands for GABAA/BzR Subtypes and Their Role in Alteration of Alcohol Dependence,” J.M. Cook, X. He, C. Ma, S. Yu, H. June, and R. McKernan, 219th National ACS Meeting, San Francisco, CA, March 26-30, 2000, abst. MEDI-101.

“Development of Selective Ligands for Benzodiazipine Receptor Subtypes,” J.M. Cook, C. Ma, X. He, and M.M. Bruendl, 219th National ACS Meeting, San Francisco, CA, March 26-30, 2000, abst. MEDI-105.

“Comparison of the Behavioral Effects of Beta-CCt and Flumazenil in Rhesus Monkeys,”C.P. France, L.R. Gerak, C. Ma, and J.M. Cook, 62nd Meeting of theCollege on Problems of Drug Dependence, Oral Communications XVIII, Puerto Rico, June 17-22, 2000.

“Search for Benzodiazepine/GABAA Subtype Selective Ligands and Implications in Alcohol Self-Administration,” X. He, C. Ma, H. June, and J.M. Cook, 62nd Meeting of the College on Problems of Drug Dependence, Poster Session IV (85), Puerto Rico, June 17-22, 2000.

“General Approach for the Synthesis of Sarpagine/Ajmaline/Corynanthe Alkaloids *via* the Asymmetric Pictet-Spengler Reaction. Enantiospecific Synthesis of Ajmaline, Vellosimine, Geissoschizine and Corynantheidine,” T. Wang, S. Yu, and J.M. Cook, (Planery Lecture), 32nd Great Lakes 2000 Regional Meeting of the ACS, Fargo, North Dakota, June 4-6, 2000, abst.74.

“Approach to the Total Synthesis of the Indole Alkaloid Na-Methylsarpagine and the Bisindole Alkaloid Macralstonine,” S. Zhao and J.M. Cook, 32nd Great Lakes 2000 Regional Meeting of the ACS, Fargo, North Dakota, June 4-6, 2000, abst.93.

“Progress Towards the Total Synthesis of 10-Methoxyanhydromacrosalhine-methine *via* the Asymmetric Pictet-Spengler Reaction, X. Liao, S. Zhao, and J.M. Cook, 32nd Great Lakes 2000 Regional Meeting of the ACS, Fargo, North Dakota, June 4-6, 2000, abst. 145.

“Studies Towards the Total Synthesis of the Bisindole Alkaloid Macralstonine,” X. Liu, C. Ma, and J.M. Cook, 32nd Great Lakes 2000 Regional Meeting of the ACS, Fargo, North Dakota, June 4-6, 2000, abst. 146.

“Enantiospecific Synthesis of Vellosimine and Norsuaveoline as well as an Approach Toward Quebrachidine,” T. Wang and J.M. Cook, 32nd Great Lakes 2000 Regional Meeting of the ACS, Fargo, North Dakota, June 4-6, 2000, abst.150.

“Enantiospecfic Approach Towards the Total Synthesis of the Enantiomer of (+) Ajmaline,” Q. Xu, T. Wang, and J.M. Cook, 32nd Great Lakes 2000 Regional Meeting of the ACS, Fargo, North Dakota, June 4-6, 2000, abst. 152.

“Construction of [5.5.5.5] Tetracycles via the Tandem Pauson-Khand Reaction and New Entry into [5.8.5] Ring Systems,” H. Cao, S. Van Ornum, M. Bruendl, and J.M. Cook, 32nd Great Lakes 2000 Regional Meeting of the ACS, Fargo, North Dakota, June 4-6, 2000, abst. 158.

“General Approach to the Corynanthe Alkaloids: Enantiospecific Total Synthesis of (-) Corynantheidol and (+)-Geissoschizine,” M. Berner, S. Yu, and J.M. Cook, 32nd Great Lakes 2000 Regional Meeting of the ACS, Fargo, North Dakota, June 4-6, 2000, abst.173.

“Total Synthesis of the Enantiomer of the Indole Alkaloid Affinisine and Approach to the Total Synthesis of Alstophylline and Macralstonine,” X. Liu, T. Wang, C. Ma, Q, Xu, and J.M. Cook, 220th National ACS Meeting, Washington, D.C., August 20-24, 2000, abst. ORG -122.

“General Approach for the Synthesis of (-)Corynantheidine, (-)Corynantheidol, (+)-Geissoschizine, and (-)-Geissoschizol from a Common Intermediate,” M. Berner, S. Yu, and J.M. Cook, 220th National ACS Meeting, Washington, D.C., August 20-24, 2000, abst. ORG - 131.

“Approach to the Total Synthesis of the Bisindole Alkaloid Macralstonidine,” S. Zhao and J.M. Cook, 220th National ACS Meeting, Washington, D.C., August 20-24, 2000, abst. ORG - 137.

“Enantiospecific Total Synthesis of the Sarpagine Indole Alkaloid (+)-Vellosimine as well as a Study Toward the Total Synthesis of the Bisindole Alstonisidine,” T. Wang and J.M. Cook, 220th National ACS Meeting, Washington, D.C., August 20-24, 2000, abst. ORG - 140.

“Enantiospecific Synthesis of Sarpagine, Ajmaline, and Corynanthe Indole Alkaloids via the Asymmetric Pictet-Spengler Reaction,” (planery lecture), The Twenty-third Gulf Coast Chemistry Conference, Pensacola, Florida, September 14-16, 2000 (Thursday Lecture 2:40).

“Discriminative Stimulus Effects of the Novel 1,4-Benzodiazpine QHII-66 in Ethanol-and Triazolam-Trained Squirrel Monkeys,” S. Lelas, D.M. Platt, J.K. Rowlett, R.D. Spealman, J. Cook, and C. Ma, 30th Annual Meeting of the Society for Neuroscience, New Orleans, LA, November 4-9, 2000, Soci. Neurosci. Abst., 26, Part 1, 280 (abst. 103.2).

“Selective GABAA α1 Subunit Ligands (BCCt, 3PBC) Attenuate Responding Maintained by Ethanol Following Microinjection into the Ventral Pallidum,” M.R. Carroll, K.L. Foster, S. Harvey, P.F. McKay, J.M. Cook and H. June, Alcoholism: Clin. Exp. 24: 47A (abst. 24).

“Development of Selective Ligands for GABAA/BzR Subtypes and Their Role in Alteration of Alcohol Dependence,” X. Li, X. He, C. Ma, S. Harvey, and J.M. Cook, 221st National ACS Meeting, San Diego, CA, April 1-5, 2001, abst. MEDI-83.

“High-yield Generation of the [5.5.5.5]Tetracyclic Systems *via* Molybdenum Carbonyl Mediated Tandem Pauson-Khand Reaction,” H. Cao and J.M. Cook, 221st National ACS Meeting, San Diego, CA, April 1-5, 2001, abst. ORGN-420.

“Approach to the Total Synthesis of 10-Methoxyanhydromacrosalhine-methine *via* the Asymmetric Pictet-Spengler Reaction,” X. Liao, S. Zhao, and J.M. Cook, 221st National ACS Meeting, San Diego, CA, April 1-5, 2001, abst. ORGN-586.

“General Approach to the Total Synthesis of Macroline/Sarpagine Indole Alkaloids as well as Their Enantiomers,” X. Liu and J.M. Cook, 221st National ACS Meeting, San Diego, CA, April 1-5, 2001, abst. ORGN-591

“General Approach for the Synthesis of Sarpagine Ajmaline and Corynanthe Alkaloids *via* the Asymmetric Pictet-Spengler Reaction,” (planery lecture) Royal Society of Chemistry, Perkin Division, 15th Lakeland Symposium: Grasmere, Grasmere Village, UK, May 10-14, 2001, (Friday morning lecture).

“Alcohols Euphoric Properties are Regulated by the GABAA Receptor α1 Subtype,” W. Yin, M. Carroll, H. June, and J.M. Cook, College on Problems of Drug Dependence, 63rd Annual Scientific Meeting, Scottsdale, AZ, June 16-21, 2001, Oral Communications IX (1:45 p.m.).

“Approach to Cyclopentapentalenes. Regiospecific Synthesis of the Highly Functionalized [5.5.5.5]Tetracycles via the Molybdenum Carbonyl-Mediated Tandem Pauson-Khand Reaction,” H. Cao, J.M. Cook, and J. Flippen-Anderson, 37th National Organic Chemistry Symposium, Montana State University, Bozeman, MT, June 10-14, 2001, abst. 58.

“Research in Search of Selective Ligands for GABAA/BZR Subtypes and Their Role in Alteration of Alcohol Dependence,” X. Li, X. He, C. Ma, S. Harvey, and J.M. Cook, 37th National Organic Chemistry Symposium, Montana State University, Bozeman, MT, June 10-14, 2001, abst.-122.

“Studies Directed Toward the Antimalarial Bisindole Alkaloid Macralstonine O-Methyl Ether as well as Macralstonine,” X. Liu and J.M. Cook, 37th National Organic Chemistry Symposium, Montana State University, Bozeman, MT, June 10-14, 2001, abst.-126.

“Studies Directed Toward the Total Synthesis of the Bisindole Villalstonine,” J. Ma, S. Yu, O.M. Berner, and J.M. Cook, 37th National Organic Chemistry Symposium, Montana State University, Bozeman, MT, June 10-14, 2001, abst.-132.

“Studies Directed Toward the Enantiospecific Total Synthesis of Oxindole Alkaloids: Approach to the Total Synthesis of Alstonisine,” X. Wearing, P. Yu, and J.M. Cook, 37th National Organic Chemistry Symposium, Montana State University, Bozeman, MT, June 10-14, 2001, abst.-219.

“Search for Benzodiazpine/GABAA Subtype Selective Ligands that Reverse Alcohol Self-Administration,” W. Yin, C. Zhang, M. Carroll, H. June, and J,M, Cook, 37th National Organic Chemistry Symposium, Montana State University, Bozeman, MT, June 10-14, 2001, abst.-234.

“Study of Pharmacophore/Receptor Models for GABAA/BzR Subtypes,” Chunchun Zhang and J.M. Cook, 37th National Organic Chemistry Symposium, Montana State University, Bozeman, MT, June 10-14, 2001, abst.-238.

“The Enantiospecific Total Synthesis of the Alstonia Bisindole Alkaloid, Macralstonidine,” X. Liao, S. Zhao, and J.M. Cook, 37th National Organic Chemistry Symposium, Montana State University, Bozeman, MT, June 10-14, 2001, abst.-239.

“Enantiospecific Synthesis of a Very Potent Tryprostatin Diastereomer, Active Against Human Cancer Cell Lines,” S. Zhao, X. Liu, C. Zhang, A. Morin, K. Smith, T. McDonald, and J.M. Cook, 37th National Organic Chemistry Symposium, Montana State University, Bozeman, MT, June 10-14, 2001, abst. 240.

“Search for Benzodiazepine/GABA(A) Subtype Selective Ligands that Reverse Alcohol Self-Administration,” J. Cook, W. Yin, C. Zhang, X. Li, and H. June, (plenary lecture), 53rd Southeastern Regional Meeting of the ACS, Savannah, GA, September 23-26, 2001, plenary lecture, abst. 379.

“The Enantiospecfic Synthesis of Sarpagine, Ajmaline, and Corynanthe Indole Alkaloids *Via* the Asymmetric Pictet-Spengler Reaction,” T. Wang, S. Zhao, X. Liu, and J.M. Cook, 19th Meeting of the Northeast Chapter of the International Isotope Society, Pearl River, N.Y., October 26, 2001 (plenary lecture).

“The Role of the GABA(A) α1 Subtype in Mediating the Sedative and Anxiolytic Properties of Benzodiazepines,” M.R. Carroll, J. Woods, R.Y. Seyoum, and H. June, presented at the RCM Meeting, 2001.

“Involvement of GABA(A) Receptors Containing the α5 Subunit in Nitrous Oxide Withdrawal,” L. Vaughn, R. Lindau, W. Yin, and J.M. Cook, presented at the Neuroscience Meeting, San Diego, CA, 2001.

“The Role of BZ/α1 and BZ/α5 Receptors in Discriminative Stimulus Effects of Triazolam in Squirrel Monkeys,” S. Lelas, J.K. Rowlett, R.D. Spealman, J.M. Cook, X. Li, and W. Yin, presented at the Neuroscience Meeting, San Diego, CA, 2001.

“Role of GABA(A)/α1 Receptor Mechanisms in the Discriminative Stimulus Effects of Ethanol in Squirrel Monkeys,” D.M. Platt, J.K. Rowlett, R.D. Spealman, J.M. Cook, and W. Yin, FASEB Summer Reasearch Conference, Arizona, August 2001.

“Search for Benzodiazepine/GABA(A) Subtype Selective Ligands that Reverse Alcohol Self-Administration,” W. Yin, C. Zhang, M. Carrol, H. June, and J.M. Cook, 21st Symposium on Medicinal Chemistry, 10th Annual Meeting of the Division of Medicinal Chemistry, Kyoto, Japan, November 28-30th, 2001, (plenary lecture).

“Enantiospecific Synthesis of Sarpagine, Ajmaline and Corynanthe Alkaloids *via* the Asymmetric Pictet-Spengler Reaction,” T. Wang, S. Zhao, X. Liu, and J.M. Cook, Mini- Symposium of the Society of Synthetic Organic Chemistry(Japan), Chiba, Japan, November 30, 2001 (plenary lecture).

“The Enantiospecific, Stereospecific Total Synthesis of the Alstonia Bisindole, Macralstonidine,” S. Zhao, X. Liao, and J.M. Cook, The Mona Symposium 2002, Natural Products and Medicinal Chemistry, University of the West Indies, Mona Jamaica, Jan. 7-10, 2002, p.21.

“Search for Benzodiazepine/GABAA Subtype Selective Ligands to Treat Alcohol Abuse,” W. Yin, C. Zhang, H. June, and J.M. Cook, 28th National Medicinal Chemistry Symposium, San Diego, CA, June 8-12, 2002 (plenary lecture).

“Approach to Cyclopentapentalenes: Regiospecific Synthesis of the Highly Functionalized [5.5.5.5]Tetracycles *via* the Molybdenum Carbonyl-Mediated Tandem Pauson-Khand Reaction,” H. Cao, J.M. Cook, and J. Flippen-Anderson, 223rd National Meeting of the ACS, Orlando, FL, April 7-11, 2002, abst. ORGN 301.

“Progress Towards The Synthesis of Antimalarial Bisindole Alkaloids,” X. Liao and J.M. Cook, 223rd National Meeting of the ACS, Orlando, FL, April 7-11, 2002, abst. ORGN 104.

“General Approach for the Synthesis of Indole Alkaloids *via* the Asymmetric Pictet-Spengler Reaction,” J. Cook, 2002 Gordon Research Conference on Heterocyclic Compounds, Salve Regina University, Newport, RI, 2002 (plenary lecture)

“Search for Benzodiazepine/GABAA Subtype Selective Ligands that Reverse Alcohol Self-Administration,” W.Yin, J. Cook, and H. June, 34th Great Lakes Regional Meeting of the ACS, Minneapolis, MN, June 2-4, 2002, abst. 85.

“Enantiospecific Synthesis of a Very Potent Tryprostatin Diastereomer Active Against Human Cancer Cell Lines,” C. Zhang, S. Zhao, and J.M. Cook, 34th Great Lakes Regional Meeting of the ACS, Minneapolis, MN, June 2002, abst. 92.

“Regiospecific Synthesis of the Highly Functionalized [5.5.5.5]Tetracycles,” Hui Cao and J.M. Cook, 34th Great Lakes Regional Meeting of the ACS, Minneapolis, MN, June 2-4, 2002, abst. 110.

“The First Enantiospecific Total Synthesis of Alstonisine from D-(+)-Tryptophan *via* the Asymmetric Pictet-Spengler Reaction,” X. Wearing, P.Yu, and J.M. Cook, 34th Great Lakes Regional Meeting of the ACS, Minneapolis, MN June 2-4, 2002, abst. 203.

“Study of Selective Ligands for GABA/BzR Subtypes and their Role in Alteration of Alcohol Dependence,” X. Li, W. Yin, S. Harvey, and J.M. Cook, 34th Great Lakes Regional Meeting of the ACS, Minneapolis, MN, June 2-4, 2002, abst. 78.

“Approach Toward the Total Synthesis of the Antimalarial Alkaloid Villalstonine,” J. Ma, S. Yu, O. Mathias, and J.M. Cook, 34th Great Lakes Regional Meeting of the ACS, Minneapolis, MN, June 2-4, 2002, abst. 90.

“The Total Synthesis of Bisindole Dispegatrine,” X. Liao and J.M. Cook, 34th Great Lakes Regional Meeting of the ACS, Minneapolis, MN, June 2-4, 2002, abst. 105.

“Search for Benzodiazepine/GABA(A) Subtype Selective Ligands that Reverse Alcohol Self-Administration,” W. Yin, X. Liao, H. June, and J. Cook, 224th ACS National Meeting, Boston, MA, August 18-22, 2002, abst. MEDI-244.

“Studies in Search of Memory Enhancing Agents Which Act *via* GABA(A)/BzR Receptors,” X. Li, C. Cook, F.J. Helmstetter, and J.M. Cook, 224th ACS National Meeting, Boston, MA, August 18-22, 2002, abst. MEDI-245.

“Enantiospecific Stereospecific Total Synthesis of Alstonisine,” X. Wearing, J.M. Cook, and J.L Flippen-Anderson, 224th ACS National Meeting, Boston, MA, August 18-22, 2002, abst. O361.

“Approach to Cyclopentapentalenes, Regiospecific Synthesis of the Highly Functionalized [5.5.5.5]tetracycles *via* the Molybdenum Carbonyl-mediated Tandem Pauson-Khand Reaction,” H. Cao, J.M. Cook, and J. Flippen-Anderson, 224th ACS National Meeting, Boston, MA, August 18-22, 2002, abst. O835.

“The GABA(A) Receptor α1 Subtype in the Ventral Pallidum Regulates Alcohol-Seeking Behaviors,” W. Yin, C. Zhang, H. June, and J.M. Cook, The 12th Neuropharmacology Conference, GABA(A) Receptors in Cellular and Network Excitability, Sheraton World Resort, Orlando, FL, October 31-November 2, 2002, poster P-D05.

“GABA(A)/α1, 5HT1A, Alcohol and Agression in Rats,” S.L. Gourley, J.F. Debold, J.M. Cook and K.A. Miczek, Society for Neuroscience 32nd Annual Meeting, Orlando, FL, November 2-7, 2002, abstract 607.9.

“Role of GABAA/α5 Receptor Mechanisms in the Discriminative Stimulus Effects of Ethanol in Squirrel Monkeys,” D.M. Platt, J.K. Rowlett, R.D. Spealman, J.M. Cook, and W. Yin, Alcohol Society Meeting, June, 2003.

“Biological Activity of the Tryprostatins and their Diastereomers on Human Carcinoma Cell Lines,” C.C. Zhang, S. Zhao, and J.M. Cook, 225th ACS National Meeting, New Orleans, LA, March 23-27, 2003 (abst MEDI-87).

“Studies of Memory Enhancing Agents which act via GABAA/BzR Receptors,” X. Li, H. Cao, C. Cook, F. Helmstetter, and J.M. Cook, 225th ACS National Meeting, New Orleans, LA, March 23-27, 2003 (abst MEDI-221).

“Enantiospecific, Sterospecific Total Synthesis of Alstonisine and Approach to the Total Synthesis of *N*b-Demethylalstophylline Oxindole,” Xiangyu Z. Wearing and J.M. Cook, 225th ACS National Meeting, New Orleans, LA, March 23-27, 2003 (abst ORG-412).

“Sterospecific, Enantiospecific Total Synthesis of the Sarpagine Indole Alkaloids (*E*)16-Epiaffinisine, (*E*)16-Epinormacusine B and Dehydro-16-epiaffinisine,” Jianming Yu and James M. Cook, 225th ACS National Meeting, New Orleans, LA, March 23-27, 2003, Organic Section (March 25th).

“α1 Subunit Containing GABAA Receptor Antagonism and Alcohol Heightened Aggressive Behavior in Male Rats,” D.L. Zitzman, J.F. DeBold, S.L. Gourley, J.M. Cook, and K.A. Miczek, Neuroscience Meeting, New Orleans, LA, November 12-17, 2003, #852.5.

“The Reinforcing Effects of Amphetamine in the Selectivity Bred High Alcohol Drinking (HAD-1) and Low Alcohol Drinking (LAD-1) Rat Lines,” J.E. Woods, J.Cook, And H.L. June, Neuroscience Meeting, New Orleans, LA, November 12-17, 2003, #852.12.

“Rational Design of Indoleamine 2,3-Dioxygenase Inhibitors,” A. Martin, C. Austin, J. Mizdrak, V. MacFarlane, C. Zhang, W. Yin, X. Li, J. Jamie, R. Truscott, J. Cook, and R. Griffith, 19th Royal Australian Chemical Institute Conference, Lorne, Victoria, Australia, July 6-11, 2003.

“Elucidating Benzodiazepine Receptor Subtype Mechanisms Using Zolpidem and the Putative GABAA/α5 Selective Agonist QH-ii-066,” A.N. Duke, D. Platt, R. Spealman, J.M. Cook, X. Li, and J. Rowlett, Sixty-fifth Annual Scientific Meeting of the College on Problems of Drug Dependence, Bal harbour, FL, June 14-19, 2003.

“The SAR and Possible Treatment of Alcohol Abuse with α1 Selective Benzodiazepine/ GABAA Receptor Antagonists,” James Cook, Sixty-fifth Annual Scientific Meeting on the College on Problems of Drug Dependence, Bal Harbour, FL, June 14-19, 2003. Invited Lecture-Workshop (30 min).

“Search of Benzodiazepine/GABA(A) Subtype Selective Ligands that Reverse Alcohol Self-Administration,” W. Yin, C. Zhang, X. Li, H. June, and J.M. Cook, Sixty-fifth Annual Scientific Meeting of the College on Problems of Drug Dependence, Bal Harbour, FL, June 14-19, 2003.

“Approach Towards the Total Synthesis of Villalstonine,” J. Ma and J.M. Cook, 38th National Organic Symposium, Indiana University, Bloomington, IN, June 8-12, 2003, Abstract Number: B64

“Study of the Conformation of GABAA-Benzodiazepine Receptor Bivalent Ligands by Low Temperature NMR,” D. Han, F. Holger, X. Li, J.R. Deschamps, H. Cao, J. Ma, W. Yin, and J.M. Cook, 38th National Organic Symposium, Indiana University, Bloomington, IN, June 8-12, 2003, Abstract Number: A76.

“General Approach for the Synthesis of Natural and Non-natural Products via the Tandem Pauson-Khand Reaction: Synthesis of 14π Annulenes and [5.8.5] Systems,” H. Cao, J. Flippen-Anderson and J. M. Cook, 228th ACS National Meeting, Philadelphia, PA, August 22-26, 2004 (abst. ORG-390).

“Stereocontrolled Total Synthesis of (-)-11-Methoxy-17-Epivincamajine and (-)-Vincamajinine,” X. Z. Wearing, Y. Yu, F. Rivas and J. M. Cook, Philadelphia, PA, August 22-26, 2004 (abst. ORG-391)

“GABAA/α1 Receptor Involvement in the Hyperphagic Effect of Benzodiazepines in Squirrel Monkeys,”A. Duke, D. Platt, J. M. Cook, W. Yin and J. K. Rowlett, 66th Annual Meeting of the College on Probems of Drug Dependence, San Juan, Puerto Rico, June 12-17, 2004, Poster Session III, Poster 32.

“GABA-A Receptor Mechanisms Underlying Motor Effects of Benzodiazepines in Monkeys,” S. C. Licata, D. M. Platt, A. N. Duke, J. M. Cook, P. V. V. S. Sarma, and J. K. Rowlett, Neuroscience Meeting, San Diego, CA October 22-28 (2004).

“The GABA(A)/α1 Receptor-Preferring Antagonist BCCt Does Not Attenuate Benzodiazepine-Induced Suppression of Locomotor Activity,” A. N. Duke, D. M. Platt, W. Yin, J. M. Cook and J. Rowlett, Neuroscience Meeting, San Diego, October 22-28 (2004).

“Search for Benzodiazepine/GABA(A) Subtype Selective Bivalent Ligands That Reverse Alcohol Self-Administration,” W. Yin, C. Zhang, S. S. V. V. Pullela, H. June and J. M. Cook, 227th ACS National Meeting, Anaheim, CA March 28 – April 1, 2004 (abst. MEDI 0286).

“Synthesis, in vitro Affinity and Efficacy of the First Bivalent α5 Subtype Selective BzR/GABA(A) Antagonist,” X. Li, W. Sieghart, G. R. Wenger and J. M. Cook. 227th ACS National Meeting, Anaheim, CA March 28 – April 1, 2004 (abst. MEDI 0348).

“Preparation of Analogs of the Cytotoxic Tryprostatins A and B. Study of Structure Activity Relationships as well as Irreversible Inhibitors for Mechanistic Work,” C. Zhang, J. Ma and J. M. Cook, 227th ACS National Meeting, Anaheim, CA March 28 – April 1, 2004 (abst. MEDI 0115).

“Study of the Structure-Activity Relationships of GABA(A)-Benzodiazepine Receptor Bivalent Ligands by Low Temperature NMR Spectoscopy and X-ray Analysis,” D. Han, F. H. Forsterling, X. Li, J. R. Deschamps, H. Cao, and J. M. Cook, 227th ACS National Meeting, Anaheim, CA March 28 – April 1, 2004 (abst. MEDI 0285).

“Development of Selective Ligands for Benzodiazepine Receptor Subtypes by Manipulating the Stereochemistry of Optically Active BzR Ligands,” X. Li, J. R. Atack, and J. M. Cook, 227th ACS National Meeting, Anaheim, CA March 28 – April 1, 2004 (abst. MEDI 0287).

“MEDI-0285 Also Chosen for Sci-Mix (represented).”

“MEDI-0287 Also Chosen for Sci-Mix (represented).”

Regiospecific, Enantiospecific Total Synthesis of the 12-Alkoxy-substitutal Sarpagine Alkaloids, (+)-12-Methoxy-Na-Methylvellosimine, (+)-12 Methoxyaffinisine and (-)-Fuchsiaefoline,” H. Zhou, W. Yin and J. M. Cook, 227th ACS National Meeting, Anaheim, CA March 28 – April 1, 2004 (abst. ORGN 0444).

“Use of the Molybdenum Hexacarbonyl-Mediated Tandem Allenic Pauson-Khand Reaction for the Synthesis of a Dicyclo[a,e]pentalene,” H. Cao, J. L. Flippen-Anderson, J. L. Chen and J. M. Cook, 227th ACS National Meeting, Anaheim, CA March 28 – April 1, 2004 (abst. ORGN 0083).

“Mechanistic Study on the Asymmetric Pictet-Spengler Reaction. Evidence Supporting the Carbocationic Pathway,” D. Han, X. Liu, and J. M. Cook, 227th ACS National Meeting, Anaheim, CA March 28 – April 1, 2004 (abst. ORGN 0485).

“First Enantiospecific Total Synthesis of a Quaternary Voachalotine Alkaloid, (+)-Dehydrovoachalotine,” J. Yu, J. Ma, X. Wearing and J. M. Cook, 227th ACS National Meeting, Anaheim, CA March 28 – April 1, 2004 (abst. ORGN 0439).

“Progress Toward the Total Synthesis of the Antimalarial Bisindole Alkaloid Villastonine,” J. Ma, C. Zhang, J. Yu, and J. M. Cook, 227th ACS National Meeting, Anaheim, CA March 28 – April 1, 2004 (abst. ORGN 0443).

“Progress Toward the Enantiospecific Stereospecific Total Synthesis of Nb-Demethylalstophylline Oxindole,” X. Z. Wearing and J. M. Cook, 227th ACS National Meeting, Anaheim, CA March 28 – April 1, 2004 (abst. ORGN 0483).

“General Approach to the Synthesis of Sarpagine/Macroline Bisindole Alkaloids,” X. Liao, H. Zhou and J. M. Cook, 227th ACS National Meeting, Anaheim, CA Mar. 28 – Apr. 1, 2004 (abst. ORGN 0442).

“Stereoselective Total Synthesis of (-)-Vincamajinine and (-)-11-Methoxy-17-epivincamijine,” X. Z. Wearing, J. Yu and J. M. Cook, 227th ACS National Meeting, Anaheim, CA March 28 – April 1, 2004 (abst. ORGN 0484)

“ORGN-0483 Also chosen for Sci-mix (represented).”

“General Approach for the Synthesis of Natural and Non-natural Products via the Tandem Pauson-Khand Reaction. Synthesis of 14π Annulenes and [5.8.5] Systems,” H. Cao, J. Flippen-Anderson and J. M. Cook, 36th Great Lakes Regional ACS Meeting, Peoria, IL, October 17-20 (2004), abstract 294.

“Synthesis, In Vitro Affinity and Efficacy of the First Bivalent Alpha 5 Subtype Selective BzR/GABA(A) Antagonist,” W. Yin, F. Rivas, R. Furtmueller, X. Li, W. Sieghart, G. Wenger and J. M. Cook, Neuroscience 2004, San Diego, CA, October 23-27 (2004), Tue, Posterboard MM31.

“Alcohol Drinking in Baboons: Effects of 3-Propyloxy Beta-Carboline,” E. M. Weerts, B. J. Kaminski, W. Yin, P.V.V.S. Sarma and J. M. Cook, College on Problems of Drug Dependence, June 19-25, Orlando, FL (2005).

“Neurochemical and Behavioral Effects of Novel 8-Acetylenyl Analogs of Triazolam,” S. Licata, D. M. Platt, J. M. Cook, H. Zhou, P.V.V.S. Sarma, R. Fürtmueller, W. Sieghart, S. Huck and J. K. Rowlett, 2005 Neuroscience Meeting, November 12-17, Washington, DC (2005).

“General Approach to the Synthesis of Ring-A Alkoxy Substituted Indole Alkaloids via the Asymmetric Pictet-Spengler Reaction,” H. Zhou, X. Liao, J. Ma, A. Wearing and J. M. Cook, The 21st Mona Symposium on Natural Products and Medicinal Chemistry, Mona Jamaica, January 3-6 (2006).

“General Approach to the Synthesis of Ring-A Alkoxy Substituted Indole Alkaloids via the Asymmetric Pictet-Spengler Reaction,” J. M. Cook,H. Zhou, X. Liao, J. Ma, and P.V.V.S. Sarma, Abstracts, 37th Great Lakes Regional Meeting of the American Chemical Society, Milwaukee, WI, May 31-June 2, 2006, GLRM-307.

“Electronic Effects On the Cis to Trans Epimerization of Pictet-Spengler Produced 1,2,3,4-Tetrahydro-β-Carbolines,” M. L. Van Linn, D. Han, H. J. Kumpaty, F. H. Forsterling, J.R. Deschamps, J. M. Cook, Abstraccts of Papers, 232nd ACS National Meeting, San Francisco, CA, Sept. 10-14, 2006, ORGN-832.

“Synthesis of Optically Active Subtype Selective BZR Ligands,” S. Huang, T. Clayton, M. Dai, R. Edwankar, C. Sawant, J. M. Cook, Abstracts of Papers, 232nd ACS National Meeting, San Francisco, CA, Sept. 10-14, 2006, MEDI-502.

“Search For Benzodiazepine/GABA(A) Subtype Selective Ligands That Reverse Alcohol Self-Administration” M. L. Van Linn, E. Weerts, D. Platt, W. Yin, P.V.V.S. Sarma, J. M. Cook, Abstracts, 37th Great Lakes Regional Meeting of the American Chemical Society, Milwaukee, WI, May 31-June 2 2006, GLRM-156.

“The SAR Study of Benzodiazepine Receptor Bivalent Ligands by Low Temperature NMR Spectroscopy and X-Ray Analysis,” S. Huang, T. Clayton, M. Dai, W. Yin, J. Ma, R. Edwankar, C. Sawant, M. Van Linn, Y. Teng, M. Johnson, H. F. Forsterling, and J. M. Cook, Abstracts, 37th Great Lakes Regional Meeting of the American Chemical Society, Milwaukee, WI May 31 – June 2, 2006, GLRM-155.

“Enantiospecific Synthesis of (+)-Na-Methyl-pericyclivine, (-)-Na-Methylakuammidine, (+)-10-Methoxy-Na-Methylpericyclivine and 10-Hydroxy-Na-Methylpericyclivine,” P.V.V.S. Sarma, R. V. Edwankar, C. R. Edwankar, S. Huang, J. M. Cook, Abstracts, 37th Great Lakes Regional Meeting of the American Chemical Society, Milwaukee, WI May 31-June 2, 2006, GLRM-143.

“General Approach to the Synthesis of Oxygenated Bisindole Alkaloids,” M. Dai, S. Huang, J. M. Cook, Abstracts, 37th Great Lakes Regional Meeting of the American Chemical Society, Milwaukee, WI, May 31-June 2, 2006, GLRM-142.

“General Approach Towards the Total Synthesis of 9-Methoxy Indole Alkaloids: 9-Methoxygeissoschizol, 9-Methoxy-Nb-Methyl-geissoschizol and the Opioid Analgesic Active Mitragynine,” J. Ma, J. M. Cook, Abstracts, 37th Great Lakes Regional Meeting of the American Chemical Society, Milwaukee, WI, May 31-June 2, 2006, GLRM-141.

“Progress Towards the Total Synthesis of the Opioid Analgesic Indole Alkaloids Mitragynine and 7-Hydroxymitragynine as well as the Antimalarial Bisindole 10-Hydroxysambaresine,” J. Ma, W. Yin, J. M. Cook, Abstracts of Papers, 231st ACS National Meeting, Atlanta, GA, March 26-30, 2006, ORGN-174.

“General Approach for the Synthesis of 12-Methoxy Substituted Sarpagine Indole Alkaloids Including 12-Methoxy-Nb-Methyl-voachalotine and Fuschsiaefoline,” H. Zhou, J. M. Cook, Abstracts of Papers, 231st ACS National Meeting, Atlanta, GA, March 26-30, 2006, ORGN-173.

“Total Synthesis of Antileishmanial and Antibacterial Alkaloids (+)-Na-Methylpericyclivine and (-)-Na-Methylakuammidine as well as the Ring A-Oxygenated Natural Products, (+)-10-Methoxy Na-Methylpericyclivine and 10-Hydroxy Na-Methylpericyclivine,”P.V.V.S. Sarma, J. M. Cook, Abstracts of Papers, 231st ACS National Meeting, Atlanta, GA, March 26-30, 2006, ORGN-172.

“Modulation of Alcohol-heightened Aggression in Mice by α-5-Containing GABA(A) Receptors,” S. Faccidomo, J. G. Maggin, S. Melief, T. Clayton, J. M. Cook, K. A. Miczek, Society for Neuroscience, October, 2006, Atlanta, GA.

“Differential Sedative and Motor Effects of GABA(A) Subtype Selective Compounds in Rhesus Monkeys,” A. Duke, D. Platt, S. Licatta, R. Edwankar, S. Huang, J. M. Cook, R. Furtmueller, W. Sieghart, and J. K. Rowlett, Society for Neuroscience, October, 2006, Atlanta, GA.

“Attenuation of Motor and Sedative-like Effects of Alparzolam by Flumazenil and BCCt in Rhesus Monkeys,” A. Duke, D. M. Platt, J. M. Cook, W. Yin and J. K. Rowlett, CPDD 68th Annual Meeting, June 17-22, 2006, Scottsdale, AZ.

“Synthesis, Pharmacological Studies, and Molecular Modeling of Novel 1,3-Diazipinium Chlorides,” J. A. Grant, Y. A. Jackson, M. Gossel-Williams, T. Clayton, J. M. Cook, Latest Trends in Organic Synthesis, Brock University, St.Catherines, Ontario, CA, 2006.

“General Approach to the Synthesis of Indole Alkaloids via the Asymmetric Pictet-Spengler Reaction,” J.M. Cook, (**Plenary Lecture**,) presented at the New Horizons in Catalysis (Synthetic Heterocyclic Chemistry), at the Palau de Congressos de Catalunya, Barcelona, April 12-13 (2007).

“Synthesis of Subtype Selective Ligands for Alpha -5 Containing GABA (A) / Bz Receptors to Treat Memory Deficits,” T. Clayton, M.Ernst, L. Richter, S. Sankar, T. Delorey, W. Sieghart, R. Furtmüeller, G. Ecker, and J.M. Cook, 233rd ACS National Meeting, March 25-29, Chicago, Ill., 2007, MED - 299.

“Design and Synthesis of Stereoenantiomeric Benzodiazepine Receptor Ligands,” S.Huang, M. Savic, R. Furtmueller, A.Duke, T.Clayton, W. Sieghart, J.K. Rowlett and J.M. Cook, 233rd ACS National Meeting, March 25-29, Chicago, Ill., 2007, MED – 302.

“Epimerization Kinetics of Electronically Altered 1-Phenyl-1,2,3,4 – Tetrahydro β-carbolines,” M. Van Linn, F.H. Forsterling, H.J. Kumpathy, J. Deshamps and J.M. Cook, 233rd ACS National Meeting, March 25-29, Chicago, Ill., 2007, Org-86.

“Progress Toward the Total Synthesis of the Bisindole Alkaloid Angusticraline: Emphasis on the Northern Hemisphere as well as the Total Synthesis of Other Monomeric Indole Alkaloids,” C.R. Edwanker, R. Edwanker and J.M. Cook, 233rd ACS National Meeting, March 25-29, Chicago, Ill., 2007 ORG-418.

“The First Enantiospecific Total Synthesis of the Important Biogenetic Intermediates, (+) - Polyneuridine and (+)-Polyneuridine Aldehyde, as well as 16-epi-Vellosimine and Macusine A,” W. Yin, J. Ma, J.M. Cook, Abstracts of Papers, 233rd ACS National Meeting, Chicago, IL, United States, March 25-29, 2007.

“GABA-A/alpha 5 Receptor Mechanisms in the Discriminative Stimulus Effects of GABA-A Modulators” D. Platt, M. Van Linn, T. Clayton, J.M. Cook, J. Rowlett, 69th Annual Meeting of the College on Problems of Drug Dependence, June 16-21, Hilton, Quebec, Canada, Poster Session III (2007).

“Differential Antagonism of the Sedative and Motor Effects of Zolpidem and Alprazolam by BCCt,” A.N. Duke, D.M. Platt, J.M. Cook, M. Van Linn, J. Rowlett, 69th Annual Meeting of the College on Problems of Drug Dependence, June 16-21, Hilton, Quebec, Canada (2007).

“General Approach to the Synthesis of Alkoxy Substituted Indole Alkaloids,” J.M. Cook, Scientific Update Meeting, August 28-31, San Diego, CA (2007), (**Plenary Lecture**.)

“Linear Free Energy Relationship of the cis to trans Epimerization of Substituted 1-Phenyl-1,2,3,4-Tetrahydro-β-Carbolines,” M.L. Van Linn, F.H. Forsterling, M.P. Ver Haag, J.R. Deschamps, J.M. Cook, Abstracts of Papers, 234th ACS National Meeting, Boston, MA, United States, August 19-23, 2007.

“Serendipity Rediscovered - An Oxymoron or Rational Drug Design: Studies on Subtype Selective BzR/GABAergic Ligands,” J.M. Cook, H. June, E. Weerts, M.L. Van Linn, D. Platt, T. DeLorey, M. Savic, T. Clayton, Abstracts of Papers, 234th ACS National Meeting, Boston, MA, United States, August 19-23, 2007 (**Plenary Lecture**.)

“Activity of Phenoxysytrene and Stilbene Analogs Against Clinically Important Gram-positive Bacteria,” K. Engelbrecht, M.S. Kabir, J.M. Cook, A. Monte, M. Rott, W.R. Schwan, Abstracts of Papers, 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, September 17-21, 2007.

“Antibacterial Activity of (E)-3-Methoxy-5-Hydroxy-Stilbene and Analogs Against Clinically Significant Gram/positive Bacteria,” E. Kathleen, M.S. Kabir, J.M. Cook, A. Monte, M. Rott, W.R. Schwan, Abstracts of Papers, North Central Branch Meeting of the American Society for Microbiology, Marshfield, WI, October 5, 2007.

“Role of GABA(A) Receptors in Diazepam-induced Attenuation of the Anxiogenic Effects of Acute Citalopram Treatment in BALB/c Mice,” M. Birkett, A. Duke, J. Meyer, J.M. Cook, S. Huang, M. Van Linn, J.K. Rowlett, Society for Neuroscience, November, San Diego, CA (2007).

“Differential Precipitated Withdrawal by Flumazenil and BCCt Following Chronic Alprazolam Administration,” A.N. Duke, D. Platt, M. Van Linn, P.V.V.S. Sarma, J.M. Cook, J.K. Rowlett, Society for Neuroscience, November, San Diego, CA (2007).

“Antagonism of the Reinforcing Effects of Triazolam by Selective Antagonists in Rhesus Monkeys,” K.M. Bano, D.M. Platt, J.M. Cook, M.L. Van Linn, J.K. Rowlett, Society for Neuroscience, November, San Diego, CA (2007).

“Ry-023, a Selective Inverse Agonist at the Benzodiazepine Binding Site on the GABA-A α5 Receptor, Improves Performance in a Delayed-Match-to-Sample Task in Rhesus Monkeys,” M. Weed, T. Clayton, J.M. Cook, 46th American College of Neuropsychopharmacology, December 9-13, Boca Raton, FL, Abst. #158 (2007).

“Role of Alpha-5/GABA(A) Receptor Mechanisms in the Reinforcing Effects of Ethanol in Rhesus Monkeys,” D.M. Platt, D. Rüedi-Bettschen, S. Rallapalli, J.M. Cook, Meeting of the European Behavioral Pharmacology Society (2007).

“Progress Toward the Total Synthesis of the Alpha-Adrenergic Blocking Agent Dispegatrine, as well as the Total Synthesis of Other Monomeric Indole Alkaloids,” Edwanker, C.R., Edwanker, R.V., and Cook, J.M. In Abstracts of Papers, 235th ACS National Meeting, New Orleans, LA, United States, April 6-10, 2008; pp ORGN-649.

“Progress Toward the Total Synthesis of the Bisindole Alkaloid Macrospegatrine: Emphasis on the Northern Hemisphere as well as the Total Synthesis of Other Monomeric Indole Alkaloids,” Edwanker, R.V., Edwanker, C.R., and Cook, J.M., Abstracts of Papers, 235th ACS National Meeting, New Orleans, LA, United States, April 6-10, 2008, ORGN-652.

“Progress Toward the Enantiospecific Total Synthesis of 18-Hydroxyaffinisine and Voacoline,” Jain, H.; and Cook, J.M.; Abstacts of Papers, 235th ACS National Meeting, New Orleans, LA, United States, April 6-10, 2008, ORGN-651.

“New Classes of Gram-Positive Antibacterials: Inhibitors of MRSA and Surrogates of the Causative Agents of Anthrax and Tuberculosis,” Kabir, M.S.; Engelbrecht, K.; Monte, A.P.; Rott, M.A.; Schwan, W.R.; Cook, J.M., Abstracts of Papers, 235th ACS National Meeting, New Orleans, LA, United States, April 6-10, 2008, MEDI-031.

“Straightforward and Efficient Cu-Catalyzed Cross-Coupling Reaction of Arylvinyl Iodides and Phenols as well as Thiophenols: Facile Regioselective Synthesis of E-[Phenoxystryrenes and (E)-1-Phenyl-2-(arylthio)ethylenes [(E)-phenyl(styrl) sulfanes],” Kabir, M.S.; Monte, A.P.; Cook, J.M., Abstracts of Papers, 235th ACS National Meeting, New Orleans, LA, United States, April 6-10, 2008, ORGN-650.

“Insight into the Mechanism of the Pictet-Spengler Reaction for the Synthesis of Natural Products,” Van Linn, M.L.; Forsterling, F.H.; Cook, J.M., Abstracts of Papers, 235th ACS National Meeting, New Orleans, LA, United States, April 6-10, 2008, ORGN-163

“Progress Toward the Enantiospecific Total Synthesis of Accedinisine and N’-Demethylaccedinisine,” Yang, J.; Sarma, P.V.V.S.; Cook, J.M., Abstracts of Papers, 235th ACS National Meeting, New Orleans, LA, United States, April 6-10, 2008, ORGN-648.

“Pharmacokinetics Interaction Between Ritonavir and Quinine,” Soyinka, J.O.; Onyeji, C.O.; Owolabi, A.R.; Sarma, P.; Cook, J.M., 48th Annual ICAAC/IDSA Meeting, Washington, D.C., October 25-28, 2008.

“Hypolocomotor Activity of Diazepam in Wistar Rats is Mediated by GABA(A) Receptors Containing the α1, but not the α5 Subunit,” Savic, M. Rallapalli, S.; Milinkovi, M.; Samard, J.; Van Linn, M.; and Cook, J.M., CINP Congress, Munich, Germany, July 2008.

“Evaluation of Novel Gram Positive Specific Antimicrobials Derived From (E)-3-Hydroxy-5-Methoxystilbene,” Polanowski, R.; Engelbrecht, K.; Schwan, W.; Monte, A.; Kabir, M.; Cook, J.; Stemper, M.; and Rott, M.A.; American Society for Microbiology, St. Cloud, MN, October 17, 18 (2008).

“The Selective α5 GABA(A) Receptor Antagonist Xli-093 Reverses Diazepam Induced Memory Deficits in the Holeboard Task,” Shinday, N.; Rallapalli, S.; Cook, J.M.; Meyer, J.S.; and Rowlett, J.K., Neuroscience Meeting, Washington, DC, November (2008).

“In Vitro and In Vivo Characterization of the Novel Benzodiazepine Analog NEP-510,” Fischer, B.D.; Bano, K.M.; Duke, A.; Platt, D.; He, X.; Huang, Q.; Johnson, E.M.; Furtmueller, R.; Sieghart, W.; Cook, J.M.; Rowlett, J.K., Neuroscience Meeting, Washington, DC, November (2008).

“Serendipity Rediscovered, An Oxymoron or Rational Drug Design.” Cook, J. M. *Abstracts of Papers, 38th Great Lakes Regional Meeting of the American Chemical Society, Chicago, IL, United States, May 13-16*, **2009**, GLRM-025, plenary lecture.

“Progress Toward the Total Synthesis of -Adrenergic Blocking Agent Dispegatrine as well as the First Enantiospecific Total Synthesis of Lochvinerine, (+)-16-Episarpagine and Lochnerine.” Edwankar, C. R.; Edwankar, R. V.; Cook, J. M. *Abstract of Papers, 238th ACS National Meeting, Washington, DC, United States, August 16-20*, **2009**, ORGN-748.

“Progress Toward the Total Synthesis of -Adrenergic Blocking Agent Dispegatrine as well as the First Enantiospecific Total Synthesis of Lochvinerine, (+)-16-Episarpagine and Lochnerine.” Edwankar, C. R.; Edwankar, R. V.; Liao, X.; Cook, J. M. *Abstracts of Papers, 237th ACS National Meeting, Salt Lake City, UT, United States, March 22-26*, **2009**, ORGN-514.

“New Benzodiazepine-related Agents to Treat Neuropathic Pain.” Edwankar, C. R.; Edwankar, R.V.; Zeilhofer, H.; Stables, J. P.; Roth, B. L.; Furtmuller, R.; Sieghart, W.; Cook, J. M. *Abstract of Papers, 238th ACS National Meeting, Washington, DC, United States, August 16-20*, **2009**, MEDI-169.

“Progress Toward the Total Synthesis of Alstonia Indole Alkaloids Peraksine and Macrosalhine Bromide as well as the Formal Total Synthesis of Secotalcarpine and Macrocarpine B.” Edwankar, R. V.; Edwankar, C. R.; Cook, J. M. *Abstracts of Papers, 238th ACS National Meeting, Washington, DC, United States, August 16-20*, **2009**, ORGN-743.

“The First Enantiospecific Total Synthesis of *Alstonia* Indole Alkaloid Peraksine as well as Progress Toward the Total Synthesis of Secotalcarpine and Macrocarpine B.” Edwankar, R. V.; Edwankar, C. R.; Cook, J. M. *Abstracts of Papers, 238th ACS National Meeting, Salt Lake City, UT, United States, March 22-26*, **2009**, ORGN-531.

“Novel Nonsedative Agents to Treat Epilepsy. Benzodiazepine-related Ligands that do not Develop Tolerance.” Edwankar, R. V.; Edwankar, C. R.; Stables, J. P.; Roth, B. L.; Furtmuller, R.; Sieghart, W.; Cook, J. M. *Abstracts of Papers, 238th ACS National Meeting, Washington, DC, United States, August 16-20*, **2009**, MEDI-099.

“Progress Toward the Total Synthesis of Nb-Demethylalstophylline Oxindole Alkaloid.” Fonseca, G. O.; Cook, J. M.; *Abstracts of Papers, 237th ACS National Meeting, Salt Lake City, UT, United States, March 22-26*, **2009**, ORGN-516.

“Progress Toward the Total Synthesis of Dicyclopenat [a,f] pentalene.” Fonseca, G. O.; Cook, J. M.; *Abstracts of Papers, 237th ACS National Meeting, Salt Lake City, UT, United States, March 22-26*, **2009**, ORGN-515.

“New Classes of Novel Gram-positive Specific Antimicrobials: Inhibitors of *E. coli*, *S. aureus*, and Surrogates of the Causative Agents of Methicillin-resistant S.aureus, Tuberculosis and Anthrax.” Kabir, M. S.; Ara, S.; Polanowski, R. L.; Engelbrecht, K.; Krueger, S. M.; Stemper, M. E.; Rott, M. A.; Schwan, W. R.; Monte, A. P.; Cook, J. M.. *Abstracts of Papers, 237th ACS National Meeting, Salt Lake City, UT, United States, March 22-26*, **2009**, MEDI-047.

“New Agents to Treat Drug-Resistant Gram-positive Antimicrobial Infections as well as Anthrax and Drug Resistant Tuberculosis.” Kabir, M. S.; Ara, S.; Polanowski, R. L.; Engelbrecht, K.; Stemper, M. E.; Krueger, S. M.; Rott, M. A.; Schwan, W. R.; Monte, A. P.; Cook, J. M. *Abstracts of Papers, 238th ACS National Meeting, Washington, DC, United States, August 16-20,* **2009**, MEDI-343.

“Enolate Driven Copper-Mediated Intramolecular Cross-Coupling Strategies for the Asymmetric Total Synthesis of Antimalarial, Antileishmanial and Antimicrobial Alkaloids and Unnatural Agents.” Kabir, M. S.; Edwankar, C. R.; Edwankar, R. V.; Yang, J.; Jain, H. D.; Ara, S.; Monte, A. P.; Cook, J. M. *Abstracts of Papers, 237th ACS National Meeting, Salt Lake City, UT, United States, March 22-26****,* 2009**, ORGN-499.

“Highly Active Thio Ligated Cu-Catalyst: Easy Access to Stereo and Regiospecific Vinyl Ethers.” Kabir, M. S.; Van Linn, M. L.; Cook, J. M.. *Abstracts of Papers, 238th ACS National Meeting, Washington, DC, United States, August 16-20*, **2009**, ORGN-465.

“Progress Toward the Total Synthesis of the Sarpagine Related Alkaloids Amervolfine and Ervincidine.” Rallapalli, S. K.; Cook, J. M.” *Abstracts of Papers, 237th ACS National Meeting, Salt Lake City, UT, United States, March 22-26*, **2009**, ORGN-517.

“Synthesis of Bivalent Ligands Including the Subtype Selective Antagonist Xli-093 for 5 BzR/GABAAergic Receptors. Approach to Treatment of Cognitive Deficits.” Rallapalli, S. K.; Majumder, S.; Roth, B.; Shinday, N. M.; Rowlett, J. K.; Cook, J. M. *Abstracts of Papers, 238th ACS National Meeting, Washington, DC, United States, August 16-20*, **2009**, MEDI-326.

“Mechanistic Studies on the Asymmetric Picter-Spengler Reaction,” Van Linn, M. L.; Cook, J. M*. Abstracts of Papers, 238th ACS National Meeting, Washington, DC, United States, August 16-20*, **2009**, ORGN-470.

“Investigation of the Kinetics of the Cis to Trans Isomerization of 1,2,3-Trisubstituted Tetrahydro--Carbolines: A Hammett Study,” Van Linn, M. L.; Cook, J. M. *Abstracts of Papers, 237th ACS National Meeting, Salt Lake City, UT, United States, March 22-26*, **2009**, ORGN-394.

“New Agents to Treat Alcohol Abuse Effective Against Anxiety and Anhedonia,” Van Linn, M. L.; Yin, W.; Namjoshi, O.; Platt, D.; Weerts, E.M.; June, H. L.; Roth, B.; Majumder, S.; Cook, J. M. *Abstracts of Papers, 238th ACS National Meeting, Washington, DC, United States, August 16-20*, **2009**, MEDI-321.

“Development of GABA (A) Subtype Selective Agents for the Treatment of Alcohol Abuse.” Van Linn, M. L.; Yin, W.; Platt, D.; Weerts, E.M.; June, H. L.; Cook, J. M. *Abstracts of Papers, 237th ACS National Meeting, Salt Lake City, UT, United States, March 22-26*, **2009**, MEDI-108.

“The First Enantiospecific Total Synthesis of the 3-Oxygenated Sarpagine Indole Alkaloids Affinine and 16-Epiaffinine,” Yang, J.; Rallapalli, S. K.; Cook, J. M. *Abstracts of Papers, 238th ACS National Meeting, Washington, DC, United States, August 16-20,* **2009**, ORGN-783.

“Screening Synthetic Stilbene Analogs for Antimicrobial Activity Against *Mycobacterium smegmatis* and *Staphylococcus aureus*”, Krueger, S. M.; Polanowski, R.; Engelbrecht, K.; Kabir, M. S.; Cook, J. M.; Monte, A. P.; Rott, M. A.; Schwan, W. R. *109th American Society for Microbiology, ASM, Philadelphia, PA*. Date presented: May 20, **2009**.

“Alpha-5/GABA(A), but not alpha-1/GABA(A), receptor mechanisms contribute to the reinforcing effects of ethanol in monkeys,” D. M. Platt, D. Ruedi-Bettschen, S. Rallapalli, M. Van Linn, O. Namjoshi, and J. M. Cook, *Behav Pharmcol* 20:S69-70. 13th Biennial Meeting of European Behavioural Pharmacology Society, Rome, Italy, 2009.

“Evaluation of Novel Gram positive Specific Antimicrobials Derived from (E)-3-Hydroxy-5-methoxystilbene”, Polanowski, R.; Engelbrecht, K.; Schwan, W. R.; Monte, A. P.; Kabir, M. S.; Cook, J. M.; Monte, A. P.; Rott, M. A.; Stemper, M. E.; Rott, M. A. *American Society of Microbiology-North Central Branch, American Society of Microbiology, St.Cloud, MN. Academic, Regional, http://, Poster*. Date presented: October 18, **2008**.

“WYS-8, a Novel Ligand at GABA(A) Receptors: a Step Forward to Linking in vitro with in vivo Selectivity? “ S. M. Joksimovic, M.M.Savic, M. M. Milinkovic, M. Van Linn , J. Ramerstorfer, S. Majumder, W. Yin, B.L. Roth, W. Sieghart, J. M. Cook. *22nd ECNP Congress*, *September 12-16*, **2009**, Istanbul, Turkey.

“Behavioral Characterization of JY-XHE-053, a Benzodiazepine Ligand Less Efficacious at GABA(A) Receptors Containing 1 and 5 than 2 and 3 Subunits,” M. M. Milinkovic, M. M.Savic, S. Huang, R. Furtmuller, S. Majumder, J. Samardzic, J. M. Divljakovic, B. L. Roth, W. Sieghart, J. M. Cook. *22nd ECNP Congress, September* 12-16, **2009**, Istanbul, Turkey.

“The Alpha-5 GABA(A) Inverse Agonist PWZ-029 Attenuates Isolation Rearing-Induced Context Fear Deficits,” S. Powell, J. Perez, J. Gresack, J. Cook, M. Geyer and V. Risbrough, *ACNP meeting, December 7-12, Westin, Hollywood, Fla.* **2009**.

“Role of GABA(A) Receptor Subtypes in Benzodiazepine Self-administration by Rhesus Monkeys”, B. Fischer, D. Platt, M. Van Linn, S. Rallapalli, T. Clayton, J. M. Cook and J. K. Rowlett, *71st Annual Meeting of the College on the Problems of Drug Dependence*, *June 20-25, Reno, NV*, **2009**.

“GABA-A Receptor Subtype Mechanisms in the Discriminative Stimulus Effects of Ethanol in Monkeys”, D. Platt, M. Van Linn, S. Rallapalli, T.Clayton and J. M. Cook*, 71st Annual Meeting of the College on the Problems on Drug Dependence, June 20-25, Reno, NV*, **2009**.

“PWZ-029, An Inverse Agonist Selective for 5 Subunit Containing GABA(A) Receptors, Enhances Performance on an Executive Function Task in Monkeys”, J. K. Rowlett, C. A. Moran, T. Clayton, S. Rallapalli, B. Roth and J. M. Cook, *European Behavioral Pharmacology Society, Fall, Rome, Italy*, **2009**.

“Rat Genetic Models with Natural Deficits in Cognition for Drug Development,” S. Nye, B. Abroe, J. K. Rowlett, S. Rallapalli, A. Kerr, R. Swain and J. M. Cook, *Society of Neuroscience Meeting, Oct 19-23, Chicago, IL*, **2009**.

“Alpha 5/GABA(A) But not Alpha 1/GABA(A) Receptor Mechanisms Contribute to the Reinforcing Effects of Ethanol in Monkeys,” D. Platt, D. Ruedi-Bettschen, S. Rallapalli, M. Van Linn and J. M. Cook, *European Behavioral Pharmacological Society, Fall, Rome, Italy*, **2009**; Behav. Pharmacol, 20:S69-70.

“Pharmacokinetic Interaction Between Ritonavir and Quinine,” J. Soyinka, C. Onyejii, A. Owolobi, P. Sarma and J. M. Cook, *48th Annual ICAAC/IDSA Meeting, Oct 25-28, Washington, DC*, **2009**.

“Role of Alpha 5 Containing GABA(A) Receptors in Mediating Benzodiazepine Actions in Neocortical Circuits” J. Schweizer, U. Rudolph, J. M. Cook and B. Antkowiak, **2009**.

“HZ-166, A Novel GABA(A) Receptor Subtype Selective Benzodiazepine Site Ligand , is Antihyperalgesic in Mouse Models of Inflammatory and Neuropathic Pain,” A. DiLio, Z. Wang, R. Edwankar, H. Zeilhofer, J. M. Cook, 66th Southwest and 62nd South Eastern Regional Meeting of the ACS, New Orleans, LA, Riverside Hilton, 11/30/2010-12/4/2010.

“SH-I 048A, A Novel Positive Modulator of GABA(A) Receptor: In Vitro and Behavioral Profile,” S. Joksimovic, S. Huang, J. Rammerstorfer, M. Milinkovic, J. M. Divljakovic, B. Roth, W. Sieghart, M.M. Savic, J. M. Cook, Congress of European College of *Neuropsychopharmacology*, Amerstam, July (2010).

“Contribution of 1 Subunit-Containing GABA (A) Receptors to Diazepam Motor Impairment,” J. Divljakovic, M. VanLinn, M. M. Milinkovic, W.Yin, B. Batinic, J. Cook, M. Savic. Congress of European College of *Neuropsychopharmacology*, Amerstam, July (2010).

“Acute Dependence in Squirrel Monkeys Following Zolpidem Administration: Role of 1 GABA (A) Receptors,’ L. Teixeira, B. Fischer, M. VanLinn, O. Namjoshi, W. Yin, T. Clayton, J. Cook, J. Rowlett, Society for Neuroscience Meeting, San Diego, Fall 2010.

“Role of 1 and 5 Subunit Containing Receptors in the Cognitive Impairing Effects of Benzodiazepines,” C. Moran, O. Namjoshi, S. Rallapalli, J. M. Cook, J. Rowlett, Society for Neuroscience Meeting, Fall 2010.

“Evaluation of 1 GABA (A) Receptor Mechanisms in the Reinforcing Effects of Alcohol in Rhesus Monkeys,” M. Szafir, M. VanLinn, O. Namjoshi, W. Yin, T. Clayton, J. Cook, D. M. Platt, Society of Neuroscience Meeting, Fall, 2010.

“The Role of 5 GABA (A) Receptors in Tests of Learning and Memory in Rhesus Monkeys,” P. Soto, S. Rallapalli, J. M. Cook, N. Ator, M. Weed, Society of Neuroscience Meeting, Fall, 2010.

“Alpha5/GABA-A Receptor Inverse Agonists Attenuate the Abuse Related Effects of Ethanol in Monkeys,” Platt D. M., Ruedi-Bettschen D., Rowlett J.K., Rallapalli S., Clayton T., and Cook J.M., *Alcohol Clin Exp Res* 34:**538**. Research Society on Alcoholism 33rd Annual Meeting, San Antonio, TX, 2010.

“HZ-166, A Nonsedating Anxiolytic Active Against Neuropathic Pain,” A. DiLio, R. Edwankar, U. Zeilhofer, J. M. Cook, ISHC Meeting, Glasgow, Scotland, July 31- August 4, 2011

“HZ-166, A Nonsedating Anxiolytic Active Against Neuropathic Pain,” J. M. Cook, Medical College of Wisconsin, Pain Meeting, Summer 2011.

“The Design and Synthesis of GABAergic Subtype Specific Ligands to Treat Diseases,” J.M. Cook, CTSI Drug Development Workshop Meeting, Medical College of Wisconsin, Spring 2012

“Withdrawal from Repeated Haloperidol Reduces the Efficacy of Subsequent Novel Antipsychotic Treatment in MAM Model of Schizophrenia”, T. Grace, et al., M. Poe, J.M. Cook, Society for Neuroscience Meeting, San Diego, Fall, 2013.

“Reversal of Ketamine-Induced Cognitive Impairment by an α2/α3 GABAA Receptor Modulator in Rhesus Monkeys”, Z. Meng, M.M. Poe, Zhi-jian Wang, J.M. Cook, J.K. Rowlett, Society for Neuroscience Meeting, San Diego, Fall, 2013.

“General Approach Towards the Enantiospecific Synthesis of Macroline Oxindoles. Total Synthesis of Isoalstonisine, Affinisine Oxindole and an Improved Total Synthesis of Alstonisine”, G. Fonseca, J.M. Cook, 245th ACS National Meeting, New Orleans LA, April 7-11, (Abst. ORGN 180), 2013.

“Synthesis of Biological Evaluation of α5 GABAergic Subtype Selective Ligand PWZ-029”, P. Biawat, S. Rallapalli, C. Lauer, J. Rowlett, B. Curry, C. Kazerowski, J.M. Cook, 245th ACS National Meeting, New Orleans LA, April 7-11, (Abst. MEDI 147), 2013.

“Synthesis of Benzodiazepines Active Against Neuropathic Pain as well as Schizophrenia”, M. Poe, Z. Wang, A. Di Lio, S. Rallapalli, R. Edwankar, J. Cook, H.U. Zeilhofer, 245th ACS National Meeting, New Orleans LA, April 7-11, (Abst. MEDI 371), 2013.

“Design and Synthesis of a New Class of Antibacterials with Activity Against *Mycobacteria* and Gram-Positive Bacteria”, C.M. Witzigmann, V.V. Tiruveedhula, J.M. Cook, A. Monte, W. Schwan, 245th ACS National Meeting, New Orleans LA, April 7-11, (Abst. MEDI 391), 2013.

“Design and Synthesis and SAR Studies on a New Class of Antimycobacterials”, V.V. Tiruveedhula, M. Kabir, J.M. Cook, A. Monte, W. Schwan, M. Rott, R. Polanowski, 245th ACS National Meeting, New Orleans LA, April 7-11, (Abst. MEDI 390), 2013.

“Synthesis of 2-Isopropoxy Beta Carboline; A Compound Active Against Alcohol Self-Administration in P Rats with No Effect on Sucrose Responding”, Jana Beth Plotkin, Undergraduate Research Symposium, UW-Milwaukee, Milwaukee, Spring, 2013.

“MK-801-Induced Hyperlocomotion in Rats is Affected by Modulation of α5-Containing GABA Receptors”, T. Timic, S. Joksimovic, M.M. Poe, J. Ramerstorfer, P. Biawat, T. Radulovic, B. Roth, W. Sieghart, J.M. Cook, M. Savic, 26th ECNP Congress, Barcelona, Spain, Oct. 2013.

“PWZ-029 Alleviates NMDA Receptor Antagonist-Induced Deficits in Water Maze and Object Recognition Test in the Rat: Implications for the Treatment of Cognitive Impairment in Schizophrenia”, S. Joksimovic, A. Obradovic, T. Timic, T. Radulovic, P. Biawat, J. Kovacevic, M. Milic, B. Batinic, J. Cook, M. Savic, 26th ECNP Congress, Barcelona, Spain,, Oct. 2013.

“Role of Alpha 3 GABHReceptor Modulation in the Anti-Conflict Effects of Benzodiazepine – Type Drugs in Monkeys,” Sawyer, E.; Fischer, B.; Meng, Z.; Poe, M.; Namjoshi,O.; Cook, J.; Rowlett, J., presented at The CPDD Meeting, San Diego, CA. Hilton Bayfront Hotel, June 17-21 (2013).

“Little Role for Alpha1 GABA-A, Receptor Subtypes in the Reinforcing Effects of Ethanol in Rhesus Monkeys,” Platt D. M., Moran C., Sawyer E., Sirbu M., Van Linn M., Namjoshi O., Clayton T., and Cook J.M., *Alcohol Clin Exp Res* 37:**247A**. Research Society on Alcoholism 65th Annual Meeting, Orlando, FL, 2013.

“Synthesis of Natural Products and Related Heterocyclic Compounds. Search For Agents to Treat Neuropathic Pain Epilepsy and Anxiety Disorders as well as Simple Molecules to Treat TB and MRSA Infections,” Plenary Lecture, Cook, J.; Edwankar, C.; Poe, M.; Tiruveedhula, P.; Witzigmann, C., 25th Mona Symposium on Natural Products and Medicinal Chemistry, UWI, Mona Kingston Jamaica, Jan. 5-9, 2014.

“Behavioral Effects of the Novel, Benzodiazepine Positive Modulator SH-053-2’F-S-C H in an Immune-Mediated Neurodevelopmental Disruption Model,” Richetto, J.; Labouesse, M.; Poe, M.M.; Cook, J.; Graie, A.; Riva, M.; Meyer, U, presented at the SIRS Congress (2014).

“Chiral Subtype Selective Imidazobenzodizepines Important as Potential Agents to Treat Schizophrenia,” Poe, M.; Radditz, N.; Baker, D.; Cook, J., 247th ACS National Meeting, Dallas, TX, March 16-20 (Abst.MEDI 282), 2014.

“Design and Synthesis of Novel Small Molecule Stilbenes with Activity Against Gram-Positive Bacteria and Mycobacterium,” Witzigmann, C.; Tiruveedhula, V.; Monte, A.; Schwan, W.; Cook, J.M. 247th ACS National Meeting, Dallas, TX, March 16-20 (Abst.MEDI 266), 2014.

“Design and Synthesis of Novel Antimicrobials for the Treatment of Drug Resistance Bacterial Infections, Including *M. Tuberculosis*,” Tiruveedhula, V.; Witzigmann, C.; Rott, M.; Schwan, W.; Monte, A.; Cook, J.M. 247th ACS National Meeting, Dallas, TX, March 16-20 (Abst.MEDI 263), 2014.

“Selective Pharmacologic Targeting of the GABAAα4 Submit in Airway Smooth Muscle to Alleviate Bronchospasm,” Gene T. Yocum, Ryo Wakita, Michael R. Stephen, James M. Cook, Charles W. Emala, George Gallos.

.      “Selective Pharmacologic Targeting of the GABA-A Receptor α4 Subunit in Airway Smooth Muscle to Alleviate Bronchoconstriction” Yocum, G.; Gallos, G.; Ernst, M.; Cook, J.; Emala, C. Anesthesiology 2015, San Diego, California, October 24-28, 2015.

.      “Reinforcing Effects of Ethanol are Attenuated by Alpha 5, GABA-A Receptor Inverse Agonists in Monkeys,” Ruedi-Bettschen, D.; Rallapalli, S.; Clayton, T.; Cook, J.; Platt, D.M.  38th Annual Research Society on Alcoholism Scientific Meeting, San Antonio, Texas, June 20-24, 2015.

“A Novel Trojan Horse for IN-vivo Sensitivity Testing of Medulloblastoma Therapies,” Sengupta, S.; Jones, O.; galligaris, Cook. J.; Peo, M.; Methuku, K.; Archer, T.; Francois, J.j Tranghese, F.; Pomeroy, S.; Agar, N.; Langer, R.; 19th Society of Neuro-oncology Metting, Miami, FIA, Nov. 13-16 (2014).

“Design and Synthesis of Novel β-Carbolines as a GABAA Subtype Selective Agent for the Treatment of Alcohol Abuse,” Tiruveedhula, V.; Menthuka, K.; Warnock, K.; June, H.; Cook, J.M., 248th ACS National Meeting, San Francisco, CA, August 10-14 (Abst. MEDI 0128), 2014.

“Inducing Airway Smooth Muscle Relaxation by Targeting the Restricted α-Subunit Repertoire of GABAA Receptors Using MD-45,” Stephen, M.J.; Jahan, R.; Gallos, G.; Emala, C.W.; Cook, J.M., 248th ACS National Meeting, San Francisco, CA, August 10-14 (Abst. MEDI 057), 2014.

“Stereospecific Total Synthesis of the Indole Alkaloid Ervindidine: Establishment of the C-6 Hydroxyl Stereochemistry,” Verma, R.S.; Rallapalli, S.K.; Verma, A.R.; Cook, J.M., 248th ACS National Meeting, San Francisco, CA, August 10-14 (Abst. MEDI 433), 2014.

“Effects of Hz-166, a Novel α2 and α3 Subunit-Containing GABAA Receptor Agonist, on Inflammatory Pain and Operant Behavior in Mice,” Fischer, F.; Kroll, C.; Poe, M.; Cook, J.M., Presented at The CPDD 76th Annual Scientific Meeting, June 14-19, 2014, Caribe Hiltonm, San Juan, Puerto Rico.

“Tonic Inhibition in the Central Amygdala Controls Anxiety Behavior,” Botta, P.; Kasugal, Y.; Demmou, L.; Xu, C.; Rudolph, U.; Ferraguti, F.; Luthi, A.; Poe, M.M.; Cook, J., PhD Conference in Europe, 2014.

“Examining the Effect of an α5 Subunit-Containing GABAA Receptor-Positivie Allosteric Modulator on UCMS-Induced Emotionality Behavior in the Mouse,” Meyer, U.; Poe, M.M.,; Cook, J.M.; *et al.* Presented at Conference in Europe, 2014.

“Design and Characterization of a Novel System XC-Substrate,” Raddatz, A; Neary, M.; Hjelmhaug, J.; Edwarde, M.; Mueller, C.; Xie, X.; Cook, J.; Fucks-Lokensgard, R.; Mantsch, J.; Lobner, D.; Baker, D., Presented at the Fall Meeting of The Society for Neuroscience, 2014.

“Identifying New Treatments for the Brain,” “Electrophysiological Assay and Generation of a Stable Recombinanat Cell Line,” Yuan, N.; Poe, M.; Witzigmann, C.M.; Sieghart, W.; Cook, J.M.; Arnold, A.L.; Gordon Research Conference-Ion Channels, South Hadley, MA, July 8th, 2014.

“Development of High Throughput Assays to Identify New Alpha Subtype-Selective GABA(A) Receptor Modulators to Treat Anxiety and Depression Disorders,” Yuan, N.; Cook, J.M.; Arnold, A.L.; Gordon Research Seminar- Ion Channels, South Hadley, MA, July 6th, 2014 (oral).

“The First Enantiospecific Total Synthesis of Macrosalhine Chloride and Progress Towards the Total Synthesis of Macrocarpine A, B and C,” Rahman, M.; Jahan, R.; Edwankar, R.; Deschamps, J.; Cook, J.M.; 249th ACS National Meeting, Denver, Co, March 22-26, (Abst. ORGN 164), 2015.

“Novel Strategy For the Treatment of Asthma by Targeting GABAA  Receptors in the Lung,” Jahan, R.; Stephen, M.R.; Gallos, G.; Emala, C.; Cook, J.M.; 249th ACS National Meeting, Denver, CO, March 22-26, (Abst. MEDI 101), 2015.

“Development of α6β3γ 2 Subtype Selective Ligands for GABAA Receptors,” Verma, R.; Witzigmann, C.; Cook, J.M.; 249th ACS National Meeting, Denver CO, March 22-26, (Abst. MEDI 275), 2015.

“Design and Synthesis of Novel β-Carbolines as a Potential Anti-Alcohol Agents,” Tiruveedhula, V.V.N. P. B.; Methuku, R.; Warnock, K.T.; June, H.L., Cook, J.M.; 7th Yao Yuan Biotech-Pharma Symposium, University of Illinois at Chiscago, Chicago, IL, April 18th, 2015 (2015).

“Targeting the Restricted α-Subunit Reperoire of Bz/GABAA Receptors: A Drug Strategy for Bronchoconstrictive Disorders,” Stephen, M.; Jahan, R.; Gallos, G.; Emala, C.; Ernst, M.; Sieghart, W.; Cook, J.M.; 7th Yao Yuan Biotech—Pharma Symposium, University of Illinois at Chicago, Chicago, IL, April 18, 2015 (2015).

“Behaviorial Effect of Novel Benzodiazepine Analog Methyl 8-Ethynyl-6-(pyridine-2-yl)-4H-benzo{f}imidazo{1,5-a}{1,4}diazepine-3-carboxylate (MP-III-024),” Fischer, B.D.; Hamade, B.Z.; Poe, M.M.; Cook, J.M.; Annual meeting of the American Society for Pharmacology and Experiemental Therapeutics: Boston, MA, 2015.

“Reinforcing Effect of Ethanol are Attenuated by Alpha5 GABA-A Receptor Inverse Agonists in Monkeys,” Ruedi-Bettschen, D.; Rallapalli, S., Clayton, T.; Cook, J.M.; Platt, D.M.; Presented at the RSA Meeting, 2015.

“Selective Pharmacologic Targeting of the GABA α4 Subunit in Airway Smooth Muscle to Alleviate Bronchospasm,” Yocum, G.; Wakita, R.; Stephen, M.; Cook, J.; Emala, C.; Gallos, G.; Presented at Am Thoracic Meeting, 2015.

“Evidence of Sedative Effects of Benzodiazepines Involving Unexpected GABA Receptor Subtypes,” Rowlett, J.; Duke, A.; Platt, D.; Nasjoshi, O.; Poe, M.; Tiruveedhula, P.; Cook, J.; 77th Annual Meeting of The College on Drug Dependence, June 13th-19th, Phoenix, Az; Poster Session IV, paper 5 (2015).

“Reducation of Alcohol Self-Administration by 3-ISO-PBC,” Weerts, E.; Tiruveedhula, V.; Cook, J.M.; CPPD Meeting, June 2016.

“Novel α5 Selective Benzodiazepine Site Ligands,” Rehman, S.; Puthenkalam, R.; Scholze, P.; Steudle, F.; Poe, M.; Li, G.; Cook, J.; Savic, M.; Stamenic, T.; Emala, C.; Gallos, G.; Ernst, M.; *Austrian Society of Neurosciences Metting,* Austria (2015).

“Enantiospecific Stereospecific Total Synthesis of a Series of C-19 Methyl Substituted Sapagine/Macroline Alkaloids via an Efficient Method of Copper-Mediated Enolate Driven Cross-Coupling Process,” Cook, J.M.; Rahman, Md.; 26th Mona Symposium, Mona, UWI JA Jan 3-Jan 7, 2016.

“Design and Regiospecific Synthesis of 3-Substituted β-carbolines as a GABAA Subtype Selective Agents for the Treatment of Alcohol Abuse”, V. V. N. Phani Babu Tiruveedhula, Kaitlin Warnock, Harry June, Xenia Simeone, Margot Ernst, Marjorie C. Gondre-Lewis, James M Cook. 250th ACS National Meeting, Boston, Massachusetts, August 16-20, (Abst. MEDI 433), 2015.

“Imidazobenzodiazepines for Improving α5-GABAAR Subtype Selectivity and their Pharmacological Relevance,” M.M. Poe, G. Gallos, R. Puthenkalam, M.M. Savic, C.W. Emala Sr., M. Ernst, J.M. Cook; 250th ACS National Meeting, Boston, MA, August 16-20, (Abst. MEDI 70), 2015.

“Selective Targeting of α4β3γ2 GABAA Receptors on Airway Smooth Muscle as a Novel Strategy to Treat Asthma”, Michael Rajesh Stephen, Rajwana Jahan, George Gallos, Charles W. Emala, Margot Ernst, Werner Sieghert, and James M. Cook 250th ACS National Meeting, Boston, Massachusetts, August 16-20, (Abst. MEDI 121), 2015.

“First Total-​Synthesis of Macroline Indole Alkaloids Macrocarpine A-​G via an Efficient, Enolate-​Driven, Copper-​Mediated Cross-​Coupling Process” M. Toufiqur Rahman; Jeffrey R. Deschamps; James M. Cook. ACS Milwaukee Meeting, Carroll University, WI, March 31, 2016.

“Novel Strategy for The Treatment of Asthma by Targeting the α4 Subunit of GABAA Receptors in Airway Smooth Muscle”. Rajwana Jahan, Michael Stephen, Gene T. Yocum, George Gallos, Yi Zhang, Revathi Kodali, Zdravko Varagic, Roshan Puthenkalam, Margot Ernst, Leggy A. Arnold, Douglas Stafford, Charles Emala, James M. Cook. ACS Milwaukee Meeting, Carroll University, WI, March 31, 2016.

“Novel Strategy for The Treatment of Asthma by Targeting the α4 Subunit of GABAA Receptors in Airway Smooth Muscle”. Rajwana Jahan, Michael Stephen, Gene T. Yocum, George Gallos, Yi Zhang, Revathi Kodali, Zdravko Varagic, Roshan Puthenkalam, Margot Ernst, Leggy A. Arnold, Douglas Stafford, Charles Emala, James M. Cook. The 8th Yao Yuan Biotech-Pharma Symposium, Chicago, IL, April 23rd (Poster # 7), 2016. [Poster and Talk]

“Synthesis of Novel β-carbolines as a GABAA Subtype Selective Agents for the Treatment of Alcohol Abuse. Regiospecific Solution to the Problem of 3,6-Disubstituted β- and Aza-β-carboline Specificity”, V. V. N. Phani Babu Tiruveedhula, Kaitlin Warnock, Harry June, Xenia Simeone, Margot Ernst, Marjorie C. Gondre-Lewis, James M. Cook. The 8th Yao Yuan Biotech-Pharma Symposium, Chicago, IL, April 23rd (Poster # 10), 2016.

“Synthesis of Novel β-carbolines as a GABAA Subtype Selective Agents for the Treatment of Alcohol Abuse. Regiospecific Solution to the Problem of 3,6-Disubstituted β- and Aza-β-carboline Specificity”, V. V. N. Phani Babu Tiruveedhula, Kaitlin Warnock, Harry June, Xenia Simeone, Margot Ernst, Marjorie C. Gondre-Lewis, James M. Cook. 251st ACS National Meeting & Exposition, San Diego, CA, March 13-17, (Abst. MEDI 111), 2016.

“First Total-​Synthesis of Macroline Indole Alkaloids Macrocarpine A-​G via an Efficient, Enolate-​Driven, Copper-​mediated Cross-​coupling Process” M. Toufiqur Rahman; Jeffrey R. Deschamps; James M. Cook. 251st ACS National Meeting, San Diego, CA, March 13-17, (Abst. ORGN 206), 2016.

“Search for Water Soluble α-​6 Bz​/GABA(A) Receptor Subtype Selective Ligands in Order to Determine Their in *vivo* Activity” Ranjit S. Verma, Daniel Knutson, Christopher M. Witzigmann, Matheus A. Meirelles Margot Ernst , Werner Sieghartand James M. Cook. 251st ACS National Meeting, San Diego, CA, March 13-17, (Abst. ORGN 320), 2016.

"Potential Novel Targets for Schizophrenia: Stereospecific GABAA Receptor Subtype Selective Imidazobenzodiazepines" Guanguan Li; Michael M. Poe; Nicholas J. Raddatz; David A. Baker; Margot Ernst; James M. Cook. 251st ACS National Meeting, San Diego, CA, March 13-17, (Abst. MEDI 325), 2016.

"Stereospecific Total Synthesis of Macroline-Related Oxindoles: Macrogentine and Alstonoxine" G.O. Fonseca; M. Ahmed Khan; J. Deschamps; J.M. Cook. 251st ACS National Meeting, San Diego, CA, March 13-17, (Abst. ORGN 226), 2016.

“Novel Strategy for The Treatment of Asthma by Targeting the α4 Subunit of GABAA Receptors in Airway Smooth Muscle”. Rajwana Jahan, Michael Stephen, Gene T. Yocum, George Gallos, Yi Zhang, Revathi Kodali, Zdravko Varagic, Roshan Puthenkalam, Margot Ernst, Leggy A. Arnold, Douglas Stafford, Charles Emala, James M. Cook. 251st ACS National Meeting, San Diego, CA, March 13-17, (Abst. MEDI 167), 2016.

“Benzodiazepine- GABAA α1 Antagonist 3-Iso-PBC Selectively Reduce alcohol Self- Administration”, E. M. Weerts; A. F. Holtyn; VVNPB Tiruveedhula and J. M. Cook presented at The ISBRA ESBRA joint meeting in Europe, Sept. 2-5 (2016).

“Different Benzodiazepines Seen to Interact Differently with GABAA Receptors”, P. Scholze; A. Elgarf; F. Steudle; G. Li; J.M. Cook; M. Ernst,; Society for Neuroscience (2016).

“Effects of Ro5-4864 on Methamphetamine Self- Administration in Male and Female Rats”, G. Guerin; S. Harold; S. Porter; C. Schmoutz; J.M. Cook; G. Li; N. Goeders; Society for Neuroscience (2016).

“Targeting The Immune System with Subtype- Selective GABAA Receptor Modulators to Alleviate Symptoms”, A. Neiman; G. Forkuo; M. Guthrie; N. Yuan; O.B. Yu; R. Kodali; R. Jahan; M.R. Stephen; M.M. Poe; B. Hartzler; C. W. Emala; J.M. Cook; D.C. Stafford; L. A. Arnold; AAI Annual Meeting, 2016.

“Pharmacodynamics and Pharmacokinetics of Novel GABAA α4 Subunit Selective Ligands that Treat Bronchoconstriction”, G. Yocum; Y. Zhang; G. Furkuo; M. Guthrie; A. Youmans; R. Jahan; M. Stephen; D.C Stafford; James Cook; Alexander Arnold and Charles Emala; American Respiratory Society Meeting (2016).

“Ataining in *vivo* Selectivity of Positive Modulation of α3 GABAA Receptors in Rats: A Hard Task”, Batinic B.; Stankovio, T.; Poe, M.M.; Cook, J. M.; Savic, M.M.; *European Society* For Neuroscience (2016).

“Behavioral Effects of Novel GABAA Receptors Positive Allosteric Modulator in Rats”, Lakeisha, Lewter; J.M. Cook; Jun-Xu Li; BBC Meeting, April 4-6, 2016, San Antonio, Texas.

“Reduction of Alcohol Self-administration by 3-Iso-PBC”, E. Weerts, V.V.N.P.B. Tiruveeddhulaad, J.M. Cook, CPDD 78th Annual Meeting La Quinta Resort and Club, Palm Springs, CA, June 11-16, 2016.

“Novel α5 Selective Benzodiazepine Site ligands”, S. Rehman, R. Puthenkalam, P. Scholze, F. Steudle, M. Poe, G. Li, J.M. Cook, M. Savic, T. Stamenic, C. Emala, G. Gallos, M. Ernst, Medical Neuroscience Cluster, IG Neuropsychopharmacology (2016).

“A Novel GABA(A) Receptor α5 Subunit Selective Allosteric Modulator That Does Not Cross The Blood Brain Barrier Relaxes Airway Smooth Muscle Contracted with Diverse Ligands”, G. Yocum, P. Yim, Y. Zhang, J. Perez-Zoghbi, A. Arnold, J. Cook and C. Emala, American Thoracic Society (2017).

“First Total Synthesis of Macroline Indole Alkaloids Macrocarpine A-G via an Efficient, Enolate-Driven Copper- Mediated Cross-Coupling Process”, M. Toufiqur Rahman, Jeffrey R. Deschamps, James M. Cook; ACS Milwaukee Meeting, Carrol University, WI, March 31, 2016.

“Novel Strategy for The Treatment of Asthma by Targeting the α4 Subunit of GABAA Receptors in Airway Smooth Muscle”. Rajwana Jahan, Michael Stephen, Gene T. Yocum, George Gallos, Yi Zhang, Revathi Kodali, Zdravko Varagic, Roshan Puthenkalam, Margot Ernst, Leggy A. Arnold, Douglas Stafford, Charles Emala, James M. Cook; ACS Milwaukee Meeting, Carrol University, WI, March 31, 2016.

“Novel GABAAR Agonists Under the Preclinical Development for the Treatment of Asthma” Rajesh, S. M., Jahan, R., Yocum, G. T., Zhang, Y., Varagic, Z., Puthenkulam, R., Gallos, G., Emala, C. W., Margot Ernst, Arnold, L. A., Stafford, D., and Cook. J. M. 5th Annual International Chemical Biology Society Conference, Madison WI, October 24-26, (Abst. 24), 2016.

“Novel Strategy for The Treatment of Asthma by Targeting the α4 Subunit of GABA(A) Receptors in Airway Smooth Muscle” Rajwana Jahan, Michael Stephen, Gene T. Yocum, George Gallos, Yi Zhang, Revathi Kodali, Zdravko Varagic, Roshan Puthenkalam, Margot Ernst, Leggy A. Arnold, Douglas Stafford, Charles Emala, James M. Cook. 5th Annual International Chemical Biology Society Conference, Madison WI, October 24-26, (Abst. 25), 2016.

"Enantiospecific, Stereospecific Total Synthesis of a Series of C-19 Methyl Substituted Sarpagine/Macroline Indole Alkaloids via an Efficient Method of Copper-Mediated Enolate-Driven Cross-Coupling Process" Rahman, M.T, Deschamps, J.R., Cook, J.M. 5th Annual International Chemical Biology Society (ICBS) Conference, Madison, WI, October 24-26, (Abst. 108), 2016.

“The Search for Selective and Water Soluble α6 Bz/GABA(A) Receptor Subtype Selective Ligands in Order to Determine their in vivo Activity” Ranjit Verma, Daniel Knutson, Christopher Witzigmann, James Cook, L.C. Chiou, Margot Ernst. 5th Annual International Chemical Biology Society (ICBS) Conference, Madison, WI, October 24-26, (Abst. 36), 2016.

"Synthesis of Nonsedating and Selective α2- or α3-GABAAR Agonists as Potential Novel Anxiolytics against Neuropathic Pain" Guanguan Li, Kashi R. Methuku, Michael M. Poe, Jeffrey M. Witkin, Jeffrey M. Schkeryantz, James M. Cook. 5th Annual International Chemical Biology Society Conference, Madison WI, October 24-26, (Abst. 121), 2016.

“Novel Deuterated GABAAR-α6 Subtype Selective Ligands with Improved Metabolic Stability. Targeting Trigeminal Orofacial Pain, Neuropsychiatric Disorders, & Depression” Knutson, D. E., Verma, R. S., Stephen, M. R., Kodali, R., Arnold, L. A., Cook, J. M., Mihovilovic, M. D., Wimmer, L., Ernst, M., Sieghart, W. 5th Annual International Chemical Biology Society Conference, Madison WI, October 24-26, (Abst. 36), 2016.

“Alpha5 GABAA Receptors, a Potential Therapeutic Target for the Treatment of Alcohol Related Disorders: Evidence from Rodent Studies” Chandler, C.; Reeves-Darby. J.; Jones, S.; Rahman, M.; Li, G.; Cook, J.; Platt, D. M, 40th Annual RSA Scientific Meeting, Denver, CO, (Poster No. 068, Abst. No. 397), June 2017.

“General strategy for the total synthesis of C-19 methyl substituted sarpagine/macroline indole alkaloids including macrocarpines A-G, peraksine, and dihydroperaksine” Rahman, M. T.; Deschamps, J.R.; Cook, J.M, Oral Presentation (ORGN 654), 253rd ACS National Meeting, San Francisco, CA, April 2017.

“General Strategy for the Total Synthesis of C-19 Methyl Substituted Sarpagine/Macroline Indole Alkaloids” Rahman, M. T.; Deschamps, J. R.; Cook, J. M., 34th H. C. Brown Lectures in Organic Chemistry, Department of Chemistry, Purdue University,

(Poster # 50), April 2017.

“Pro-cognitive and neurotrophic effects of a novel molecule enhancing α5-GABA-A receptor function in adult or aged mice”, Sibille, E.; Cook, J.; Li, G.; Knutson, D.E; Mian, Y.; Mondal, P.; David, D.J.; Mendez-David, I.; Guilloux, J-P.; Prevot, T.D., ACNP, Orllando, Dec 2019.

F. **Invited Lectures Presented at Universities, Industry, etc.**

Carthage College, "Hallucinogenic Principles Employed by Yanomamo Indians of South America," 1973.

Carroll College, "Hallucinogenic Principles Employed by Yanomamo Indians of South America," Fall, 1973.

Ripon College, "Synthesis of Antihypertensive Agents," 1974.

Lakeland College, "Electrophilic‑Nucleophilic Additions to Indole Double Bonds," 1974.

Lewis University, "The Use of N‑Oxides in the Biomimetic Synthesis of Indole Alkaloids," 1974.

Calvin College, "Synthesis of Antihypertensive Agents," 1975.

National Institutes of Health, *Alstonia* Alkaloids: Structures, Synthesis and Relation to Antihypertensive Agents," 1975.

St. Norberts College, "Isolation and Use of Psychoactive Drugs by the Yanomamo Indians of South America," 1976.

University of Wisconsin‑Eau Claire, "The Synthesis of Cyclopentanoid Compounds," 1976.

University of Wisconsin‑Parkside, "Isolation and Use of Psychoactive Drugs by the Yanomamo Indians of South America," 1976.

Western Illinois University, "Synthetic and Stereochemical Studies of Disubstituted‑ 1,2,3,4‑ tetrahydro‑ß‑Carbolines on the Road to Potential Antihypertensive Agents." National Institutes of Health, Bethesda, Maryland, planery lecture at the Symposium of Bioorganic and Synthetic Chemistry entitled, "Reactions of Dimethyl ß‑Ketoglutarate and Diketones," in honor of Ulrich Weiss, April 10, 1978.

Northeastern University, "Synthetic and Stereochemical Studies in the ß‑Carboline Area," July 21, 1978.

University of Wisconsin‑River Falls, "Isolation and Use of Psychoactive Drugs by the Yanomamo Indians of South America," September 27, 1978.

University of Wisconsin‑Stevens Point, "Isolation and Use of Psychoactive Drugs by the Yanomamo Indians of South America," September 29, 1978.

Marquette University, "General Method for the Synthesis of Cyclopentanoid Compounds," Spring, 1979.

Unversity of Louisville, "General Method for the Synthesis of Cyclo‑pentanoid Compounds," Spring, 1979.

Northern Illinois University, "Progress Toward the Synthesis of Staurane and Modhephene," Fall, 1979.

Winona State University, Minnesota, "General Approach toward the Synthesis of C Cyclopentanoid Compounds: Studies Directed Toward Synthesis of Staurane and Modhephene," Fall, 1979.

University of Michigan, "General Approach for the Synthesis of Polyquinanes," Fall, 1980.

University of Wisconsin‑Eau Claire, "General Approach for the Synthesis of Polyquinanes," Fall, 1980.

Hope College, "Synthesis of Polyquinanes," Spring, 1980.

Calvin College, "General Approach for the Synthesis of Polyquinanes," Spring, 1980.

University of Wisconsin‑Eau Claire, "Synthesis of ß‑Carbolines: Search for Valium Angonists and Antagonists," Fall, 1981.

University of Wisconsin‑Oshkosh, "Synthesis of ß‑Carbolines: Search for Valium Angonists and Antagonists," Fall, 1981.

Winona State University, "Synthesis of ß‑Carbolines: Search for Valium Angonists and Antagonists," Fall, 1981.

Vanderbilt University, "General Approach for the Synthesis of Polyquinanes," Summer, 1981.

Illinois State University, "Synthesis of ß‑Carbolines: Search for Valium Agonists and Antagonists," Fall, 1981.

Searle Laboratories, "Synthesis of ß‑Carbolines: Search for Valium Agonists and Antagonists," Spring, 1982.

University of Illinois at the Medical Center, Department of Medicinal Chemistry, "Synthesis of ß‑Carbolines: Search for Valium Agonists and Antagonists," Spring, 1982.

University of Alberta, Canada, "Synthesis of ß‑Carbolines: Search for Valium Agonists and Antagonists," Fall, 1982.

University of Wisconsin‑River Falls, "Synthesis of ß‑Carbolines: Search for Valium Agonists and Antagonists," Fall, 1982.

Hope College, "General Approach for the Synthesis of Polyquinanes. Synthesis of Modhephene and Triquinacene," Fall, 1982.

Michael Reese Hospital, Department of Anesthesiology, "Synthesis of ß‑Carbolines: Search for Valium Agonists and Antagonists," Spring, 1983.

University of Minnesota, "General Approach for the Synthesis of Polyquinanes," Spring, 1983.

Elmhurst College, "ß‑Carbolines: Search for Valium Agonists and Antagonists," Spring, 1984.

University of Chicago, "General Approach for the Synthesis of Polyquinanes," Spring, 1984.

University of Wisconsin‑River Falls, "ß‑Carbolines: Search for Valium Agonists and Antagonists," Fall, 1983.

Winona State University, "General Approach for the Synthesis of Polyquinenes," Fall, 1985.

College of St. Catherines, "ß‑Carbolines: Search for New Valium Agonists and Antagonists," Fall, 1985.

National Science Foundation Workship on Organic Synthesis, "General Approach Toward the Synthesis of Polyquinenes," Pingree Park, Colorado, Summer, 1985.

Illinois State University, "ß‑Carbolines: Search for New Valium Agonists and Antagonists," Spring, 1986.

Eastern Illinois University, "ß‑Carbolines: Search for New Valium Agonists and Antagonists," Spring, 1986.

University of Wisconsin‑Eau Claire, "ß‑Carbolines: Search for New Valium Agonists and Antagonists," Spring, 1986.

Ball State University, "ß‑Carbolines: Search for New Valium Agonists and Antagonists,"Spring, 1986.

Incell Chemical Co., "ß‑Carbolines: Search for New Valium Agonists and Antagonists,"Spring, 1986.

University of Wisconsin‑Madison, "General Approach for the Synthesis of Polyquinenes," Spring, 1986.

Wayne State University, "General Approach for the Synthesis of Polyquinenes," Fall, 1986.

University of Wisconsin‑Stevens Point, "ß‑Carbolines: Search for Valium Agonists and Antagonists," Fall, 1986.

Uniformed Services University, Bethesda, MD, "ß‑Carbolines: Search for Valium Agonists and Antagonists," Fall, 1986.

College of St. Catherines, "ß‑Carbolines: Search for New Valium Agonists and Antagonists," Fall, 1985.

Iowa State University, "General Approach for the Synthesis of Polyquinenes," Spring, 1987.

Searle Laboratories, "ß‑Carbolines: Search for Valium Agonists and Antagonists," 1987.

Muskingam College, "Indole Alkaloids: Synthesis of Macroline‑Related Alkaloids and Search for the Pharmacophore for the Benzodiazepine Inverse Agonist Site," Fall, 1987.

Eli Lilly & Co., "ß‑Carbolines: Search for New Valium Agonists and Antagonists," Fall, 1987.

University of Louisville, "Indole Alkaloids: Synthesis of Macroline‑Related Alkaloids and Search for the Pharmacophore for the Benzodiazepine Inverse Agonist Site," Spring, 1988.

University of Kentucky, "Indole Alkaloids: Synthesis of Macroline‑Related Alkaloids and Search for the Pharmacophore for the Benzodiazepine Inverse Agonist Site," Spring, 1988.

Kansas State University, "Indole Alkaloids: Synthesis of Macroline‑Related Alkaloids and Search for the Pharmacophore for the Benzodiazepine Inverse Agonist Site," Spring, 1988.

Utah State University, "Synthesis of Biologically Active Indole Alkaloids," Spring, 1988.

University of Utah, "General Approach to the Synthesis of Polyquinenes," Spring, 1988.

Warner‑Lambert‑Parke Davis, "Pictet‑Spengler Reactions in Aprotic Media. Stereospecific Approach to Macroline‑Related Alkaloids," Fall, 1988.

UW‑Stevens Point, "Pictet‑Spengler Reactions in Aprotic Media. Stereospecific Approach to Macroline‑Related Alkaloids," Fall, 1988.

UW‑Eau Claire, "Pictet‑Spengler Reactions in Aprotic Media. Stereospecific Approach to Macroline‑Related Alkaloids," Fall, 1988.

St. Olafs, "Pictet‑Spengler Reactions in Aprotic Media. Stereospecific Approach to Macroline‑Related Alkaloids," Fall, 1988.

Ohio State University, "Pictet‑Spengler Reactions in Aprotic Media. Stereospecific Approach to Macroline‑Related Alkaloids," Spring, 1989.

UW‑River Falls, "Pictet‑Spengler Reactions in Aprotic Media. Stereospecific Approach to Macroline‑Related Alkaloids," Fall, 1988.

Ripon College, "Pictet‑Spengler Reactions in Aprotic Media, Synthesis of Biologically Active Alkaloids," Fall, 1989.

Michigan Technological University, "Pictet‑Spengler Reactions in Aprotic Media, Synthesis of Biologically Active Alkaloids," Fall, 1989.

St. Norbert College, "Pictet‑Spengler Reactions in Aprotic Media, Synthesis of Biologically Active Alkaloids," Fall, 1989.

Marquette University, "Pictet‑Spengler Reactions in Aprotic Media, Synthesis of Biologically Active Alkaloids," Fall, 1989.

Calvin College, "Pictet‑Spengler Reactions in Aprotic Media, Synthesis of Biologically Active Alkaloids," Fall, 1989.

Hope College,"Pictet‑Spengler Reactions in Aprotic Media, Synthesis of Biologically Active Alkaloids," Fall, 1989.

ACS Milwaukee Section Award Address, "New Drugs for the Age of Anxiety. Rigid Probes to Study Benzodiazepine (Valium) Receptors," Fall, 1989.

Benedictine College, "Pictet‑Spengler Reactions in Aprotic Media, Synthesis of Biologically Active Alkaloids," Spring, 1990.

North Dakota State University, "Stereospecific Synthesis of Macroline‑Related Indole Alkaloids," Spring, 1990.

University of North Dakota, "Stereospecific Synthesis of Macroline‑Related Indole Alkaloids," Spring, 1990.

Clemson University, "The Structure, Topology and Function of the Benzodiazepine (Valium) Receptor," Fall, 1990.

Loyola of Chicago, "The Structure, Topology and Function of the Benzodiazepine (Valium) Receptor," Fall, 1990.

Illinois State University, "The Structure, Topology and Function of the Benzodiazepine (Valium) Receptor," Fall, 1990.

UW‑Oshkosh, "Rigid Probes to Study the Structure, Function and Topology of the Benzodiazepine Receptor. The Synthesis of an Anxioselective Anxiolytic," Spring, 1991.

Kent State University, "General Approach for the Synthesis of Polyquinenes *via* the Weiss Reaction," Spring, 1991.

Searle Research Laboratories, Skokie, Illinois, "Novel Strategies for the Synthesis of Ring‑A Methoxylated Indole Alkaloids," June 6, 1991.

ACS Meeting, Rockriver Section, Rockford, Illinois, "Probes to Study the Structure and Function of the Benzodiazepine (Valium) Receptor. The Synthesis of a New Selective Anxiolytic/Anticonvulsant," September 25, 1991.

Abbott Laboratories, Chicago, Illinois, "Studies on the Pictet‑Spengler Reaction. Strategies for the Synthesis of Ring‑A Methoxylated Indole Alkaloids," January, 1992.

Abbott Laboratories, Chicago, Illinois, "The Age of Anxiety: Probes to Study the Structure and Function of the Benzodiazepine (Valium) Receptor and Its Influence on Everyday Living," January, 1992.

Medical College of Wisconsin, Department of Pharmacology, Milwaukee, WI, "Molecular Yardsticks: Rigid Probes With Which to Study the Structure and Function of the Benzodiazepine Receptor Site," Spring, 1992.

Boston University, Boston, Massachusetts, "Studies on the Pictet‑Spengler Reaction. New Strategies for the Synthesis of Ring‑A Methoxylated Indole Alkaloids," Spring, 1992.

Northeastern University, Boston, Massachusetts, "Studies on the Pictet‑Spengler Reaction. New Strategies for the Synthesis of Ring‑A Methoxylated Indole Alkaloids," Spring, 1992.

University of Illinois‑Chicago, "Studies on the Pictet‑Spengler Reaction. New Stratgies for the Synthesis of Ring‑A Methoxylated Indole Alkaloids," Spring, 1992.

University of South Dakota, "Molecular Yardsticks. Rigid Probes With Which to Study the Structure and Function of the Benzodiazepine Receptor, Spring, 1992.

Anaquest, "Studies on the Pictet‑Spengler Reaction. New Strategies for the Synthesis of Ring‑A Methoxylated Indole Alkaloids," Fall, 1992.

North Carolina State, "Studies on the Pictet‑Spengler Reaction. New Strategies for the Synthesis of Ring‑A Methoxylated Indole Alkaloids," Fall, 1992.

University of Missouri at Columbia, "Synthetic Organic Chemistry and Drug Design," Spring, 1993.

R.W. Johnson Pharmaceutical Research, "The Inclusive Pharmacophore of Benzodiazepine Receptor Sites," Fall, 1993.

Indiana University‑Purdue University at Indianapolis, "Enantiospecific Synthesis of Macroline/Sarpagine/Ajmaline Alkaloids, Fall, 1993.

Promega Corporation, "Computer and Chemical Assisted Development of the Inclusive Pharmacophore of Benzodiazepine Receptors," Spring, 1994.

R.W. Johnson Pharmaceutical Research, "Recent Advances in GABAA Receptor Subtype Modeling," Fall, 1994.

National Institutes of Health, "Enantiospecific Synthesis of Macroline/Sarpagine/Ajmaline Alkaloids," Fall, 1994.

National Institutes of Health, "The Inclusive Pharmacophore of Benzodiazepine Receptors and its Relationship to Subsite Selectivity," Fall, 1994.

Xavier University of Louisiana, "Recent Advances in GABAA/Benzodiazepine Receptor Subtype Selectivity," Spring, 1995.

Memorial Sloan-Kettering Cancer Center, "Enantiospecific Synthesis of Macroline/ Sarpagine/Ajmaline Alkaloids," Spring, 1995.

Abbott Laboratories, "Enantiospecific Synthesis of Macroline-Related Sarpagine and Ajmaline Indole Alkaloids," Fall, 1995.

University of Wisconsin-Eau Claire, "Enantiospecific Synthesis of Macroline-Related Antimalarial and Antiamoebic Bisindole Alkaloids," Fall, 1995.

University of Chicago, "Enantiospecific Synthesis of Macroline, Sarpagine and Ajmaline Alkaloids. Biomimetic Approach to Bisindoles," Fall, 1995.

Augsburg College, "Synthesis of ß-Carbolines as Valium Agonists and Antagonists," Fall, 1995.

University of Wisconsin-River Falls, Enantiospecific Synthesis of Macroline-Related Antimalarial and Antiamoebic Bisindole Alkaloids, Spring, 1996.

Northwestern University, “Enantiospecific Synthesis of (+) Ajmaline and Tryptostatin A.”, Spring 1997.

Northwestern University, “Search for Subtype Specific Ligands for BzR Subtypes”, Spring, 1997.

Merck, “Enantiospecific Synthesis of Ajmaline, Alkaloid G, Talpinine and Talcarpine via the Asymmetric Pictet-Spengler Reaction,” Fall, 1997.

Schering-Plough, “Enantiospecific Synthesis of Ajmaline, Alkaloid G, Talpinine and Talcarpine via the Asymmetric Pictet-Spengler Reaction,” Fall, 1997.

Parke-Davis, “Enantiospecific Synthesis of Ajmaline, Alkaloid G, Talpinine and Talcarpine via the Asymmetric Pictet-Spengler Reaction,” Fall, 1997.

International Conference Hall, “Construction of Pharmacophore Receptor Models for GABAA/ Benzodiazepine Receptor Subtypes,” Annual Meeting of the Pharmaceutical Society of Japan, Kyoto, JAPAN, April 1, 1998.

Taiho Pharmaecutical Co, “Construction of Pharmacophore Receptor Models for GABAA/ Benzodiazepine Receptor Subtypes,” JAPAN, April 3, 1998.

Eisai Pharmaceutical Co., “Enantiospecific Total Synthesis of Sarpagine/Ajmaline Alkaloids via the Asymmetric Pictet-Spengler Reaction,” JAPAN, April 6, 1998.

Hokkaido University, “Enantiospecific Total Synthesis of Sarpagine/Ajmaline Alkaloids via the Asymmetric Pictet-Spengler Reaction,” Sapporo, JAPAN, April 7, 1998.

FUJI Film Co, “Construction of Pharmacophore Receptor Models for GABAA/Benzodiazepine Receptor Subtypes,” JAPAN, April 10, 1998.

University of Louisville, “Synthesis of Agents and Antianxiety Agents in Enantiospecific Fashion,” April 28, 1998.

Gordon Conference, Regina Salve University, Rhode Island, “Enantiospecific Synthesis of Sarpagine/Ajmaline Alkaloids *via* the Asymmetric Pictet-Spengler Reaction,” July 2, 1998.

Eli Lilly and Company, Indianapolis, Indiana, “Enantiospecific Synthesis of Sarpagine/ Ajmaline/Macroline Alkaloids via the Asymmetric Pictet-Spengler Reaction,” March, 1999.

University of Illinois at Chicago, “Enantiospecific Synthesis of Ajmaline, Sarpagine Indole Alkaloids,” May, 1999.

The 48th Gordon Research Conference on Natural Products, New England College, Rhode Island, “General Approach for the Synthesis of Sarpagine/Ajmaline Alkaloids, July, 1999.

Sepracor, Marlborough, MA, “Synthesis of Indoles, Tryptophans and Tryprostatins,” October, 1999.

Harvard Medical School, New England Regional Primate Center, Sudbury, MA, “The Search for Subtype Selective Ligands for Bz/GABAA Receptors and Effect on Alcohol Self-Administration,” October 1999.

Karolinska Institutet, Stockholm, Sweden, General Approach to the Synthesis of Macroline/ Sarpagine/Ajmaline Indoles Alkaloids,” October 1999.

Karolinska Institutet and Royal Institute of Chemistry, Novum Lecture, “Search for Benzodiazepine/GABA(A) Subtype Selective Ligands and Implications in Alcohol Self- Administration,” October, 1999.

Research Triangle Institute, Research Triangle Park, NC, “Enantiospecific synthesis of Indoles, Tryptophans and Tryprostatins,” November, 1999.

Rhône-Poulenc, Research Triangle Park, NC, “Enantiospecific Synthesis of Indoles, Tryptophans and Tryprostatins,” November, 1999.

University of Minnesota, Medicinal Chemistry and Pharmacy, Minneapolis, MN, “Search for Benzodiazepine/GABA Subtype Selective Ligands and Implications in Alcohol Self-Administration,” November, 1999.

University of Wisconsin-Milwaukee, Department of Psychology and Society for Neuroscience, “Search for Benzodiazepine/ GABA Subtype Selective Ligands and Implications in Alcohol Self-Administration,” December, 1999.

Indiana University-Purdue University at Indianapolis,”Search for Benzodiazepine/GABA Subtype Selective Ligands,” April, 2000.

Pfizer Pharmaceutical Co., “General Approach to the Synthesis of Indole Alkaloids. Enantiospecific Synthesis of Ajmaline, Vellosimine, Norsuaveoline and Geissochizine,” April, 2000.

R.W. Johnson Pharmaceuticals, “Enantiospecific Total Synthesis of Sarpagine, Ajmaline and Corynanthe Indole Alkaloids,” February, 2001.

Pfizer Global Research and Development, “Enantiospecific Synthesis of Sarpagine, Ajmaline and Corynanthe Indole Alkaloids *via* the Asymmetric Pictet-Spengler Reaction,” July, 2001.

Dupont Pharmaceuticals, “Enantiospecific Synthesis of Sarpagine, Ajmaline and Corynanthe Indole Alkaloids *via* the Asymmetirc Pictet-Spengler Reaction,” July, 2001.

Wyeth-Ayerst Pharmaceuticals, “General Approach for the Synthesis of Sarpagine, Ajmaline and Corynanthe Alkaloids *via* the Asymmetric Pictet-Spengler Reaction,” October, 2001.

Waseda University, “Enantioselective Synthesis of Sarpagine, Ajmaline and Corynanthe Alkaloids *via* the Asymmetric Pictet-Spengler Reaction,” November, 2001.

The University of Tokyo, “Studies on the Synthesis of Antimalarial Bisindole Alkaloids,” November, 2001.

Tokyo Institute of Technology, “The Pictet-Spengler Reaction in Milwaukee,” November, 2001.

Science University of Tokyo, “The Synthesis of Polyquinenes *via* the Weiss and Tandem Pauson-Khand Reactions,” November, 2001.

Institute for Physical Chemistry Research (RIKEN), “Search for Benzodiazepine/GABA(A) Subtype Selective Ligands that ReverseAlcohol Self-Administration,” November, 2001.

Hokkaido University, “Enantioselective Synthesis of Sarpagine, Ajmaline and Corynanthe Alkaloids *via* the Asymmetric Pictet-Spengler Reaction, November, 2001.

Tohoku University, “Enantioselective Synthesis of Sarpagine, Ajmaline and Corynanthe Alkaloids *via* the Asymmetric Pictet-Spengler Reaction,” November 2001.

Nagoya University, “Studies on the Synthesis of Antimalarial Bisindole Alkaloids,” November, 2001.

Kyushu University, “Enantioselective Synthesis of Sarpagine, Ajmaline and Corynanthe Alkaloids *via* the Asymmetric Pictet-Spengler Reaction,” November, 2001.

Okayama University, “Studies on the Synthesis of Antimalarial Bisindole Alkaloids,” November, 2001.

Tokushima Bunri University, “Enantioselective Synthesis of Sarpagine, Ajmaline and Corynanthe Alkaloids *via* the Asymmetric Pictet-Spengler Reaction,” November, 2001.

Osaka University, “Enantioselective Synthesis of Sarpagine, Ajmaline and Corynanthe Alkaloids *via* the Asymmetric Pictet-Spengler Reaction,” November, 2001.

Sankyo Company Limited, “Enantioselective Synthesis of Sarpagine, Ajmaline and Corynanthe Alkaloids *via* the Asymmetric Pictet-Spengler Reaction,” December, 2001.

University of Tokyo, “Enantioselective Synthesis of Sarpagine, Ajmaline and Corynanthe Alkaloids *via* the Asymmetric Pictet-Spengler Reaction,” December, 2001.

Ligand Pharmaceutical, “General Approach to the Synthesis of Indole Alkaloids *via* the Asymmetric Pictet-Spengler Reaction,” April, 2002.

UCB Pharmaceutical Co., Boston, MA, “General Approach to the Synthesis of Indole Alkaloids *via* the Asymmetric Pictet-Spengler Reaction,” August 2002.

Roche Biosci Inc., Palo Alto, CA, “General Approach for the Synthesis of Indole Alkaloids *via* the Asymmetric Pictet-Spengler Reaction,” January 2003.

Wayne State University, “Synthesis of Antimalarial Bisindole Alkaloids *via* the Asymmetric Pictet Spengler Reaction,” April 2003.

Eli Lilly & Co., “General Approach for the Synthesis of Macroline, Sarpagine and Ajmaline Indole Alkaloids,” Summer 2003.

Sepracore, “Search for Subtype Selective Ligands that Reverse Alcohol Self-Administration,” Fall 2003.

UW Stevens Point, “Serendipity Rediscovered: An oxymoron or Rational Drug Design?” Spring, 2005.

Olivet Nazarene University, “The Synthesis of Antimalarial Alkaloids *via* the Asymmetric Pictet-Spengler Reation,” Spring, 2005.

Virginia Commonwealth University, “Serendipity Rediscovered: An Oxymoron or Rational Drug Design?” Spring 2005.

Abbott Laboratories, “General Approach to the Synthesis of Ring-A Alkoxy Substituted Indole Alkaloids via the Asymmetric Pictet-Spengler Reaction,” Fall, 2005.

Clemson University, “Serendipity Rediscovered: An Oxymoron or Rational Drug Design?” Fall, 2005.

Bristol Meyers Squibb, “Serendipity Rediscovered: An Oxymoron or Rational Drug Design? Development of Orally Active, Nonsedating Anxiolytics,” Fall, 2005.

Sepracor, “Serendipity Rediscovered: An Oxymoron or Rational Drug Design? Search for Subtype Selective Ligands,” Fall, 2005.

Brandeis University, “General Approach to the Synthesis of Ring-A Alkoxy Substituted Indole Alkaloids via the Asymmetric Pictet-Spengler Reaction,” Spring, 2006.

WiSys (UW-System), “Serendipity Rediscovered: An Oxymoron or Rational Drug Design,” Spring, 2006.

North Carolina State University, “General Approach to the Synthesis of Ring-A Alkoxy Substituted Indole Alkaloids,” Spring, 2006.

55th Natural Products Gordon Research Conference, “General Approach to the Synthesis of Ring-A Alkoxy Substituted Indole Alkaloids via the Asymmetric Pictet-Spengler Reaction (**Plenary Lecture**),” Tilton, NH, July 23-28, 2006.

Biofine/Sci Update Meeting, “Palladium and Copper-Mediated Strategies for the Asymmetric Synthesis of Antimalarial, Antileishmanial and Antimicrobial Agents, New Directions in Chemical Process Design,” Sanibel Island, Florida, December 2,3 (2008). (**Plenary Lecture**.)

Illinois State University, “Palladium and Copper-Mediated Strategies for the Asymmetric Synthesis of Antimalarial, Antileishmanial and Antimicrobial Agents,” Bloomington-Normal, IL, November (2008).

RTI, “Palladium and Copper-Mediated Strategies for the Asymmetric Synthesis of Antimalarial, Antileishmanial and Antimicrobial Agents,” Raleigh-Durham, NC, October (2008).

Mona Jamaica, Mona Symposium, “General Approach to the Stereospecific Synthesis of the Antileishmanial Alkaloid (+) Dispegatrine and other Alkaloids.” C. Edwankar and James M. Cook, Jan 3-Jan 7, 2012.

Concordia University, “Synthesis of Alpha 2/Alpha3 Agonists to Treat Anxiety Disorders and Neuropathic Pain”. James M. Cook, Fall 2012.

Northern Illinois University, “General Approach to the Stereospecific Synthesis of Bisindole Alkaloids (+)-Dispegatrine, Accedinisine and N-Demethylaccedinisine”, James M Cook, Nov1, 2012, Dekalb, IL.

Illinois State University, “Synthesis of Alpha 2/Alpha3 Agonists to Treat Anxiety Disorders and Neuropathic Pain”. James M Cook, Nov 1, 2012. Bloomington-Normal, IL.

Medical College of Wisconsin, Synthesis of Nonsedating Anxiolytics Active Against Neuropathic Pain as well as Seizures, Milwaukee, WI, May 30, 2013.

Gunderson Hospital Forum, Lacrosse, WI, “Synthesis of Nonsedating Anxiolytics Active Against Neuropathic Pain as well as Siezures, August 18, 2014.

University of East Anglia, UK, Anorcq Meeting, Synthesis of Bisindole Alkaloids Targeted at Parasitic Diseases as well as Simple Molecules to Treat MRSA Infections, July 2, 2014; Plenary Lecture.

Cook, J. “Synthesis of Bisindole Antimalarial Alkaloaids as well as Ligands to Treat Drug Resistant MRSA Infections,” Cambridge Major Laboratories, December 2, 2014.

“Synthesis of Nonsedating Anxiolytics Active Against Neuropathic Pain as well as Seizures,” James M. Cook, Alessandra Di Lio, Zhi-jianWang, Rahul Edwankar, HannsUlrich Zeilhofer. University of Wisconsin-LaCrosse, Department of Chemistry & Biochemistry, LaCrosse, WI, August, 2015.

“Enantiospecific, Stereospecific Total Synthesis of a Series of C-19 Methyl Substituted Sarpagine-Macroline Indole Alkaloids via an Efficient Method of a Copper-Mediated Enolate Driven Cross-Coupling Process,” James M. Cook, M. Rahman. 26th Natural Products and Medicinal Chemistry Symposium, University of the West Indies, Chemistry Department, Mona Campus, Jamaica, January 4-7, 2016.

“Enantiospecific, Stereospecific Total Synthesis of a Series of C-19 Methyl Substituted Sarpagine-Macroline Indole Alkaloids via an Efficient Method of a Copper-Mediated Enolate Driven Cross-Coupling Process,” James M. Cook; M. Toufiqur Rahman. 17th Florida Heterocyclic and Synthetic Conference (FloHet 2016), University of Florida, FL, USA, February 28- March 2, 2016.

“Drug Design Stories and Chemical Development” James M. Cook. Industry Leader Seminar Series, Concordia University, WI, April 29th, 2016.

“Design of Benzodiazepine/ GABA(A) ergic Subtype Selective Ligands as Potential Nonsedating Treatments for Pain Disorders, Epilepsy and Anxiety Disorders with Little or No Tolerance” James M. Cook, Kashi Reddy Methuku, and Michael M. Poe. The University of Kansas, Lawrence, KS, USA, September 21st, 2016.

“Design of Benzodiazepine/ GABA(A) ergic Subtype Selective Ligands as Potential Nonsedating Treatments for Pain Disorders, Epilepsy and Anxiety Disorders with Little or No Tolerance” James M. Cook, Kashi Reddy Methuku, and Michael M. Poe. Stanford Research Institute, Menlo Park, CA, USA, October 14th, 2016; Also Ohio State U., Feb 21st, 2017.

“General strategy for the total synthesis of C-19 methyl substituted sarpagine/macroline indole alkaloids including macrocarpines A-G, peraksine, and dihydroperaksine” Rahman, M. T.; Deschamps, J.R.; Cook, J.M. Oral Presentation, 253rd ACS National Meeting, San Francisco, CA, April 4-7, (Abst. ORGN 654), 2017.

“A Novel Asthma Treatment: Targeting the GABA(A) Receptors Present in the Lung”, Rajwana Jahan, Michael Stephen, Gloria S. Forkuo, Revathi Kodali, Margaret L. Guthrie, Amanda N. Nieman, Nicolas M. Zahn, Gene T. Yocum, Margot Ernst, Leggy A. Arnold, Douglas Stafford, Charles Emala, James M. Cook, UWM Department of Chemistry and Biochemistry Awards Day and Symposium, Milwaukee, WI, May 22, 2018.

“Identifying of the Molecular Target for the Potent Antimicrobial Agent TI-I-100 to Treat Drug Resistance Bacteria”, Tiruveedhula, V. V. N. Phani Babu.; Kodali, Revathi.; Han, Lanlan.; Bardy, Sonia L.; Mirza, Shama P.; Silvaggi, Nicholas R.; Stafford, Douglas.; Arnold, Leggy A.; Cook, James M. Nobel Symposium Poster Section, Department of Chemistry and Biochemistry, UW-Milwaukee, September 29, 2017

“Identifying of the Molecular Target for the Potent Antimicrobial Agent TI-I-100 to Treat Drug Resistance Bacteria”, Tiruveedhula, V. V. N. Phani Babu.; Kodali, Revathi.; Han, Lanlan.; Bardy, Sonia L.; Mirza, Shama P.; Silvaggi, Nicholas R.; Stafford, Douglas.; Arnold, Leggy A.; Cook, James M. Research Symposium, Department of Chemistry and Biochemistry, UW-Milwaukee, May 23, 2017

“Identifying of the Molecular Target for the Potent Antimicrobial Agent TI-I-100 to Treat Drug Resistance Bacteria”, Tiruveedhula, V. V. N. Phani Babu.; Kodali, Revathi.; Han, Lanlan.; Bardy, Sonia L.; Mirza, Shama P.; Silvaggi, Nicholas R.; Stafford, Douglas.; Arnold, Leggy A.; Cook, James M. 35th H. C. Brown Lectures in Organic Chemistry, Department of Chemistry, Purdue University, April 13th, (Poster # 22), 2018.

“General Strategy for the Total Synthesis of C-19 Methyl Substituted Sarpagine/Macroline Indole Alkaloids” Rahman, M. T.; Deschamps, J. R.; Cook, J. M., 34th H. C. Brown Lectures in Organic Chemistry, Department of Chemistry, Purdue University, April 13, (Poster # 50), 2017.

“Total Synthesis of Bioactive Sarpagine/Macroline/Ajmaline Indole Alkaloids” Cook, J. M.; Rahman, M. T.; Proceedings of the 27th Mona Symposium, University of the West Indies, Mona, Kingston, Jamaica, January 8-11, 2018.

“Total Synthesis of Sarpagine-Related Bioactive Indole Alkaloids” Rahman, M. T., Oral Presentation at Nobel Graduate Seminar, arranged by Milwaukee Institute for Drug Discovery (MIDD) on the occasion of 2016 Chemistry Nobel Laureate Professor Bernard L. Feringa’s visit to The UWM Chemistry Department, September, 2017.

“General Strategy for the Total Synthesis of C-19 Methyl Substituted Sarpagine/Macroline Indole Alkaloids” Rahman, M. T.; Deschamps, J. R.; Cook, J. M., Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee Awards Day Symposium, May 23rd, 2017.

“General Strategy for the Total Synthesis of C-19 Methyl Substituted Sarpagine/Macroline Indole Alkaloids” Rahman, M. T.; Deschamps, J. R.; Cook, J. M., ACS-Milwaukee Meeting, May 3rd, 2017.

“Unprecedented Stereocontrol in the Synthesis of 1,2,3- Trisubstituted Tetrahydro-β-carbolines via a New Asymmetric Pictet-Spengler Reaction Towards SarpagineType Indole Alkaloids” Rahman, M. T.; Deschamps, J.R.; Cook, J. M., 35th H. C. Brown Lectures in Organic Chemistry, Department of Chemistry, Purdue University, April 13th, (Poster # 21), 2018.

“Design and synthesis of novel deuterated GABAAR-a6 subtype selective ligands with improved metabolic stability and enhanced bioavailability” Knutson, D. E. K., Revathi; Stephen, Michael R.; Verma, Ranjit S.; Witzigmann, Christopher; Meirelles, Matheus A.; Zahn, Nicolas M.; Huber, Alec T.; Arnold, Leggy; Savic, Miroslav M.; Ernst, Margot; Sieghart, Werner; Cook, James M. In 35th Herbert C. Brown Lectures in Organic Chemistry, Purdue University, 2018.

“Novel Deuterated GABAAR-α6 Subtype Selective Ligands with Improved Metabolic Stability and Enhanced Bioavailability Targeting Trigeminal Orofacial Pain, Neuropsychiatric Disorders, and Depression” Knutson, D. E.; Kodali, R.; Stephen, M. R.; Zahn, N. M.; Arnold, L. A.; Cook, J. M.; Dobricic, V.; Savic, M. M.; Mihovilovic, M. D.; Treven, M.; Ernst, M.; Sieghart, W. In 254th ACS National Meeting, Washington, DC, 2017.

“Design and synthesis of novel deuterated GABAAR-a6 subtype selective ligands with improved metabolic stability and enhanced bioavailability” Knutson, D. E. K., Revathi; Stephen, Michael R.; Verma, Ranjit S.; Witzigmann, Christopher; Meirelles, Matheus A.; Zahn, Nicolas M.; Huber, Alec T.; Arnold, Leggy; Savic, Miroslav M.; Ernst, Margot; Sieghart, Werner; Cook, James M. In 255th ACS National Meeting, New Orleans, LA, 2018.

“Synthesis of New Benzodiazepines that Function as α5-GABAA Receptor Ligands to Target Group 3 Medulloblastomas” F. Rashid, T. Ahmed, K. R. Methuku, O. Jonas, S. Sengupta, and J. M. Cook, 35th HC Brown Lectures, West Lafayette IN, April 12-13, (poster #38), 2018.

“Synthesis of New Benzodiazepines that Function as α5-GABAA Receptor Ligands to Target Group 3 Medulloblastomas” F. Rashid, T. Ahmed, K. R. Methuku, O. Jonas, S. Sengupta, and J. M. Cook, Milwaukee ACS Section, Milwaukee WI, May 3, 2018.

“Design and synthesis of novel deuterated GABAAR-a6 subtype selective ligands with improved metabolic stability and enhanced bioavailability” Knutson, D. E. K.; Revathi; Stephen, Michael R.; Verma, Ranjit S.; Witzigmann, Christopher; Meirelles, Matheus A.; Zahn, Nicolas M.; Huber, Alec T.; Arnold, Leggy; Savic, Miroslav M.; Ernst, Margot; Sieghart, Werner; Cook, James M. UWM Department of Chemistry and Biochemistry Awards Day and Symposium, Milwaukee, WI, May 22, 2018.

“Approach Towards the Total Synthesis of Unnatural Enantiomers of Sarpagine/Macroline Indole Alkaloids” Kamal P Pandey, Md Toufiqur Rahman, James M. Cook. UWM Department of Chemistry and Biochemistry Awards Day and Symposium, Milwaukee, WI, May 22, 2018.

“Design and Synthesis of α5-GABAA Receptor Subtype Ligands to Treat Group 3 Medulloblastoma” Md Yeunus Mian, Guanguan Li, Farjana Rashid, Taukir Ahmed, Kashi Reddy Methuku, Oliver Jonas, Soma Sengupta, and James M. Cook. UWM Department of Chemistry and Biochemistry Awards Day and Symposium, Milwaukee, WI, May 22, 2018.

“Unprecedented Stereocontrol in the Synthesis of 1,2,3-trisubstituted Tetrahydro-β-carbolines via a New Asymmetric Pictet-Spengler Reaction Towards Sarpagine-type Indole Alkaloids” Rahman, M. T.; Deschamps, J. R.; Cook, J. M., Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee Awards Day Symposium, May 22, 2018.

"Progress toward the enantiospecific and stereospecific total synthesis of a number of sarpagine-related indole alkaloids including hystrixnine and gelsempervines A and B", Md Zubair Ahmed Khana, Md Toufiqur Rahman, James M. Cook. Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee Awards Day Symposium, May 22, 2018.

“Synthesis of New Benzodiazepines that Function as α5-GABAA Receptor Ligands to Target Group 3 Medulloblastomas” F. Rashid, T. Ahmed, K. R. Methuku, O. Jonas, S. Sengupta, and J. M. Cook. Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee Awards Day Symposium, May 22, 2018.

“Synthesis of novel imidazobenzodiazepine oxazole bioisosteres as potential alpha 2, 3 subtype selective GABA(A) receptors agonists with excellent metabolic stability, pharmacokinetics, and anxiolytic efficacy” Li, G.; Methuku, K.R.; Poe, M.M.; Witkin, J.M.; Schkeryantz, J.M.; Ernst, M.; Cook, J.M. 253rd ACS National Meeting, San Fransico, CA, April 2-6, (Abst. MEDI 99), 2017.

“Synthesis of novel imidazobenzodiazepine oxazole bioisosteres as potential alpha 2, 3 subtype selective GABA(A) receptors agonists with excellent metabolic stability, pharmacokinetics, and anxiolytic efficacy” Li, G.; Methuku, K.R.; Poe, M.M.; Witkin, J.M.; Schkeryantz, J.M.; Ernst, M.; Cook, J.M. UWM annual symposium, Milwaukee, WI, May 23, (Abst. 1), 2017.

“Design and Synthesis of Anxiolytic, Anticonvulsant and Antinociceptive Benzodiazepine/GABA(A)ergic Receptor Subtype Selective Ligands as Potential Nonsedating Treatment for Anxiety Disorders, Epilepsy and Pain Disorders” Li, G.; Witkin, J.M.; Schkeryantz, J.M.; Cerne, R.; Fisher, J.; Li, J; Lewter, L.; Freeman, K.B.; Davis, P.; Stafford, D.C.; Arnold, L.A. and Cook, J.M. UWM annual symposium, Milwaukee, WI, May 22, (Abst. 22), 2018.

* 2 years behind on talks

V. **RESEARCH IN PROGRESS**

Current Research:

Major areas of interest at the present time include Medicinal Chemistry, Synthetic Organic Chemistry, and Natural Products Chemistry. More specifically, we are interested in the synthesis of natural products with biological activity or related analogs with enhanced activity. Research of this type has led us into the alkaloid, quinoline, indole, ß-carboline, benzodiazepine and coumarin fields. Much of our research effort has been concerned with the synthesis of small molecules active in the CNS, to search for receptor subtype selective activity.

A. The benzodiazepines employed to treat anxiety are a group of compounds with wide therapeutic application as anxiolytics, anticonvulsants, hypnotics and muscle relaxants. However, the sedative-hypnotic, muscle-relaxant, ataxic and amnesic side effects limit their use in the elderly and in many other patients. Recently, a number of ß-carbolines were prepared in our laboratory which have intrinsic effects opposite to the benzodiazepines (anxiogenic, convulsant, etc.) and have been employed to study mechanisms in anxiety. Moreover, there is some selectivity [Bz1-selective (Bz1 = α1β3γ2), BCCt and 3-PBC antagonists] in their mode of action in vivo. More importantly, we have recently discovered inverse agonist and antagonist activity in the rigid, planar pyridodiindole Bz receptor ligands which simplifies computer modeling of the receptor subtypes. A collaboration with a network of 19 pharmacologists has been set up to search for selective action, work in progress is detailed below:

1. To prepare new and better anxioselective anxiolytics. These agents would be selective for antianxiety effects but would not possess sedative-hypnotic, ataxic or muscle-relaxant effects; a BzR selective agonist potentially devoid of abuse potential. We have now prepared anxioselective anxiolytics devoid of muscle-relaxant, ataxic and sedative-hypnotic effects. These orally active agents are currently being characterized and should be useful in treatment of panic disorders, general anxiety disorders, social anxiety disorders, agrophobias and post traumatic stress disorders. It appears potential abuse potential for these new agents is decreased in comparison to that of Valium, Xanax, etc. We have now developed potent 2/3 agonists active as nonsedating analgesics.
2. Push our α2/α3 subtype selective PAMS, which do not develop tolerance nor sedation/ataxia or dependence into the clinic to treat epilepsy neuropathi pain and anxiety.
3. To prepare potent, long-lived, selective (Bz1, Bz2, Bz5, Bz6, etc) benzodiazepine receptor selective agonists and antagonist/inverse agonists. These inverse agonists/ antagonists would be employed to reverse the effects of benzodiazepine-induced anesthesia and to indirectly reverse barbiturate-induced CNS depression. This would help in surgery in the elderly, who oftentimes experience respiratory arrest with the barbiturate/haloalkanes presently in use.
4. Study the effect of anxiogenic agents on the levels of endorphins in the brain (Endocrinology, 1985).
5. Use the SAR of the rigid, planar pyridodiindoles to computer model the topography of each of the benzodiazepine receptor subtypes (Bz1-Bz6). This has been published, but 200 new ligands will be added to this modeling strategy this year.
6. To differentiate between Bz1, Bz5, and Bz6 receptors as well as between Bz1, Bz2 and Bz3 receptor subtypes.
7. To determine if the ability of Ro 15-4513 to reverse the effects of alcohol is mediated by the Bz6 [diazepam-insensitive site (Bz6)] site, the Bz5 site, the Bz1 receptor site or a related site. The α1 preferring, orally active BzR antagonists, BCCt and 3PBC have recently been shown to reverse alcohol self-administration in rats, and may have clinical potential in the treatment of alcoholism. These agents exhibit very weak anxiolytic activity in alcoholic rat models as well as potently reversing alcohol self-administration.
8. To employ our Bz5 receptor ligands to design BzR ligands with 200 fold selectivity for Bz5 sites after which the pharmacology of the Bz5 site can be elucidated to use these to enhance cognition and to treat Alzheimer's disease. These compounds are active against alcohol abuse as well.
9. To employ the same approach under 8 with molecular modeling and chemical synthesis to define the pharmacology of Bz1 and Bz6 subtypes.
10. Eventually, with receptor subsite selective ligands, define the exact pharmacology of all major BzR (GABA(A) sites and employ this in drug design for the preparation of anxioselective anxiolytics, anticonvulsants and sedative hypnotics with decreased abuse potential and a better understanding of tolerance.
11. Study the interrelationship between GABAergic and dopaminergic systems, in regard to the prevention of alcohol/drug abuse. This work is presently underway in collaboration with Dr. Donna Platt and Dr. Weerts.
12. Ultimate goal - to determine the differences at the molecular level between the various BzR sites via modeling, synthesis, site directed mutagenesis, cloning, and X-ray crystallography of irreversibly bound photolabels to the specific GABA(A)/BzR Cl ion channels, beginning with α1β3γ2 and α5β3γ2 subtypes.
13. To use Bz5 (α5β3γ2) subtype selective inverse agonists and agonists to push forward our GABA approach for the treatment of Alzheimers disease and age-associated memory impairment in the elderly.
14. A program on Design of 4 Subtype Selective Ligands for treatment of Asthma.

B. In mammals L-tryptophan and other indoleamines are oxidized to formylkynurenines via the kynurenine pathway by indoleamine 2,3-dioxygenase (IDO) or tryptophan 2,3-dioxygenase (TDO). Although both enzymes catalyze the same transformation, TDO is found only in the liver, while IDO is present in a wide variety of tissues such as brain, lung, and small intestine, as well as macrophages that are found in the CNS. Furthermore, IDO is a 4l kD, monomeric heme containing protein that utilizes superoxide to cleave the 2,3-double bond of indoleamines.

Many inflammatory diseases and neurodegenerative diseases have been hypothetically linked to aberrant L-tryptophan metabolism caused by activation of IDO. Moreover, Heyes and coworkers have recently reported evidence which implicates the activation of IDO in inflammatory diseases, such as AIDS, dementia and wasting, meningitis and sepsis. Interferon γ has been shown to induce the production of IDO. One of the ways in which the body responds to infection by foreign organisms and head injuries is to produce large amounts of interferon-gamma and other immune system activators. High levels of interferon-gamma eventually induce the production of high levels of IDO which results in the catabolism of large amounts of L-tryptophan and the production of high levels of metabolites of the kynurenine pathway. This can lead to extremely high levels of quinolinic acid in the CNS which can effect many neuropathological changes including nerve cell death and dementia.

Recently we have prepared both competitive and noncompetitive (modulatory ß-carboline binding site) inhibitors of IDO (Med. Chem. Res., 1993, 1994). N-a-methyl L(-)-tryptophan is the most active competitive inhibitor reported to date; however, the noncompetitive inhibitors 3-nitro ß-carboline and 3-butyl ß-carboline look even more promising. We plan, via molecular modeling and chemical synthesis, to search for even more potent inhibitors of IDO in collaboration with Dr. Melvin Heyes and Dr. Markey at NIH as well as Dr. Jamie (Australia). Drs. Mellor and Dunn have recently employed N-a-methyl-D-tryptophan (prepared first in this laboratory) as an IDO inhibitor with clinical potential. The N-a-methyl-D-tryptophan, first prepared and reported here in Milwaukee, has been employed by Drs. Mellor and Dunn to shed light on the "pregnancy paradox" and is being studied as a treatment for immune-system related diseases.

C. Multidrug resistance (MDR) in neoplastic cells is usually due to decreased cellular retention of drugs such as vincristine or doxorubicin. An ATP-dependent drug efflux pump has been detected in MDR-1-phenotypic cells and inhibition of the MDR pump is presumably a primary mechanism for reversal of MDR. Although quinine and quinidine are reversal agents and inhibitors of the MDR pump, a mixture of diastereomeric epoxides of quinine 10,11-epoxide was 8 fold more active in inhibiting the MDR pump. It is believed one of the diastereomers of the epoxide is covalently (Mol. Pharmacol., 1994) bonding to the pump. At present, the stereospecific synthesis of both epoxides is under study to determine which is the active agent, and how effective. Moreover, other agents known to inhibit this pump will be converted into epoxides to attempt to increase activity. Goal - find a way to block the pump so that vincristine/etc can kill drug resistant strains of cancer cells. The natural product tryprostatin-A, synthesized first here in Milwaukee, is the most potent inhibitor of breast cancer resistant protein reported to date (Joel Turner). Analogs of this natural product are being synthesized to find even more potent inhibitors of this member of the ABC transporter family. The goals of much of this work are to develop small molecules which can be employed to treat multidrug resistant forms of cancer.

D. The MDR pump is reported to be ubiquitous in nature, consequently, our pure diastereomeric quinine-10,11-epoxides will be employed with quinine and chloroquine in drug resistant strains of *P.falciparum* to determine if this simple approach would be effective in treating drug-resistant strains of malaria.





Figure 1

E. During recent years an increasing number of macroline related alkaloids has been isolated from various species of Alstonia. At the present time this group contains over 90 indole alkaloids, at least 21 of which are bisindoles. The hypotensive base macralstonine isolated from *Alstonia macrophylla* Wall is a member of this family, as well as the bisindole villalstonine. This latter alkaloid has been found to exhibit potent antimalarial activity against *Plasmodia falciparum*, while the related macrocarpamine is active against *Entamoeba histolytica* and *Plasmodia falciparum*. One of these alkaloids is active against drug resistant strains of *Plasmodia falciparum* while the other is active only at the chloroquine sensitive strain. The activity of these alkaloids confirms the use of *Alstonia angustifolia* in traditional medicine for the treatment of malaria as well as amoebic dysentery.

We have recently completed the total synthesis of dispegatrine (C. Edwankar). The antihypertensive bisindole employed in Chinese medicine. This was completed in 12 steps via our enantiospecific, stereospecific doubly convergent strategy.




The enantiospecific total synthesis of these bisindole alkaloids (see Figures 1 and 2) as well as the cardiovascularly active alkaloid ajmaline and a number of other macroline related sarpagine alkaloids is being pursued. The synthetic route to these bisindole alkaloids which employs the trans, stereospecific Pictet-Spengler reaction developed in this laboratory is both enantiospecific and doubly convergent [J. Am. Chem. Soc. (1994); J. Org. Chem. (2003)]. Recently the total synthesis of the bisindoles macralstonine and macralstonidine [J. Org. Chem. (2003)] as well as the partial synthesis of macrocarpamine and villalstonine has been completed and reported. A number of indole alkaloids (over 30) have been synthesized over the past three years employing the recently developed enolate-driven palladium-catalyzed cross coupling reaction in combination with the asymmetric Pictet-Spengler reaction. A related palladium-mediated method of Larock has been employed to develop the first stereospecific, regiospecific synthesis of 6-methoxy and 7-methoxy (D or L) tryptophan building blocks for total synthesis or as IDO active ligands.




Figure 3: Synthesis of Bisindoles accedinisine and N’-demethylaccedinisine

F. Attempts to prepare strained 10pi and 14pi annulenes (see below) termed cyclopentapentalenes in order to study homoconjugation, stability, electron delocalization, aromaticity (bonding character in organic molecules) are underway. The first stable disubstituted linear 14p annulene was recently prepared [J. Am. Chem. Soc. (2003)] in this series with the tandem Pauson-Khand reaction as the key step to generate molecular complexity.



G. We have in progress two projects directed toward the preparation of molecules which may house a planar four coordinate carbon atom. Initial targets are shown below. The Weiss reaction continues to be important in this work.



Licensed Aza Beta Carboline compounds/patents to MPP Group and Addiction Therapeutix Inc. a Milwaukee-based start up company (2008).

Licensed Cysteine prodrugs and patent to Promentis Pharmaceuticals (Baker, Cook; Marquette/UWM), (2008-2009).

WISYS and Neuroamp. WISYS signed an option to license with NeuroAmp on the Alzheimers-Directed Compounds (α5 Ligands at GABAergic BzR) from the memory deficit patent of Cook, Clayton and Han, assigned to WISYS, NeuroAmp is a new, Milwaukee-based start up company (Physiogenix). Previously, had nonsedating anxiolytic in human phase I clinical trials (had licensed to BMS).

VI. **STATEMENT OF TEACHING RESPONSIBILITIES AT UW-MILWAUKEE**

There are a large number of students who enter UW‑Milwaukee with career goals directed toward the Health Sciences in various subdisciplines including: premedical, predental, preveterinarian, and medical technology. The candidate's expertise in Medicinal Chemistry and Natural Products Chemistry, as well as his experience in Organic Chemistry enables him to teach students, academically, in this area quite readily. He has been responsible for teaching the survey course in Organic Chemistry (341) and the laboratory (342) to students in the medical technology, biology and environmental engineering fields. In addition, he has taught the standard organic sequence (343 and 345) to chemistry, premedical, predental, and preveterinarian students, which also included the laboratories 344 and 346. The candidate will continue to teach the above courses at the undergraduate level for it is extremely important to bridge the gap between Organic, Medicinal, and Biological Chemistry. At the graduate level, the candidate is interested in teaching Synthetic Organic and Medicinal Chemistry to students who are enrolled in all disciplines of chemistry. This teaching also includes courses in Medicinal Chemistry, The Biogenesis of Natural Products, A Survey of Natural Products Chemistry and The Total Synthesis of Indole Alkaloids.

A. **Experience as a teacher**

**Courses Taught at the University of Wisconsin‑Milwaukee**

**Undergraduate Level**

Chemistry 101 General and Organic Chemistry for Nursing Students

Chemistry 341 Introductory Survey of Organic Chemistry

Chemistry 343 Organic Chemistry, Semester 1

Chemistry 345 Organic Chemistry, Semester 2

Chemistry 342 Introductory Organic Chemistry Laboratory

Chemistry 344 Organic Chemistry Laboratory

Chemistry 346 Organic Chemistry Laboratory‑Advanced Lab

Chemistry 399 Special Chemical Problems‑Undergraduate Research

Chemistry 599 Special Projects in Chemistry‑Undergraduate Research

Chemistry 691 Senior Thesis ‑ Undergraduate Research

Chemistry 692 Senior Thesis, Capstone Course

Chemistry 693 Chemical Literature

**Graduate Level**

Chemistry 740 Modern Methods in Synthetic Chemistry (taught every other year).

Chemistry 741 Biogenesis of Natural Products

Chemistry 741 Heterocyclic Chemistry

Chemistry 741 Medicinal Chemistry

Chemistry 741 The Total Synthesis of Indole Alkaloids (taught every other year)

Chemistry 781 Modern Industrial Organic Chemistry

Chemistry 900 Colloquium

Chemistry 912 Graduate Seminar

Chemistry 990 Advanced Research ‑ Organic

Chemistry 934 Advanced Seminar in Organic Chemistry

VII. **UNDERGRADUATE AND GRADUATE RESEARCH PROJECTS, THESIS AND DISSERTATIONS DIRECTED.**

**Undergraduate Research 399, 599, and 691 -** Students and their Next Position

*Sandra Neuendorf* ‑ "Study of the Steering Effects in the Nitration of Aromatic Compounds," 1975‑1976 (PhD, Biochemistry, UW‑Madison, Vice President for Research, Incell Chemical, now UW‑Oshkosh Faculty).

*Larry Hutchins* ‑ "Pictet‑Spengler Reactions in Refluxing Benzene," 1974‑1976 (PhD, University of British Columbia; M.D., UW‑Madison, now Marshfield Clinic).

*Steven Tung* - "Synthesis of Indole Alkaloids," (Medical School, believed to be at Columbia University).

*Eric Richfield* ‑ "Studies directed toward the Synthesis of the Indole Alkaloid, Macroline," 1975‑1976 (Medical Doctor, Marquette Medical School).

*Nancy Bratanow* ‑ "Studies Directed Toward the Synthesis of Cellulase Inhibitors," 1975-1976 (Medical School, now Associate Professor, Medical College of Wisconsin).

*Cynthia Albanese* ‑ "NMR Spectroscopy of Indole Alkaloids," 1975‑1976 (Ph.D. Marquette University)

*Anita Miswald* ‑ "Preparation of Galactose Derivatives," 1976.

*Mechtild Mueller‑Johnson* ‑ "Reaction of α‑Diketones with Dimethyl ß‑Ketoglutarate," 1975‑1976 (Graduate School, UW‑Milwaukee, Department of Mathemetics).

*Robert Schumaker* ‑ "Synthesis of Cyclopentanoid Compounds," 1975.

*Paulann Haas* ‑ "Synthesis of Antimalarial Agents‑‑A Review," 1975.

*Edward Amberger* ‑ "Synthesis of 4‑Oxo‑4,5,6,7‑tetrahydroindole," 1975‑1976.

*Neil Palassari* ‑ "Synthesis of Methyl‑4‑deoxy‑4‑thio‑D‑glucopyranoside," 1975‑1976 (Graduate School, Biochemistry, University of Minnesota).

*Regina Prenger* ‑ "Studies on Galactose," 1975‑1976 (employee in government laboratory).

*David Wichman* ‑ "Chemistry of Aromatic α‑Dicarbonyl Compounds and Dimethyl 3‑Keto-glutarate," 1975‑1976 (Lecturer, Math, UW‑Milwaukee).

*Terri Chipman* ‑ "Preparation of Bioinorganic Laboratory Experiments for Chemistry 342," 1976 (Medical School).

*Janet Koch* ‑ "Amine Oxides," 1976 (MS, Department of Chemistry; Major, Biochemistry).

*Gary Bode* ‑ "Applications of High Pressure Liquid Chromatography‑‑A Review," 1976.

*Robert Weber* ‑ "General Method for the Synthesis of [n.3.3.]propellanes, n3," 1976‑1977 (PhD, UW‑Milwaukee, CENTOCORE).

*Michael DiPierro* ‑ "Pictet‑Spengler Reactions; Synthesis and Stereochemistry," 1977‑1979 (PhD, University of Minnesota, Abbott Laboratories; now Pfanstiehl Laboratories).

*Vernon Hasenstein* ‑ "Preparation of 1‑Ethyl‑1,2,3,4‑tetrahydro‑ß‑Carboline Derivatives," 1977‑1978 (sales representative).

*Frank Ungemach* ‑ "Stereospecific Synthesis of 1,3‑Disubstituted‑1,2,3,4‑Tetrahydro ß‑ Carbolines," (PhD, Vanderbilt University, now Patent Attorney, Amgen).

*John Conrad* ‑ "Synthesis of Bicyclo[3.3.0]octanedione Derivatives," 1977.

*Robert Mantei* ‑ "Studies Directed Toward the Synthesis of the ß‑Carboline Alkaloid, Crenatine," 1980 (Chemist, Abbott Laboratories).

*Gary Callen* ‑ "Studies Directed Toward the Synthesis of Suaveoline," (Ph.D., University of Michigan, now Abbott Laboratories).

*Paul Larscheid* ‑ "Synthesis of ß‑Carboline Alkaloids to be Employed as Valium Antagonists," 1980‑1985 (Graduate School, UW‑Milwaukee, Eli Lilly at one time).

*Mike Alexander* ‑ "Synthesis of Coumarins and Carbostyrils for Mechanistic Studies," 1980 (Graduate School, UW‑Madison).

*Jeff Schneider* ‑ "Studies Directed Toward the Synthesis of Antimalarial Agents," 1980 (Graduate School, UW‑Milwaukee).

*Jay Wrobel* ‑ "Studies Directed Toward the Synthesis of Modhephene," 1980 (PhD, Cornell; Ayerst Laboratories).

*Mike Schoemaker* ‑ "Studies Directed Toward the Synthesis of 7‑Substituted‑1,6‑ Diazaphenalenes," 1979‑1980 (Freeman Chemical Corporation).

*Barry Johnson* ‑ "Entry into 3, 4‑Disubstituted ß-Carbolines *via* the Claisen Rearrangement," 1983‑1984 (PhD, University of California‑Berkeley, now Manager, Aldrich Chemical).

*Rick Craig* ‑ "Synthesis of 3, 4‑Disubstituted ß‑Carbolines," 1982‑1984, MS degree, Marquette University (now Abbott Laboratories).

*Steve Welsenbach* ‑ "Regiospecific Mono and Dialkylation of *cis*‑Bicyclo‑[3.3.0]octane‑3,7‑ dione Systems," 1984‑1985 (Gross Laboratories).

*Willis Yets* ‑ "General Approach to the Synthesis of Polyquinenes," 1984‑1985 (MS in Chemistry, University of California‑Riverside, now Ameritech).

*David Remsen* ‑ "Search for Polyaromatic Hydrocarbons from Sediment Taken from Green Bay," 1983‑1984 (Graduate school, UW‑Madison).

*Deborah Tuszkiewicz* ‑ "Synthesis of ß‑Carbolines," 1984‑1985.

*Jeff Names* ‑ "Synthesis of Indole Alkoloids," 1986‑1987 (Chemical Industry, Milwaukee).

*Liesl Schindler* ‑ "Synthesis of Inverse Agonists for Bz Receptors." Synthesis of Polyquinenes." 1987‑1989 (PhD, University of Minnesota), Director of Operations in Europe, Shell Oil Co.

*Michael Martin* - "Partition Coefficients of Benzodiazepine Inverse Agonists & Synthesis of Ligands for Valium Receptors." "Synthesis and Alkyation of Pyridodiindoles. Search for New Antianxiety Agents." 1987‑1988 (Graduate School, UW‑Milwaukee, Chemistry; now Eli Lilly and Company).

*Jeff Schkeryantz* ‑ "Synthesis of Polyquinanes," 1986‑1987 (PhD, University of Michigan, Postdoctoral study, Sloan Kettering; now Abbott Laboratories).

*Mark Derkowski* ‑ "Synthesis of ß‑Carbolines," 1986.

*Adiga Godi* ‑ "Synthesis of 3‑Amino ß‑Carbolines," 1986‑1988 (Aldrich Chemical Company).

*Brian Opanski* ‑ "Synthesis of Quinidine Metabolites." "Synthesis of Polyquinenes." 1988 (PhD, University of Colorado, now Senior Design Engineer, Storage Tek).

*Ron Lefever* ‑ "Synthesis of Polyquinenes *via* the Weiss Reaction," 1988 (Incell Chemical, now Aldrich Chemical Co.).

*Anthony J. Laloggia* ‑ "ß‑Carbolines: Synthesis of Inverse Agonists," 1988 (Aldrich Chemical Co.).

*Jerry Menzia* ‑ "Synthesis of Indole Alkaloids," 1988 (Abbott Laboratories).

*Tim Feiter* ‑ Literature Searches on "Indole and Tropane Alkaloids," 1990.

*Mike Magawa* ‑ "Synthesis of Indole‑2,3‑Dioxygenase Inhibitors," 1991‑1993 (PhD, Medicinal Chemistry, University of Michigan).

*Mark Theis* ‑ "Synthesis of Alstonia Alkaloids," 1991‑1992.

*Mark Minton*(high school student) -“Synthesis of BzR Ligands,” 1992 (Ph.D. student, University of Colorado-Boulder).

*Ann Marie Kuhn* ‑ "Synthesis of IDO Inhibitors," 1994-1995 (Medical School, Washington University).

*Andrew H. Geise* ‑ "Synthesis of IDO Inhibitors," 1994 (PhD student, Medicinal Chemistry, UW-Madison, Fall, 1995).

*Sam Dashi* - "Search for New *Alstonia* Alkaloids," 1994.

*Heidi Pirkov* - "Search for Subtype Specific Ligands for BzR," 1994.

*Chris Plambeck* - "Search for 522 Subtype Specific Ligands for BzR," 1995 (Medical School, MCW).

*Raza Ghadi* - "Organic Chemistry Experiments," (PhD, UW-Madison; Professor, Scripps Research Institute).

*Poitr Kaszyinski* - "Chemistry of Polyquinenes," (PhD, Univ. of Colorado; Assoc. Professor, Vanderbuilt Univ.).

*Erik Johnson* - “Synthesis of Polyquinenes,” 1997.

*Steve Taylor* - “Search for New GABAA/BzR Antianxiety Agents,” 1998-1999.

*Dan Mass (high school student)* - “Search for New GABAA/BzR Antianxiety Agents,” 1998.

*Yelena Ostrerova* - "Synthesis of Potential Antianxiety Agents," 1999. (Aldrich Chemical Company).

*Jelena Plavsic* - “Synthesis of Antianxiety Agents,” 2004. UW-Madison (School of Pharmacy).

*Daniel Sem -* “Synthesis of Heterocyclic Compounds” now Professor at Concordia University, Department of Chemistry.

*Dustin Fisher* - “Agents to Treat Neuropathic Pain,” 2009.

*Ara Tahniyath -* “ Search for New Antimicrobials,” 2009.

*Keni-Anne Paulina Francis - “*Search for Agents to Treat Schozophrenia,” 2009.

*Angie Grzybkowska -* “Synthesis of Antialcohol Compounds,” 2010, now in Medical School.

*Jana Beth Plotkin -* “Research into Causes of Schizophrenia and Drugs to Treat Alcohol Abuse,” 2011-2013.

*Matheus Meirelles-“*Synthesis of α6β3γ2 receptor PAM’s,” 2014-2016.

*Rodrigo De Souza- “*Synthesis of α6β3γ2 receptor PAM’s,” 2015.

*C.J. Kleischmidt- “*Synthesis of α6β3γ2 receptor PAM’s,” 2015.

*Demi Woods-* “Searchfor α6 Subtype Selective Ligands,” 2014.

**Graduate Level - Graduate Students, Thesis Title or Research Project in Progress**

*Daisy Yang‑Lan* (MS) ‑ "Synthesis of [10.3.3] Propellane and [6.3.3] Propellane Derivatives," degree conferred August 1976.

*James Oehldrich* (MS) ‑ "Addition of Activated Methylene Compounds to 1,2‑and 1,3‑Dicarbonyl Compounds," degree conferred August 1976 (Wisconsin Crime Bureau).

*Frank Ungemach* (MS) ‑ "Pictet‑Spengler Reactions in Refluxing Benzene and Toluene: Synthetic and Stereochemical Consequences of this Condensation," degree conferred in May 1978 (Abbott Laboratories, Group Leader, now Patent Attorney, Amgen).

*Dave Soerens* (PhD) ‑ "I. Studies of the Pictet‑Spengler Reaction in Aprotic Media. II. Studies Directed Toward the Total Synthesis of the Indole Alkaloid, *Suaveoline*," thesis defense completed in August 1978 (3M, now Kimberly Clarke).

*Olivia Campos* (PhD) ‑ "I. Synthesis of Potential Antihypertensive Agents. II. Studies Directed Toward the Total Synthesis of *Brevicolline*," thesis defense completed in August 1978 (Associate Professor, University of Brasila, Brazil).

*Randall Mitschka* (MS) ‑ "Synthesis of Tetracyclo [5.5.1.O4,13O10,13] tridecane‑2,6,8,12-tetraketone," thesis defense completed in August 1978 (Eli Lilly, now Abbott Laboratories).

*Patti Mokry Brettell* (MS) ‑ "Pictet‑Spengler Reactions in Aprotic Media: Use of Acid‑Labile Aldehydes in this Condensation," thesis defense completed in August 1979 (S.C. Johnson and then Kimberly Clarke, now Medical Doctor).

*Jen‑Chun Chang* (MS) ‑ "Synthesis of 1, 6‑Diazaphenalene," thesis defense completed in August 1980.

*Wen‑Ching Han* (MS) ‑ "Studies Directed Toward the Synthesis of [5.5.6.6] Fenestrane," thesis defense completed in August 1982 (Squibb).

*Mike Cain* (PhD) ‑ "I. Synthesis of the ß‑Carboline Alkaloids Canthine‑6‑one and Crenatine. II. Synthesis of Benzodiazepine Antagonists," thesis defense completed in December 1982 (Abbott Laboratories).

*Shieu‑Jeing Lee* (MS) ‑ "Chemistry of l, 6‑Diazaphenalene," thesis defense completed in May 1984 (PhD Student, Chemical Engineering, Yale University).

*Robert Weber* (PhD) ‑ "I. Studies Directed Toward Synthesis of the Alkaloid, *Suaveoline*. II. Construction of Potential Antimalarial Agents," PhD, November l984 (Mallinkrodt and then CENTOCOR).

*Filadelfo Guzman* (MS) ‑ "Studies Directed Toward the Synthesis of a Specific Bz1 Receptor Antagonist," MS in December 1984 (Schering Plough and then Rikker Laboratories).

*Mahendra Deshpande* (PhD) ‑ "General Approach to the Synthesis of Polyquinenes. Synthesis of Staurane‑2,5,8,ll‑tetraene," thesis defense completed in August 1985 (Abbott Laboratories).

*Mani Venkatachalam* (PhD) ‑ "General Approach to the Synthesis of Polyquinenes *via* the Weiss Reaction," thesis defense completed in August 1986 (Supelco, Inc.).

*Greg Lannoye* (PhD) ‑ "I. Synthesis of Triquinacene *via* the Weiss Reaction. II. Studies Directed Toward the Synthesis of Strained Polyquinenes," thesis defense completed in August 1987 (Abbott Laboratories).

*Greg G. Kubiak* (PhD) ‑ "I. Mechanistic and Synthetic Studies on the Scope of the Weiss Reaction. II. Studies Directed Toward the Preparation of Staurane‑1,3,5,7,9,11‑Hexaene on the Route Towards Tetracoordinate Planar Carbon," thesis defense completed in May 1989 (Rhone Poulenc).

*Christopher Schultz* (MS) ‑ "Studies Directed Toward the Synthesis of ß‑Carbolines and Indolocarbazoles as Ligands for the Benzodiazepine Receptor," MS thesis defense completed in August 1987 (PhD Student,Geology).

*Timothy Hagen* (PhD) ‑ "I. The Synthesis of Benzodiazepine Receptor Antagonists and Inverse Agonists. II. The Total Synthesis of the Cytotoxic Indole Alkaloid: 1‑Methoxy Canthine‑6‑one," PhD thesis defense completed in May 1988 (Searle Laboratories).

*Mark L. Trudell* (PhD) "I. The Synthesis and Study of the Pharmacologic Activity of 7,12‑Dihydropyrido[3,2‑b:5,4‑b']diind oles. A Novel Class of Rigid, Planar Benzodiaze-pine Receptor Ligands. II. The Total Synthesis of the Indole Alkaloid, (±) Suaveoline," thesis defense completed in March 1989 (Distinguished Professor, University of New Orleans).

*Sherry Lifer* (MS) ‑ "Studies on the Synthesis, Electrophilic Substitution, and SAR Studies on the Biological Activity of 7,12‑Dihydropyrido[3,2‑b:5,4‑b']diindole," thesis defense completed in August 1987 (Eli Lilly and Co).

*Hernando Diaz‑Arauzo* (MS) ‑ "Synthesis, High Resolution NMR Spectroscopy of the Metabolites of Quinine and Quinidine and Antibody‑Mediated Platelet Destruction," MS thesis defense completed in July 1988 (PhD student, UW‑Milwaukee).

*Michael Allen* (PhD) ‑ "I. The Synthesis of Benzodiazepine Receptor Antagonists and Long‑lived Inverse Agonists *via* the Template Approach. II. The Synthesis of 6‑Methoxy‑D‑(+)‑Tryptophans by the Moody Azide‑Schollkopf Protocol," PhD Thesis completed January 1992 (Abbott Laboratories).

*Lin‑Hua Zhang* (PhD) ‑ "General Strategy for the Synthesis of Macroline/Sarpagine Alkaloids. Enantiospecific Total Synthesis of (‑)Alstonerine," PhD thesis defense completed in March 1990. (Postdoctoral work, University of California‑Berkeley, Merck‑Dupont Pharmaceutical Co., now Boehringer Ingelheim Pharmaceuticals, Inc.).

*Yun-Chou Tan* (MS) ‑ "Synthesis and Study of the Biological Activity of 7,12‑Dihydro-pyrido-[3,2‑b:5,4b']diindole Derivatives," thesis defense completed in June 1988 (Ciba Geigy).

*Joseph Sandrin* (PhD writing in progress) ‑ "Stereospecificity of the Pictet‑Spengler Reaction," (Vice President, C.M. Hill).

*Xiayong Fu* (PhD) ‑ "I. General Approach to the Synthesis of Polyquinenes *via* the Weiss Reaction. The Syntheis of Ellacene and Studies of the Attempted Dimerization to a Substituted Dodecahedrane. II. General Approach to the Synthesis of the Ajmaline Related Alkaloids. Enantiospecific Total Synthesis of (‑)Suaveoline, (‑)Raumacline, and (‑)Nb‑Methyl-raumacline," PhD thesis completed May 1992 (Schering‑Plough Pharmaceutical Co.).

*Yingzhi Bi* (PhD) ‑ "General Approach for the Synthesis of Macroline/Sarpagine Indole Alkaloids. Enantiospecific Total Sythesis of (+)‑Macroline and a Partial Synthesis of the Bisindole Villalstonine," PhD thesis completed May 1994 (University of California-Berkeley, Postdoctoral Appt., also Affymax Co.; now Bristol Meyers Squibb)

*Li Deng* (MS) ‑ "I. The Synthesis of 7, 12‑Dihydropyrido[3,2‑b:5,4‑b']diindole and Indolo-[3,2‑b] isoquinoline Ligands with which to Study the Pharmacophore of the Benzodiazepine Receptor Inverse Agonist Site. II. The Study of *Trans* Diastereoselectivity in the Pictet‑Spengler Reaction," thesis defense completed in August 1990 (Harvard University, PhD; now Assistant Professor Brandeis University).

*Paul May* (MS) ‑ "I. Unusual, Non‑Proteinogenic Alpha‑Amino Acids Derived from Chiral Heterocyclic Templates. II. Asymmetric Epoxidation," thesis defense completed in 1990 (Upjohn).

*Linda Hamaker* (PhD) ‑ "Studies Directed Toward the Synthesis of Ring-A Methoxylated Indole Alkaloids. An Enantiospecific Approach to the Total Synthesis of Alstophylline and the Bisindole Macralstonine," thesis defense completed in August 1995 (Advanced Chem Tech, Louisville, Kentucky, then Texas Biotechnology Corp., now AtheroGenics, Inc.).

*Linda Dorn* (MS) ‑ "Synthesis of Rigid, Planar 8H‑Pyrido[1'',2'':1',2']imidazo[4'5':5,6]-pyrido [3,4,‑b]indoles to Study the Topography of the Benzodiazepine Receptor," thesis defense completed in July 1991 (Abbott Labs).

*Michael Martin* (MS) ‑ "Synthesis of Rigid Probes to Define the Dimensions of the Benzodiazepine Receptor Cleft," thesis defense completed in September 1992 (Eli Lilly).

*Kevin Czerwinski* (PhD) ‑ "Studies on the Pictet-Spengler Reaction. I. Stereospecific Synthesis of *Trans*-1,3-Disubstituted-1,2,3,4-tetrahydro-ß-carbolines. II. Approach to Cytotoxic Canthin-6-one Alkaloids," thesis defense completed in August 1995 (Professor, University of Wisconsin-Stevens Point).

*Wei Zhang* (PhD) ‑ "I. Chemical and Computer‑Assisted Development of an Inclusive Pharmacophore for the Benzodiazepine Receptor. Studies Directed Toward the Synthesis of Anxioselective Anxiolytics. II. Molecular Yardsticks: Probes to Study the Actual Dimensions of Benzodiazepine Receptors," thesis defense completed in August 1994, (Iowa State University, Postdoctoral research associate; Abbott Laboratories, now Thervance).

*Jacqlynn Behnke* (MS studies) ‑ "NMR Spectroscopy of *Alstonia* Alkaloids."(Aldrich Chemical Co.)

*Hernando Diaz‑Arauzo* (PhD) ‑ "Synthetic and Computer Assisted Analysis of the Pharmacophore for Agonists at Benzodiazepine Receptors. Synthesis of a Selective Anxiolytic/Anticonvulsant," thesis defense completed in July 1991 (Nalco Oil Company).

*Eric Cox* (PhD) ‑ "I. Synthesis and Evaluation of Analogues of the Partial Agonist 6-proploxy-4-methoxymethyl- -Carboline-3-carboxylic Acid Ethyl Ester and the Full Agonist Zk93423. II. Studies Directed Toward the Enantiospecific Synthesis of the Indole Alkaloid Pleiocarpamine and the Bisindole Alkaloids Villalstonine and Macrocarpamine,” thesis defense completed in July 1997 (Pfizer Pharmaceutical Co.).

*Ruiyan Liu* (PhD) ‑ "An Enantiospecific Synthesis of 5-Methoxy-(D)-Tryptophan and Related Indole Amino Acids Which Serve as Building Blocks Required for The Synthesis of Alkaloids and Cyclic Peptides. II. Synthesis and Pharmacological Properties of Novel Imidazobenzo-diazepines: High Affinity, Selective Probes for α5-Containing GABAA Receptors,” thesis defense completed, October 1996 (Pharmacopia).

*Scott Van Ornum* (PhD) ‑ "Studies Directed Toward the Synthesis of Dicyclopenta-[a,e]pentalene and Dicyclopenta[a,f]pentalene via the Tandem Pauson-Khand Reaction,” thesis defense completed in April 1998 (Abbott Laboratories, Cedarburg Laboratories, now Professor Concordia University).

*Tong Gan* (PhD) - I. "An Enantiospecific Total Synthesis of (-)-Anhydromacrosalhine-Methine and A Partial Synthesis of The Antiamoebic Bisindole Alkaloid (-)-Macrocarp-amine." II. "Enantiospecific Synthesis of Optically Active 6-Methoxytryptophan Derivatives and Total Synthesis of Tryprostatin A,” thesis defense completed in August 1997 (Schering Plough, now MLB).

*Qi Huang* (PhD) ‑ "I. A Chemical and Computer Assisted Approach to Pharmacophore/Receptor Models for GABAA/BZ Receptor Subtypes. II Predictive Models for GABAA/BzR Subtypes *via* Comparative Molecular Field Analysis,” thesis defense completed in June 1998 (Amgen, now Union Biopharmaceutical co).

*Peng Yu* (PhD) ‑ "Enantiospecific Total Synthesis of the Indole Alkaloids Talpinine, Talcarpine, Alstonerine and Anhydromacrosalhine-methine as well as Studies Directed Toward the Synthesis of the Oxindole Alkaloid Alstonisine," thesis defense completed in February 1999 (Medi Chem Research, now Professor in China).

*Jin Li* (PhD) ‑ "Enantiospecific Total Synthesis of (+)- Ajmaline and Alkaloid G as well as Studies Directed Toward the Total Synthesis of 19-Hydroxy-Nb-Methylraumacline via the Asymmetric Pictet-Spengler Reaction," thesis defense completed in February 1999 (Pfizer Pharmaceutical Co.; now President of Shenogen Pharmaceutical Co.)

*C. Ma* (PhD) - I. "Efficient Asymmetric Synthesis of Ring-A Substituted Tryptophans. Synthesis of 6-Methoxy-(D)-Tryptophan Required for the Total Synthesis of Ring-A Oxygenated Indole Alkaloids. II. Synthesis of Selective Ligands for GABAA/Benzo-diazepine Receptor Subtypes," thesis defense completed in July 2000 (Pfizer, now Takeda Pharmaceutical).

*X. He* (PhD) - “Studies of Molecular Pharmacophore/receptor Models for GABAA/BzR Subtypes: Chemical and Computer Assisted Approach in Search of Selective Ligands for GABAA/BzR Subtypes,” thesis defense completed in August 2000 (COMBI-CHEM, Dupont, now GNF corporation).

*T. Wang* (PhD) - "Enantiospecific Total Synthesis of (+)-Vellosimine, (+)-Normacusine B and (-)-Norsuaveoline as well as an Improved Enantiospecific Total Synthesis of (+)-Ajmaline and (+)-Alkaloid G,” thesis defense completed in March 2001 (Schering Plough).

*S. Zhao* (PhD) - "I. The Enantiospecific Total Synthesis of Tryprostatin A and B as well as Their Enantiomers and Mismatched Pairs. II. The Enantiospecific, Stereospecific Total Synthesis of the Ring-A Oxygenated Sarpagine Indole Alkaloids (+)-Majvinine, (+)-10-Methoxyaffinisine, and (+)-Na)-Methylsarpagine as well as the First Total Synthesis of the Alstonia Bisindole Alkaloid Macralstonidine,” thesis defense completed in August 2001 (Ligand Pharmaceutical, now Biogenecide).

*X. Liu* (PhD) - "Enantiospecific Stereospecific Total Synthesis of the Enantiomers of the Indole Alkaloids Na-Methylvellosimine, Affinisine and Macroline as well as the Total Synthesis of Indole Alkaloids Trinervine, Alstophylline and the Antimalarial Bisindole Macralstonine." thesis defense completed in February 2002 (postdoctoral position, Yale University, then Wyeth, now Schering-Plough, now Patent Attorney (2012).

*H. Cao* (PhD) - “Synthesis of 14π Dicyclopentapentalenes *via* the Tandem Pauson- Khand Reaction.” thesis defense completed in June 2003 (Enanta Pharmaceuticals).

*X. Liao* (PhD) - “The First Total Synthesis of the Indole Alkaloids, Macralstonine, 6-Oxo-alstophylline, 10-Methoxyvellosimine, Lochnerine, Sarpagine, and an Improved Total Synthesis of Macralstonine and Macroline, as well as a Formal Total Synthesis of Dispegatrine,” thesis defense completed in April , 2007 (postdoctoral position, University of Illinois at Champagne-Urbana, now Professor in Chinese University).

*W. Yin* (PhD) - "I. Synthesis of Optically Active Tryptophan Derivatives with Potential Activity as Indoleamine 2,3-dioxygenase Inhibitors: An Approach *via* Asymmetric Catalytic Hydrogenation. II. Design, Synthesis and Pharmacology of Selective Ligands for α1-Containing GABAA/benzodiazepine Receptor Subtypes: SAR Studies of β-carbolines at Positions -3 and -6 and Their Corresponding Bivalent Ligands. III. First Enantiospecific Total Synthesis of the Important Biogenetic Intermediates, (+)-Polyneuridine and (+)-Polyneuridine Aldehyde, as well as 16-Epi-Vellosimine and Macusine A,” thesis defended Oct.1, 2007; Promentis Pharmaceutical Co (2008-2012).

*X. Li* (PhD) - "Synthesis of Subtype Specific Ligands for BzR/GABA(A) Receptors,” thesis defense completed in October 2004 (US Army PHS, was in Aldrich Chemical).

*X. Wearing Zhu* (PhD) - Enantiospecific Stereospecific Total Synthesis of the Oxindole Alkaloid (+)-Alstonisine and Stereocontrolled Total synthesis of (-)-11-Methoxy-17-epivincamajine as well as Studies Directed Toward the Total Synthesis of Nb-Demethyl-alstophylline,” Thesis defense completed in September 2004 (Esai Pharmaceuticals).

*J. Ma* (PhD) - “I. General Approach to the Total Synthesis of 9-Methoxy Substituted Indole Alkaloids: Total Synthesis of the Opioid Agnostic Indole Alkaloid, Mitragynine, as well as 9-Methoxygeissoschizol and 9-Methoxy-Nb-Methylgeissoschizol. II. Studies Toward the Total Synthesis of the Antimalarial Alkaloid Villalstonine,” thesis defended September 25, 2006 (Sloan Kettering, NY, now Enanta Pharmaceuticals).

*C. Zhang* (PhD) - "I. The Structure Activity Relationships and Cytotoxic Activity of Analogs of Tryprostatin A and B. Preparation of Irreversible Inhibitors for Studies of Mechanism of Action. II. Pharmacophore/Receptor Models for the GABAA/Bz Receptor Subtypes,” Thesis defense completed in June 2004 (Pfizer Pharmaceuticals).

*S. Huang* (PhD) - “Synthesis of Optically Active Subtype Selective Benzodiazepine Receptor Ligands,” Thesis defended August 9, 2007, job in California startup company.

*Michael Van Linn* (PhD ) - “ Studies on the Mechanism of the Cis to Trans Epimerization of Cis-1,2,3-Trisubstituted-1,2,3,4 – Tetrahydro -Carbolines into their Trans Diastereomers via Kinetic Analysis,” Thesis defended August 26, 2009. Postdoctoral appointment, Drexel University, CML-Labs.

*Yun Teng Johnson* (PhD) - “Synthesis of Subtype Selective Ligands for GABA(A)/Benzodiazepine Receptors Including Homomeric and Heteromeric Bivalent Ligands,” Thesis defended August 15, 2009. Pharmacy School (UW-Madison).

*Shamim Ara (MS) -“*Synthesis of Optically Active C-4 Substituted Subtype Selective Imidazobenzodiazepine Receptor Ligands*”* Thesis defended August, 2010

*Rahul Edwankar (PhD) - “*I. Hz166, A Novel -Aminobutyric Acid (A) Receptor Sub-Type Selective Ligand Active Against Neuropathic Pain II. The First Enantiospecific, Stereospecific Total Synthesis Of The C-19 Methyl Substituted Sarpagine Indole Alkaloids 19(*S*),20(*R*)-Dihydroperaksine, 19(*S*),20-(*R*)-Dihydroperaksine-17-Al And Peraksine. III. Application Of Metal-Carbenoid Chemistry And Brönsted Acid Mediated Cyclization Of Enaminones For The Rapid And Efficient Access To The Tetracyclic (Abce) Skeleton Of The *Strychnos* Alkaloids Contained In Bisindole Alkaloids.” Thesis defense completed in November 2010. Post doctoral appointment, University of North Carolina, now at Broad Institute, MIT, MA/GSK.

*Shahjahan Kabir (PhD) -“* I. Development of New Organic Synthetic Methods: Palladium and Copper Catalyzed Carbon-Carbon, Carbon-Sulfur, Carbon-Nitrogen, and Carbon-Oxygen Bond Formation as well as DABCO-Mediated Stereospecific Synthesis of Acrylate Ethers and Amines. Part II. Design, Synthesis and SAR Studies of New Classes of Agents to Treat Drug-Resistant Bacteria, Anthrax and Tuberculosis Infections”. August 2011, FDA.

*C. Edwanker* (PhD) – “I. The First Regio- and Atropdiastereoselective Total Synthesis of the Dimeric Indole Alkaloid (+)-Dispegatrine, as well as the First Total Synthesis of the Sarpagine Alkaloids (+)-Spegatrine, (+)-Lochvinerine, and (+)-Lochneram and an Improved Total Synthesis of (+)-10- Methoxyvellosimine, (+)-Lochnerine and (+)-Sarpagine. Part II. Studies Directed Toward the Total Synthesis of the C-19 Methyl Substituted Sarpagine-Macroline Alkaloids (+)-acrosalhine Chloride as well as Macrocarpine A, B and C.” Thesis defense completed in December, 2011, Post doctoral appointment, at Broad Institute, MIT, MA

*T. Clayton* (PhD) - “Part I. Unified Pharmacophoric Protein Models Of The Benzodiazepine Receptor Subtypes Part II. Subtype Selective Ligands for 5 Gabaa/Bz Receptors.” Thesis defense completed in December, 2011, Vice President R&D, Chromatic Technologies, Inc

*E. Johnson* (PhD) - “Part I. Design and Synthesis of Cysteine / Cystine Prodrugs and Bioisosteres including Symmetrical and Unsymmetrical Disulfides Designed to Increase Cystine Levels in the CNS in Order to Drive the Cystine / Glutamate Antiporter: A Novel Treatment for Schizophrenia and Drug Addiction. Part II. Design and Synthesis of Subtype Selective Ester Bioisosteres of BZR Ligands for GABAA / Benzodiazepine Receptors to Enhance Metabolic Stability.” December 2012, Head Pharmacist, Milwaukee Hospital.

S. Rallapalli (PhD) - “Part I. The First Enantiospecific, Stereospecific Total Synthesis Of The Indole Alkaloid Ervincidine Part II. The Synthesis of Alpha 5 Subtype Selective Ligands for GABA (A) /Benzodiazepine Receptors". December 2012, Postdoctoral appointment, UWM-Milwaukee; Cambridge Major Labs. May, 2014.

*P. Biawat (MS)*-“The Synthesis of Alpha5 Subtype Selective GABA(A)/Benzodiazepine Receptor(s) Ligands,” 2014; Sigma-Aldrich Chemical Company.

*G. Fonseca* (PhD) -"Enantiospecific Stereospecific Strategy for The Total Synthesis of Sarpagine and Macroline Related Oxindole Alkaloids: First Total Synthesis of Affinisine Oxindole, IsoaLstonisine, Alstofoline, Macrogentine, N(1)-Demethylalstonisine, Alstonoxine A And Second Generation Synthesis of Alstonisine". August, 2015. Job in Uruguay, South America.

*M. M. Poe* (PhD) - “Synthesis of Subtype Selective Bz/ GABA(A) Receptors Ligands for the Treatment of Anxiety, Epilepsy

and Neuropathic Pain as well as Schizophrenia and Asthma”, May, 2016. Postdoctoral appointment, UCONN.

*C. Witzigmann* (PhD) - “Part 1: Design, Synthesis, and Evaluation of Novel Gram-Positive Antibiotics; Part 2: Synthesis of Dihydrobenzofurans via a New Transition Metal Catalyzed Reaction; Part 3: Design, Synthesis, and Evaluation of Bz/GABAA α6 Positive Allosteric Modulators”, December, 2016. Alcami, Germantown, WI.

*V. V. N. Phani Babu Tiruveedhula* (PhD) - “Part-I: Development of a two-step regiospecific synthetic route for multigram- scale synthesis of β-carboline analogs for studies in primates as anti-alcohol agents, Part-II: Design and synthesis of novel antimicrobials for the treatment of drug-resistant bacterial infections, Part-III: A novel synthetic method for the synthesis of the key quinine metabolite (3*S*)-3-hydroxyquinine", August 2017, University of Wisconsin-Milwaukee. T3 Bioscience; Wonik Materials North America, Germantown, WI.

*Md* *Toufiqur Rahman* (PhD)- “Part I: Shorter and improved access to the key tetracyclic core of C-19 methyl substituted bioactive sarpagine-macroline-ajmaline indole alkaloids via a new ambidextrous asymmetric pictet-spengler react-ion beginning from either D-(+)- or L-(-)-tryptophan, Part II: The total synthesis of a number of bioactive C-19 methyl substituted macroline-sarpagine indole alkaloids including macrocarpines A-G, talcarpine, *N*(4)-methyl-*N*(4),21-secotalpinine, deoxyperaksine, dihyd-roperaksine, talpinine, *O*-acetyltalpinine, as well as *N*(4)-methyltalpinine” December, 2018. RTI International, NC.

*Guanguan Li* (PhD) – “Synthesis of New Treatments for Bipolar Disorders and Schizophrenia.” May 2019.

*Md Zubair Ahmed Khan* (PhD) – “Synthesis of New Treatments for Diseases”, 2021. PPD, WI.

*Rajwana Jahan* (PhD) - “Part-I: Design and synthesis of novel drugs to treat asthma by targeting gabaa receptors in the lung, Part II: Design and synthesis of novel α2/α3 subtype selective gabaar ligands for CNS disorders”, May 2019. RTI International, NC.

*Daniel Knutson (*PhD) - “Synthesis of New Drugs to Treat Migraine and Tic disorders”, August 2020. A-Chem, WI.

*Farjana Rashid* (PhD) – “Design and synthesis of achiral and chiral benzodiazepines and imidazodiazepines to modulate the activity of GABAA receptors for the treatment of cancer, CNS disorders and pain”, August 2021. PPD, WI.

*Taukir Ahmed* (PhD) – “The activity of QH-II-66 and it’s analogs in medulloblastoma, melanoma and non-small cell

lung cancer cell lines”, May 2022. PPD, WI.

*Md Yeunus Mian* (PhD) – “Design and synthesis of chiral and achiral benzodiazepines and imidazodiazepines as α–subtype selective gabaar positive modulators to treat schistosomiasis, epilepsy, asthma and some mental disorders”, March 2022. Sterling Pharma Solutions, WI.

*Kamal Prasad Pandey* (PhD) – “Part-I: Enantiospecific total synthesis of unnatural enantiomers of C-19 methylated sarpagine/macroline/ajmaline-type biologically active indole alkaloids via pictet-spengler reaction/dieckmann cyclization process, Part-II: Design, synthesis, and characterization of novel gammaaminobutyric acid type a (GABAA) receptor ligands for the treatment of neurological disorders including epilepsy, depression, anxiety, pain, and the synthesis of back up compounds for the clinically progressing KRM-II-81 for the treatment of pharmacoresistant epilepsy and dravet syndrome”, Jan 2023, Dupont.

*Dishary Sharmin* (PhD) – “Design, synthesis, and biological evaluation of gabaar subtype selective (α6, α2/3, and α5) ligands to treat migraine, neuropathic pain, trigeminal pain, tourette syndrome, epilepsy, anxiety and cognitive disorders as well as asthma”, August 2023. UWM, WI.

*Prithu Mondal* (PhD work in progress) – “Synthesis of New Agents to Treat Depression and Alzheimer’s Disease”.

*Sepideh Rezvanian* (PhD work in progress) – “Synthesis of Agents to Treat Anxiety Disorders, Neuropathic Pain and Epilepsy”.

*Morteza Panahzadeh Khanmiri* (PhD work in progress) – “Strategic Design and Synthesis of Benzodiazepines for Targeted

Cancer Therapies and Multi-Disease Treatment Approaches”.

**Postdoctoral Trainees and Visiting Scientists**

*Denis Foerst* ‑ "Preliminary Exploration of Synthetic Routes to Antihypertensive and Antimalarial Agents," 1976 (NIOSH, Cincinnati, Ohio).

*Geng Wu* ‑ "Synthesis of Indole Alkaloids and Antihypertensive Agents," 1978 (Ash‑Stevens, Detroit, Michigan).

*Etsuji Yamanaka* ‑ "Studies Directed Toward the Total Synthesis of the Indole Alkaloids, Macroline and Pyridindolol," 1977‑1978 (Associate Professor, Chiba University, Japan).

*Mustafa El‑Sheikh* ‑ "Synthesis of Antimalarial Agents, Chemistry of 1,6‑Diazaphenalene," 1977‑1979 (Faculty Member, United Arab Emirates).

*Ali Gawish* ‑ "General Approach for the Synthesis of Polyquinanes," 1979‑1981 (Research Chemist, ARAMCO then Incell).

*Kazu Takahashi* ‑ "Studies Directed Toward the Synthesis of Modhephene," 1981‑1982 (Associate Professor, Industrial Chemistry, Chiba University, now deceased).

*K. Avasthi* ‑ "Studies on the Chemistry of 1,6‑Diazaphenalene," "General Approach for the Synthesis of Polyquinanes," 1980‑1981 (Chemist, India, now Professor in India).

*Vidya Honkan* ‑ "Synthesis of Modhephene," 1982‑1983 (Chemist for the Government, Jamaica, West Indies, deceased in car crash).

*Mikolaj Jawdosiuk* ‑ "Synthesis of Polyquinanes and of Indole Alkaloids," 1983‑1985 (Aldrich Chemical Co., now President of CRO).

*N. Fukada* ‑ "Hydrazine‑mediated Amination‑Oxidation of 4‑Oxo‑substituted‑1,2,3,4‑tetra-hydro ß‑Carbolines," 1984 (Associate Professor, Chiba University).

*Ashok Kumar Gupta* ‑ "Synthetic Approach to Planar Tetracoordinate Carbon *via* the Weiss Reaction," 1987‑1990 (Abbott Laboratories).

*Kotha Sambasivarao* ‑ "General Approach to the Synthesis of Polyquinenes *via* the Weiss Reaction. Synthesis of Dicyclopentapentalenes," 1987‑1989 (Hoechst Celanese Corporation, now Professor, India).

*Krishnaswamy Narayanan* ‑ "Synthesis of New Ligands for Benzodiazepine Receptors." "Carboxy‑mediated Pictet‑Spengler Reaction," 1987‑1990 (Teaching Position, Mount Mary College).

*Sean Patrick Hollinshead* ‑ "Studies Directed toward the Synthesis of the Macroline‑Derived Indole Alkaloid, Alstonisine," 1987‑1989 (Pfizer Pharmaceutical Firm, England, now SPHINX, N.C.).

*Robert Badger* ‑ "General Approach to the Synthesis of Polyquinenes. Synthesis of 1,10‑ Disubstituted Triquinacenes," 1988 (Associate Professor of Chemistry, University of Wisconsin‑ Stevens Point).

*Mundla S. Reddy* ‑ "I. Enantiospecific Synthesis of Indole Alkaloids *via* the Pictet‑Spengler Reaction. II. Fenestrane Approach Toward a Planar Tetracoordinate Carbon Atom," 1992-1994 (Proctor and Gamble Co., Cincinnati, OH, now President Sreeni Labs, India).

*Andrew Peterson* ‑ "I. Synthesis of Indole 2,3‑Dioxygenase Inhibitors. II. Enantiospecific Synthesis of Ajmaline and Alstonisine," 1992-1994 (Clarion Pharmaceuticals, then Columbia Chemical).

*Puwen Zhang* ‑ "I. Enantiospecific Synthesis of Alstonia Alkaloids. II. Synthesis of α5 Subtype Specific Ligands at BzR," 1993-1995 (Wyeth-Ayerst Pharmaceuticals, now Pharmaron Corp, China).

*Shu Yu* - “I. Synthesis of α1β3γ2 Selective Ligands for BzR/GABAA Receptors. II. Studies on the Total Synthesis of Pleiocarpamine,” 1997-1999 (Pfizer).

*M. Bruendel* - “I. Studies on the Tandem Pauson-Khand Reaction. II. Synthesis of New Ligands for BzR/GABAA Receptor Subtypes,” 1997-1999 (Pfizer).

*Mathias Berner*  - “I. Studies in the Enantiospecific Synthesis of Indole Alkaloids. II. Synthesis of Novel Benzodiazepines,” 1999-2000 (Postdoctoral position, Professor Enders, now REACHLAW).

*Dongmei Han* - “I. Synthesis of Benzodiazepine Receptor Subtype Specific Ligands. II.The Asymmetric Pictet-Spengler Reaction.” (company in California)

*Jianming Yu* - “I. Synthesis of Benzodiazepine Subtype Specific Ligands. II.The Total Synthesis of the Bisindole Alkaloid Alstonisidine,” 2003-2004 (FMC, then Lundbeck, now Pharma Corp.)

*Hao Zhou* - “I. Synthesis of New Anxiolytic Agents. II. Stereospecific Synthesis of Indole Alkaloids,” 2004-2006 (Lundbeck)

*P.V.V.S. Sarma* - “Synthesis of BzR Subtype Selective Anxiolytics,” 2004-2006 (Cambridge-Major Labs)

*Felix Rivas* - “Synthesis of BzR Subtype Selective Ligands for Treatment of Epilepsy,” 2004-2005, Associate Professor (Chicago State University).

*H. Jain* - “Synthesis of Anticonvulsant and Antimalarial Agents,” 2009, Business, India.

*J. Yang* - “Synthesis of Anxiolytic and Antileishmanial Agents,” Albany Molecular Research Institute, 2008.

*H. Kumpaty* - “Mechanism of the Pictet – Spengler Reaction.” Associate Professor,UW-Whitewater.

*Ross Wang -* “Synthesis of Nonsedating Anticonvulsant and Anxiolytic Agents” 2009-2012, (now Washington University Medical School, Postdoctoral; Now Berkley); Now startup in CA.

*Ojas Namjoshi -* “Synthesis of New α5 GABA(A)ergic Ligands for Studies on Cognition and Antialcohol Agents.” 2008-2012 (RTI, North Carolina).

*Michael Lorenz -* “Synthesis of Cysteine-Cystine Bioisosteres.” 2010, BASF, Germany.

*Ranjit Verma -* “Synthesis of Antimicrobial and Anticonvulsant Agents as well as Prodrugs to Treat Schizophrenia.” 2009-2011; 2013-2016 (Cytometrix); Now Medical College of Wisconsin, Project Director.

*Sundari K. Rallapalli -* “Synthesis of α5 GABA(A)ergic Ligands for Studies on Schizophrenia and Neuroblastoma”, 2012-2013; (CML, then Analytical Co. in Atlanta).

*Wenyuan Yin -* “Synthesis of Prodrugs to Treat Schizophrenia.” 2008-2012 (was Promentis Pharmaceutical Co., now a company on the West Coast).

*Stephen Michael Rajesh* - “Synthesis of α4- α6 GABA(A)ergic Ligands for Treating Asthma, and Agents for Pain.” 2013 – 2018; Jubilant Biosynthesis, Bangalore, India.

*Kashi Reddy Methuku -* “Synthesis of α4- α6 GABA(A)ergic Ligands for Treating Asthma, as well as Agents for Pain and Schizophrenia.” Alcami, Germantown, WI.

*Ashwini Verma* - “Synthesis of Agents to Treat Schizophrenia and Pain”. Medical College of Wisconsin, Program Director.

*Lalit Kumar Golani* – “Synthesis of Agents to Treat Pain and Schizophrenia”.

*Dishary Sharmin* – “Synthesis of Agents to Treat Depression, Neuropathic Pain, Epilepsy, and Migraine”.

VIII. **CONSULTING SERVICES**

Consulted for Aldrich Chemical Company, Milwaukee, on classification of cytochalasin B and the synthesis of dicarbonyl compounds. Fee: $1,500. Time: Three‑five days per year. Paid by Aldrich Chemical. (For details, contact Dr. Alfred Bader, President).

Consulted with the UW‑Extension on the thesis of Mr. Paul Thoma. Fee: $100. Time: One day.

Consulted for Aldrich Chemical on the Synthesis of *cis*‑bicyclo[3.3.0]octane‑3,7‑dione and Na‑methyltryptophan. $6,000.00 (10 days) 1979‑1985.

Consulted for Incell Chemical. Fee: $100/day. Time: Four days.

Consulted for Research Biochemical Incorporated on Synthesis of ß‑Carbolines. Fee: $4,250. Time: Seven days.

Consulted for Searle Research Laboratories on evaluation of their new CNS program. Fee: $800/day, for several days. (1986‑1987)

Consulted for Eli Lilly. Fee: $450/day. (1987)

Consulted for Aldrich Chemical. Fee: $2,500.00, Synthesis of *cis*‑bicyclo[3.3.0]octane‑ 3,7‑dione. (1988)

Consulted for Research Biochemical Incorporated on Synthesis of ß‑Carbolines. Fee: $1,500.00. (1988)

Consulted for Gillick, Gillick, Murphy, and Wicht (Law Firm) on the case of student Jeff Schkeryantz. Fee: $500.00. (1988)

Consulted for Parke Davis‑Warner Lambert. Fee: $500.00/day. (1988)

Consulted for Monsanto Chemical Co. (Agr. Division), on Synthesis of Compounds for Biological Screening. Fee: $6,600. (1989‑1990)

Consulted for Aldrich Chemical Co. on the Synthesis of Isoreserpine and other Alkaloids. Fee: $800. (1989)

Consulted for Searle Laboratories on Compounds for Gastrointestinal Studies. Fee: $1,000. (1989)

Consulted for Universal Foods on the Isolation of Carminic Acid. Fee: $1,000. (1989)

Consulted for Aldrich Chemical on the Synthesis of *cis*‑Bicyclo[3.3.0]octane‑3,7‑dione. Fee: $6,000. (5 days, 1990)

Consulted for Universal Foods on the Structure of New Flavors and Pigments. Fee: $1,000. (1991)

Consulted for Aldrich Chemical on the Synthesis of New Indoles and ß‑Carbolines. Fee: $2,900. (1991)

Consulted for Aldrich Chemical on the Synthesis of Tryptophans. Fee: $1,700. (1992)

Consulted for Aldrich Chemical on the Synthesis of Tryptophans. Fee: $2,900. (1993‑94)

Consulted for R.W. Johnson Pharmaceutical Co. on Benzodiazepines. Fee: $1,000. (1994).

Consulted for Aldrich Chemical Co. on the Synthesis of Bicyclo[3.3.0]octane‑3,7‑dione. Fee: $7,000. (1994).

Consulted for Aldrich Chemical Co. on the Synthesis of Indoles. Fee: $1,400. (1994).

Consulted for Abbott Laboratories on Indole Alkaloids. Fee: $1,500. (1995).

Consulted for Aldrich Chemical Co. on the Synthesis of Indoles. Fee: $750. (1995).

Consulted for Ciba-Corning on Synthesis of Quinine diols. Fee: $1,000; $2,000 donated to the Department of Chemistry. (1995).

Consulted for Aldrich Chemical Co. on the Synthesis of Bicyclooctan-3,7-diones. Fee: $9,000. (1996).

Consulted for Aldrich Chemical Co. on the Synthesis of Indoles *via* The Moody Azide pyrolysis. Fee $6,000 (1996).

Consulted for Aldrich Chemical Co. on the Synthesis of Indoles. Fee: $11,000. (1996).

Consulted for Merck and Co. on Samples for Screening. Fee: $1,000. (1996).

Consulted for Aldrich Chemical Co. on Synthesis of Heterocycles. Fee $3,450 (1996-97).

Consulted and Supplied Compounds for Broad Based Screening to ASTRA Pharmaceutical and Dupont. Fee paid to UW-Milwaukee: $18,350 (1997).

Consulted and Supplied Compounds for Broad Based Screening to ASTRA/ARCUS Pharmaceutical Co. Fee paid to UW-Milwaukee: $47,000.

Consulted for Aldrich Chemical Co on the Synthesis of Indoles and Polyquinanes. Fee $20,000 (1997-98).

Consulted and Supplied Compounds for Broad Based Screening to ASTRA/ARCUS Pharmaceutical Co. Fee paid to UW-Milwaukee $20,000.

Consulted and Supplied Compounds for Broad Screening to Dupont. Fee paid to UW-Milwaukee $9,000.

Consulted for Cal Biochem on the Synthesis of Trypostatins. Fee $4,000 (1998).

Consulted for Albany Molecular Research on the Synthesis of Tryptophans. Fee paid to UW-Milwaukee $4500 (1999).

Consulted for Aldrich Chemical on Synthesis of Indoles. Fee donated to UW-Milwaukee $1250 (1999).

Consulted for Albany Molecular Research. Fee paid to UW-Milwaukee $3000 (2000).

Consulted for Dr. Andy Mellor, Georgia Medical School. Fee paid to UW-Milwaukee $3000 (2000).

Consulted for Aldrich Chemical Company. Fee donated to UW-Milwaukee Foundation (Chemistry) $20,000 (2000).

Consulted for Pfizer Global Research and Development. $2500 (2001).

Consulted for Dupont Pharmaceuticals. $1000 (2001).

Consulted for Aldrich Chemical Company. Fee donated to the UW-Milwaukee Foundation (Chemistry) $10,000 (2001).

Consulted for Ligand Pharmaceutical. $500 (2002).

Consulted for UCB Pharmaceutical. $1000 (2002).

Consulted for Roche Biosci, Inc. $1500 (2003).

Consulted for Eli Lilly & Co., $2000 (2003).

Consulted for Sepracore, $1250 (2003).

Consulted for Aldrich Chemical Company, $11, 167 (2003).

Consulted for Aldrich Chemical Company, $5600 (2004).

Consulted for GMP Pharmaceutical Co., $12,500 ($8,500 donated to UWM-Foundation) (2005).

Consulted for Abbott Laboratories, $1500 (2005).

Consulted for Sepracor, $1000 (2005).

Consulted for Aldrich Chemical Co., $20,000 (donated to UWM-Foundation) (2005).

Consulted for Aldrich Chemical, $20,000 (donated to UWM-Foundation) (2006).

Consulted for Xintria Pharmaceutical Corp., 2006

Consulted for Xintria Pharmaceutical Corp., $8000 (2007).

Consulted for Xintria Pharmaceutical Corp., $1500 (2008).

Consulted for Cambridge-Major Labs, $2500 (2008).

Consulted for Physiogenix, $5000 (2008).

Consulted for MPP Group, $16,000 (2008).

Consulted for Promentis, $15,000 (2009).

Consulted for MPP Group, $12,000 (2009).

Consulted for Aldrich Chemical Co., $1500-3000 (2009).

Consulted for CML, $2500 (2009).

Consulated for Promentis, $15,000 (2010)

Consulated for Addiction Therapeutix, $12,000 (2010)

Consulated for Promentis, $18,750 (2011)

Consulated for Addiction Therapeutic, $7000 (2011)

Consulted for Promentis $3750 (2012)

Consulted for CML, $2500 (2010)

Consulted for CML, $2500 (2011)

Consulted for CML, $2500 (2012)

Consulted for HMS, $5600 (2013)

Consulted for CML, $2500 (2013)

Consulted for CML, $5500 (2014)

Consulted for CML, $5000 (2015)

Consulted for Cortex Pharmaceutical Co., $2500 (2015)

Consulted for Cortex Pharmaceutical Co., $4000 (2016)

Consulted for Alcami, $5000 (2016-Paid in 2015; Dec 31, 2015)

Consulted for Expansion Therapeutics, $10,000 (2018 – 2019)

Consulted for the Medical College of Wisconsin, Dr. Sengupta, on agents to treat bladder pain, $8000 (2018 – 2019)

Consulted for the University of Cinncinati on Cancer, $9000 (2019 – 2020)

IX. **MEMBERSHIPS**

|  |  |
| --- | --- |
| * The American Chemical Society: Organic & Medicinal Chemistry Divisions |  |
| * The Chemical Society |  |
| * Society of Neuroscience * College on Problems of Drug Dependence * International Congress on Heterocyclic Chemistry * European Union Academy of Sciences |  |